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ABSTRACT
This thesis focused on cognitive and MRI measures of early change and 
progression in Huntington’s disease (HD). HD is clinically heterogeneous and 
previous findings about the location of brain atrophy in the early stages, and its 
relation to cognition, are equivocal. A pilot study assessed the practicality of 
using serial volumetric MRI in early HD and the usefulness of cognitive tasks in 
longitudinal assessment. A larger study investigated cross-sectional and 
longitudinal aspects of these domains in premanifest and early HD.
Global and regional cerebral volumes were investigated using manual volumetry 
and voxel-based morphometry (VBM). The work describes the application of 
the Brain Boundary Shift Integral (BBSI) to measure of whole-brain atrophy rate. 
Preparatory technical work included choice of templates for optimum scan 
alignment and segmentation in VBM, and adjustment of BBSI parameters to 
obtain maximum agreement between it and manual measures. Cognitive ability 
was assessed using a wide-ranging battery of tests, some standard and some 
novel.
Atrophy in early HD was found to be more extensive than previously reported, 
involving widespread extra-striatal loss, and not all functional deficits could be 
attributed to striatal damage. Emotion recognition deficits were broad and 
associated with striatal and extra-striatal brain regions. Executive function and 
memory tasks demonstrated decline over one year. Whole-brain atrophy rates 
were increased in early HD and associated with decline in cognition and GAG 
repeat length.
This work elucidates the extent of, and associations of, atrophy and cognitive 
impairment in HD, and adds weight to the suggestion that variability in 
progression rates is partly explained by genetic factors. The suggestion that 
motor learning might be impaired even in very far-from-onset gene carriers, and 
that tasks other than those tapping executive function were sensitive to decline, 
should motivate further work aimed at detecting the very earliest signs of change 
in this disease.
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Unified Huntington’s Disease Rating Scale: the clinical
assessment tool developed for use in HD
Voxel-based morphometry
Visual Object and Space Perception Battery
Wechsler Adult Intelligence Scale
White matter
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1 HUNTINGTON’S DISEASE
1.1 BACKGROUND AND HISTORY OF HUNTINGTON'S DISEASE 
One of the earliest descriptions of “hereditary chorea” is ascribed to George 
Huntington in 1872 (Huntington 1872) based on his observations of a set of 
families on Long Island with abrupt, rapid involuntary movements of the body, 
or chorea. In these families he noted that the chorea was hereditary, that onset 
was “invariably” between the ages of 30 and 40, and that there was a tendency 
towards insanity or suicide as the disease progressed and the mind became more 
impaired. He spoke of the disease “. . . hardly ever manifesting itself until adult 
or middle life, and then coming on gradually but surely, increasing by degrees, 
and often occupying years in its development, until the hapless sufferer is but a 
quivering wreck of his former self.” He wrote that he knew nothing of its 
pathology and ended the paper saying “. . . I have never known a recovery or 
even an amelioration of symptoms in this form of chorea; when once it begins it 
clings to the bitter end. No treatment seems to be of any avail, and indeed 
nowadays its end is so well-known to the sufferer and his Mends, that medical 
advice is seldom sought.” (Huntington 1872).
George Huntington was describing what is now known as Huntington's disease 
(HD), which, as he so astutely noted over 100 years ago, is an autosomal 
dominant neurodegenerative disorder usually of adult onset. Although for many 
years it was characterised primarily as a movement disorder, it is now well 
recognised that cognitive and psychiatric problems accompany and frequently 
precede motor signs. Early in the disease psychomotor and executive skills (such 
as planning or set switching) tend to be affected, and depression, apathy or
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irritability are some of the more common behavioural disturbances (Craufurd and 
Snowden 2002; Thompson et al. 2002). It has a prevalence in the UK of ~1 per 
10,000 individuals with many more at risk of the disease (Harper 2002). It 
progresses slowly and inexorably, with increasingly distressing and disabling 
symptoms associated with considerable care-giver and family burden, with 
morbidity and death occurring 15-20 years from onset, by which time the patient 
is often bed-bound and mute. Much more is now known about the pathology of 
the disease, and the gene that causes it, than in George Huntington’s day. 
However, although a number of symptoms can be alleviated there is still no 
treatment known to stop or even slow the course of the disease.
1.1.1 The HD gene and pathology
In 1993 the genetic abnormality underlying HD was discovered to be a CAG 
expansion on chromosome 4 (Huntington's Disease Collaborative Research 
Group 1993). Alleles of up to 35 repeats are normal, whilst alleles with 40 or 
more repeats are fully penetrant and the carrier is likely to show signs of the 
disease within a normal lifespan. The intermediate repeat numbers (36-39) are 
not fully penetrant but there have been reports of 36 CAG repeats leading to the 
disease, and of people living into their 90s with 39 CAG repeats and no signs of 
HD (Rubinsztein et al. 1996). Higher CAG repeat lengths are associated with 
earlier onset although CAG repeat length only explains about 50-70% of the 
variance in age at onset and other genetic or environmental factors are likely to 
influence this (Duyao et al. 1993). The repeat is unstable and can change during 
transmission, with larger expansions particularly likely to occur in transmission 
from the male. Non-abnormal or intermediate repeat lengths can also expand
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into the pathogenic range, leading to new mutations in previously unaffected 
families (Bates 2005).
The gene encodes the protein huntingtin which is expressed widely throughout 
the brain and central nervous system. The precise role of huntingtin is unclear 
but it appears to be multifunctional, and it is generally believed that the 
symptoms seen in HD are caused by toxicity of the mutant form of the protein 
(Wanker and Droge 2002) although there is some evidence that reduced wild- 
type huntingtin function might also contribute to the disease process (Cattaneo et 
al. 2005). The presence of mutant huntingtin leads to the selective neuronal 
dysfunction and death which underlie the clinical features of the disease.
The most striking atrophy in HD is seen in the striatum (caudate nucleus and 
putamen), in which atrophy progresses along a dorso-medial -  ventro-lateral 
gradient (Vonsattel et al. 1985). At post-mortem extensive and relatively 
uniform atrophy is also seen throughout the cortex, with probably slightly more 
loss of white matter relative to grey matter (de la Monte et al. 1988; Mann et al. 
1993). It is not yet clear whether cortical atrophy is secondary to striatal atrophy 
or an independent process, nor why some neurons are selectively vulnerable in 
HD, although this may be in part due to mutation length gains within some cell 
types and regions (Shelboume et al. 2007). Brain volume at post-mortem is 
almost 20% less than in controls, and cortical volume has been shown to 
correlate with striatal volume, suggesting that linked degenerative processes 
might underlie the loss in both regions (Halliday et al. 1998). Further structural 
and functional abnormalities that can be seen in vivo are discussed in section 1.2.
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1.1.2 Testing, diagnosis and treatment
The discovery of the causative gene made it possible for the presence or absence 
of the abnormal allele to be confirmed by genetic testing. Patients showing signs 
of HD can be offered a confirmatory test, and adults at risk of HD by virtue of 
having an affected parent can be offered predictive testing, although this needs to 
be approached extremely carefully and currently only between 10 and 25% of 
those eligible to have the test do so, perhaps because of the knowledge that there 
is, as yet, no cure (see Tibben 2002).
Clinical “onset” of HD is not diagnosed until the clinician is confident that the 
patient is showing unequivocal motor signs. However, as mentioned above, it is 
not uncommon for subtle motor, cognitive or behavioural abnormalities to be 
present many years prior to this (e.g., Lawrence et al 1998a; Williams et al 
2007). Motor symptoms such as abnormal eye movements may also be present 
in premanifest gene carriers (Golding et a l 2006). Depression and other 
affective disorders can precede motor symptoms by many years, and this is not 
merely a response to the situation in which carriers of the abnormal gene find 
themselves because it is the case even in those who do not know that they are at 
risk of the disease (Craufurd and Snowden 2002; Julien et al 2007). Cognitive 
symptoms are described in more detail in section 1.3.
As yet there are no pharmaceutical interventions known to delay or prevent onset 
of HD although symptoms such as chorea and depression can be alleviated. A 
number of groups are testing potential neuroprotective compounds, some of 
which have been shown to be safe and well-tolerated, although larger studies are 
needed to see if they can demonstrate any effect on function. Other strategies
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such as striatal grafts and gene therapy are also being considered although 
currently these approaches are somewhat held back by both ethical and technical 
issues and so more research needs to be done if either approach is to become 
useful for treating HD (Handley et al 2006).
1.1.3 Current clinical measures in HD
Therapeutic trials in HD investigating disease-modifying effects are challenging 
for a number of reasons in addition to those mentioned in the previous section, 
predominantly the difficultly in measuring and quantifying disease-related 
decline over time, and by extension, the difficulty in determining whether the 
rate of that decline has been slowed by an intervention. This is primarily because 
of the heterogeneity of the disease, and the inadequacy of the current clinical 
measurement scales, particularly in the very earliest stages of the disease.
In HD, disease progression is relatively slow, and the disease is highly clinically 
heterogeneous, so patients with HD present with variable clinical phenotypes 
(differing burden of motor, cognitive and psychiatric symptoms). There is also a 
suggestion that higher CAG repeat length is associated with faster clinical 
progression, and that this interacts with time since diagnosis (Rosenblatt et al. 
2006). This inherent variability and non-linearity makes it hard to detect small 
differences between groups, or change over time.
The current clinical rating scales are the Unified Huntington’s Disease Rating 
Scale (UHDRS) and Total Functional Capacity (TFC) rating scales (Shoulson 
and Fahn 1979; Huntington Study Group 1996) and they are widely used, but 
have high measurement variability, particularly in the behavioural/psychiatric 
assessment (Craufurd and Snowden 2002). The motor subscale of the UHDRS
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shows only fair agreement between clinicians (Hogarth et al. 2005) and the 
authors recommend that investigators be selected and trained carefully if they are 
to perform such assessments in therapeutic trials. Because of this variability 
these scales can require long assessment intervals and large subject numbers in 
order to have the statistical power to detect effects on function (Kieburtz and 
Shoulson 2002) and importantly the scales have limited ability to distinguish 
effects on disease progression from symptomatic benefit. They are also subject 
to floor and ceiling effects, with premanifest and even early disease subjects 
unlikely to score below ceiling for the TFC and independence scales, and those 
in the final stages of the disease likely to be immobile and totally dependent and 
thus scoring at floor level.
As mentioned above, disease onset is defined as the time at which a clinician 
confirms the unequivocal presence of motor signs, but subtle motor signs, as well 
as cognitive and behavioural changes, can be present prior to this in the so-called 
“premanifest” population. Therapies that delay onset or slow functional decline 
are likely to be targeted at premanifest or very early HD patients. However, on 
standard tests most premanifest subjects perform in the clinically normal range 
(Paulsen et al. 2006a; Solomon et al. 2007) and, as discussed, current clinical 
measures are insensitive in both premanifest and very early HD populations. 
Inevitably clinical scales measuring “symptoms” will be completely inadequate 
for measuring progression in subjects who are asymptomatic.
Therefore it is clear that more reliable, validated measures are needed, both to 
define and predict disease onset, and to quantify and track change over time 
accurately. Such measures would give a clearer picture of the disease,
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particularly the functional and anatomical changes in the premanifest and early 
stages, and could potentially be used as markers of disease progression or 
surrogate endpoints against which to test the efficacy of therapies. The following 
sections summarise findings in neuroimaging, and cognition, both of which have 
the potential to provide more information about these aspects of HD.
1.2 NEUROIMAGING IN HD
Brain imaging can provide a non-invasive assessment of brain structure, 
function, metabolites or perfusion, and through the use of radio-labelled ligands 
allows estimates of specific receptor (e.g.. Dopa) or molecular (e.g., amyloid) 
densities. Imaging is increasingly being used in neurological disorders both for 
diagnosis and for locating regions of dysfunction or atrophy and measuring 
progression. It can be repeated over time to give an idea of where change is 
occurring, and at what rate. It is also useful to visualise early brain abnormalities 
in the period prior to clinical diagnosis, i.e., at a point where clinical, behavioural 
or functional abnormalities are not noticeable or are too subtle for detection with 
standard clinical scales. In HD, because a genetic marker exists, imaging work 
has focused on predicting clinical onset from structural or functional 
abnormalities, and measuring rate of decline.
1.2.1 Imaging modalities
Structural MRI uses the signal emitted by protons in different brain tissues, when 
aligned in a magnetic field and exposed to a radio-frequency pulse, to reconstruct 
an image of those tissues. Parameters can be altered to adjust the relative signal 
intensities fi"om different tissue types, in order to highlight particular types of 
pathology, or to maximise the contrast between tissues. Structural MRI is widely
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used in studies of neurodegeneration because it is possible to visualise patterns of 
atrophy, and to quantify the volume of different structures from the MR image.
Quantification often takes the form of manual or semi-automated outlining of a 
structure of interest on an image in order to estimate its volume (a region of 
interest, or ROI approach). A different approach which has been used more 
frequently recently is to examine whole tissue types and look for regions where 
statistically significant differences in the image intensities exist between groups 
(cortical thickness measurement, and voxel-based morphometric methods are 
examples of this). The latter approaches do not require a priori hypotheses about 
the location of atrophy and are thus considered “unbiased” ways of examining 
morphometric changes across the whole brain (see sections 1.2.2 and 2.5.5). 
Manual ROI approaches are usually preferred for generating reliable estimates of 
the volume of specific anatomical structures.
Other imaging techniques allow measurement of a number of different 
parameters including: regional cerebral blood flow (rCBF); brain metabolic 
activity; brain metabolites; brain receptor binding or water diffusivity as indices 
of brain function, either in a resting state or during a behavioural task. They 
have the potential to detect functional change before clinical or volumetric 
changes are apparent and thus could be particularly useful as markers of 
“premanifest” disease onset, and as measures of potential neuroprotective 
therapies. Functional MRI (fMRI) measures the blood oxygen level dependent 
(BOLD) haemodynamic response in the brain, and thus is an indirect measure of 
neuronal activity. Position emission tomography (PET) uses radiotracers to 
measure rCBF, metabolism or brain receptor binding. Diffusion weighted
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imaging (DWI) measures the diffusivity of water in the brain which can be used 
as an index of structural integrity.
The imaging focus of this thesis is on structural MRI, and in order to set this in 
context the following sections give an overview of relevant structural and 
functional imaging findings in HD. These sections are not intended to be 
comprehensive.
1.2.2 Structural MRI
1.2.2.1 Cross-sectional studies
As mentioned in section 1.1.1 the most striking pathological changes in HD 
occur in the striatum (Halliday et al 1998; Gutenkst et al 2002) and a number of 
cross-sectional structural MRI studies in HD have demonstrated atrophy of the 
putamen and caudate nucleus in vivo (Harris et al. 1992; Harris et al. 1996; 
Rosas et al. 2001). In these studies the putamen tended to show stronger 
negative associations with motor and chorea scores (Harris et al. 1992) although 
volumes of both structures were associated with cognitive performance, (Harris 
et a l 1996) and total striatal loss was predicted by CAG repeat length (Rosas et 
al 2001).
Loss of striatal volume has also been reported in premanifest HD gene carriers,
demonstrating that striatal neuronal loss occurs even before onset of clinical
symptoms and that caudate and putamen volumes decrease with proximity to
predicted motor onset (Aylward et al 1994; Aylward et al 1996; Harris et al.
1999). In one study caudate volume alone predicted with 100% accuracy
subjects who would be diagnosed within two years (Aylward et al. 2004).
Reduced putamen volume has been found in subjects as much as 23 years from
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predicted motor onset, although caudates in this group were not significantly 
smaller than in controls (Paulsen et al. 2006b).
These volumetric imaging studies in HD were conducted to analyse volume 
changes in predefined pathologically-implicated cerebral regions of interest, 
solely in subcortical structures. However there is increasing post-mortem 
evidence that atrophy is more widespread, and that subcortical atrophy might be 
associated with cortical changes (de la Monte et al. 1988; Halliday et al. 1998). 
Similar changes have also been reported in vivo. Generalised white matter loss 
has been reported in early HD, in the absence of total brain volume or grey 
matter loss, with white matter volume associated with psychomotor and 
executive task performance (Beglinger et al. 2005). Disproportionate frontal 
lobe white matter loss has also been demonstrated, with no differences in overall 
brain volume until patients were moderately affected (Aylward et al. 1998). 
However others have reported reduced total brain volume in early HD (Rosas et 
al. 2003; Kassubek et al. 2004a). A detailed study found grey matter loss in the 
frontal and temporal lobes, and white matter loss in deep, frontal and occipital 
regions, in mild to moderate HD (Fennema-Notestine et al. 2004). These authors 
also found significant associations between caudate volume and cortical grey and 
white matter volume, suggesting that a similar or parallel neurodegenerative 
mechanism might underlie both striatal and cortical atrophy.
These findings, which are based on volumetric measurements of structures of 
interest, are reinforced by the finding of reduced cortical thickness in early to 
moderate HD, with a suggestion that the sensorimotor areas are most severely
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affected and that atrophy progresses from posterior to anterior regions with 
longer disease duration (Rosas et al. 2002; Rosas et al 2008).
Abnormal brain volume has also been found in premanifest subjects. One study 
found evidence of reduced white matter and normal grey matter volume in a 
premanifest group predicted to be ~11 years from onset. In contrast a 
premanifest group ~23 years from onset had increased grey matter, and 
decreased white matter, in the absence of any increase in ventricular size or 
cerebrospinal fluid (CSF) volume, which led the authors to postulate that this 
might represent a developmental abnormality rather than a very early 
neurodegenerative process. Total brain volume was not significantly reduced 
(Paulsen et al. 2006b) although further work on the same cohort demonstrated 
morphological grey matter abnormalities, including increased gyral surface area, 
thicker gyri and thinner sulci (Nopoulos et al. 2007). Decreased white matter has 
been reported to correlate with years to onset in premanifest subjects, and in this 
case grey matter was also reduced, although not significantly (Ciarmiello et al
2006). However grey matter thinning in regions across the cortex has also been 
reported in this population (Rosas et al 2005). In this study grey matter 
thickness in some regions correlated with striatal volumes, and thinning was also 
associated with worse performance on psychomotor and executive task 
performance.
The technique of voxel-based morphometry (VBM) (Ashbumer and Friston
2000) is increasingly used in the study of neurodegeneration, both to determine 
patterns of atrophy and to analyse associations between atrophy and behaviour. 
As mentioned above this technique is an unbiased, automated method for whole-
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brain analysis (see section 2.5.5 for more details). Its advantage over ROI 
techniques is that it requires no a priori hypotheses about particular regions of 
interest. VBM therefore has the potential to detect atrophy in areas that can be 
missed by ROI studies.
VBM findings in HD are mixed; most studies find evidence of bilateral caudate 
and putamen atrophy in both early and premanifest HD (Thieben et al. 2002; 
Peinemann et al. 2005). In contrast there is less consensus about extrastriatal 
atrophy; for example insular atrophy has been shown in premanifest (Thieben et 
al. 2002), but not in some of the early HD studies (Kassubek et al. 2004c). There 
are similarly variable results on the involvement of the thalamus, amygdala, 
hypothalamus and frontal areas (Kassubek et al. 2004c; Kassubek et al. 2005; 
Peinemann et al. 2005; Douaud et al. 2006; Mühlau et al. 2007b).
In summary, structural MRI studies in early HD tend to support the post-mortem 
findings of widespread generalised atrophy throughout the cortex, with 
disproportionate volume loss in the striatum. Where both grey matter and white 
matter are measured, there is a suggestion that white matter loss is relatively 
greater or seen earlier in the disease. Premanifest subjects have clear striatal 
atrophy and there is evidence of white matter loss but the involvement of grey 
matter is less clear. There is considerable variation between studies both with 
regard to the extent of extra-striatal atrophy and the point in the disease at which 
loss in different regions starts to become significant. In many cases these 
differences might be due to methodological differences, or lack of statistical 
power. Alternatively they may reflect true heterogeneity in the populations 
sampled. Overall this section demonstrates that although it is clear that
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widespread structural losses occur early in the disease, the pattern, time course, 
severity, significance and evolution are all still unclear with some conflicting 
claims in the literature.
1.2.2.2 Longitudinal studies
The majority of longitudinal structural MRI studies in HD have focused on the 
striatum. Early evidence was that in close-to-onset and early HD striatal atrophy 
rates were fairly uniform across stages, but that higher CAG repeat lengths 
(associated with earlier age at motor onset) were associated with greater atrophy 
rates (Aylward et al. 1997; Aylward et al. 2000). It was later reported that the 
putamen and caudate began to atrophy at rates significantly greater than zero up 
to 11 years before disease onset with evidence of some non-significant decline 
between 20-10 years prior to onset, i.e. that atrophy rates were non-linear, at least 
in the premanifest stage (Aylward et al. 2004). These conclusions were based on 
“snapshots” of subjects at different years to onset, and atrophy rates were not 
shown to be greater than those seen in normal ageing, so longer prospective 
studies are needed in order to clarify the exact way in which atrophy rates change 
over time. Rate of caudate atrophy has been suggested as a surrogate marker of 
disease progression (Aylward et al. 2003; Aylward 2007).
There have been few other longitudinal structural MRI studies in HD. One study 
looked at total grey, white matter and CSF and found that these volumes did not 
change significantly over 18 months in early HD although white matter volume 
decreased in premanifest subjects over 16 months (Ciarmiello et al. 2006). VBM 
approaches have yielded slightly different results: a two-year study of 
premanifest subjects found evidence of subcortical grey matter atrophy, but no
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changes in white matter (Kipps et al 2005). In contrast a one-year study of early 
HD subjects found change in these regions as well as the insula, cerebellum and 
some cortical regions, although whether these changes are specific to HD is 
unclear as the age ranged from four to 73 but results were not adjusted for either 
age or head-size (Ruocco et al 2007).
Overall recent evidence suggests that it may be possible to detect volume loss 
over time in regions outside the striatum but little work has focussed on 
quantifying this in more detail.
1.2.2.3 Effect o f  CA G repeat length on brain volume
CAG repeat length is known to account for between 50 -  70% of the variance in 
age at onset (Duyao et al. 1993; Langbehn et al. 2004) but there is debate as to 
what extent it contributes to other aspects of HD, including brain atrophy.
Some post-mortem studies have found no effect of CAG repeat length on cortical 
or sub-cortical cross-sectional areas (Sieradzan et al. 1997) whereas others find 
that CAG repeat length either predicts the ratio of cell loss to age at death (i.e. 
rate of cell loss) in the striatum (Furtado et al. 1996; Penney, Jr. et al 1997), or 
atrophy rates in the cortex but not subcortical structures (Halliday et al 1998). 
In contrast to the latter finding, in vivo MRI studies have shown that CAG repeat 
length is correlated with striatal but not cortical volumes in manifest HD patients 
(Ruocco et al. 2006) (unadjusted for age) and predicts age-adjusted striatal 
volume loss (Rosas et al. 2001) as well as rate of striatal loss (Aylward et al. 
1997).
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VBM approaches to this question have also yielded mixed results: an effect of 
CAG repeat length was found only in the right inferior frontal sulcus in 
premanifest subjects (Thieben et al. 2002), and of two studies which investigated 
the subcortical grey nuclei on a voxel-by-voxel basis in early HD, one found no 
relationship (Douaud et al. 2006) whilst the other found a negative association 
between CAG repeat length and caudate volume (Peinemann et al. 2005). 
Another VBM study examined this indirectly in early HD patients, comparing a 
“low” CAG group with controls, and a “high” CAG group with controls, and 
showed that the high CAG group had more extensive atrophy of the striatum but 
both groups showed similar amounts of extrastriatal atrophy (Kassubek et al. 
2004c). However the two groups were not compared directly. In early HD, 
higher CAG repeat length has been associated with smaller striatal and sub­
postcentral gyri white matter volume (Jech et al. 2007) and with increased extent 
and rate of atrophy in extra-striatal, but not striatal regions (although this was not 
corrected for age) (Ruocco et al. 2007).
Overall, most studies suggest that there is an influence of CAG repeat length on 
the location and amount of brain atrophy in HD but there are discrepancies as to 
exactly which regions are affected.
1.2.3 Functional imaging
Both hypoperfusion and (possibly compensatory) hyperperfusion have been 
demonstrated in early HD subjects. Reduced BOLD responses in frontal and 
occipital regions were found using an implicit learning task (Kim et al. 2004). 
Increased activation in the anterior cingulate, insula and frontal and parietal 
regions was shown in an executive function task (Georgiou-Karistianis et al.
39
2007) and this group has also reported relatively reduced functional connectivity 
in prefrontal regions using the same task (Thiruvady et al 2006).
Reduced activity has also been shown in premanifest gene carriers, sometimes in 
the absence of measurable clinical or cognitive deficits (Reading et al 2004; 
Hennenlotter et al 2004). Paulsen et al (2004) found that close-to-onset (<12 
years) gene carriers had smaller caudate nuclei, worse time discrimination 
performance and reduced activation in the caudate, thalamus and putamen 
relative to controls. They were also perhaps the first to show reduced activation 
in the same areas in a group of gene carriers whose estimated time to onset was 
>12 years, in the absence of any volumetric or behavioural differences. Similar 
effects have been shown with a working memory task, with hypometabolism of 
the left dorsolateral prefrontal cortex related to working memory load in 
relatively far-from-onset premanifest subjects, again in the absence of 
behavioural or volumetric changes (Wolf et al 2007), and a time reproduction 
task (Zimbelman et al 2007).
PET studies have shown decreased striatal glucose metabolism and dopamine 
receptor binding in premanifest and early HD, with reduction in both measures 
associated with proximity to onset in premanifest subjects (Lawrence et al 
1998c; Ciarmiello et al 2006; Feigin et al 2007). Dopamine receptor binding 
may be a more sensitive marker of dysfunction in HD than glucose metabolism 
(van Oostrom et al 2005), and increased rates of decline in striatal receptor 
binding have been shown in both premanifest and early HD subjects (Andrews et 
al 1999; Pavese et al 2003) with relatively linear change over three or four 
years (Pavese et al 2003; Feigin et al 2007). In early HD progressive reduction
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of glucose metabolism and dopamine receptor binding has also been reported in 
the amygdala, frontal and temporal cortices (Pavese et al. 2003), and white 
matter (Ciarmiello et al 2006), whilst hypermetabolism of the thalamus has been 
suggested as a possible compensatory mechanism in far-from-onset premanifest 
subjects (Feigin et al. 2007). PET has also been used as a marker of striatal graft 
treatment (Gaura et al. 2004; Furtado et al. 2005).
DWI studies have found compromised tissue integrity in early and premanifest 
HD in subcortical grey matter as well as white matter (Mascalchi et al. 2004; 
Reading et al. 2005), with increases in white matter diffusivity associated with 
decreased cognitive performance (Rosas et al. 2006). Compared with control 
subjects, premanifest subjects have a smaller percentage of white matter tracts 
from frontal areas to the caudate and this correlates with their performance on 
voluntary-guided saccades (Kloppel et al. 2008).
Functional imaging techniques have demonstrated widespread abnormalities in 
early and premanifest HD, and it is of particular note that compensatory 
mechanisms have been demonstrated, and that functional decline can be shown 
prior to behavioural or volumetric abnormalities. Functional imaging therefore 
shows promise as a tool for detecting the earliest premanifest change in HD and 
could be used longitudinally to measure rates of change.
1.2.4 Summary
As structural MRI techniques have moved from hypothesis-driven ROI 
approaches to more exploratory analyses of the whole brain, the concept of HD 
as a primarily striatal disorder has changed. Although atrophy of the striatum 
appears most severe and is apparent very early on, widespread cortical grey and
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white matter loss, in both premanifest and early HD, has also been shown. The 
exact extent and time course of volume changes, and how they relate to CAG 
repeat length is unclear. Functional techniques have shown putative markers of 
dysfunction in HD, in some cases before volumetric or behavioural change was 
detectable. In one study functional changes showed little overlap with 
volumetric changes, suggesting that they were reflecting reduced striatal input to 
cortical regions, rather than structural changes (Gavazzi et al. 2007).
All these measures have been suggested as possible markers of disease 
progression, given that they are sensitive to abnormalities in HD and not subject 
to floor, ceiling, or practice effects as so many clinical scales are. Analyses can 
be shown to be highly reproducible and can be performed blinded to subject 
characteristics.
Structural imaging with MRI is non-invasive, widely available and relatively 
fast. Volumes and rates of change can be easily and reliably quantified. It is 
apparent from previous work that structural change in HD is extensive and 
progressive, but more needs to be known about the patterns of atrophy and how 
they develop in the early stages. In addition, it is clear that atrophy in HD is not 
restricted to the striatum, so it may be that measures that encompass the whole 
brain are also sensitive markers, at least at certain points in the disease. The 
majority of studies have been cross-sectional and so future work would benefit 
from longitudinal analysis of changes across the brain.
1.3 COGNITION IN HD
Many studies have examined cognitive deficits in HD with a view to clarifying 
the nature of the disorder and the problems that people with HD face. In relation
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to the current need for reliable markers of disease progression, recent large-scale 
studies are starting to focus not only on which skills are impaired in HD, but on 
which tests are the most sensitive to deficits and to decline over time. The 
following review therefore focuses on the sensitivity and usefulness of tests as 
much as on what they can tell us about function in HD.
Early HD patients tend to be impaired at psychomotor tasks, executive function, 
with some perceptual problems and mild memory problems, whilst language 
comprehension, semantic memory and skill learning are considered relatively 
unaffected until later in the disease process (Bachoud-Lévi et al 2001; Craufurd 
and Snowden 2002). Performance also tends to be worse in patients with longer 
CAG repeat lengths or disease duration (Jason et al 1997; Rosenblatt et al 
2006). In premanifest gene carriers deficits are less obvious, and although subtle 
changes can be detected many gene carriers perform within normal limits 
(Paulsen et al 2006a).
1.3.1 Cross-sectional studies 
y.j.7.7
IQ as measured by the Wechsler Adult Intelligence Scale (WAIS) (Wechsler 
1981) tends to be below the normal range in early manifest HD, with impairment 
on most subtests where they are reported (e.g., Josiassen et al. 1983; Giordani et 
al 1995; Snowden et al 2001) (but see also de Boo et al. 1997). Findings are 
less clear cut in premanifest HD, with reports of both normal function (de Boo et 
al. 1997; Lemiere et al. 2002) and an overall impairment (Giordani et al. 1995; 
Witjes-Ane et al. 2003). Findings on individual subtests are also mixed with 
some premanifest cohorts impaired only on picture completion (Giordani et al.
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1995) and others showing problems with arithmetic and digit symbol (Kirkwood 
et al. 2000), as well as a version of picture arrangement (Snowden et al. 2002).
A French-language estimate of premorbid IQ found early HD patients to be in 
the normal range (Bachoud-Lévi et al. 2001), and this has also been 
demonstrated using the National Adult Reading Test (NART) (Snowden et al. 
2002). However a large study of premanifest subjects found that errors on the 
AN ART (the American-language version of the NART) increased slightly with 
proximity to estimated motor onset, which suggests that these tests may not be 
entirely insensitive to disease effects (Solomon et al. 2007).
1.3.1.2 Executive function
Patients with HD often demonstrate broad impairments in executive function 
(planning, shifting attention, decision-making, monitoring performance) and 
psychomotor tasks. Performance on the Stroop task is generally impaired in 
early HD (Giordani et al. 1995; de Boo et al. 1997; Snowden et al. 2001) 
although in one study the deficit was only shown on the more automated parts of 
the task (colour- and word-reading) with sparing of the interference part 
(Bachoud-Lévi et al. 2001). Similarly early HD patients often perform poorly on 
phonemic fluency and the Symbol Digit Modalities Test (SDMT) (Snowden et 
al. 2001; Lemiere et al. 2002), which together with the Stroop test comprise the 
cognitive parts of the UHDRS. However, not all studies find that phonemic 
fluency is impaired (de Boo et al. 1997; Bachoud-Lévi et al. 2001) and mixed 
findings are also reported for category fluency (Bachoud-Lévi et al. 2001; 
Lemiere et al. 2002). It has recently been suggested that impairments in fluency 
tasks in HD are commensurate with subjects’ verbal ability and motor
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impairments, and thus might reflect dysfunction in these areas rather than a 
disproportionate impairment in executive function per se (Henry et al. 2005); this 
might explain why not all studies have found these tasks to be impaired in the 
early stages.
Impairment on the SDMT can also be detected in premanifest subjects (Paulsen 
et al. 2001; Witjes-Ane et al. 2003) but the other tasks discussed above tend to 
be performed within the normal range by this group (e.g., Giordani et al. 1995; 
Lemiere et al. 2002). However some deficits have been shown in phonemic 
fluency (de Boo et al. 1997), category fluency (Lawrence et al. 1998a; Vemy et 
al. 2007) and the Stroop test (Paulsen et al. 2001; Snowden et al. 2002; Vemy et 
al. 2007) although in the latter two studies subjects were impaired only at the 
colour-reading subtest, not word-reading or interference. Deficits in attentional 
set-shifting have also been shown, in the absence of concurrent problems with 
planning and working memory (Lawrence et al. 1998a).
1.3.1.3 Psychomotor
Craufurd and Snowden (2002) point out that psychomotor slowing distinguishes 
sub-cortical from cortical dementias and is prominent in HD. It is often 
demonstrated on tasks such as Stroop and SDMT (discussed above) as well as 
Trail Making tests, performance on which is usually impaired in manifest 
patients (e.g., Bachoud-Lévi et al. 2001) but not always in premanifest (Giordani 
et al. 1995; Witjes-Ane et al. 2003). Manifest subjects also tend to perform 
badly on cancellation tasks (Bachoud-Lévi et al. 2001).
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1.3.1.4 Language
Language comprehension appears to be relatively unaffected at least until the 
later stages of the disease when there is some evidence of difficulty following 
complex instructions (Craufurd and Snowden 2002). Problems with picture- 
naming are generally attributed to perceptual difficulties rather than a linguistic 
deficit per se (Hodges et al. 1991). In the later stages of the disease speech is 
affected due to problems with motor production. Bachoud-Levi et al. (2001) 
found no evidence of an impairment on the Token Test with manifest subjects 
although the opposite has also been reported (Lemiere et al. 2002) but whether 
this deficit was due to problems with comprehension or response selection is not 
discussed. The Token Test requires attention to different stimulus aspects and a 
series of different responses so it might be argued that an executive function, or 
even working memory deficit would impair performance on the task.
1.3.1.5 Memory
There is some evidence that memory declines prior to motor onset and that this 
decline may be less gradual than that seen in executive skills (Snowden et al. 
2002; Solomon et al. 2007). Both immediate and long-term auditory recall of 
word lists is generally impaired in manifest HD (Giordani et al. 1995; Bachoud- 
Lévi et al. 2001; Lemiere et al. 2002) (but see also de Boo et al. 1997). In 
contrast premanifest subjects have tended not to show an impairment in these 
tasks (Lemiere et al. 2002) although a recent large study of premanifest subjects 
found that although they were not performing at levels indicative of clinical 
impairment, they were significantly below control levels (Solomon et al. 2007; 
Vemy et al. 2007). Reports that recognition is better than recall in HD have led 
to theories that the deficit is primarily one of retrieval, and that this is a feature of
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“subcortical” dementia. However a recent meta-analysis has challenged this, 
with evidence that recall and recognition impairments are of similar magnitudes 
(Montoya et al. 2006), and others have suggested that recognition is impaired in 
HD when false positives are taken into account (Lang et al. 2000a).
Digit span seems to be impaired in all but the earliest stages of HD (e.g., 
Lawrence et al. 1998b; Lemiere et al. 2002). Mild HD patients have shorter 
spatial spans than controls (Lawrence et al. 1996). On the same task premanifest 
subjects an estimated 11 years from motor onset were unimpaired relative to 
controls (Lawrence et al. 1998a) whilst a group estimated to be eight years from 
onset did demonstrate an impairment (Lawrence et al. 1998c). Memory for the 
source of information is also impaired in early HD in the absence of a deficit in 
the recall of that information (Brandt et al. 1995). In general memory problems 
in the early stages of HD are thought to reflect problems with organisation and 
retrieval strategies, rather than a storage deficit per se (Brandt 1993).
1.3.1.6 Visuo spatial
Early HD patients have been shown to be impaired on perceptual matching and 
discrimination tasks (Lawrence et al 2000) as well as face perception, drawing 
and block design (Craufurd and Snowden 2002), tasks which require attention to 
and integration of multiple stimulus parts, and some planning. Deficits are also 
seen in pattern and spatial recognition tasks (Lawrence et al. 2000). 
Visuoconstructional tasks such as drawing and block design, which require 
planning, organisation and motor skills, are also impaired; Backman et al (1997) 
found that mild to moderate HD patients were impaired at the block design 
subtest of the WAIS as well as the copy and memory phases of the Rey-
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Osterrieth figure. However, again presymptomatic subjects tend not to show 
impairment on these measures, although there is some evidence that this group 
can be impaired at visual and facial recognition (Witjes-Ane et al. 2003; Paulsen 
et al. 2006a).
Mild to moderate patients show little impairment on the Visual and Object Space 
Perception (VOSP) battery: impairments have been shown in mild patients on the 
object decision subtest (Lawrence et al. 2000) and the silhouette subtest (Lemiere 
et al. 2002) but otherwise patients tend to demonstrate intact performance, as do 
premanifest subjects (Lemiere et al. 2002). The overall pattern suggests that in 
the early stages of HD attentional factors may underlie perceptual problems, as 
basic perceptual skills seem to be preserved.
1.3.1.7 Emotion recognition
Deficits in emotion recognition have been reported in both premanifest and early 
HD with disgust recognition thought to be particularly impaired (Sprengelmeyer 
et al. 1996; Gray et al. 1997). This finding has now been replicated 
(Sprengelmeyer et al. 1997; Wang et al. 2003; Hennenlotter et al. 2004; 
Sprengelmeyer et al. 2005; Montagne et al. 2006), and bas even been found to 
extend to vocal emotion recognition (Sprengelmeyer et al. 1996) and the 
olfactory and gustatory domains (Mitchell et al. 2005; Hayes et al. 2007).
However, not all studies have replicated the finding of disproportionately 
impaired disgust recognition in HD. For example Milders et al. (2003) examined 
facial emotion recognition in a large number of pre- and post-motor onset HD 
patients and found that whilst post-motor onset patients were impaired at a 
number of emotions, including disgust, fear was the most severely affected
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emotion in the post-motor onset group and also in the pre-motor onset group. 
Recent data from the PREDICT-HD study have reinforced this, showing that 
premanifest subjects were impaired at recognition of all negative emotions 
(sadness, disgust, anger and fear) and showed no evidence of a disproportionate 
impairment in any one emotion (Johnson et al. 2007). The latter study also 
pointed out that omitting to adjust for factors such as age and IQ, which were 
correlated with recognition performance in their cohort, might contribute to 
differences between studies.
1.3.2 Longitudinal studies
Mild to moderate HD patients show more severe deficits on a wider range of 
tasks than early patients which suggests that cognitive performance declines as 
the disease progresses, and a number of studies have set out to investigate this 
prospectively. Longitudinally, decline in early HD has been demonstrated in 
some components of the UHDRS (Total Functional Capacity, Independence and 
Motor scores) (Bachoud-Lévi et al. 2001; Mahant et al. 2003).
In early HD patients the majority of studies report that cognitive decline can be 
detected in executive function and psychomotor tasks such as the SDMT, Trail 
Making Tasks A and B, Stroop colour and word reading, and category and 
phonemic fluency (Bachoud-Lévi et al. 2001; Snowden et al. 2001; Ho et al. 
2002; Ho et al. 2003; Lemiere et al. 2004; Ward et al. 2006). The exception is 
Stroop interference in which performance only declined after taking practice 
effects into account in one study (Bachoud-Lévi et al. 2001), whilst most others 
find no decline even with several follow-ups over a number of years (Snowden et 
al. 2001; Lemiere et al. 2004; Ward et al. 2006). It has been suggested that this
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and similar findings might be explained by a deficit in executing more automated 
tasks, as opposed to those under more cognitive control (Snowden et al. 2001).
Findings in the domain of memory are more mixed. Most studies fail to find 
evidence of decline in measures of auditory list learning (Bachoud-Lévi et al. 
2001; Ho et al. 2003; Lemiere et al. 2004). Findings on digit span, spatial span 
and story recall are equivocal (Bachoud-Lévi et al. 2001; Snowden et al. 2001; 
Lemiere et al. 2004), whilst immediate and delayed object recall has been shown 
to decline but this has not been widely tested (Snowden et al. 2001).
Tests of language are less well represented in longitudinal studies and again 
findings tend to be mixed, with one study finding that Token Test performance 
declined over time whilst confrontation naming did not (Ho et al. 2003), and 
another the reverse pattern (Lemiere et al. 2004). The same two studies found 
either no decline, or significant decline on the VOSP. Others report no change in 
visual-motor integration (Ward et al. 2006), judgment of line orientation or 
mental rotation (Bachoud-Lévi et al. 2001) although interestingly whilst this was 
confirmed in a map-tracing task requiring mental rotation skills, subjects’ tracing 
time in the same task got slower over time (a task with the same motor but fewer 
cognitive demands) (Snowden et al. 2001).
Where it has been investigated, CAG repeat length seemed to have little effect on 
rate of cognitive decline (Bachoud-Lévi et al. 2001; Snowden et al. 2001; Ward 
et al. 2006), whereas IQ and gender have both been reported to influence rates of 
decline on some tests (Snowden et al. 2001; Ward et al. 2006). The best 
predictor of cognitive decline in these two studies was motor ability, although a 
similar relationship has not been found elsewhere (Bachoud-Lévi et al. 2001).
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Despite the fact that a number of cross-sectional studies have shown that 
performance decreases with estimated proximity to onset (e.g., Solomon et al. 
2007; Stout et al 2007), findings of significant decline in premanifest cohorts 
followed longitudinally are rare. Only one large study has found evidence of 
decline across executive and psychomotor tasks in premanifest subjects who 
were subsequently diagnosed as symptomatic during the two-year study period 
(Paulsen et al 2001) although the same tests have been used with many other 
premanifest cohorts (Giordani et al 1995; Lemiere et al 2002; Snowden et al 
2002; Lemiere et al 2004; Witjes-Ane et al 2007).
Decline over time has also not been detected in tests of digit and visual span, 
verbal list learning and stoiy recall in this population (Lemiere et al 2002; 
Lemiere et a l 2004; Witjes-Ane et al 2007), although object recall performance 
has been shown to decline around the time of clinical onset (Snowden et al 
2002). Examination of longitudinal change in language and visuospatial skills is 
again less common, and where it has been investigated there has either been no 
change, or for some visuospatial tests, slight improvement over time (Lemiere et 
al 2002; Snowden et al 2002; Lemiere et al 2004; Witjes-Ane et al 2007).
In early HD most cognitive change has been measured over a minimum of two 
years with few investigating it over one year or less. Time intervals in studies 
looking at premanifest subjects have tended to be longer, with most studies 
having two or three assessment sessions over at least three years.
Overall there is little decline that is detectable in the premanifest population, 
despite evidence that, cross-sectionally, performance at a level below controls is 
often shown. Decline in early manifest subjects is more notable, particularly in
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the domain of executive function and psychomotor tasks, although findings on 
the extent and rate of change in other domains are mixed. However there are a 
number of factors which could influence these findings, in particular small 
subject numbers, different statistical methods and highly heterogeneous groups, 
which are discussed more in section 1.4.
1.3.3 Relationship between cognitive performance and brain atrophy 
The presence of focal striatal atrophy in HD (Vonsattel et al. 1985; Halliday et 
al. 1998), together with findings of behavioural deficits, often leads to 
suggestions that striatal damage underlies whatever impairment is seen. A 
number of imaging studies have confirmed the existence of a relationship 
between striatal volumes and cognitive deficits. Caudate volume has been 
associated with complex psychomotor skills, verbal memory and visuospatial 
skills, using a CT index (Bamford et al. 1989); with memory/speed of 
processing, using volumetric MRI measurements (Starkstein et al. 1992; Brandt 
et al. 1995); and with score on the Mini-Mental State Examination (MMSE) 
(Harris et al. 1996). Putamen volume and metabolism have been found to 
correlate with neurological symptoms (Harris et al. 1996) and timed 
psychomotor and executive function tasks (Backman et al. 1997). Striatal 
dopamine receptor binding levels also correlate with tasks requiring scheduling 
and sequencing of responses (Lawrence et al. 1998c).
However, as discussed in section 1.2.2, it is clear that atrophy in HD is not 
confined to the striatum, even in the premanifest population, and there is now 
evidence that volume in other brain regions is associated with cognitive 
performance in premanifest and early HD. Measures of frontal lobe size
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correlate with memory and planning performance (Bamford et al. 1989; Bamford 
et al. 1995; Backman et al. 1997). Insula activation has been found to be related 
to disgust recognition (Hennenlotter et al. 2004). One study included an index of 
whole-brain atrophy by calculating the percentage of the brain volume that was 
cerebrospinal fluid, and concluded that this was the best correlate of 
neuropsychological measures (executive, psychomotor and visual) (Harris et al.
1996).
Other studies have taken a whole-brain approach to this question and found 
regions including the thalamus (Kassubek et al. 2005), insula (Peinemann et al. 
2005), white matter (Beglinger et al. 2005; Rosas et al. 2006) and widespread 
cortical regions (Rosas et al. 2005; Rosas et al. 2008) to be associated with 
cognitive performance in HD. Most of these studies focussed on a few tests in a 
specific domain (executive function) so it is not clear whether atrophy in similar 
regions is also associated with the dysfunction that is seen in other cognitive 
domains.
1.3.4 Summary
A number of studies have demonstrated cognitive impairments in a range of 
areas in patients with early and premanifest HD. Deficits have been shown in 
executive function (planning, shifting attention, decision-making, monitoring 
performance), psychomotor skills, and some perceptual and spatial skills, as well 
as mild memory problems, whilst language comprehension, semantic memory 
and skill learning and priming are relatively unaffected. Deficits on a number of 
tasks can sometimes be explained in terms of the executive function demands of 
the tasks rather than reflecting a primary problem in these areas.
53
Within the premanifest and early HD populations there is sometimes conflicting 
evidence over the type and extent of cognitive impairment. In some cases this is 
likely to be due to methodological differences, or lack of power to detect small 
effects in some studies, a fact highlighted by the evidence of deficits coming 
from PREDICT-HD, one of the largest studies of premanifest subjects to date 
(Paulsen et al. 2006a). However this is also likely in part to reflect the 
heterogeneity of the disease, and the different characteristics of the groups 
described as "premanifest" or “early” HD.
Overall it has been suggested that in early HD psychomotor tasks are most 
impaired, followed by planning, phonemic fluency, attentional span (digit span 
and spatial) and short-term memory (Ho et al 2003). It is hard to make the same 
comparison for premanifest subjects but what findings there are suggest that 
some psychomotor tasks might decline gradually prior to motor onset, with 
memory undergoing a more abrupt fall-off around the time of onset (Paulsen et 
al. 2001; Snowden et al. 2002).
Cognitive change over time is much less clear. Again, many of the discrepancies 
might be due to methodological differences, some of which are discussed further 
in section 1.4.1. It is still unclear at what point decline in premanifest subjects 
can be detected and at what rate change occurs. The pattern in early HD patients 
is better defined but there are still many domains in which results are conflicting, 
and more work is needed to elucidate the pattern of cognitive progression in the 
disease.
Many early studies made the assumption that because the striatum was 
preferentially affected in HD, striatal damage must underlie the behavioural
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déficits seen in the disease, and in the absence of imaging data this was not often 
challenged. However it is now clear that other subcortical nuclei, white matter, 
and cortical regions are abnormal early on in the disease and it is likely that 
damage to cortico-striatal networks causes at least some of the impairments seen 
in the disease. Future work needs to focus on clarifying the structure-function 
relationships in HD.
1.4 TRACKING CHANGE IN HD
Section 1.1.3 discussed the heterogeneity of HD and the fact that current clinical 
measures had drawbacks. However, much work is focused on developing 
therapies that will slow progression, if not prevent onset in HD, and good 
markers of disease progression are needed in order to test the efficacy of such 
therapies. The final section of this chapter discusses the definition of such a 
marker, and some of the problems associated with both cognitive and imaging 
measures, and the disease itself, which need to be addressed in the search for a 
reliable biomarker.
A biomarker is “A characteristic that is objectively measured and evaluated as an 
indicator of normal biological processes, pathogenic processes, or pharmacologic 
responses to a therapeutic intervention.” (Biomarkers Definitions Working 
Group 2001, p91). A biomarker can be used for diagnosis or staging of disease, 
as an index of disease progression, or for monitoring clinical response to an 
intervention. In the case of HD the genetic mutation is known and this therefore 
serves as a diagnostic marker for the disease. However, as discussed above, few 
clinical measures are reliable indicators of the disease process, being highly 
variable, subject to floor and ceiling effects, and in some cases unable to
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distinguish between symptomatic benefit and effects on disease progression. A 
useful marker in HD therefore needs to be sensitive to the early stages of the 
disease, be able to distinguish symptomatic benefit from true progression, be 
associated with a pathogenic process and clinical manifestation of the disease, 
and be able to be measured objectively and reliably; in other words it must give a 
clear picture of part of the disease process. It is then assumed that treatments 
affecting the marker will also affect the associated clinical characteristics of the 
disease and lead to clinical benefit to the patient. In addition, to be useful in a 
typical clinical trial context, a biomarker needs to be tolerated, non-invasive, 
reliable and reproducible in multi-centre settings.
Markers that can predict clinical benefits may potentially serve as surrogate 
endpoints. Currently in HD typical clinical endpoints are motor onset, and death, 
but trials in which these outcomes were used to assess drug efficacy would take 
decades. A surrogate endpoint which predicted motor onset (or death) could be 
used in their stead and perhaps allow therapeutic testing in the years prior to 
motor onset, and reduce trial times. Only a subset of biomarkers will be 
surrogate endpoints (Biomarkers Definitions Working Group 2001).
It is likely that no single biomarker will fully capture the extent of HD. In 
addition markers may not respond to treatment in predicted manners. Whole- 
brain atrophy rates, and rates of cognitive decline, are known to be increased in 
Alzheimer’s disease relative to normal ageing (Jack, Jr. et al. 2004). It was 
assumed that effective treatments for the disease would reduce the rate of volume 
loss, as well as cognitive decline. However, a recent study of a potential 
treatment found that whole-brain volume loss was greater in those who had
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responded to the antibody than in non-responders. In contrast cognitive change 
in the same subjects seemed less severe in the responders. It was suggested that 
the increased brain volume loss might have been caused by a reduction in 
amyloid deposits in the brain, rather than an increased rate of the pathological 
process. One effect of the treatment was therefore to invert the relationship 
between atrophy rate in cognitive decline in these subjects, at least over the short 
time course of that study (11 months). Without the concurrent measurement of 
cognitive performance, the improvement in clinical outcomes for the patients 
would not have been known (Fox et al. 2005). This suggests that therapeutic 
effects might need to be evaluated on a number of markers simultaneously in 
order to get a more comprehensive picture of the relationships between change in 
different modalities.
In HD, caudate volume has been suggested as a potential biomarker, because it 
can be measured objectively, is associated with the major site of pathology in the 
disease, and predicts motor onset (Aylward 2007). The subject numbers on 
which the latter statement is based are relatively small, and further work needs to 
be done to refine what is known about the predictive value of this measure. In 
addition, the work used manual measurements, and the author herself admitted 
that semi- or fully-automated techniques might improve the reliability of the 
technique. Another issue, which is relevant to all potential markers in HD, is that 
motor onset is itself subjective and does not fully reflect the insidious onset of 
symptoms across domains which is now known to occur in HD. An ideal 
surrogate endpoint should fully predict existing clinical outcomes, but this will 
depend on how well the existing clinical outcome measures reflect the disease in 
the first place, as well as the variability of the surrogate measure.
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It is clear that more work is needed to measure the change in the natural course 
of HD, and to determine better indicators of onset, in order to determine which 
measures are the most reliable indices of the disease. This is particularly true for 
the premanifest and early manifest populations, the patients who are most likely 
to enter clinical trials.
1.4.1 Measuring change in cognition
Cognitive testing presents some difficult problems in the search for reliable 
markers of disease progression. Unlike more direct measures (such as MRI or 
rating scales like the TFC) cognitive performance can be affected by factors 
which are highly variable, for example subject mood or time of day. It can vary 
between timepoints because of these factors, and additional ones such as a 
change in testing venue or personnel, and so these need to be kept constant 
wherever possible. Like clinical scales, some tasks are subject to floor and 
ceiling effects, although sometimes this can partly be overcome by investigating 
qualitative results (e.g., analysing error patterns and strategies as well as number 
of correct responses) or using timed tasks. Performance is also subject to 
practice effects, with many subjects showing no decline, or even improvement 
over time, due to familiarity with the test (Bachoud-Lévi et al. 2001), although 
some tests now have alternative versions to help overcome this.
Performance often improves with increasing IQ, and declines with age. 
Although groups are often described as being well-matched for these variables, a 
non-significant difference could still affect results and so it is sensible to adjust 
findings for age and IQ where appropriate (see e.g., Johnson et al. 2007).
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There are further problems with interpreting the results of other studies. Choice 
of control group will affect the relative impairment seen in the HD group, and 
this varies from healthy “normal” controls, to spouses or gene-negative siblings 
of HD patients, to at-risk subjects who are not told of their negative gene status 
until some time after cognitive testing. Different studies also use different tests 
to draw conclusions about the same underlying skills. Many studies which 
include a large battery of cognitive tests do some form of correction for multiple 
comparisons to limit the chance of a type I error (rejecting the null hypothesis 
when it is in fact true). However it is not clear what the best form of correction 
is (a simple Bonferroni one may not be appropriate for non-independent 
cognitive tests), and this also increases the chance of a type II error (accepting 
the null hypothesis when it is false). Given that the chosen alpha level will then 
also vary arbitrarily depending on the number of tests in the battery it may be 
preferable not to correct and simply to interpret the results with this in mind 
(Rothman 1990). Most published longitudinal studies of cognition in 
premanifest HD take this approach, or if they are more stringent still report less 
significant effects to give an idea of trends (e.g., Snowden et al. 2002). One 
recent study opted to correct more stringently and reported that there was no 
evidence of significant change in premanifest subjects (Witjes-Ane et al. 2007). 
Non-significant effect sizes and p values were not reported making it hard to 
compare the effects seen here with those in other studies.
In interpreting differences between studies many of these issues need to be 
considered as potential explanations. A number of factors can be controlled in 
prospective studies, for example the testing conditions or use of alternative test 
forms where available, whilst interpretation of results can be aided by reporting
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effect sizes as well as p values. This is important both for gaining a clearer 
picture of cognitive progression throughout the disease and in the search for 
reliable markers of cognitive decline.
1.4.2 Measuring change on MRI
In comparison with measuring change in cognition, MRI measures appear to 
have many advantages. Brain volume is unaffected by subject mood or the 
scanner environment. MRI images can be analysed blind to subject identity and 
gene status, and if necessary data collected over a number of sites can be 
analysed by a single investigator and so measures can be objective and highly 
reproducible (Aylward 2007).
However brain volume can be affected by medication or comorbidity, as well as 
nutritional factors such as hydration (Duning et al. 2005). Although efforts are 
often made to exclude subjects with medication suspected of affecting brain 
volume, or comorbid conditions, and subjects can be advised to abstain from 
alcohol prior to scanning, some inter- and intra-individual variability will 
doubtless remain as a result of factors such as these.
Technical issues such as scanner type and consistency can also affect scan 
measurements. If scans are acquired over a period of time it is important to 
ensure that changes in scanner calibration have not biased measurements. Serial 
images can be registered to the same space to correct for this (Whitwell et al. 
2004). In addition subjects need to remain still in the scanner for adequate scan 
quality, which means that in a disease such as HD some subjects will be 
unsuitable for scanning, a factor which means that cross-sectional studies will 
tend to focus on the premanifest or early stages, and that longitudinal studies may
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risk drop-out from the more advanced subjects or only be representative of those 
with less severe motor problems.
Despite the fact the MRI measures are thought to be more objective and show 
high levels of intra- and inter-rater reliability there are again disparate findings in 
terms of both absolute brain volumes, patterns of atrophy, and the size of group 
differences in HD. In many cases these are likely to be technical and related to 
scan sequences or software, in which case whilst absolute measures might differ, 
the relative differences between groups should still be similar. Where this is not 
the case, analytical or statistical differences may be to blame. For example, brain 
volume is likely to be related to subject head size (usually unaffected by disease) 
and thus some sort of adjustment for this is often, although not always, made. 
Some researchers adjust volumes for total brain, or grey matter volume (which 
may be affected by disease as well as being related to head size) and hence are 
adjusting for the global effects of the disease, but not necessarily for head size. 
Semi-automated whole-brain methods often have a range of preprocessing 
options which can affect outcomes, and these are discussed in more detail in 
chapter 6.
As with cognitive findings in HD it has become clear that methodological 
differences in imaging studies are making it hard to generalise or to get a sense 
of the robustness of the results, and recently there has been a suggestion that 
work needs to focus on validating different methods as well as replicating earlier 
work (Nopoulos et al. 2007). The influence that different methods can have on 
results needs to be considered more carefully in interpreting and planning
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studies, and ideally future work should consolidate disease-specific findings 
rather than introduce technique-specific differences.
1.4.3 Stratifying subjects with HD
HD is diagnosed when a clinician confirms the unequivocal presence of motor 
signs, and staging thereafter is based on the TFC score (Shoulson and Fahn 
1979). Motor symptoms account for -25% of the variance in TFC, whilst 
cognitive and psychiatric symptoms account for much less, suggesting that TFC 
may not be such a good indicator of cognitive and psychiatric problems (Nehl 
and Paulsen 2004). Thus subjects at the same stage of HD (including 
premanifest) are likely to be more similar in terms of motor scores and ability 
than in terms of cognitive, psychiatric or psychosocial function. This is 
particularly true for the premanifest / early HD distinction, since by definition 
this distinction must be based solely on motor signs, even if some at-risk gene 
carriers have been showing symptoms of cognitive or behavioural problems in 
the absence of motor signs. Although it is clear that as the disease advances, 
performance in all three domains declines, it may be that different 
subpopulations show “onset” and decline in domains other than motor, or that 
rate of decline in different domains varies (Marder et al. 2000; Mahant et al.
2003). Group analyses in HD are therefore subject to the caveat that the make­
up of the groups may mask cognitive or behavioural differences whilst at the 
same time emphasising motor differences.
Disease duration is defined as the length of time since motor onset, and as such is 
subject to similar problems as staging, namely that it is predominantly an index 
of motor sign duration, and may not be the best measure of duration of other
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symptoms. It is also somewhat imprecise, relying as it does on confirmation by a 
clinician, since subjects may be seen in clinic for diagnosis some time after 
“true” onset of motor signs.
However, within the manifest HD population the use of stages based on TFC is a 
way to organise subjects into approximately similar groups, and duration is a 
rough index of the length of time of the disease. In the premanifest population 
stratification based on clinical scores is more difficult since subjects tend to score 
at ceiling on UHDRS motor and functional assessments, and within normal 
ranges on cognitive tests. There have been some attempts to quantify the relative 
stage of the disease process in premanifest subjects based on CAG repeat length 
and age (Penney, Jr. et al 1997) or repeat length, age and parental age at onset 
(e.g., Aylward et a l 1996). UHDRS diagnostic confidence levels for the 
presence or absence of motor signs have also been used (Paulsen et al 2006a; 
Stout et a l  2007). More recently a probabilistic survival model has been 
developed which can be used to estimate probability of motor onset within a 
given interval, based on current age and CAG repeat length (Langbehn et al
2004). The model is based on data from nearly 3000 subjects and has been 
widely adopted, meaning that in later work it has been possible to estimate 
proximity to motor onset in premanifest subjects with more confidence, and 
importantly that proximity to onset can be used to see if premanifest cohorts are 
comparable between studies. A comparison of CAG-based and diagnostic 
confidence level-based stratification of premanifest subjects showed that the two 
did not correlate, and that the former was generally more sensitive for detecting 
trends in more cognitive measures whilst the latter was better for motor measures 
(Stout et a l 2007).
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When considering differences between studies, whatever the domain being 
tested, the heterogeneity of the cohorts under investigation therefore needs to be 
taken into account. Conflicting findings may well be the result of subjects being 
at different stages of the disease, and negative findings may be because small 
groups are highly variable, rather than because mean group differences are 
negligible. This is particularly true of earlier studies of premanifest subjects, 
some of which were carried out before an unequivocal test for the presence of the 
abnormal gene was available, and many of which were not able to estimate their 
subjects’ estimated proximity to onset. One study of cognition included eight 
premanifest subjects with a mean age of 26 (Giordani et al. 1995). CAG repeat 
lengths were unknown but subjects would have had to have a CAG repeat length 
of at least 52 to be within five years of estimated onset, i.e. in the period in which 
deficits are more likely to be detectable. The lack of deficits cannot be taken to 
be representative of the whole population of premanifest HD gene carriers.
A final point when considering moving from research into clinical trials is the 
population that presents itself for research. Some of those who carry the HD 
gene and are seen in the multidisciplinary HD clinic at the National Hospital for 
Neurology and Neurosurgery in London do not wish to participate in research, 
and many who are at risk of carrying the gene opt not to have their status 
confirmed by testing, which precludes them from entry to a number of research 
studies. There is a possibility that only those with milder behavioural 
phenotypes, or less rapid rates of decline, enrol in and complete research studies 
which means that generalisation of results to the population as a whole is not 
guaranteed.
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1.4.4 Rate o f  decline in HD
As mentioned above, HD is highly clinically heterogeneous and therefore it is 
unlikely that the disease will progress at the same rate in everyone. Two issues 
that are relevant to the problem of tracking change are firstly whether rate of 
change varies depending on disease stage or duration, i.e. whether or not change 
is linear; and whether rate of change varies between individuals who are 
otherwise at similar stages, e.g. whether genetic factors such as CAG repeat 
length influence rate of change.
Rate of change on the UHDRS scales has been shown to be a non-linear function 
of baseline scores, with minimum change when subjects scored at the low or high 
ends of the scales and maximum change when they were somewhere in the 
middle (Marder et al. 2000; Mahant et al. 2003). However this could reflect 
floor and ceiling effects on the scales in question as well as non-linearity in the 
rate of change (Mahant et al. 2003). Data from the large PREDICT-HD study 
suggest that across modalities (including volumetric imaging measures) decline 
in premanifest subjects starts slowly up to two decades prior to motor onset, and 
is then faster (but relatively linear) in the last 5-10 years before diagnosis 
(Paulsen et al. 2007), although this has been inferred from cross-sectional data 
and needs to be confirmed longitudinally.
A number of studies have suggested that rate of decline (functional, cognitive or 
volumetric) is greater in those with earlier age at onset (de la Monte et al. 1988; 
Mahant et al. 2003). Given that age at onset is strongly associated with CAG 
repeat length this has led to suggestions that rate of decline is governed by the 
length of the abnormal trinucleotide repeat, and this has been demonstrated for
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functional, volumetric and dopamine receptor binding decline (Brandt et al 
1996; Aylward et a l 1997; Andrews et a l 1999) although has also been disputed 
(Squitieri et a l 2002) and is not always the case for cognitive decline (Snowden 
et a l 2001 ; Ward et a l 2006). In contrast, CAG repeat length is thought to have 
little effect on the extent or rate of progression of psychiatric symptoms, 
although this has been less widely studied (Berrios et a l 2001).
A recent large study has demonstrated that CAG repeat length has a small but 
measurable effect on rates of neurological, cognitive and functional decline, and 
that this effect interacts with disease duration, such that for a given duration rates 
are faster in those with longer CAG repeat lengths (and vice versa) (Rosenblatt et 
a l 2006). This means that change is likely to be non-linear, and different in 
people who otherwise appear similar (for example people of the same age or 
stage, but with different CAG repeat lengths).
1.4.5 Summary
Much work in HD is currently focused on finding a suitable biomarker of disease 
progression in order to test the efficacy of possible therapies. It is likely that 
more than one marker will be needed in order to give a comprehensive view of 
different aspects of HD. Cognitive testing and neuroimaging may provide useful 
measures of change although both domains have drawbacks which need to be 
addressed in order to maximise the reliability and reproducibility of any markers.
It is clear that many of the conflicting findings are not simply reflecting the 
heterogeneity of the disease. Technical or analytical differences between studies 
contribute to cause disparate results, as do the demographics and stratification of 
the HD subjects themselves.
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Overall, group differences (or their absence) do not always generalise which can 
make it hard to draw conclusions about the profile of impairment across the 
disease. Future work might benefit from the use of more stringent criteria for 
both analysis and subject selection in order to consolidate findings.
1.5 CONCLUSION
HD is a devastating neurodegenerative disorder for which there is currently no 
cure, and very limited symptomatic therapy. The discovery of the causative gene 
has meant that it is possible to identify those who will go on to develop the 
disease well before the onset of overt motor symptoms and it is now known that 
both brain atrophy, and subtle cognitive, motor and psychiatric symptoms are 
detectable some time before the criteria for clinical diagnosis are reached.
Whilst atrophy is most pronounced in the striatum, a number of studies have 
found atrophy in cortical grey matter, white matter, and other subcortical 
structures, although accounts differ as to the extent of atrophy which can be seen 
at different disease stages, and the pattern of change. The majority of 
longitudinal imaging studies have focused on the striatum with much less work 
done on rates of change in extra-striatal regions, despite the finding that atrophy 
in these regions can be widespread even early in the disease.
In the early stages of HD cognitive deficits are predominantly seen in
psychomotor and executive function tasks, although problems with memory and
emotion recognition have also been documented. There is particular debate as to
the specificity of the emotion recognition deficit in HD, and the underlying
neural substrates. Language and visuospatial skills remain relatively unaffected,
and problems in these areas can usually be attributed to the underlying executive
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function deficits. Recent work has shown that similar deficits can be detected 
prior to motor onset, although effects are usually small and premanifest subjects 
often perform within clinically-normal ranges. A number of studies have 
assessed the rate of cognitive decline over time, and there is some consensus that 
decline can be detected reliably in some psychomotor and executive skills in 
early HD. Findings in the other cognitive domains are varied, and very few 
studies have been able to detect cognitive decline in premanifest subjects despite 
the fact that cross-sectional studies consistently show that performance seems to 
be lower in subjects who are closer to estimated motor onset.
There is some debate in the literature as to the extent to which CAG repeat length 
influences rate of decline; both rate of brain volume loss and cognitive decline 
have been associated with CAG repeat length, but not consistently. It is also 
unclear whether change in either domain is linear, an issue which is compounded 
by the fact that change on some scales may appear to be non-linear when in fact 
this is merely a reflection on the insensitivity of those scales at the very early and 
late stages of the disease. There is some evidence that change across domains is 
relatively linear in the years immediately prior to motor onset, but also evidence 
that rate of change increases with increasing time since motor onset.
With much work focusing on potential therapies for HD it is important that the 
natural course of the disease is well-documented, and in particular that reliable 
measures of disease progression are identified in order to have something against 
which to test the efficacy of such therapies. The fact that many findings in HD 
are equivocal has led to some researchers to call for more careful stratification of 
subjects, and more validation of different neuroimaging techniques, in order to
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consolidate what is known about the disease (Nopoulos et al. 2007; Witjes-Ane 
et al. 2007).
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PROBLEMS THAT NEED TO BE ADDRESSED IN HD
Huntington’s disease is an autosomal dominant neurodegenerative disease, 
usually of adult onset, for which there is currently no cure. Since the discovery 
of the causative gene (Huntington's Disease Collaborative Research Group 1993) 
it has been possible to identify gene carriers prior to symptom onset and 
therefore to learn more about the disease in its very early stages. Since then 
much work has focused on identifying markers which could predict disease onset 
or monitor disease progression, in order to test the efficacy of potential therapies. 
Both neuroimaging and cognitive measures have been used to demonstrate the 
extent of brain atrophy and associated functional deficits in the disease, and to try 
and track change over time.
However, many findings in HD are equivocal, making it difficult to generalise 
results and to feel confident about the robustness of findings. This is partly due 
to the clinical heterogeneity of the disease and the fact that stratification of 
patients with HD into relatively homogeneous groups is difficult. Some 
discrepant findings can also be attributed to very different uses of imaging 
techniques, and to inadequate consideration being given to the influence of non- 
disease-speciflc factors on results. The natural course of the disease needs to be 
more carefully documented if reliable markers of disease progression are to be 
found.
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AIMS OF THIS THESIS
This work aims both to disambiguate some of the findings discussed above, and 
to investigate the pattern of change in HD with a view to suggesting more 
reliable measures of disease progression. It also aims to address a number of 
methodological issues highlighted previously, by using a large, well-defined 
cohort, optimising image analysis techniques, and taking care to control for non­
disease-specific confounds in analysis. Both neuroimaging and cognitive 
measures will be investigated in order to define the pattern of neurodegeneration 
and associated cognitive changes in HD better.
Specific aims are to;
1. assess the pattern of atrophy of the HD brain using both manual volumetry 
and voxel-based morphometric methods;
2. identify relative deficits across a broad range of cognitive domains, and 
investigate the association between cognitive and neuroimaging measures, 
with particular focus on emotion recognition and its neural correlates;
3. compare the ability of cognitive and neuroimaging measures to detect change 
over time in HD, and investigate whether CAG repeat length is associated 
with rate of change;
4. assess a semi-automated measure of whole-brain atrophy as a potential 
marker of disease progression in terms of whether it can detect disease- 
related change and whether this is predictive of clinical function.
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2 GENERAL METHODS
2.1 SUBJECTS
2.1.1 HD gene carriers
The majority of subjects described in this thesis were recruited from the multi­
disciplinary Huntington’s disease clinic based at the National Hospital for 
Neurology and Neurosurgery, Queen Square, London. Further subjects were 
recruited from the Huntington’s disease clinic run by Dr Roger Barker at 
Addenbrooke’s Hospital, Cambridge. Subjects were diagnosed as carrying the 
HD gene following a DNA test. Subjects were included with a CAG repeat 
length of 40 or higher (Rubinsztein et al. 1996). Only those subjects who had 
had a positive test for the HD gene were included in these studies; subjects with 
an affected parent who were at-risk of developing HD but who had not been 
tested were not recruited.
2.1.2 Healthy controls
Neurologically healthy subjects were recruited as controls. Most of the controls 
were spouses or partners of HD gene carriers who were in the study, or were 
non-gene carriers from an at-risk family (i.e. they had had a negative test for the 
HD gene). Some controls in the pilot study (see chapter 3) were healthy 
volunteers from the National Hospital or University College London. Controls in 
the main longitudinal study (chapters 4 -1 1 )  were offered £50 over the course of 
the two study visits, although most declined this and requested that the money be 
put towards research costs.
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2.1.3 Exclusion criteria
Exclusion criteria for all subjects were contraindication to scanning (such as 
metal implants or claustrophobia), history of substance abuse, or significant 
medical, neurological or psychiatric comorbidity, i.e. conditions that were non- 
HD related. Detailed records were made of medications and supplements. No 
subjects were taking any medication known or suspected to influence brain 
volume.
2.1.4 Ethical issues
All subjects were offered reimbursement for all travel and meal costs for 
themselves and a companion. All subjects gave written informed consent for 
involvement in all the studies, which had Local Ethics Research Committee 
approval. Patients were followed up clinically at either the London or the 
Cambridge clinic. Research assessments had the potential to increase anxiety 
about the implications of HD for the patients, and so patients were made aware 
that if they were concerned about any aspect of the study or their performance in 
it they could be referred to the appropriate clinical specialist for further 
assessment, advice and support.
2.2 CLINICAL ASSESSMENT
All subjects were assessed by a neurologist who took a full medical and family 
history. Subjects were also assessed using the clinical part of the Unified 
Huntington’s Disease Rating Scale (UHDRS) (Huntington Study Group 1996) 
which comprises:
1. Standardised ratings of the typical motor features seen in HD, leading to a 
motor score ranging from zero (normal) to 124.
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2. Functional assessments: a series of yes / no questions about the subject’s 
ability to perform everyday functions, and a Total Functional Capacity (TFC) 
(Shoulson 1981) score based on the subject’s capacity to work, manage 
finances, do domestic chores, activities of daily living, and care requirements, 
which yields a score ranging from 13 (normal) to 0. It is from this score that 
clinical stage is derived (Shoulson and Fahn 1979), 11-13 being stage 1,7-10 
stage 2, 3-6 stage 3,1-2 stage 4 and 0 stage 5.
3. An independence scale against which the subject’s current level of 
independence is judged, ranging from 100 (“No special care needed”) to 10 
(“Tube fed, total bed care”).
4. Standardised ratings of the severity and frequency of behavioural symptoms.
Patients (but not controls) in the pilot study (chapter 3) were assessed using the 
full UHDRS rating scale. All subjects in the other studies were assessed using 
the first three components of the scale mentioned above, and a novel behavioural 
assessment scale, the Short Behavioural Assessment (SBA), a short version of 
the Problem Behaviours Assessment for HD (PBA-HD) (Craufurd et al. 2001). 
Subjects in the latter studies also filled out a Beck Depression Inventory (BDI- 
lA) (Beck and Steer 1993). The UHDRS also includes a set of cognitive tests, 
which for all subjects in this thesis were administered as part of the 
neuropsychological battery (described in the relevant chapters).
2.3 DNA TESTING
All premanifest or early HD subjects had undergone a DNA test prior to 
inclusion in the study (see section 2.1). Subjects carrying the HD gene in studies 
other than the pilot study (chapter 3) consented to a further DNA test and all
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CAG repeat lengths for these patients were subsequently resized in the same 
laboratory.
2.4 COGNITIVE ASSESSMENT
All subjects underwent neuropsychological assessment, with batteries designed 
to be comprehensive but brief enough to administer in a single session. All 
assessments were done by me. Wherever possible subjects were tested in a 
single session, during which they were offered refreshment and breaks as needed. 
Details of each battery are given in the relevant chapters, and descriptions of the 
standard neuropsychological tests are in Appendix 3.
2.5 IMAGING
2.5.1 Imaging as a measure
MRI has become the imaging modality of choice for the brain with its multiple 
different parameters that can be altered to achieve different contrasts between 
tissue types, and true three-dimensional volumes have become standard. 
However, because these images are a visual reconstruction of the radio signal 
emitted by different tissue types in the MR scanner it is important to realise that 
there is not a one-to-one correspondence between the brain and the MR image; 
this depends on the tissue qualities and scan parameters (Figure 2-1).
The intensities o f the voxels that make up the image vary depending on the tissue
type which they represent and make it possible to visualise brain structure in
vivo. Software can be used to outline structures of interest in the image, either
manually (based on visual judgement of the border between two tissue types) or
semi-automatically (e.g. by setting an intensity threshold such that voxels below
a certain cut-off are excluded, leaving only those voxels which represent the
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tissue type of interest) (see section 2.5.3.1). Since each voxel represents the 
signal from a particular 3D region in the brain it is possible to sum the voxels 
contained within a structure outlined in this manner and hence calculate its 
volume.
Figure 2-1 A) shows a post-mortem brain in coronal section, and B) a 
similar slice from a brain imaged in vivo using T1-weighted MRI
Note that there are regions in the MR image where the grey /  white contrast and 
tissue boundaries are not very well-defined compared with the post-mortem 
section
Differences in intensities between corresponding voxels on one or more scans 
can also be used to estimate inter-subject differences, or intra-subject change 
over time. For example, the technique of voxel-based morphometry (see sections
2.5.3.2 and 2.5.5) uses differences in the normalised intensities at each voxel in a 
set of images to measure group differences in volume at that voxel. 
Alternatively, if two scans from the same subject, taken some time apart, are 
aligned and displayed in the same space, differences in intensity between 
corresponding voxels can be used to estimate volume loss, or change over time.
All these measures are based on the intensity at each voxel, which as well as
representing signal from brain tissue, will contain some noise caused by factors
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such as variation in the scanner (e.g., in the magnetic field strength), movement 
of the subject, the positioning of the subject in the scanner, or the particular 
software used to reconstruct the signal. Some of these sources of error can be 
measured and adjusted for (see section 2.5.4.1). In addition, there are limits to 
the resolution of the images, both in the sense that the signal is acquired from a 
finite region in the brain, so the image cannot represent differences within that 
region (pixel or voxel), and because some tissue types may emit similar signals 
and hence not be distinguishable on certain types of image. It is important to 
consider that any measure derived from MRI will only be as accurate as these 
limitations allow.
The following sections describe in more detail image acquisition, the two 
software packages used for estimating volumes and group differences, and the 
image processing involved.
2.5.2 Acquisition
All images were acquired on a 1.5T Signa MRI scanner (General Electric, 
Milwaukee, Wisconsin, USA) using a spoiled gradient echo technique. Scans 
generally included a sagittal T1-weighted localising sequence, and a T1-weighted 
volumetric image. At the first visit scans usually also included an axial dual­
echo sequence (T2-weighted and proton-density weighted). The dual echo 
sequence was checked by an experienced radiologist for non-HD pathology and 
not used further in any analysis. Exact imaging parameters for each study are 
given in Appendix 1.
Volumetric images were reconstructed as 124 contiguous 1.5mm coronal slices 
and images were digitised for analysis.
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2.5.3 Software
2.5.3.1 MIDAS
The Medical Information Display and Analysis System (MIDAS) software was 
used for the volumetry described in this thesis. MIDAS was developed by 
Freeborough et al. (Freeborough et al. 1997) and runs on both Unix and Linux 
platforms and is implemented in the C programming language. The software 
allows 3D data to be displayed simultaneously in two or three orthogonal views 
(see Figure 2-2).
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Figure 2-2 Screenshot of MIDAS software showing a whole brain being 
outlined in coronal and sagittal views
Brain structures can be outlined using both semi-automated and manual 
techniques. Manual techniques rely on the operator delineating borders with a 
mouse-driven cursor, based on visual judgement of intensities. Semi-automated
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techniques usually involve a threshold being set by the operator which then 
excludes all voxels above or below a certain intensity. Segmenting brain from 
non-brain in MIDAS is semi-automated and uses interactive thresholding to 
generate an initial region. This region can then be eroded and dilated a number 
of times, to separate brain tissue from non-brain (see Appendix 2). Segmentation 
of sub-structures such as the caudate nucleus is also semi-automated; thresholds 
which separate the structure of interest from surrounding tissue are used to 
delineate borders automatically, after manual placement of a seed within the 
structure. The borders can then be edited manually in one view using the mouse- 
driven cursor, and simultaneously seen in one or two orthogonal views.
2.5.3.2 Statistical Parametric Mapping (SPM)
SPM is an image analysis package developed by Friston et al. at the Functional 
Imaging Laboratory, Institute of Neurology, London (Friston et al. 1995). The 
work in this thesis used SPM2 running on a Matlab platform (MathWorks, 
Natick, Mass., USA).
When SPM is used to analyse structural (rather than functional) images this 
technique is known as voxel-based morphometry (VBM) (Ashbumer and Friston 
2000). VBM uses the SPM package to perform a series of preprocessing steps, 
including segmenting images into grey matter (GM), white matter (WM) and 
cerebrospinal fluid (CSF), and spatially aligning these segments into standard 
sterotaxic space (see section 2.5.5.1). After the segments are aligned a statistical 
test is performed at each voxel. In general intensity at each voxel (which 
represents either volume or tissue density) is regressed on a number of 
explanatory (or nuisance) variables to look for differences between groups or
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associations between variables. Whether the voxel represents volume or tissue 
density depends on the preprocessing and is discussed in more detail in section 
7.4.3. The resulting map of the brain highlights all those voxels for which the 
differences or associations are statistically significant.
2.5.4 Image Processing
2.5.4.1 Intensity inhomogeneity correction
Ideally, scans will have good contrast between tissue types (grey matter, white 
matter, and CSF), and uniformity within a tissue type. This makes structural 
boundaries clear and aids both manual and semi-automated (interactive 
thresholding) segmentation, and registration methods which use intensity-based 
matching algorithms. However scans can be subject to intensity inhomogeneity, 
or bias, (for example, the mean intensity varies smoothly fi*om one side of the 
image to the other), for a number of reasons, including inhomogeneity of the 
magnetic field in the scanner, inhomogeneity of the radioffequency pulse or 
nonuniformity in the sensitivity of the receiver coils used to detect the MR signal 
(see, for example, Vovk et al. 2007). Prior to any analysis images in this study 
had such intensity inhomogeneities corrected using the N3 algorithm (Sled et al. 
1998).
However if such fields are not entirely removed this can also cause problems 
when scans are registered into the same space for comparison (see section 
2.5.4.2). If  any residual bias field on the two images is different this will 
introduce an artificial difference in the intensity value of corresponding points on 
those images, which could affect intensity-based atrophy calculations (Lewis and 
Fox 2004). In the work presented in this thesis the differential bias field between
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registered scan pairs was estimated and adjusted for; this does not remove bias 
per se but removes differences in the bias fields so that the residual 
inhomogeneity in each scan is similar, thus reducing differences in intensity 
which were a product of the different bias fields (Lewis and Fox 2004).
2.5.4.2 Linear registration
Serial MRI is useful to detect brain volume change over time. Change in volume 
between two timepoints can be derived by subtracting the volume of the region 
of interest on a repeat scan from that on a baseline scan. However the resulting 
difference score is susceptible to error, in particular from segmentor 
inconsistencies or fi-om scanner drift (changes in scanner calibration over time 
which could mean for example that voxel size changes slightly over time).
Registration of serial MRI scans allows more precise quantification of volume 
changes, and also allows regions of change to be visualised. In simple terms, the 
repeat image is spatially aligned to the baseline, and the alignment process can 
correct for problems such as change in voxel size (Freeborough et a l 1996; 
Whitwell et a l 2004) and allow a direct visual comparison of the scan pair fi-om 
which the difference in volumes is measured. More specifically, the registration 
algorithm aims to align a follow-up image (FU) to match a baseline image (B). 
This is an optimisation process, in which a set of parameters that will transform 
FU to B are calculated that will maximise a similarity measure, or cost function. 
After finding the best set of parameters this transformation is applied to FU 
which is resampled to have the same image space as B. As voxels in FU are 
unlikely to map exactly onto voxels in B an interpolation model is used to work 
out the correct voxel value; the voxel value in the transformed image is some
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function of the values of neighbouring voxels in the original FU image. In 
practice, interpolation is also needed during estimation of the transformation 
parameters in order to calculate the cost function.
In linear registration the transformation parameters are applied equally to every 
voxel in the image. Once the two images are aligned a point in one image should 
correspond to the same point in the other. In practice, where volume has been 
lost over time the two images will not correspond exactly and the amount by 
which they differ, which will often be seen around borders, can be used to 
estimate the amount of volume lost (see Figure 2-3).
Figure 2-3 Left panel shows a difference image derived from two non­
registered scans taken a year apart; right panel shows a difference image 
from the same scans after 12dof registration
The left différence image highlights the misalignment o f the scans, whilst the 
right highlights regions that remain different after realignment, most obviously 
around the ventricles. Note that the skull, neck and ears are less well-matched, 
because the registration algorithm is applied to the brain region only.
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The work in this thesis used Automated Image Registration (AIR, v 5.2.5) 
(Woods et al. 1998). Registrations were affine (12 degrees of freedom, 12dof) 
which meant that the transformations were trainslations, rotations, scalings or 
shears along each of the three orthogonal axes of the image. The cost function to 
be minimised was the standard deviation of the ratio of the intensities of the two 
images (calculated at each voxel). This is a measure of the uniformity of the 
ratio image; the more uniform the ratio image, the more likely the two images are 
to be well-aligned. Follow-up images were resampled using chirp-z interpolation 
(Rabiner et al. 1969). Affine registration is also implemented through MIDAS 
(section 2.5.3.1).
2.5.4.3 The Boundary Shift Integral
Registration corrects for changes in voxel size due to adjustment or drift in 
scanner calibration over time (scanner drift) and therefore measuring the 
difference between the volumes of two registered images would improve upon a 
difference measure based on unregistered images. However this method still 
relies on the accuracy of the two segmentations. Once two images have been 
registered it is possible to estimate volume change by measuring directly the 
difference between the boundaries of the two aligned structures of interest, rather 
than measuring the volume of each separately. This makes the measurement less 
susceptible to segmentor error than simply subtracting the segmented volume of 
the follow-up image from that of the baseline image.
The boundary shift integral (BSI) uses the shift in intensity differences on a pair 
of registered intensity-normalised images (i.e., where the edges of the structures 
have moved from baseline to repeat scan) to quantify the difference between the
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two (Freeborough and Fox 1997). Firstly a 3D region within which this 
difference is to be measured is defined. The regions of the structure of interest 
(for example, the whole brain) are outlined on both scans using MIDAS (see 
section 2.5.3).
Baseline Repeat
Repeat registered to baseline 
with boundary shift highlighted
Figure 2-4 Schematic showing repeat brain registered to baseline and the 
resulting shift in boundary
The shift in boundary between the two images is highlighted in grey. The 
boundary shift integral is calculated in a region encompassing this shift: the 
intersection o f the two brain regions is eroded by one voxel to give an inner 
boundary (inner dotted line), and the union o f the two regions is dilated by one 
voxel to give an outer boundary (outer dotted line). Together these define a 
region which encompasses all the borders on the tw’o images.
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These regions are used to define the region in which the boundary shift integral is 
calculated (see Figure 2-4). Figure 2-5 shows a plot of the changes in intensity 
that might be expected as one moves across the CSF/GM border of a brain 
image.
Boundary shifted by Aw:
*reg(x) = ibase(x + Aw)
CSF Brain
Displacement along line through brain boundary, x
Figure 2-5 Graph showing a one-dimensional representation of the shift in 
intensity associated with the borders of a baseline and registered repeat scan
The dotted line ( i b a s e )  represents the intensity profile (boundary or edge) for the 
baseline scan; the solid line (ireg) represents the same edge on the repeat scan; 
that edge has shifted by Aw due to atrophy.
We wish to know Aw, the distance through which the boundary has shifted along 
X. A simple measure would be to quantify the shift at a single value of I (where I 
is an intermediate intensity, between that inside the brain, and that outside). 
However Aw would then be dependent on the value of I that was chosen, so a 
more robust estimate is to estimate Aw over a range of values of I, and then 
average them (where the range of values of I falls between the intensity in the
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bulk of the structure, and the intensity on the other side of the boundary). This is 
the integral, with respect to I, of the area between the curves within the range of I 
chosen (equation 2.1).
Aw =  ^ f  ’ (0  -  {i))di (2.1)
7 ,  - 7 ;  • ' I
In practice however we do not measure the spatial distance between two points 
of equal intensity, but the difference in intensity between two spatially aligned 
points: this is represented as the integral with respect to x.
This integral can be extended to three-dimensions to measure change in volume. 
Av. The integral is estimated by sampling the image at small intervals (every 
voxel) and multiplying the result by voxel volume. The integral is only 
evaluated within the set of voxels already defined (see above, and Figure 2-4) as 
encompassing the boundary regions of both images.
The range of the integral is the intensity window, which is defined in terms of its 
centre T = Ii/2 + I2/2 , and width Iw = Ii -  I2. Ideally this window should fall 
within all the intensity transitions that are associated with the boundaries of the 
structure of interest. However in order to improve the signal to noise ratio the 
window should be made as wide as possible. In practice the optimal window can 
be determined as that which maximises the agreement between the volume 
difference as measured by the BSI, and the volume difference as measured by 
segmenting the two images. Ideally this optimisation process should be run on 
simulated data (where the real change in volume is known). Where this is not 
possible the optimal parameters can be determined from a subset of data and then 
applied to the remaining images.
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Atrophy rates measured using the BBSI show relatively good agreement with 
rates calculated by volume subtraction, although atrophy may be consistently 
underestimated very slightly because of scan variability (e.g., in a noisy scan the 
boundary region might fall slightly outside the chosen intensity window). 
However, within-group variance (which may be attributable to scanner or 
segmentor error) is reduced and separation between groups increased 
(Freeborough and Fox 1997). This technique has been well validated in 
Al2dieimer’s disease (AD) and normal ageing and shown to have a high level of 
precision for measuring cerebral changes including rate of whole-brain atrophy 
(Fox and Freeborough 1997; Scahill et al. 2003).
2.5.5 Voxel-based morphometry
The images were processed using MATLAB 7.0 (The MathWorks, Inc, Natick, 
Massachusetts, USA) and SPM2 (Wellcome Department of Cognitive 
Neurology, ION, London). VBM was performed following a modified version 
of the optimised method (Good et al. 2001b). The background to this method 
and its suitability for the cohort used here is the subject of section 6.1.1.
2.5.5.1 Image preprocessing
The preprocessing steps are represented in Figure 2-6. The initial processing 
used a modified version of the script provided by Christian Gaser (available at 
http : //dbm. neuro. uni - i ena. de/vbm/). The native space images were affine- 
registered using the standard SPM2 T1 template to put them into standard space 
(initial normalisation), and underwent initial segmentation.
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1. Affine registration to 
SPM2 T1 template
Native space Images
Standard space images
2. Segmentation 
using SPM2 GM prior I
3. Estimation of normalisation 
parameters for GM segments 
to SPM2 GM template
GM segments
I
Standard space images
I
Normalisation parameters 
GM to GM
GM segments
4. Normalisation using parameters 
from step 3; GM is well-aligned
5. Segmentation 
using SPM2 GM prior
6. Modulation: correcting for 
spatial changes introduced 
in normalisation
CMasked GM J  “
7. Masking: segments are 
multiplied by binary region 
exclude any non-brain
4 8. Smoothed at 8mm FWHM
Smoothed, masked, mod GM J
Figure 2-6 VBM preprocessing
The native space images are affine-registered and segmented, and the grey matter segments are used to estimate normalisation parameters to 
the grey matter template (left side). These normalisation parameters are then used to normalise the native space images again, and these are 
segmented, modulated, masked and smoothed prior to statistical analysis.
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New normalisation parameters were estimated for warping the resulting grey 
matter segments onto the SPM2 grey matter template. These normalisation 
parameters were then used to warp the original native space images.
SPM2 uses a combination of prior probability maps and intensity histograms to 
segment these images automatically into GM, WM and CSF, after which voxel 
values range from 0-1 and represent the probability of each voxel being the 
particular tissue type. Because the normalisation process could correct for some 
volume differences which were actually due to atrophy, the segmentations were 
modulated. Modulation entails multiplying the value of each voxel by the 
Jacobian value from the normalisation process. The Jacobian is an index of by 
how much the voxel was expanded or contracted during normalisation so after 
the modulation process voxel intensity represents volume.
The WM and CSF segments were not used in any further analysis as this work 
was primarily focused on grey matter changes. Preliminary work (discussed in 
detail in section 6.1.1) showed that normalising grey matter to a grey matter 
template resulted in better alignment of the grey matter segments compared with 
standard normalisation. This was achieved with the standard SPM templates; 
using customised (study-specific) templates for normalisation and segmentation 
did not produce any additional improvement. Each grey matter segment then had 
spurious non-brain tissue removed according to a brain mask derived from the 
corresponding original image using MIDAS (Freeborough et al. 1997). Finally 
the images were smoothed using an 8mm full width half-maximum (FWHM) 
Gaussian kernel.
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2.5.5.2 Presentation o f statistical parametric maps
After models were fitted and parameters estimated (described in the relevant 
chapters) an explicit mask was applied to the maps to exclude any voxels for 
which more than 10% of the images had a value of less than 0.1. This "majority 
masking" was preferred to the default “absolute” mask option in SPM, which 
would exclude any voxels for which one or more images had a value of less than
0.1 and thus perhaps be unduly influenced by a single poorly-registered or highly 
atrophied scan. All maps were displayed as overlays on a smoothed version of 
the Montreal Neurological Institute (MNI) 152 T1 template. MNI coordinates 
were converted to Talairach coordinates using the mniltal MATLAB function 
provided by Matthew Brett (http://imaginu.mrc-
cbu.cam.ac.uk/imaging/MniTalairach) and regions of atrophy were localised 
using the Talairach daemon developed by Lancaster et al. 
(http://ric.uthscsa.edu/new/resources/talairachdaemon/talairachdaemon.html).
A statistical parametric map consists of many comparisons (one at each voxel)
and so some form of correction is usually applied (the threshold for what is held
to be statistically significant is adjusted to decrease the chance of false positive
results). However, points in the image are spatially correlated to some degree,
both because of the inherent properties of the image, and because of the
smoothing applied during preprocessing, so a simple adjustment for independent
comparisons (e.g. Bonferroni) is not appropriate. The degree of correlation can
be estimated by estimating the smoothness of the image, using the residuals from
the fitted model, and the smoothness in each direction is multiplied to give the
size of a “resolution element” or resel. The number of resels is an estimate of the
number of truly independent samples in the image and once it is known it can be
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used to calculate a threshold for the t map, at a given alpha (Worsley et al. 1992). 
With family-wise error (FWE) correction (see chapter 6) the threshold depends 
on the smoothness of the image, and the number of resels, as well as the 
underlying effects, and hence smoothness and resel counts are reported for each 
analysis in this thesis.
2.6 STATISTICAL ANALYSIS
Statistical analysis of volumetric, cognitive and clinical data was done using 
STATA version 9.2 (Stata Corporation, College Station, Texas, 2006). 
Statistical analysis of structural brain images on a voxel-wise basis was 
performed using SPM2 (see section 2.5.3.2).
In general significance levels were not adjusted to take into account the number 
of comparisons because all the associations being investigated were thought to be 
of independent scientific interest (Rothman 1990). One of the primary aims of 
the thesis was to compare a broad number of tests as measures of change over 
time and false acceptance of the null hypothesis might mean that many 
potentially sensitive markers were discarded.
Significance levels were however adjusted for the VBM analyses, as in this case 
many thousands of comparisons were being made simultaneously and they were 
not of independent scientific interest.
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3 USE OF SERIAL MRI AND COGNITIVE TESTING TO TRACK 
CHANGE IN HUNTINGTON’S DISEASE: A PILOT STUDY
3.1 INTRODUCTION
As discussed in chapter 1, HD is clinically heterogeneous and tracking change 
(disease progression) over time reliably has proved challenging using clinical, 
cognitive or imaging measures. This chapter describes a small study which was 
run in order to pilot the BBSI (see section 2.5.4.3), which had not been used in 
HD before, as well as to gather cognitive and clinical data on the same cohort.
There is increasing evidence that atrophy in HD occurs throughout the brain, 
even in the early stages (see section 1.2.2). Whole-brain atrophy, although it 
does not provide information about the exact location of loss, can be measured 
using semi-automated methods which are quick and tend to be less susceptible to 
segmentor error than manual outlining (Freeborough and Fox 1997). The brain 
boundary shift integral (BBSI), which estimates whole-brain volume loss from 
the intensity differences around the borders of a registered pair of scans, is one 
such method which has already been used in clinical trials in Alzheimer’s disease 
(Fox et al. 2005).
In the early stages of HD, whole-brain atrophy may well be relatively small and
within normal ageing ranges if atrophy is essentially confined to the striatum,
which loses about 0.5ml per year (i.e. less than 0.1% of total brain volume per
year) (Ay 1 ward et al. 2000). One of the aims of the pilot study was therefore to
determine whether there was enough signal (i.e. diffuse losses), over relatively
short time periods, for increased whole-brain atrophy rates to be detected with
this technique. Although at autopsy atrophy is marked throughout cortical
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regions it is unclear when atrophy spreads beyond the striatum (Halliday et al. 
1998). In addition, one of the signs of HD is chorea, and movement during an 
MRI scan can affect its quality and hence the accuracy of any measure derived 
from it. Therefore this study also set out to investigate whether subjects could 
tolerate repeat MRI scans well enough to obtain good quality serial imaging so 
that change over time could be measured accurately.
Cognitive findings in HD have also been mixed, and there is a lack of consensus 
over which skills show reliable, measurable decline in the early stages (Bachoud- 
Lévi et al. 2001; Snowden et al. 2001; Ho et al. 2003). Longitudinal cognitive 
testing is also hampered by the existence of practice effects, as well as 
environmental factors which are hard to control at different timepoints, such as 
subject mood and fatigue, and testing conditions. Therefore a second aim was to 
pilot a fairly comprehensive battery of tasks, covering areas which are known to 
be affected in HD as well £is those which are thought to be relatively spared, in 
order to see which tasks were most useful for measuring decline, given the 
problems mentioned above; these findings would then be used to refine the 
battery for future studies.
Few studies in HD have measured change over intervals shorter than one year, or 
combined structural imaging measures with a comprehensive battery of 
psychological tests. Some that do have used CT measures or reduced large 
cognitive batteries to a number of factors so that conclusions about structure- 
function relationship remain limited (e.g., Starkstein et al. 1992; Bamford et al. 
1995). Therefore the pilot data were also used to assess the relationship between 
whole-brain atrophy, and cognitive and clinical decline. Initially the study aimed
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to assess subjects twice, a year apart, but an unforeseen scanner software upgrade 
was then planned during month nine of the study. Since such an upgrade could 
affect scan quality and hence the BBSI measure, the second assessment was 
brought forward to six months, with a further cognitive and clinical follow-up at 
twelve months, so that both baseline and six-month scans were obtained before 
the software change.
In summary, this chapter describes a pilot study, set up to examine the 
tolerability of serial MRI and usefulness of the BBSI as a measure in HD, and to 
investigate how cognitive measures changed in the same cohort, with a view to 
introducing the best measures into a larger follow-up cohort, if successful.
3.2 METHODS
3.2.1 Subjects
Fifteen subjects with genetically-confirmed HD were studied (all early disease at 
baseline with 10 subjects at stage I, and five at stage 2 (Shoulson and Fahn 
1979)). Nine controls were group-matched for age, sex and premorbid IQ. As 
subjects with early HD displayed motor symptoms it was not possible for clinical 
or neuropsychological examinations to be performed blinded to gene status; 
however scan segmentation was done blind to gene status.
3.2.2 Assessments
3.2.2.1 Clinical assessment
Subjects were clinically assessed at baseline and 12 months by the same two 
senior neurologists whose intra- and inter-rater reliability coefficients were >0.9,
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using the UHDRS clinical rating scale which comprised motor, psychiatric and 
functional assessments (Huntington Study Group 1996) (see section 2.2).
3.2.2.2 MRI acquisition
Subjects had T1-weighted volumetric inversion recovery prepared, spoiled 
gradient recall scans on the same 1.5T GE scanner at baseline and six months 
(for parameters see Appendix 1). Whole brains were segmented as described in 
Appendix 2, with the segmentor blinded to group membership. Six-month scans 
were positionally matched to their baseline image using an affine registration 
with 12 degrees of freedom, and change in brain volume was quantified from 
registered pairs using the BBSI (Freeborough and Fox 1997) (see sections 2.5.4.2 
and 2.5.4.3).
Registered scan pairs were checked by an experienced imager with no 
knowledge of disease status, and any pairs which were inadequate due to motion 
or other artefact were discarded from the analysis. Only those subjects who had 
adequate MRI follow-up, 13 subjects and seven controls, were included in the 
longitudinal analysis. Demographic details of these subjects are given in Table 
3-1.
3.2.2.3 Cognitive assessment
All subjects underwent neuropsychological assessment at baseline, six months 
and 12 months. The battery was designed to be comprehensive but brief enough 
to complete in a single session (typical duration was under two hours). Whilst it 
focussed on areas known to be impaired in HD, e.g. executive function, 
psychomotor and memory tasks, it also covered naming and visuoperceptual 
skills, which were predicted to be less affected.
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The battery comprised the following tests, further details of which are in 
Appendix 3:
Estimated Pre-morbid JQ: National Adult Reading Test (NART). As 
performance on other cognitive tasks can be IQ-dependent it was important to 
obtain an estimate of pre-morbid IQ so that this could be controlled for in the 
analysis.
Executive function /  psychomotor tasks: three tasks were included as part of the 
standard UHDRS assessment. They were the Stroop word-reading and colour- 
word interference (old version) (Stroop 1935); phonemic (letter) fluency (Benton 
and Hamsher 1978); and the Symbol Digit Modalities Test (SDMT) (Smith 
1968). These tests have a motor component but are also thought to test more 
“executive” skills; word generation is thought to depend to some extent on 
frontal lobe integrity, as is the interference task of the Stroop in which subjects 
must ignore the automatic reading response in order to name the ink colour.
The trail-making subtest of the D-KEFS (Delis et al. 2001) which has separate 
sections for number cancellation, number sequencing, letter sequencing, 
alternating sequencing, and motor speed, was included. This task allows one to 
measure scanning time, motor speed, and basic sequencing, before the more 
complex number-letter sequencing test.
A simple reaction time task was designed and presented on SuperLab Pro 2.0 
(Cedrus Corporation, San Pedro, CA). This required subjects to use the index 
finger of their dominant hand to press one of four numbered buttons on a 
response pad. The numbers 1-4 were centrally presented on the screen in a
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pseudo-random order in 20 blocks of 4, with a pause after the 10th block. 
Subjects were requested to press the buttons as quickly as possible and mean 
reaction time was measured.
Memory: immediate memory was assessed using digit span forward and 
backward with three trials at each length (Wechsler 1981). Three trials were 
used rather than the standard two because this tends to give a more robust 
measure of the subject’s span. The Recognition Memory Test (RMT) 
(Warrington 1984) was also included, assessing face and word memory.
Naming: naming was measured using the Graded Naming Test (ONT) (McKenna 
and Warrington 1983). This was presented on a computer using SuperLab Pro
2.0 (Cedrus Corporation, San Pedro, California, USA). Stimulus presentation 
was controlled by the investigator and response latency was recorded by 
experimenter button press.
Visuoperceptual: basic visuoperceptual skills were assessed with the silhouette 
subtest of the Visual Object and Space Perception Battery (VOSP) (Warrington 
and James 1991).
Neuropsychological tasks were administered at each visit by me, in a single 
session lasting about VA hours. The order of tasks was kept constant. 
Alternative versions of the digit span and RMT were used at the six-month 
assessment in order to try and minimise practice effects.
5.2.3 Statistical Analysis
Group differences in age and estimated premorbid IQ at baseline, and scan
interval, were investigated using t-tests assuming unequal variance. Fisher’s
97
exact test was used to see if the proportion of right-handed subjects, or males, 
differed between groups, t-tests (assuming unequal variance where necessary) 
were also used to investigate whether the stage 1 and stage 2 HD subjects 
differed in terms of age or CAG repeat length.
In all the following analyses the effects of variables which can independently 
affect brain volume (age) and cognitive performance (age and estimated 
premorbid IQ) were controlled for by including them as covariates where 
necessary. The NART, which was used to estimate IQ, may be affected by 
disease (Solomon et al. 2007). If this is the case then including it as a covariate 
will tend to reduce the significance of group effects; however failing to include it 
would mean that group effects might be attributable to (non-disease-related) 
differences in IQ alone.
3.2.3.1 Clinical measures
Linear regression models were used to investigate the relationship between CAG 
repeat length and baseline UHDRS scores. Paired t-tests (two-tailed) were used 
to look for change in UHDRS scores over 12 months. Linear regression models 
were used to investigate the relationship between CAG repeat length and change 
in UHDRS scores.
3.2.3.2 Brain volume
To correct for differences in head size baseline brain volumes were standardised 
for total intracranial volume (TIV) which was measured according to the 
protocol described in Appendix 2. In controls log-transformed brain volumes 
were regressed on log-transformed TIVs to derive the slope of the relationship
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between TIV and brain volume. This coefficient, p, was then used to adjust all 
baseline brain volumes for TIV using equation 3.1.
V = V■V tan dardised raw
meanTIV V
subject -  specifîcTIV
Where brain volume is mentioned in the results it always refers to volume 
standardised to mean control TIV.
Linear regression models, with robust standard errors to allow variance to differ 
between groups, were used to compare whole-brain volume (standardised for 
TIV) between groups at baseline, controlling for age by including it as a 
covariate. Linear regression models were also used to see whether there was a 
significant relationship between brain volume and CAG repeat length, and 
baseline UHDRS motor, independence and total functional capacity scores (again 
adjusting for age).
In addition, scan pairs were registered and the BBSI was derived for each pair. 
Atrophy rates were analysed on a logarithmic scale according to equation 3.2 in 
order to ensure that doublings and halvings be treated as effects of equal 
magnitude; follow-up volume was calculated by subtracting the BBSI from 
baseline volume.
(inffyoZ/ow-i/p /^b a se lin e  ))
time
(3.2)
Regression models relating the log-transformed variables to subject group and 
age were used to obtain individual age-standardized atrophy rates. Geometric
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mean atrophy rates (% per year) were calculated by back transformation with 
standard deviations (SDs) calculated from variance transformation formulae.
A linear regression model with robust standard errors was used to compare rates 
of whole-brain atrophy between groups. Although the effect of age on atrophy 
rates is thought to be relatively small in this age range (Scahill et al. 2003), age 
was included as a covariate in this model in order to ensure that any group 
differences seen could not be attributed to this. Atrophy rate was then regressed 
on CAG repeat length and change in UHDRS motor score, independence score 
and total functional capacity (again adjusting for age).
3.2.3.2.1 Comparison o f the BBSI and manual measures 
In addition to being estimated from the BBSI volume loss was also estimated 
from the raw volumes, and volumes standardised to mean control TIV. Also, 
because the control sample from which the relationship between TIV and volume 
was estimated was small and thus possibly not representative, volume loss was 
also estimated from volumes as a proportion of TIV. For each of these measures 
t-tests assuming unequal variance were used to assess the differences in the 
volume loss between groups.
The mean and standard deviation of loss estimated from the BBSI were 
compared with those estimated from raw volumes, and volumes standardised to 
mean TIV, using paired t-tests (means) and Pitman's tests (standard deviations). 
This was not done for the BBSI and volume as a proportion of TIV as these 
measurements have different units. Paired t-tests were also used to investigate 
whether TIV differed between timepoints.
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3.2.3.3 Cognition
Linear regression models with robust standard errors were used to compare 
cognitive measures between groups at baseline, controlling for age and estimated 
premorbid IQ. For naming latency measures, the natural log of time to correct 
response was related to group using a linear mixed model with group, question, 
age and IQ as fixed effects and subject as a random effect. Provided that data are 
“missing at random” (Rubin 1976; Feudjo-Tepie et a l 2006) such an approach is 
unbiased even if questions that take longer on average are also more likely not to 
be answered. Linear regression models were also used to investigate the 
relationship between baseline cognitive performance and CAG repeat length, 
adjusting for age and estimated premorbid IQ.
For cognitive variables a change score was generated from baseline and follow- 
up scores, such that a negative score indicated decline over time. Linear 
regression models with robust standard errors were used to compare change 
scores between groups, controlling for baseline age and estimated premorbid IQ.
Associations between change in cognitive variables and CAG repeat length were 
assessed using linear regression models, adjusting for age and estimated 
premorbid IQ. Within the HD group associations between change in cognitive 
variables and atrophy rate were also assessed using linear regression models.
3.3 RESULTS
Early HD subjects and controls were well-matched for demographic variables at
baseline, including scan interval. There were small non-significant differences in
age and IQ, gender and handedness (Table 3-1). Age did not differ significantly
between the stage 1 and stage 2 HD subjects (mean (SD) age 46.0 (7.1) years vs.
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45.0 (4.4) years, p=0.78). Stage 2 subjects tended to have higher repeat lengths 
than stage 1 but this difference was not statistically significant (stage 1: mean 
(SD) 44.6 (1.6) repeats vs. stage 2: 47.0 (2.0) repeats, p=0.06).
Table 3-1 Demographic data for the cohort at baseline
Control
(N=7)
Early HD 
(N=13)
Gender (M;F) 3:4 5:8
Age (year) 40.7(10.5) 45.8 (6.4)
Estimated premorbid IQ 106.6(10.2) 100.4(11.9)
Handedness (R:L) 7:0 11:2
CAG repeat length NA 45.2 (2.0), range 43 -  49
Disease duration (year) NA 3.5 (2.7), range 1 -  8
UHDRS Motor NA 12.7(12.7)
UHDRS Independence NA 93.5 (10.5)
UHDRS TFC NA 11.6 (2.6)
Scan interval (months) 5.8 (0.6) 6.0 (0.8)
NA: not applicable
Data are mean (S D ) with the exception o f  gender and handedness; handedness was taken as the 
hand used to write with; UHDRS: motor is out o f  124, higher score = more severely impaired; 
independence is scored as a percentage, higher score = better function; Total Functional Capacity 
is out o f  13, higher score = better function.
3.3.1 Clinical measures
At baseline longer CAG repeat length was associated with worse scores on the 
UHDRS motor task (4.6 points per CAG repeat, 95% Cl 1.6, 7.7, p=0.007), 
independence scale (-3.7 points per CAG repeat, 95% Cl -6.3, -1.0, p=0.011) and 
TFC (-0.9 points per CAG repeat, 95% Cl -1.5, -0.2, p=0.017).
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At 12-month follow-up one early HD subject had progressed from stage 2 to 
stage 3. For the entire patient group there was a statistically significant increase 
in UHDRS motor score (p=0.0001) over 12 months, indicating a decline in motor 
skills. Independence score and TFC both decreased over 12 months 
(Independence score, p=0.0145, TFC, p<0.0075) (Table 3-2).
Table 3-2 Mean (SD) UHDRS scores in the early HD group at baseline and 
12-month assessments, with change (95% confidence intervals)
Early HD (N=13) 
Baseline 12 months
Change 
(12 months - baseline)
Motor score 12.7(12.7) 15.9(14.0) 3.2 (2.0, 4.5) p=0.0001
Independence score 93.5 (10.5) 89.2 (14.4) -4.2 (-7.5,-1.0) p=0.0145
TFC 11.6 (2.6) 10.7 (3.4) -0.9 (-2.6, -0.3) p=0.0075
Longer CAG repeat length was associated with greater decline at motor score 
(decline increased by 0.6 points per CAG repeat, 95% Cl 0.1, 1.2, p=0.032) and 
TFC (decline increased by 0.3 points per CAG repeat, 95% Cl 0.02, 0.6, 
p=0.037), but there was no evidence of an association between CAG repeat 
length and decline in independence score.
3.3.2 Brain volumes
HD subjects had smaller mean brain volumes than controls (standardised to mean 
TIV) at baseline (1040 vs. 1132 ml), both with and without adjustment for age 
(both p<0.0001. Table 3-3). There was no evidence of a relationship between 
brain volume and CAG repeat length, UHDRS motor score, independence score 
or TFC. Raw volumes and TIVs are reported in the following section, 3.3.2.1.
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Table 3-3 Mean (SD) baseline brain volumes, standardised to mean control TIV, and rate of atrophy over six months, with
differences (95% confidence intervals) with and without adjustment for age
Control
(N=7)
Early HD 
(N=13)
Difference (Early HD 
Crude
- Control)
Adjusted
Brain volume (ml) 
Atrophy rate (% per year)^
1132 (40) 
0.26 (0.54)
1040 (46) 
1.10(0.88)
-92 (-133,-51)p<0.0001 
0.84 (0.17, 1.50) p=0.017
-83 (-118,-47) p<0.0001 
0.87 (0.19, 1.55)p=0.015
Negative differences indicate smaller volume or atrophy rates in HD subjects relative to controls; crude differences are the absolute difference between groups 
before adjustment for age; adjusted differences are the differences having adjusted for age by including it as a covariate in the linear regression models, 
a Loss over six months is presented as a percentage o f  baseline brain volume lost per year
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HD subjects also had greater mean rates of atrophy than controls, both with and 
without adjustment for age (without age p=0.017; with age p=0.015) (Table 3-3, 
Figure 3-1). There was no evidence of a relationship between atrophy rate and 
CAG repeat length, or decline in UHDRS motor score, independence score or 
TFC.
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Figure 3-1 Whole-brain atrophy rates (% per year) in controls and early 
HD, standardised to mean age in the whole cohort
i. S. 2.1 Comparison o f BBSI and manual measures
All four measures of volume loss (from raw volumes, volumes standardized to 
mean control TIV, volumes as a proportion of TIV, and the BBSI) showed loss 
over six months, and all demonstrated statistically significant differences in the 
amount of change between controls and HD (see Table 3-4).
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Table 3-4 Mean (SD) brain and total intracranial volumes and loss over 6 months from manual measures and the BBSI, with group
differences (95% confidence intervals)
Baseline 6 months Loss over 6 months
Control Early HD Control Early HD Control Early HD
Group difference in loss 
Early HD - Control
TIV (ml) 1370 (81) 1393 (144) 1359(82) 1377 (135) -10.8(11.3) -15.2(14.6) -4.44 (-16.98. 8.09) p=0.46
Raw"
g
1124 (59) 1043 (94) 1119(60) 1023 (90) -4.87 (6.98) -20.29 (8.05) -15.42 (-22.83,-8.01) p=0.0005
 ^ Logb 1132 (40) 1040 (46) 1126 (40) 1021 (46) -6.33 (2.63) -19.67 (6.74) -13.34 (-17.80, -8.87) p<0.0001
2 t  Prop'
PQ S  ■
0.82 (0.03) 0.75 (0.04) 0.82 (0.03) 0.74 (0.04) 0.003 (0.003) -0.007 (0.006) -0.010 (-0.014, -0.005) p=0.0002
BBSI (ml) - - - - -1.47 (2.98) -6.16(5.02) -4.68 (-8.45,-0.91) p=0.0178
Negative loss indicates smaller volume at six-month follow up than at baseline; negative group differences indicate that the HD group lost more than the control group, 
a Raw volumes are uncorrected
b Log volumes are standardised for head size assuming a linear relationship between log transformed values and log TIV, see text for details
c Proportional volumes are represented as a proportion o f  TIV (volume/TlV); unlike log correction, this method does not rely on the provision o f  normative data from the 
control group
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Mean volume loss estimated by the BBSI was smaller than that calculated from 
differences between raw or TlV-corrected volumes (BBSI vs. raw, 10.4ml, 95% 
Cl 6.7, 14.1ml, p<0.0001; BBSI vs. volumes standardised to mean control TIV, 
10.5ml, 95% Cl 6.8, 14.2ml, p<0.0001). The standard deviation of loss
estimated by the BBSI was also smaller than that calculated from the other two 
methods (BBSI vs. raw, ratio of SDs=0.5, 95% Cl 0.3, 0.6, p<0.0001; BBSI vs. 
volumes standardised to mean control TIV, ratio of SDs=0.6, 95% Cl 0.4, 0.9, 
p=0.013).
In the subject group as a whole TIVs were also smaller at six months compared 
to baseline (-13.7ml, 95% Cl 7.4, 20.0ml, p=0.0002). However there was no 
evidence that the change in TIV over six months differed between early HD 
subjects and controls (Table 3-4).
3.3.3 Cognitive performance
Differences in baseline neuropsychology, with and without adjustment for age 
and estimated premorbid IQ, are shown in Table 3-5. After adjustment HD 
subjects were generally worse than controls on all tasks, with the exception of 
digit span and naming in the GNT where they tended to perform slightly better 
than controls. Early ETO subjects were statistically significantly worse than 
controls at Stroop interference (p=0.017), phonemic fluency (p=0.029) and the 
SDMT (p=0.038) as well as recognition memory for faces (RMF) (p=0.009). 
They were significantly slower at number cancellation (p=0.015), number 
sequencing (p=0.007), letter sequencing (p=0.034), alternating sequencing 
(p=0.048), motor speed (p=0.011) and the reaction time task (p=0.005). 
Although HD subjects’ naming performance was unimpaired they had
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significantly slower mean naming latency than controls in the GNT (p<0.0001). 
Differences between HD and controls on Stroop word reading, digit span 
forwards and backwards, recognition memory for words (RMW), the recognition 
memory difference score and the silhouette subtest of the VOSP were not 
statistically significant (all p>0.1).
Longer CAG repeat length was generally associated with worse or slower 
baseline scores (after adjusting for age and premorbid IQ), and was significantly 
associated with slower times on number sequencing (4.9 sec per CAG repeat, 
95% Cl 0.0, 9.8 sec, p=0.049) and reaction time (53.3 msec per CAG repeat, 
95% Cl 1.5, 105.0 msec, p=0.045). There was a trend towards a statistically 
significant relationship with worse performance on the SDMT (-4.0 points per 
CAG repeat, 95% Cl -8.0, 0.1, p=0.055) and RMF (-1.0 points per CAG repeat, 
95% Cl -2.1, 0.1, p=0.06), and no evidence of relationships with the other 
cognitive tasks (all p>0.09).
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Table 3-5 Mean (SD) cognitive scores at baseline, with differences (95% confidence intervals) with and without adjustment for age and
estimated premorbid IQ
Controls Early HD Difference (Early HD - Control)
Area Test (N=7) (N=13) Crude Adjusted
UHDRS Stroop word (n) 91.4 (20.8) 74.5 (23.9) -17.0 (-38.3.4.4) p=0.11 -7.7 (-34.0, 18.7)p=0.55
Stroop interference^ (n) 49.0 (6.6) 34.7(10.7) -14.3 (-22.7, -5.9) p=0.002 -9.3 (-16.7,-1.9) p=0.017
Phonemic fluency (n) 50.6(16.3) 33.5(1190 -17.0 (-32.1,-2.0) p=0.029 -16.1 (-30.4,-1.8) p=0.029
SDMT (n) 55.7(14.7) 35.8(12.5) -19.9 (-33.5, -6.4) p=0.006 -15.0 (-28.9,-1.0) p=0.038
Psychomotor, Number cancellation (sec)'’ 17.9 (3.3) 25.2 (5.7) -7.3 (-11.5,-3.0) p=0.002 -5.3 (-9.4,-1.2) p=0.015
executive Number sequencing (sec)'’ :24.3 (8.1) 45.7(16.3) -21.5 (-32.9,-10.0.) p=0.001 -16.3 (-27.5, -5.0) p=0.007
function. Letter sequencing (sec)'’ 25.9 (7.7) 50.3 (28.6) -24.4 (-42.3, -6.5) p=0.01 -14.1 (-27.0,-1.2) p=0.034
reaction time Alternating (sec)'’ 69.4 (34.1) 169.4(132.9) -100.0 (-182.8, 17.3) p=0.069 -69.5 (-138.5,-0.6) p=0.048
Motor speed (sec)'’ 23.9 (5.6) 34.7(10.5) -10.8 (-18.4, -3.3) p=0.008 -7.3 (-12.6,-1.9) p=0.011
Reaction time (msec) 590(104) 808 (158) -218 (-342,-94) p=0.002 -187 (-307,-67) p=0.005
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Controls Early HD Difference (Early HD - Control)
Area Test (N=7) (N=13) Crude Adjusted
Memory Digit span forwards (/21) 11.7 (3.1) 13.2(3.1) 1.4 (-1.6, 4.5) p=0.34 2.3 (-1.0, 5.5) p=0.16
Digit span backwards (/21 ) 9.6 (2.1) 10.3 (4.9) 0.7 (-2.5, 4.0) p=0.64 2.3 (-1.2, 5.9) p-0.19
RMF (/50) 43.7 (4.0) 37.1 (4.4) -6.6 (-10.7, -2.6) p=0.003 -6.3 (-10.8,-1.8) p=0.009
RMW (/50) 47.9 (2.1) 43.8 (4.9) -4.1 (-7.4, -0.8) p=0.019 -2.5 (-5.6, 0.6) p=0.11
RMT difference 4.1 (5.5) 6.7 (3.0) -2.5 (-7.1, 2.0) p=0.26 -3.8 (-8.8, 1.2) p—0.13
Language GNT (/30) 20.3 (6.1) 20.7 (4.7) 0.4 (-4.7, 5.5) p=0.87 2.2 (-2.9. 7.3) p=0.37
Naming latency (In(msec)) 7.5 (0.5) 7.9 (0.7) -0.5 (-0.6, -0.3) p<0.0001 -0.3 (-0.5.-0.2) p<0.0001
Visuoperceptual VOSP silhouettes (/15) 10.1 (2.2) 9.1 (2.3) -1.1 (-3.3, l.l)p=0.32 -0.6 (-2.4. 1.3)p=0.54
Negative differences indicate a lower score or slower speed (longer time taken in timed tasks) in HD subjects relative to controls; crude differences are the absolute difference 
between groups before adjustment for age and IQ; adjusted differences are the differences having adjusted for age and IQ by including them as covariates in linear regression 
models.
a N=14, colour-blind subject unable to complete test
b Subtests o f  the Delis-Kaplan Executive Function System (D-KEFS) Trail Making Test
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Between baseline and six months, HD subjects tended to decline relative to 
controls at all tasks (see Table 3-6), except Stroop colour-word, phonemic 
fluency and naming latency at which, on average, they improved. HD subjects 
only declined statistically significantly relative to controls at motor speed 
(p=0.005). Both groups had faster naming latencies at six months, with HD 
subjects showing significant improvement relative to controls (p=0.002), 
probably because controls were performing nearer to ceiling at baseline and 
hence had less scope to improve. This pattern was repeated between baseline 
and 12 months with HD subjects showing, on average, non-significant decline 
relative to controls on all tasks other than Stroop word reading, number 
sequencing, reaction time and naming latency (Table 3-7). HD subjects again 
declined statistically significantly relative to controls at motor speed (p=0.028) as 
well as the RMF (p=0.02) and RWM (p=0.004). Again although both groups 
named objects faster than at baseline, the HD group showed a greater 
improvement than controls (p=0.001). There were no other statistically 
significant changes between visits.
Longer CAG repeat length was generally associated with greater decline in 
cognition over both six and 12 months (after adjusting for age and estimated 
premorbid IQ). Over six months higher CAG repeat length was statistically 
significantly associated with greater decline at Stroop colour (decline increased 
by 5.4 points per CAG repeat, 95% Cl 2.4, 8.4, p=0.003), cancellation (decline 
increased by 2.2 sec per CAG repeat, 95% Cl 1.0, 3.5, p=0.002), and over twelve 
months with greater decline at Stroop colour (decline increased by 3.5 points per 
CAG repeat, 95% Cl 1.2, 5.8, p=0.007). There was no evidence of associations 
between CAG repeat length and decline in other cognitive variables.
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Table 3-6 Mean (SD) cognitive change from baseline to six months, with group differences (95% confidence intervals) with and without
adjustment for age and estimated premorbid IQ at baseline
Change (6 months - baseline) Difference in change (Early HD - Control)
Area Test Controls
(N=7)
Early HD 
(N=13)
Crude Adjusted
UHDRS Stroop word (n) 3.3 (14.7) -0.8(12.1) -4.1 (-17.6, 9.3) p=0.53 -7.4 (-22.0, 7.2) p=0.30
Stroop interference‘s (n) -0.9 (3.5) 0.3 (5.0) 1.1 (-3.0, 5.3)p=0.58 1.3 (-3.2, 5.8) p=0.55
Phonemic fluency (n) -1.7 (6.6) 1.2 (5.4) 2.9 (-3.1,8.9) p=0.33 4.0 (-2.9, 10.8) p=0.24
SDMT (n) 0.6 (6.7) -1.4 (5.1) -2.0 (-8.0, 4.1)p=0.50 -0.7 (-6.0, 4.5) p=0.77
Psychomotor, Number cancellation (sec)'’ 1.8 (3.6) -1.2 (4.9) -3.0 (-7.0, 1.0) p=0.14 -3.9 (-8.5, 0.7) p=0.09
reaction time Number sequencing (sec)'’ 0.7 (6.1) 2.9(16.1) 2.2 (-8.5, 12.8)p=0.68 -1.0 (-12.2, 10.2) p=0.86
Letter sequencing (sec)'’ 4.2 (4.3) -4.2 (30.8) -8.4 (-26.9, 10.1)p=0.35 -8.1 (-22.0,5.9) p=0.24
Alternating (sec)'’ -9.4 (35.6) -0.4 (74.3) 9.0 (-42.8, 60.8) p=0.72 -3.6 (-83.8, 76.7) p=0.93
Motor speed (sec)'’ 5.6 (3.2) -1.5 (7.8) -7.1 (-12.3,-1.9) p=0.011 -7.5 (-12.4, -2.6) p=0.005
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Change (6 months - baseline) Difference in change (Early HD - Control)
Area Test Controls
(N=7)
Early HD 
(N=13)
Crude Adjusted
Reaction time (msec) -1(25) -20(64) -19 (-61. 24) p=0.37 -16 (-68, 37) p=0.54
Memory Digit span forwards (n) 1.1 (1.3) -1.2 (3.4) -2.4 (-4.6, -0.1)p=0.04 -1.9 (-4.1, 0.4) p-0.10
Digit span backwards (n) 0.4 (3.5) -L6(Z3) -2.0 (-5.0. 1.0) p-0.17 -1.8 (-6.2, 2.6) p=0.39
RMF (n) 1.6 (4.5) -2.3 (4.8) -3.9 (-8.3, 0.6) p=0.08 -2.2 (-7.6.3.3)p=0.41
RMW (n) 0.4 (2.4) -0.4 (3.6) -0.8 (-3.7, 2.0) p-0.56 -1.3 (-5.0, 2.3) p=0.45
Language GNT (n) 1.6 (1.4) 0.5 (1.4) -1.0 (-2.4, 0.3) p=0.13 -1.0 (-2.5, 0.4) p=0.16
Naming latency (In(sec)) 5.5 (1.6) 6.6 (1.6) 1.0 (0.6, 1.5)p<0.0001 0.8 (0.3, 1.3)p=0.002
Visuoperceptual VOSP silhouettes (n) 0.9 (1.5) 0.5 (1.9) -0.3 (-1.9. 1.3)p=0.68 -0.5 (-2.7. 1.6) p=0.60
Negative change indicates a decrease in score or in speed (longer time taken in timed tasks); negative difference in change indicates that early HD declined more than 
controls; crude differences are the absolute difference between groups before adjustment for age and IQ; adjusted differences are the differences having adjusted for age and 
IQ by including them as covariates in linear regression models, 
a N=14, colour-blind subject unable to complete test
b Subtests o f  the Delis-Kaplan Executive Function System (D-KEFS) Trail Making Test
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Table 3-7 Mean (SD) cognitive change from baseline to 12 months, with group differences (95% confidence intervals) with and without
adjustment for age and estimated premorbid IQ at baseline
Change (12 months - baseline) Difference in change (Early HD - Control)
Area Test Controls
(N=7)
Early HD 
(N=13)
Crude Adjusted
UHDRS Stroop word (n) -2.4(10.7) -3.0 (8.3) -0.6 (-10.2, 9.1)p=0.90 1.6 (-6.8. 10.0) p=0.69
Stroop interference^* (n) 0.7 (3.8) -0.2 (3.4) -0.9 (-4.5, 2.7) p=0.62 -1.4 (-4.8, 2.0) p=0.39
Phonemic fluency (n) 2.0 (8.6) -2.2 (5.5) -4.2 (-11.7,3.2) p=0.25 -2.8 (-13.3,7.6) p=0.58
SDMT (n) 0.9 (6.5) -2.0 (5.0) -2.9 (-8.7, 3.0) p=0.32 -1.7 (-9.7, 6.3) p=0.66
Psychomotor, Number cancellation (sec)** 1.3 (5.1) -0.4 (4.8) -1.7 (-6.6, 3.2) p=0.47 -1.4 (-7.1,4.3)p=0.60
reaction time Number sequencing (sec)'* 4.3 (6.8) 2.8(16.7) -1.5 (-12.7, 9.7) p=0.78 2.4 (-11.3. 16.2) p=0.71
Letter sequencing (sec)** 4.0 (7.6) 8.3(18.9) 4.3 (-8.3, 17.0) p=0.48 -1.3 (-11.7, 9.2) p=0.80
Alternating (sec)'* 4.0 (20.8) 6.5 (75.0) 2.4 (-44.7, 49.6) p=0.92 -5.2 (-61.5, 51.0) p=0.85
Motor speed (sec)'* 8.2 (4.0) 0.6 (9.4) -7.6 (-13.9,-1.3) p=0.021 -7.5 (-14.1,-0.9) p=0.028
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Change ( 12 months - baseline) Difference in change (Early HD - Control)
Area Test Controls
(N=7)
Early HD 
(N=13)
Crude Adjusted
Reaction time (msec) 14(68) -0.8(146) -15 (-116, 86) p=0.76 8 (-108, 124) p=0.89
Memory Digit span forwards (n) -0.3 (2.8) -1.4 (3.4) -1.1 (-4.1, 1.9) p=0.45 -0.8 (-3.6, 2.1) p=0.57
Digit span backwards (n) 2.3 (2.9) -0.5 (2.6) -2.8 (-5.6, -0.1)p=0.044 -2.9 (-6.8, 0.9) p=0.12
RMF (n) 2.3 (2.5) -2.2 (5.0) -4.5 (-8.1,-1.0) p=0.015 -3.5 (-6.4, -0.6) p—0.02
RMW (n) 0.6 (1.9) -0.8 (2.0) -1.3 (-3.2, 0.6) p=0.15 -2.5 (-4.1,-0.9) p=0.004
Language GNT (n) 1.3 (1.3) 0.8 (1.3) -0.4 (-1.7, 0.9) p=0.49 -0.3 (-1.8, 1.1) p=0.65
Naming latency (In(sec)) 5.8 (1.5) 6.6 (1.5) 0.9 (0.5, 1.3)p<0.0001 0.8 (0.3, 1.3)p=0.001
Visuoperceptual VOSP Silhouettes (n) 1.0 (1.4) 0.7 (1.7) -0.3 (-1.8, 1.2) p=0.67 -0.2 (-1.9, 1.5) p=0.81
Negative change indicates a decrease in score or in speed (longer time taken in timed tasks); negative difference in change indicates that early HD declined more than 
controls; crude differences are the absolute difference between groups before adjustment for age and IQ; adjusted differences are the differences having adjusted for age and 
IQ by including them as covariates in linear regression models, 
a N =I4, colour-blind subject unable to complete test
b Subtests o f  the Delis-Kaplan Executive Function System (D-KEFS) Trail Making Test
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In general atrophy rate was not significantly associated with decline in cognitive 
variables over six or 12 months (after adjusting for age and estimated premorbid 
IQ). Higher atrophy rate was associated with less decline in motor speed over 
six months (5.3 sec per % increase in atrophy rate, 95% Cl 0.8, 9.7, p=0.025) and 
12 months (6.1 sec per % increase in atrophy rate, 95% Cl 0.6, 11.6, p=0.033) 
and with less decline at GNT over six months (0.8 points per % increase in 
atrophy rate, 95% Cl 0.02, 1.5, p=0.046).
3.4 DISCUSSION
In this sample of subjects with early HD, whole-brain atrophy occurred at a mean 
rate of around 1% per year (based on the finding of 0.5% loss over 6 months) and 
the difference between this and atrophy due to normal ageing can be detected 
over this period, even with the very small groups in this study. Despite the group 
differences there was considerable overlap between groups. This could reflect 
true heterogeneity or may be in some part due to factors that were not controlled 
for (such as hydration changes) or errors related to the subject (movement 
artefact), scanner or measurement technique. The rate in early HD was around 
four times greater than that in controls. These rates of loss together with the 
baseline cross-sectional volume differences suggest that atrophy has been 
occurring for some years prior to first assessment.
Whole-brain atrophy rates are slower than striatal rates in early HD (around 5% 
per year in the caudate) (Aylward et al. 2000), consistent with the assumption 
that whole-brain volume includes areas that are not changing, together with those 
that are. Whole brain losses of 1% per year (about 10ml per year) cannot be 
attributed simply to striatal atrophy; total caudate loss is approximately 0.5ml per
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year based on published atrophy rates (Aylward et al. 2000). At post-mortem in 
end-stage HD there is a loss of 300-400 grams of brain tissue, or between 20- 
30% of brain volume in HD (de la Monte et al 1988), most of which must 
represent extra-striatal atrophy.
Cognitive deficits at baseline were similar to those reported by others (e.g., 
Craufurd and Snowden 2002), with the HD group tending to perform below 
control levels, significantly so on a number of motor and executive tasks, and 
recognition memory for faces. In contrast naming and visuoperceptual skills 
appeared relatively spared. Interestingly, although there was no evidence of a 
naming deficit in the HD group, early HD subjects had significantly longer 
naming latencies than controls, most likely indicative of general cognitive 
slowing, and also highlighting the power of timed tests.
Performance on UHDRS clinical measures declined significantly over the year, 
whilst early HD subjects showed slowed motor speed and tended to get worse at 
recognition memory for faces and words, relative to controls. However these 
changes were not significantly associated with atrophy rates. In addition, it is 
clear that measurement of cognitive change is variable, particularly over short 
time periods, since decline over six months was slightly different to that seen 
over 12 months, and effects were generally small and non-significant; these data 
must therefore be interpreted cautiously and may not be representative of the 
disease. A number of other studies have reported difficulties in detecting 
cognitive change over even longer time periods than the ones used here, 
primarily because of practice effects and performance variability (e.g., Bachoud- 
Lévi et al. 2001 ; Snowden et al 2001). The importance of testing change against
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control performance (rather than against zero) is demonstrated, as controls 
showed practice effects in some tests.
Higher CAG repeat length was generally associated with worse clinical and 
cognitive scores at baseline, and with greater decline in some of the UHDRS 
measures, although only with decline in one cognitive measure (Stroop colour 
reading). CAG repeat length was not significantly associated with brain volume, 
atrophy rate or most cognitive change, which may be indicative of the fact that 
CAG repeat length does not govern rate of disease progression; alternatively this 
may simply reflect the small sample size and lack of power to detect small 
effects.
In terms of the practical aims of the study, the results show that the BBSI can be 
used to detect change in early HD, and that serial MRI is well tolerated, at least 
in the cohort tested here. There was no loss to follow-up at any of the three 
timepoints suggesting that subjects were happy to return for repeat assessments 
despite progression of the disease in the intervening months for the early HD 
subjects. However, HD is a phenotypically heterogeneous disease (Shoulson and 
Fahn 1979), which makes it hard to find consistent patterns of deficit. The 
whole-brain atrophy rates reported here reflect that, in that they were highly 
variable and included a number of patients well within the control range. This 
was mirrored by the cognitive performance, in which decline was variable and 
hard to detect, and what significant change there was, was often attributable to a 
practice effect in the controls as well as a small decline in the HD group.
These difficulties were compounded by the fact that the scanner upgrade forced a
change in the study schedule, and meant that atrophy rates were measured over
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six months (rather than one year) and that subjects underwent the cognitive 
assessment more frequently than was ideal, making it hard to minimise practice 
effects. The short time period meant a high signal-to-noise ratio, which is likely 
to have added to the variance associated with the cognitive and imaging 
measures. As this was a pilot study the sample size was also small, and again 
this means the study was unlikely to have the power to detect small effects.
Four scan pairs (20%) were not adequate due to artefact and were discarded from 
the analysis. It is common to assume 10% loss to follow-up and 10% unusable 
scans in large-scale trials (Fox et al. 2000), so in this study slightly more scan 
pairs were unusable than would normally be predicted, although because no 
subjects were lost to follow-up the overall drop-out rate was similar to that seen 
in large-scale trials.
It is known that the BBSI tends to underestimate loss slightly (Freeborough and 
Fox 1997), and in this cohort the mean loss estimated by the BBSI was 
significantly smaller than that estimated by differences between volumes (both 
raw, and standardised to mean control TIV). However mean TIV also decreased 
significantly between timepoints, which suggests that some scanner drift had 
occurred. TIV, an index of head size, would not normally be expected to decline 
over time. It seems likely that scanner drift contributed partly to the large 
differences between brain volumes measured manually at each timepoint, and 
demonstrates the importance of registration in serial imaging, since this reduces 
such effects. This issue is discussed further in chapter 10, in terms of the "best" 
manual measure of volume change with which to compare the BBSI.
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Whole-brain atrophy is simply and reliably derived from standard volumetric 
MRIs and the BBSI. This semi-automated measure is less susceptible to 
segmentor error than manual delineation, and it is not affected by changes in 
scanner calibration which are often seen with unregistered scan pairs; this is 
reflected in the reduced within-group variance and (in this cohort) slightly 
smaller change compared to manual measures. The findings of this study 
suggest that the BBSI may be a practical measure for use in larger-scale studies 
of HD, whilst the detection of cognitive change would be improved with a longer 
time period and more sensitive tests.
3.5 CONCLUSION
This study has shown that the BBSI can be used to measure whole-brain atrophy 
in early HD, although there are a number of challenging aspects to overcome, 
such as movement artefact and ensuring scanner stability. Cognitive change is 
much harder to measure, partly because the disease is so clinically 
heterogeneous, and partly because of factors which cannot be controlled for such 
as practice effects and subjects’ mood. Because of the short time period and 
small cohort I have not attempted to interpret the cognitive findings as 
representative of the decline in HD in general. Rather, these findings lead on to 
the work reported in the following chapters in which a number of limiting factors 
were addressed: the sample size was increased; the time interval was lengthened 
to increase the signal-to-noise ratio and reduce cognitive practice effects; the 
cognitive battery was adapted; and premanifest subjects were recruited in order 
to expand these investigations across the wider spectrum of the disease.
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4 COGNITIVE DEFICITS AND THEIR RELATIONSHIP WITH 
BRAIN VOLUME IN HUNTINGTON’S DISEASE
4.1 INTRODUCTION
As discussed in chapter 1, there is increasing evidence that subtle cognitive and 
behavioural deficits can be apparent prior to motor onset and that atrophy in HD 
is not just confined to the striatum, even in the early stages (Kassubek et al 
2004a; Williams et a l 2007). Defining these changes better allows one to a) 
have a greater understanding of “clinical onset” that captures the heterogeneity of 
the disease beyond motor deficits and b) thereby develop measures of 
progression that would be most appropriate for disease-modiflcation trials aimed 
at the very earliest symptomatic stages of the disease.
Premanifest subjects are the focus of much research, in part because they are still 
"well" and are the most likely candidates for clinical trials, but this brings its own 
difficulties. Firstly, many of these subjects perform in the normal range on most 
clinical or cognitive measures, and thus it is hard to detect effects. Secondly, the 
term "premanifest" covers an extremely wide range of subjects, and until recently 
it has been difficult to predict with any accuracy, how far a premanifest subject 
was from motor onset (see section 1.4.3). This has made it hard to generalise 
results between studies of premanifest subjects, and to the population as a whole.
Following on from the pilot study (chapter 3) a larger study was set up, the
baseline assessment of which was designed to address some of the above issues.
This chapter examines the cognitive impairments seen in a large cohort of
premanifest and early HD subjects, using an extensive battery of cognitive tasks.
Whole-brain volume was measured to investigate the association between
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cognitive performance and neurodegeneration. Also, since the classification of 
gene carriers into premanifest and early HD is made purely on the basis of motor 
signs, which do not necessarily correlate with cognitive ability, this chapter also 
investigates the association between cognition and brain volume across the whole 
spectrum of gene carriers. This study aimed to establish both the cognitive 
impairments and volume reductions in a large, well-defined cohort, and the 
associations between the two.
4.2 METHODS
4.2.1 Subjects
Sixty-one subjects with genetically-confirmed HD were recruited. Forty were 
classified as patients with “early HD”, 26 stage 1 and 14 stage 2, (Shoulson and 
Fahn 1979), and 21 subjects were gene carriers without motor signs, i.e. 
premanifest (PM). Throughout the rest of this thesis the “HD” group refers to 
the early (symptomatic) HD group; the premanifest group is referred to as that. 
On the rare occasions that both groups are combined for analysis subjects are 
referred to as “all HD gene carriers”.
Twenty neurologically normal controls, either patients’ partners (N=15) or non- 
gene carriers from at-risk families (N=5), were also recruited. Seven early HD 
subjects and one control had previously participated in the study described in 
chapter 3.
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4.2.2 Assessments
4.2.2.1 Clinical assessment
Subjects were clinically assessed as described in section 2.2. Four early HD 
subjects were not asked to complete the Beck Depression Inventory (BDI) as it 
was not available to the clinician at the time of their assessments.
4.2.2.2 Cognitive assessment
Subjects underwent detailed neuropsychological testing. The previous battery 
(see section 3.2.2.3) was modified based both on the pilot study findings and 
discussion with other psychologists working in HD.
The European HD network (EHDN, www.euro-hd.net) was set up to establish a 
database of HD subjects across Europe and to discuss current assessment 
methods with an aim to getting a Europe-wide consensus on the tests used and to 
unify administration and scoring, in order to have a useful program of data 
collection in place before the start of large-scale clinical trials. The Cognitive 
Working Group of the EHDN has held several meetings to discuss the standard 
minimal battery. The cognitive tests included in the UHDRS are the Stroop test, 
phonemic (letter) fluency and the Symbol Digit Modalities Test. Whilst these 
were felt to be useful, they are all timed psychomotor tasks and it was felt that 
they did not provide a broad enough measure of skills known to be affected in 
the disease. In addition there are no validated alternative versions, so with 
repetition these tasks become subject to practice effects. Discussion within the 
working group led to the recommendation that a number of extra tests should be 
included in the minimum battery; these tests and the reasons for their inclusion 
are listed below.
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Neuropsychological tasks were administered by me at each visit, in a single 
session lasting about 1 to 2 hours. The order of the tasks was kept constant. 
Because a follow-up assessment was planned at a later date alternative test 
versions were used, where possible, on half the subjects (counterbalanced across 
subjects within each group). Tests with alternative versions were Spot the Word, 
Hopkins Verbal Learning Test, digit span. Homophone Meaning Generation Test 
and RMT.
Estimated Pre-morbid IQ: the NART was used, as in the Pilot Study (chapter 3). 
However a second measure, the Spot the Word Test, was also included 
(Baddeley et al. 1993). This is a lexical decision task in which subjects are 
shown pairs of word / non-words and asked to mark the real word. As in the 
NART the real words are uncommon, and scores on this task correlate highly 
with IQ. It was thought that the Spot the Word Test could have an advantage 
over the NART as a measure in HD patients because some patients with 
dysarthria might be penalised for poor pronunciation in the NART.
Executive function /  psychomotor tasks: the UHDRS cognitive tests were 
unchanged from the pilot study, comprising the Stroop test, phonemic (letter) 
fluency, and the SDMT. However the version of the Stroop test had recently 
been changed to include separate colour-naming and word-reading sections prior 
to the interference task. Category fluency (Benton and Hamsher 1978) was 
added to the battery at the suggestion of the EHDN working group. Many 
researchers had found performance on this to be less affected until later in the 
disease, and therefore it might detect decline at a point at which most subjects 
were performing at floor level on phonemic fluency.
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Trail Making parts A and B (TMT A and B) (Reitan and Wolfson 2004) were 
also recommended; they are quick to administer and the more simple part 
(number sequencing) can be attempted by subjects even if they find the 
subsequent number-letter sequencing part too difficult. Consequently TMT A 
and B were substituted for the more complex five-part test that was used in the 
pilot study (Delis et al. 2001), since performance on only one of these subtests 
(motor speed) had declined significantly during the pilot.
A simple, timed letter-cancellation task was included as a basic test of visual 
search and motor skills. An A4 page with a grid of the letters A, B, C, D, E in a 
pseudo-random order was presented, and subjects were asked to put a line 
through all the "As" as quickly as possible, without missing any.
The computer reaction time task was modified slightly. This task was designed 
and presented on SuperLab Pro 2.0 and required subjects to use the index finger 
of their dominant hand to press one of four numbered buttons on a response pad. 
Number presses were alternated with pressing of a central blue button. The 
numbers 1-4 were centrally presented on the screen in a pseudo-random order, 
alternating with a blue square, in 20 blocks of 4, with a pause after the 10th 
block. The experiment is demonstrated in Figure 4-1 on the following page.
Subjects were requested to press the correct button as quickly as possible in 
response to the on-screen stimulus and reaction time was recorded. After a 
correct button press a blank screen displayed for 500ms before the next stimulus. 
In the event of an error the stimulus stayed on the screen until the correct button 
was pressed, in order to ensure that all subjects had to press the central blue
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button in between the number stimuli. Error trials were not included in the RT 
analysis.
500ms
500ms
Figure 4-1 Diagram showing example screens from the RT experiment, and 
the layout of the button box
Subjects used the index finger o f their dominant hand to press either a numbered 
button, or the central blue button, in response to the on-screen stimulus. The on­
screen stimulus alternated between a number and a blue square with the 
numbers 1-4 presented randomly within each set o f four number trials.
This modification of the experiment used in the pilot study was designed to yield 
four measures of RT: far (time to press buttons 1 and 4); near (time to press 
buttons 2 and 3); return from far (time to press central button after pressing 1 and 
4); return from near (time to press central button after pressing 2 and 3). The use 
of the central blue button meant that subjects had to move from the same central
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starting point to initiate the numbered button press and also allowed investigation 
of whether subjects with HD would be slow at returning to the central button, 
which was a predictable event.
The battery also included the Homophone Meaning Generation Test (HMGT) 
(Warrington 2000), in which subjects are presented with a homophone verbally, 
and asked to generate as many different meanings for that word as they can 
(examples include words such as “tip” or “bear” which can have a number of 
different meanings). This test has been shown to be sensitive to frontal lobe 
dysfunction, is not timed, unlike many of the other tests in this section, and is 
less subject to floor and ceiling effects than some other tasks of executive 
function.
Memory', the RMT and digit span were again included in this battery as both had 
been useful in detecting some significant decline between assessments in the 
pilot study. The Hopkins Verbal Learning Test - Revised (HVLT, Brandt and 
Benedict 2001) was included on the recommendation of the EHDN. Many 
researchers found this auditory verbal memory test useful, as it yields a number 
of measures (immediate memory, delayed memory, percentage recall, and a 
recognition discrimination index), and it is available in six alternative versions 
which helps to minimise practice effects.
Naming', the GNT was still included, and was again presented on a computer
using SuperLab Pro 2.0 in order to measure latency of naming responses. In the
pilot study latency measurements had been dependent on experimenter button
press and in order to improve on the accuracy of this the experiment was
modified slightly. Stimulus presentation was controlled by the experimenter, and
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a sound was played at each stimulus onset. The whole test was recorded and the 
resulting .wav file was transferred to a Dell workstation. Goldwave software 
(www.goldwave.com) was used to insert markers between stimulus onset (the 
sound) and correct response, and naming latency was measured from this. 
Responses on which the subject was only correct after an error (e.g. mistaking 
the buoy for a sandcastle and then self-correcting) were not included in the 
latency analysis. Subjects were given unlimited exposure to stimuli although in 
practice subjects tended to indicate that they were unable to name an item within 
~15 seconds of stimulus onset at which point the next stimulus was displayed.
Visuoperceptual: basic visuoperceptual skills were again assessed with the 
silhouette subtest of the VOSP.
Face processing and fac ia l emotion recognition: the above tests comprise a 
comprehensive battery which was designed to cover the main areas of cognition 
in order to try and detect decline in HD. HD has also been used as a model for 
emotion recognition, although there are conflicting findings about which emotion 
is most impaired, and the extent of the impairment in premanifest gene carriers. 
Therefore emotion recognition was also investigated in this cohort. Facial 
emotion recognition was tested using 24 faces from the Ekman and Friesen 
battery (Ekman and Friesen 1976; after Gray et al. 1997). Subjects were shown a 
face and had to choose which of six basic emotions (written underneath) best 
described the face (see chapter 8 for more details). In order to control for face 
perception skills per se, the short form of the Benton Facial Recognition Test 
was also included in the battery (Benton et al. 1983). Total scores are reported in 
this chapter but a more detailed study of these data is presented in chapter 8.
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4.2.2.3 M R I acquisition
Subjects underwent T1-weighted volumetric inversion recovery prepared, spoiled 
gradient recall scans on the same 1.5T GE scanner (for parameters see Appendix 
1). Whole-brains and TIVs were segmented according to the protocol in 
Appendix 2.
Sixty-seven out of the 81 subjects (83%) had all three assessments (clinical, 
cognitive and MRI) on the same day. Eight early HD subjects had the clinical 
assessment after the cognitive and MRI due to the availability of the neurologist 
(mean (SD) interval 9.2 (6.0) weeks, range 1 - 2 2  weeks). Four controls were 
called back for rescans due to unacceptable motion artefact and hence their MR 
images were obtained after the other two assessments (mean (SD) interval 5.7 
(2.6) weeks, range 2 - 7  weeks). One premanifest subject had the cognitive 
assessment three days after the clinical and MRI assessments. One premanifest 
subject had all three assessments on different days for logistical and rescan 
reasons, with the scan acquired five months after the cognitive data, and seven 
weeks after the clinical assessment.
4.2.3 Statistical Analysis
In the following analyses the effects of variables which could independently 
affect cognition (age and estimated premorbid IQ) and brain volume (age) were 
controlled for by including them as covariates. An exception to this was the 
Benton Facial Recognition score, which is already age- and education-adjusted.
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4.2.2.1 Differences between alternative test versions
Linear regression models were used to compare performance between alternative 
versions of the psychological tests where they were available, across the cohort 
as a whole, adjusting for age and estimated premorbid IQ.
4.2.3.2 Group differences
Group differences in age, estimated premorbid IQ and CAO repeat length at 
baseline were investigated using t-tests assuming unequal variance. A chi^ test 
was used to compare gender across groups. Fisher’s exact test was used to 
examine whether the proportion of right-handed subjects differed between 
groups.
To correct for differences in head size whole-brains were standardised for XIV as 
outlined in section 3.2.3.2. Linear regression models with robust standard errors, 
to allow variances to differ between groups, were used to compare whole-brain 
volume (standardised for TIV), clinical and cognitive measures between groups 
at baseline. Linear regression models were also used for data which were not 
Normally distributed, but as Normality assumptions were violated 95% bias- 
corrected bootstrap confidence intervals with 1000 replicates were used; these 
data were from the RMW, TMT A and B, reaction time task, and the Ekman 
emotion recognition task.
Beck depression scores were used to classify subjects as showing signs of 
depression or not, and Fisher’s exact test was used to see if the proportion of 
subjects classified as depressed differed between groups.
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For naming latency measures, the natural log of time to correct response was 
related to group using a linear mixed model with group, question, age and IQ as 
fixed effects and subject as a random effect (see also section 3.2.3.3). This 
analysis was repeated with the UHDRS dysarthria score as an additional 
covariate to see if group differences were attenuated when the effect of dysarthria 
was adjusted for.
For TMT A and B, and the reaction time tasks, error counts were related to group 
using an overdispersed Poisson model to take into account the non-independence 
of errors made by the same person. A subset of errors on the reaction time task 
was classed as perseverative, if the subject repeated an incorrect button press, 
and these were modelled in the same way.
As there has been some debate as to the nature of the memory deficit in HD (see 
section 1.3.1.5) the HVLT was investigated in some detail. As above, linear 
regression models with robust standard errors were used to assess group 
differences in immediate recall, delayed recall, percent recalled, and recognition 
discrimination. In addition, similar models were used to investigate group 
differences in the numbers of true and false positives in the recognition 
paradigm, using 95% bias-corrected bootstrap confidence intervals with 1000 
replicates as these scores were not Normally distributed. In order to test the 
theory that recognition performance is normal, given the number of items 
initially encoded, linear regression models were then used to assess group 
differences in delayed recall, discrimination, true and false positives, having 
adjusted for encoding by including the immediate recall score as a covariate. 
Unlike the percent recall score, which represents the proportion of encoded
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stimuli which were recalled, this model tests the absolute difference between the 
number of stimuli encoded and recalled.
4.2.3.3 Effect o f  motor impairment on psychomotor tasks
In order to examine whether group differences in psychomotor tasks could be 
attributed to motor impairment, linear regression models with robust standard 
errors were used to look for differences between groups having controlled for 
UHDRS motor score by including it as a covariate.
4.2.3.4 Relationship between brain volume and clinical and cognitive measures 
in HD gene carriers
For the UHDRS independence score and TFC, at which the premanifest group 
scored at ceiling, linear regression models were used to assess the relationship 
between these measures and brain volume in the HD group alone, adjusting for 
differences due to age.
A linear regression model was also used to investigate the relationship between 
disease duration and brain volume in the early HD group, again adjusting for age. 
Disease duration is time since the diagnosis of motor signs (i.e., current age -  age 
at onset). As duration and age linearly combine to give age at onset, this model 
implicitly investigates the effect of age at onset after adjustment for age as well 
as the effect of disease duration after adjustment for age. Current age needs to be 
adjusted for, for the reasons given above, and hence it is difficult to tease out the 
effects of duration and age at onset individually.
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Linear regression models (with robust standard errors) relating either CAG repeat 
length, cognitive scores or UHDRS motor score, to brain volume, group and their 
interaction, were used to investigate whether the association between these 
variables and brain volume differed between the premanifest and HD groups. In 
situations where there were significant interactions the slope in each group was 
examined to see if, in either group, the association was significantly different 
from zero. Secondly, for variables for which there was no evidence of an 
interaction, linear regression models were used to look for an association 
between volume and score in all gene carriers, having adjusted for differences 
due to group. This ensures that group differences in score are not driving the 
correlation.
4.2.2.5 Relationship between probability o f  motor onset and other variables 
Estimated probability of motor onset within five years in the premanifest group 
was calculated using the equation given by Langbehn et a l  (2004). Probability 
of onset, rather than years to onset, was used as a regressor as it has been 
suggested that the former has more linear relationships with other clinical 
variables than the latter (Solomon et a l  2007). Where probability of onset is 
referred to in the thesis it always refers to estimated probability of onset within 
five years of baseline assessment. Linear regression models were used to see 
whether clinical, MRI or cognitive variables were associated with probability of 
motor onset in the 21 premanifest subjects. Age and IQ were included as 
covariates.
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4.2.3.6 Comparison o f  N ART and the Spot the Word Test 
The Spot the Word age-scaled scores have a mean of 10 and standard deviation 
of three, and so they were transformed to be on the same scale as the NART IQ 
(mean of 100, standard deviation of 15). Agreement between the two measures 
was assessed by calculating the mean (SD) difference (Bland and Altman 1986). 
t-tests assuming unequal variance were used to assess whether the mean 
difference between the tests differed significantly between groups, and a paired t- 
test was used to see if the IQ estimates from each test were significantly different 
for the cohort as a whole. Pitman’s test was used to compare variances of the 
two measures. The extent of association between the two measures was assessed 
using a correlation coefficient.
4.3 RESULTS
4.3.1 Group differences
There were small non-significant differences in gender, handedness and IQ 
between the groups (Table 4-1). Mean age did not differ statistically 
significantly between the controls and early HD group. The mean age of the 
premanifest group was seven and a half years lower than controls (95% Cl 1.8, 
13.5, p=0.011). The premanifest group had a shorter mean CAG repeat length 
than the early HD group (mean difference 1.5 repeats, 95% Cl 0.3, 2.7, p=0.013).
4.3.1.1 Differences between alternative test versions
There was a statistically significant difference between test forms for the HMGT 
(p=0.001) and so form was included as a covariate in any further analysis of this 
task. There was no evidence of differences between form for any other tests 
which had alternative versions.
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Table 4-1 Demographic data for the cohort at baseline
Control
(N=20)
Premanifest
(N=21)
Early HD 
(N=40)
Gender (M:F) 7:13 10:11 20:20
Age (year)® 44.9(10.5) 37.2 (7.9) 48.5 (9.6)
Estimated premorbid IQ 106.2(11.6) 103.2 (9.3) 105.3(13.0)
Handedness (R:L) 19:1 20:1 36:4
CAG repeat length^ NA 42.2(1.8), 43.7 (2.4),
range 40 -  45 range 4 0 - 5 0
Predicted years to onset‘s NA 18.2 (7.1), NA
range 9 - 3 5
Disease duration (year) NA NA 4.1 (2.6)
UHDRS Motor*' 1.1 (0.9) 3.6 (4.0) 28.9 (12.6)
UHDRS Independence 100 (0) 100 (0) 90.4 (9.6)
UHDRS TFC 13(0) 13(0) 10.9(1.8)
BDI 5.6 (3.9) 6.8 (6.3) 9.3 (8.7)
NA: not applicable
Data are mean (SD) with the exception of gender and handedness; handedness was taken as the 
hand used to write with; UHDRS: motor is out of 124, higher score = more severely impaired; 
independence is a percentage, higher score = better function; Total Functional Capacity is out of 
13, higher score = better function, 
a PM<Control (p=0.011); PM<HD (p<0.0001) 
b PM<HD (p=0.013)
c Onset was defined as a 60% chance of showing motor signs (Feigin et al. 2006) and predicted 
using the equation of Langbehn et al (2004) 
d HD<Control, HD<PM (both p<0.0001)
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4.3.2 Clinical measures
Mean UHDRS motor score was higher in the early HD group than both controls 
and premanifest subjects (both p<0.0001. Table 4-1). Mean UHDRS motor score 
in the premanifest group was also higher than controls (p=0.007). The HD group 
was also clearly scoring below ceiling at the UHDRS independence scale and 
TFC.
Most subjects scored within the non-depressed range on the Beck Depression 
Inventory (BDI) (18 controls (90%), 15 premanifest (71%) and 24 early HD 
subjects (67%)), with 20 subjects classified as depressed in total (two controls 
(10%), six premanifest (29%) and 12 early HD subjects (33%)). Although the 
proportion of controls who were depressed was slightly smaller than that in the 
other two groups this difference was not statistically significant (p=0.15).
4.3.3 Brain volumes
After correcting for head size and adjusting for differences due to age the mean 
brain volume in the HD group was smaller (9%) than that in controls (p<0.0001, 
see Table 4-2) and the premanifest group (p<0.0001). The mean volume in the 
premanifest group was smaller (3%) than that in controls (p=0.028). The 
difference between clinical stage 1 and 2 symptomatic subjects was not 
statistically significant (data not shown).
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Table 4-2 Mean (SD) baseline brain volumes, standardised to mean control TIV, with differences with and without adjustment for age
Control Premanifest Early HD Difference (Premanifest - Control) Difference (Early HD - Control)
(N=20) (N=21) (N=40) Crude Adjusted Crude Adjusted
Brain volume (ml) 1185 (34) 1175 (47) 1062(58) -9.6 (p=0.45) -27.2 (p=0.028) -122.7 (p<0.0001) ■114.4 (p<0.0001)
95% Cl 1169. 1201 1154,1197 1044, 1081 -34.7, 15.5 -51.5,-3.0 -146.3, -99.2 -133.6, -95.1
Negative differences indicate smaller volume in HD subjects relative to controls; crude differences are the absolute difference between groups before adjustment for age; 
adjusted differences are the differences having adjusted for age by including it as a covariate in the linear regression models.
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4.3.4 Cognitive performance
Group differences at baseline, adjusted for age and IQ, were converted to z- 
scores to facilitate comparisons between tests (by subtracting the control mean 
and dividing this by the control standard deviation). These are shown in Figure 
4-2. Raw and age- and IQ-adjusted differences between groups are shown in 
Appendix 4.
4.3.4.1 UHDRS and other executive and psychomotor tasks 
The HD group was statistically significantly worse than controls at category 
fluency (p<0.0001), phonemic fluency (p<0.0001), Stroop colour reading 
(p<0.0001), word reading (p<0.0001) and interference (p<0.0001), the SDMT 
(p<0.0001), the HMGT (p=0.007) and “A” cancellation (p<0.0001). The 
difference in UHDRS cognitive score (the sum of the three Stroop subtests, 
phonemic fluency and the SDMT) was also statistically significant (p<0.0001). 
The HD group was also slower than controls at TMT A and B and the difference 
between TMT B and A (all p<0.05), although not the ratio between these two 
scores. The HD group was also significantly worse than the premanifest group at 
all these measures.
There was no evidence of impairment in the premanifest group relative to 
controls although performance was approaching HD level at phonemic fluency 
(see Figure 4-2).
Very few subjects made errors on TMT A (one control (5%), five premanifest
(24%), three early HD subjects (8%)), and all of these made just one error, with
the exception of one premanifest subject who made two. The number of errors
did not differ significantly between groups. On TMT B eight controls (40%),
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seven premanifest (33%) and 21 early HD subjects (57%) made at least one 
error, and the early HD group made significantly more errors than the 
premanifest group (z=2.25, p=0.025).
4.3.4.2 Memory
The HD group was worse than controls at HVLT immediate recall (p=0.001), 
delayed recall (p<0.0001), percent recalled (p=0.01), and discrimination 
(p<0.0001). This group also scored, on average, fewer true positives (p<0.05) 
and more false positives (p<0.05) in the recognition task. After adjusting for 
immediate recall score, the early HD group was still impaired at delayed recall 
(p=0.007) and also at recognition discrimination (p=0.011). However, on 
average these subjects were no longer making fewer true positives than controls 
after adjusting for immediate recall score (p>0.05) although they were still 
making more false positives (p<0.05) (note that as 95% bootstrapped confidence 
intervals were used, precise p values were not obtained for these and similar 
analyses).
This group was also worse than controls at digit span forwards (p=0.002) and 
backwards (p<0.0001), RMF (p<0.0001) and RMW (p<0.05) and RMT 
difference (the difference between the RMF and RMW score, p=0.025, i.e. they 
were relatively more impaired on visual compared with verbal memory than 
controls were). The HD group was also significantly worse than the premanifest 
group on all these measures except the percent recalled on the HVLT.
There was no evidence of impairment in premanifest subjects relative to controls 
although they were approaching HD level in percent recalled in the HVLT.
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4.3.4.3 Naming
The HD group was worse at naming than the premanifest group (p=0.005) but 
there was no evidence that performance differed from controls. The premanifest 
group performed slightly better than controls (p=0.049). The HD group was 
slower at naming than controls (p<0.0001) and the premanifest group (p=0.002) 
and this difference remained after controlling for dysarthria by including the 
dysarthria score as a covariate (HD vs. controls, p<0.0001; HD vs. premanifest 
p=0.005).
The difference in naming latency between premanifest subjects and controls was 
not statistically significant.
4.3.4.4 Visuoperceptual
There was no evidence of differences between groups on the VOSP. The HD 
group was worse than controls at the Benton Facial Recognition Test (p<0.0001), 
and also worse than the premanifest group (p<0.0001).
4.3.4.5 Reaction time
The HD group was slower than both controls and the premanifest group at all 
numbered button presses (both near and far, p<0.05) and there was no evidence 
of a difference between premanifest subjects and controls. The HD group was 
also slower than both controls and premanifest subjects at returning to the central 
blue button after near and far numbered button presses (both p<0.05) and the 
premanifest group was also slower than controls on these measures (both 
p<0.05).
140
Thirty-two subjects made no errors, 21 made one error (seven controls (35%), 
four premanifest (19%) and 10 early HD subjects (25%)) whilst 28 made two or 
more errors (eight controls (40%), seven premanifest (33%) and 13 early HD 
subjects (33%)). The number of errors did not differ statistically significantly 
between groups, and the maximum number of errors (and therefore discarded 
trials) per subject was six trials out of 80. Very few subjects made perseverative 
errors (two controls (10%), one premanifest (5%) and six early HD subjects 
(15%)) and the number of perseverative errors did not differ statistically 
significantly between groups.
4.3.4.6 Emotion recognition
The HD group was significantly worse than controls and the premanifest group at 
total emotion recognition score (p<0.05). There was no evidence of a difference 
between premanifest subjects and controls. More detailed analysis of each 
emotion is reported in chapter 8.
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Figure 4-2 Age- and IQ-adjusted z-scores for the two patient groups relative 
to controls, with 95% confidence intervals
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Overall the HD group showed evidence of impairment in all tasks other than 
naming and visuoperceptual skills. In contrast in the premanifest group levels of 
impairment were low and generally not statistically significant, although on some 
tasks it was noted that they were approaching HD levels, and on the RT task they 
showed evidence of some impairment.
4. S. 5 Effect o f  motor impairment on psychomotor tasks in the early HD group 
When motor score was controlled for by including it as a covariate the HD group 
was no longer impaired relative to controls at phonemic fluency (p=0.27), Stroop 
colour reading (p=0.27), word reading (p=0.67), trail-making A (p>0.05), 
cancellation (p=0.68) or the four RT measures (all p>0.05). However this group 
was still impaired relative to controls at Stroop interference (p=0.041), SDMT 
(p=0.002), and trail-making B (p<0.05), and the difference nearly reached 
statistical significance for category fluency (p==0.063).
4.3.6 Relationship between brain volume and clinical and cognitive measures 
in HD gene carriers
There was no evidence of a relationship between brain volume and UHDRS 
independence score, TFC or disease duration in the HD group alone.
There was a statistically significant effect of CAG repeat length on brain volume 
in the gene-carrying group as a whole (premanifest and early HD), after adjusting 
for age and group, such that an increase of CAG repeat length by one was 
associated with a 9.2ml decrease in brain volume (95% Cl -17.5, -0.9, p=0.03. 
Figure 4-3). There was no evidence that the slope of this relationship differed 
between the premanifest and HD groups.
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Figure 4-3 Relationship between brain volume (standardised to mean age in 
the whole cohort) and CAG repeat length in the premanifest and early HD 
groups
The relationship between volume and score differed between the premanifest and 
early HD groups for a number of tests. In the HD group, but not the premanifest 
group, smaller brain volume was associated with worse performance on UHDRS 
motor (p=0.001), HVLT discrimination (p=0.001), TMT A (p<0.05), Benton 
Facial Recognition (p<0.0001), Ekman emotion recognition (p<0.05), and near 
and far button press times (both p<0.05). In the premanifest group, but not the 
HD group, smaller volume was associated with worse performance on the GNT 
(p=0.013) (Table 4-3).
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Table 4-3 Slope (95% confidence intervals) of the relationship between brain volume and score in the
patient groups, when these slopes differed between groups, adjusted for age and estimated premorbid IQ
Premanifest Early HD
(N=21) (N=40)
Test Slope (points per ml) Slope (points per ml)
UHDRS motor -0.03 (-0.07, 0.01)p=0.08 -0.10 (-0.16, -0.04) p=0.001
HVLT discrimination -0.01 (-0.02, 0.01) p=0.42 0.02 (0.01,0.03) p=0.001
GNT -0.03 (-0.06, -0.01)p=0.013 0.01 (-0.02, 0.03) p=0.76
TMT A (sec) 0.01 (-0.04, 0.07) p>0.05 -0.07 (-0.13,-0.02) p<0.05
Benton -0.02 (-0.05, 0.02) p=0.35 0.04 (0.02, 0.07) p<0.0001
Ekman -0.02 (-0.09, 0.07) p>0.05 0.10(0.04. 0.17) p<0.05
Near button press (msec) 0.07 (-0.99, 1.31)p>0.05 -1.30 (-1.95.-0.64) p<0.05
Far button press (msec) 0.01 (-1.06, 1.41)p>0.05 -1.26 (-2.02,-0.51) p<0.05
Slope indicates the effect a I ml increase in brain volume has on the respective test; units are always points per ml, unless the test is 
timed in which case units are specified in brackets; where 95% bootstrapped CIs were used precise p values were not obtained.
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Overall there was a tendency for smaller brain volume to be associated with 
worse or slower scores at all tests. There was an effect of volume on score in all 
gene carriers (premanifest and HD) for HVLT immediate (p=0.039), RMF 
(p=0.003), RMW (p<0.05), phonemic fluency (p=0.004), SDMT (p=0.001), 
HMGT (p=0.015), TMT B (p<0.05), the difference between TMT A and B, and 
the ratio between them (both p<0.05) and VOSP silhouettes (p=0.01). In all 
cases smaller volume was associated with worse performance (Table 4-4).
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Table 4-4 Slope (95% confidence intervals) of the relationship between brain
volume and score in the 61 gene carriers, adjusted for age and estimated
premorbid IQ
Test
HD gene carriers (Premanifest & HD) 
Slope (points per ml)
UHDRS cognitive 0.24 (-0.01,0.49) p=0.05
Stroop colour 0.05 (-0.01, 0.1 l)p=0.09
Stroop word 0.02 (-0.08, 0.12) p=0.69
Stroop interference 0.01 (-0.03, 0.05) p=0.66
SDMT 0.08 (0.03,0.12) p=0.001
Phonemic fluency 0.08 (0.03,0.14) p=0.004
Category fluency 0.03 (-0.00, 0.06) p=0.059
HMGT 0.01 (0.003,0.02) p=0.015
TMT B (sec) -0.41 (-0.67,-0.15) p<0.05
TMT B-A (sec) -0.36 (-0.63,-0.12) p<0.05
TMT B/A (sec) -0.007 (-0.01,-0.001) p<0.05
Cancelling As (sec) -0.03 (-0.07, 0.01)p=0.15
HVLT immediate (/36) 0.03 (0.01,0.05) p=0.039
HVLT delayed (/12) 0.01 (-0.01,0.02) p-0.14
HVLT % recalled 0.01 (-0.09, 0.12) p=0.82
Digit span forwards (/21) 0.01 (-0.01, 0.02) p=0.57
Digit span backwards (/21) 0.01 (-0.01,0.03) p=0.20
RMF (/50) 0.05 (0.02, 0.08) p=0.003
RMW (/50) 0.02 (0.01,0.04) p<0.05
VOSP (/15) 0.02 (0.01,0.03) p=0.01
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HD gene carriers (Premanifest & HD)
Test Slope (points per ml)
Return from near button press (msec) -1.48 (-2.27,-0.45) p<0.05
Return from far button press (msec) -1.10 (-1.98, -0.12) p<0.05
Slope indicates the efifect a 1ml increase in brain volume has on the respective test; units are 
always points per ml, unless the test is timed in which case units are specified in brackets.
4.3.7 Prediction o f onset in the premanifest group
In general performance tended to decline slightly with estimated proximity to 
onset, although effects were very small and close to zero. There was a very 
slight tendency for higher motor score to be associated with proximity to onset 
(an increase of 2.1 points for each 0.1 increase in probability, 95% Cl -2.7, 44.8, 
p=0.079). No other clinical, cognitive or MRl measures were associated with 
probability of motor onset.
4.3.8 Comparison o f NART and the Spot the Word Test
The two measures were highly correlated (r=0.78, p<0.0001). The mean 
difference between IQ measured by the NART and the Spot the Word Test did 
not differ between groups, and hence mean (SD) IQ measures for the whole 
cohort are shown in Table 4-5, with the Spot the Word scores converted to have 
the same distribution as the NART. The mean difference between the two 
measures was statistically significant (p=0.0053) with the Spot the Word Test 
giving, on average, significantly lower estimates of IQ than the NART.
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Table 4-5 Mean (SD) NART and Spot the Word scores for the whole cohort
at baseline, with difference (95% confidence intervals)
Mean (SD)
(N=81)
NART 105.0(11.7)
Spot the Word 102.2(13.8)
Difference 2.7 (8.6)
95% Cl 0.8, 4.6
The standard deviation of the differences was 8.6 and the limits of agreement 
were -14, 20. Variance was higher in the Spot the Word test (p=0.022) although 
this was driven by two outliers in the premanifest group and not representative of 
the data overall.
4.4 DISCUSSION
Deficits have been shown across cognitive domains in this cohort of early HD 
subjects, including immediate and delayed recall, recognition memory, face 
recognition and facial emotion recognition, as well as executive and 
psychomotor tasks. In addition, early HD subjects had increased naming latency 
although they were able to name similar numbers of items to controls. There was 
little evidence of impairment in the premanifest subjects on the same battery, 
other than increased reaction times at button pressing.
4.4.1 Cognitive deficits in the early HD cohort
The early HD cohort is fairly typical of many reported elsewhere, consisting of
predominantly stage 1 and 2 subjects, with a mean disease duration of just over
four years. Compared to the control sample their greatest deficits were mostly on
151
motor or psychomotor tasks such as the reaction time task, SDMT, Stroop colour 
and word reading, and Trail Making A, but interestingly they also showed similar 
levels of deficit on the RMW, and the Ekman emotion recognition test (based on 
the z scores of the group differences).
Early HD subjects showed a greater absolute difference between TMT A and B 
than controls, but the ratio between the two times did not differ between groups, 
suggesting that although the HD subjects were slower, they were not 
disproportionately slower for the more difficult task. HD subjects also showed 
relatively greater impairments at Stroop colour and word reading than Stroop 
interference, adding weight to suggestions that one of the primary deficits in HD 
is a loss of "automaticity" which manifests as an inability to perform relatively 
automated tasks (such as word reading) whilst tasks which naturally require more 
cognitive control (such as the Stroop interference task) are relatively less affected 
(Snowden et al. 2001).
In order to assess the contribution of motor ability to the impairments seen on 
these psychomotor tasks, group differences were adjusted for motor ability by 
including UHDRS motor score as a covariate. The HD group was no longer 
significantly impaired relative to controls at phonemic fluency, Stroop colour 
reading, word reading, trail-making A, cancellation or the four RT measures. 
However this group was still significantly impaired at Stroop interference, 
SDMT, and trail-making B, and the difference approached significance for 
category fluency. It seems likely that in the former tasks motor skills contribute 
significantly to performance but that in the latter poor motor skills alone are not 
sufficient to explain impaired performance, which may reflect problems with
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higher-level cognitive functions. It is notable that trail-making A performance 
(joining numbers in sequence) was unimpaired after motor score was taken into 
account, whereas trail-making B performance, with its more cognitively- 
demanding switching component, was still impaired. Both phonemic and 
category fluency depend on phonemic switching ability which has been shown to 
decrease with increasing motor score in HD (Rich et al. 1999; Ho et al. 2002). 
However, adjusting for motor score had a greater effect on the phonemic fluency 
than the category fluency impairment, which suggests that of the two phonemic 
fluency may rely more heavily on motor ability, perhaps because of the 
difficulties associated with rapid production of words beginning with the same 
phonemes.
Patients with HD were also impaired at the relatively novel test of homophone 
meaning generation (Warrington 2000). This test requires multiple switches 
between concepts and is untimed. It has been shown to be sensitive to frontal 
lobe dysfunction and has an advantage in being less subject to ceiling effects 
than some tests in this domain. This was demonstrated by the wide range of 
scores in all three subject groups, although the premanifest subjects tended to 
perform as well as, and in some cases better than, controls. Follow up of this 
population will demonstrate whether subtle drop off in performance can be 
detected as the premanifest subjects approach onset.
Although memory skills were generally impaired, the largest effects were seen 
for recognition memory (both words and faces and HVLT discrimination). Free 
recall of words (both immediate and delayed) and digit span forwards and 
backwards were also impaired, but to a lesser extent. This appears to contrast
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with some earlier reports that the main impairment in HD is one of retrieval (as 
opposed to storage) and that this is reflected in better recognition than free recall 
scores (see Craufurd and Snowden 2002) and agrees with a recent meta-analysis 
showing that in general the effect sizes for group differences in recall were no 
different to those for recognition (Montoya et al 2006). However, typically in 
recognition tests controls are performing at or near ceiling, and their variance is 
therefore reduced, which can artificially inflate the effect of group differences. 
An examination of the raw data suggested that this might be the case for the 
RMW and HVLT discrimination score, as well as HVLT delayed recall, at which 
a number of subjects, but mainly controls, scored at ceiling.
Relative to controls, early HD subjects were impaired at each part of the HVLT; 
they learnt fewer words in the early trials, recalled proportionately fewer after a 
delay, and recall was not improved to control levels by testing recognition. The 
recognition score reported here is the number of true positives minus false 
positives in an auditory “yes / no” recognition test, meaning that subjects could 
correctly recognise all 12 targets but subsequently be penalised for false 
recognition of distractor items. Although everyone tended to score quite highly 
on this task, the early HD group tended to get fewer true positives and more false 
positives than controls, suggesting that their impairment arose from both a failure 
to recognise target items as well as misclassification of distractors.
However, when recall and recognition performance were adjusted for the number 
of words recalled originally (an index of encoding) there was no longer a 
statistically significant difference between the number of true positives 
recognised in the early HD and control groups, although this difference remained
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for delayed recall and for the number of false positives recognised. This 
confirms theories that, given their level o f encoding, early HD subjects can 
correctly recognise as many target stimuli as controls. This also bears out Lang 
et al.'s (2000a) account, which suggests that if false positives are taken into 
account in recognition test scores then there is little to distinguish recall and 
recognition performance in HD. Early HD subjects were still making more false 
positives than controls, and this contributed to the difference in recognition 
discrimination score even when immediate recall score was taken into account.
The RMT is different, in that each target is presented with a distractor and the 
subject must choose one, meaning that the total recognition score takes errors 
into account. Again, recognition of words and faces was impaired, with a 
relatively greater impairment shown for faces, although again this might be 
partly due to the reduced variance in controls, a number of whom scored at 
ceiling on this task. It is hard to compare the RMT with the HVLT since the 
paradigms are different, but again these results demonstrate an impairment in a 
recognition task that includes false positive scores, and that these impairments 
cover auditory verbal stimuli, and visual verbal and facial stimuli.
It has been suggested that in HD a failure to organise information or to use 
strategies during encoding and recall, rather than an inability to store information 
per se, underlies the impairments seen on memory tasks, and these results seem 
to confirm this. The data presented here also suggest that subjects with early HD 
also show increased levels of false positive recognition, which may also be 
related to disruption to prefrontal regions thought to be involved in monitoring 
retrieval in recognition tasks (Henson et al. 2000). Further work with this cohort
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could investigate whether this pattern changes with the introduction of strategies 
during learning; even if this were the case, a paradigm such as the HVLT, in 
which true and false target stimuli are presented separately, might still be 
sensitive to impairment in early HD if subjects have difficulties judging their 
level of confidence in target stimuli.
The early HD group was not impaired at a very basic test of visuoperceptual 
skills, but was impaired at facial recognition and facial emotion recognition, a 
pattern of findings that is common in early disease (Jacobs et a l 1995; de Boo et 
al 1997; Lawrence et al 2000; Milders et al 2003). The facial emotion 
recognition deficit is discussed in more detail in chapter 8.
There was no evidence that naming was impaired in the early HD cohort, which 
is typical of the early stages, although naming deficits have been detected in 
subjects as the disease progresses (Hodges et al 1991; Craufurd and Snowden 
2002). Errors were too few to be analysed by category but HD subject errors 
were predominantly either “don’t know” errors or perceptual, e.g. mistaking the 
handcuffs for binoculars or the tassel for a broom and then correcting this after 
prompting. However there were also some ambiguous semantic / perceptual 
errors (mistaking the buoy for a sandcastle) and semantic / phonemic errors 
(labelling the handcuffs “cufflinks”). Despite not showing significant 
impairment at naming, early HD subjects were significantly slower than controls. 
The majority (twenty-seven) of the 40 HD subjects scored zero on the dysarthria 
subscale of the UHDRS (“normal”) with 11 subjects rated as “unclear but no 
need to repeat” and the remaining two as “must repeat”. Even when dysarthria 
scores were adjusted for in the latency analysis group differences remained,
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suggesting that slower naming was at least partly due to cognitive slowing rather 
than an articulatory deficit. Reaction times for production of phonemes with 
different articulatory requirements are unimpaired in early HD (Ludlow et al 
1987) which again reinforces the theory that the slower naming times seen here 
were not due to motor speech problems. Cognitive slowing has been 
demonstrated previously in HD using an executive function task (Hanes 1996) 
but has not been shown before in confrontation naming. It would be interesting 
to follow the premanifest cohort to investigate whether similar slowing could be 
demonstrated prior to motor onset.
4.4.2 Cognitive deficits in the premanifest cohort
The 21 premanifest subjects were on average 18 years from estimated motor 
onset, and only one of them was less than 10 years from onset so as a group these 
subjects were unlikely to show differences from control performance. However, 
although in this study there was very little evidence of impairment on any of the 
tests used, others have reported that even when performance on these tests is still 
within clinically-normal limits, deficits can be detected with sufficiently large 
subject numbers, and that performance tends to decline with proximity to 
estimated motor onset (Snowden et al 2002; Paulsen et a l 2006a; Solomon et al 
2007; Stout et a l 2007; Vemy et al 2007). It also seems likely that decline in all 
modalities in premanifest subjects is very slight until within the last 5-10 years 
prior to estimated onset, at which point the rate of decline increases and appears 
relatively linear (Paulsen et al 2007). As most of the cohort in this study were 
estimated to be more than 10 years from onset, they were likely to be 
undergoing, at most, only very subtle decline. Although there was a slight trend
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for greater UHDRS motor scores to be associated with proximity to onset, effects 
on other tasks were very small and non-significant.
Despite this, in most cases the premanifest mean was worse than controls 
suggesting that levels of performance might already be beginning to decline. 
The group was significantly impaired at returning to press a central blue button 
in the RT task which supports other findings that motor abnormalities may be 
detectable even in those more than 10 years from predicted onset (Stout et al. 
2007) although in addition to a button-pressing task these authors also found 
TMT B to be impaired, which was not found in the current study.
The RT task had two components, pressing one of four numbered buttons in 
response to an unpredictable on-screen stimulus, and then returning to press the 
central blue button in response to a predictable on-screen stimulus. The early 
HD group was impaired at both these aspects, which is consistent with their 
slowed motor abilities. The premanifest group was only impaired at the 
predictable part of the task, so they were no slower than controls in their reaction 
to the number, but failed to take advantage of the knowledge that the central 
button was always pressed after a number trial. The ratio of time to press 
unpredictable to predictable buttons in controls was 1:0.4, whilst in premanifest 
and early HD subjects it was 1:0.5 and 1:0.6 respectively.
A relatively greater decline in simple motor tasks compared with more
cognitively demanding ones has been demonstrated in manifest HD, and it was
suggested that an impairment in implementing and executing automatic tasks,
relative to those under effortful control, might underlie this (Snowden et al
2001). A similar deficit in acquiring a repetitive motor response might explain
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the pattern of results seen here, and this fits well with similar deficits in motor 
sequence learning found elsewhere (Feigin et al. 2006). In particular it has been 
shown that even under explicit learning conditions premanifest subjects are 
impaired at spatial accuracy and modulating movement time, relative to controls 
learning the same task, whereas there was no difference between groups when 
targets appeared in a random order (Ghilardi et al. 2008). However the cross- 
sectional results presented here also suggest that early HD subjects, although 
slowed, are no slower than premanifest at the predictable part of the task. This 
finding therefore needs to be replicated in a larger group, nearer to estimated 
onset and followed longitudinally. If confirmed, tasks of this nature might be 
suitable for detecting very early psychomotor deficits in this group.
It is also important to appreciate that the estimate of years to onset is likely to be 
somewhat conservative, given that here, as elsewhere in the HD literature, onset 
was defined as a 60% chance of showing motor signs, and that the existing 
model does not take into account other variables which have been suggested to 
modify age at onset (e.g. parental age at onset, paternal vs. maternal 
transmission) (Langbehn et al. 2004). Whilst this measure allows comparison of 
premanifest cohorts between studies, and it is likely that the majority of the 
current cohort are relatively far from onset, a more accurate representation of 
their current status will only be possible retrospectively, after longitudinal 
follow-up confirms their true time of motor onset.
4.4.3 Brain volumes and associations with cognitive performance 
Whole-brain volumes were similar to those reported in chapter 3, with the HD 
group on average 114ml smaller than the control group. Differences in
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methodology make it hard to compare absolute volumes between studies but this 
difference equates to a 9% loss in HD relative to controls, which is similar to the 
differences found in other early HD populations, ~9% by Kassubek et al. 
(2004a), and between 10% (grey matter) and 17% (white matter) by Fennema- 
Notestine et al. (2004). Others have found reductions of smaller magnitudes 
which were not significant or only reached significance in more advanced 
subjects (Aylward et al. 1998; Beglinger et al. 2005), but this may be partly to do 
with the smaller sample sizes (and corresponding lack of statistical power) in 
these studies. As the striatum is less than 20ml in healthy adults (Aylward et al. 
2004) some (the majority) of the loss in the HD group must be attributable to 
extra-striatal atrophy.
Total brain volume in the premanifest group was also decreased relative to the 
controls. Although smaller brain volumes have been reported elsewhere in 
premanifest subjects these differences were not statistically significant (Reading 
et al. 2005; Paulsen et al. 2006b). Brain volume in all gene carriers was 
associated with CAG repeat length (having adjusted for age). Neither age nor 
CAG repeat length was associated with disease duration in the early HD cohort 
so this was not simply an effect of those with longer CAG repeat lengths having 
had the disease for longer at the time of entry to the study. It may be that those 
with higher CAG repeat lengths have a faster rate of progression but this needs to 
be confirmed longitudinally.
In the gene carriers as a whole smaller brain volume was indicative of worse 
performance at memory tests, as well as some executive function tasks and a 
visuospatial task, suggesting that performance at these tasks falls off gradually
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with increasing brain loss. In contrast smaller brain volume was associated with 
worse performance at the more overt motor tasks, as well as HVLT 
discrimination, and face and emotion recognition, in the HD group alone, 
suggesting that performance on these tasks is not strongly related to atrophy until 
after a certain point has been reached (in this case motor onset). Smaller brain 
volume was associated with worse performance on the GNT in the premanifest, 
but not the early HD group, which is hard to interpret given that this was one of 
the few tasks on which neither group showed impairment relative to controls.
This suggests that whole-brain volume is a sensitive measure, despite the fact 
that it encompasses regions of the brain that are likely to be unaffected as well as 
those that are. Structure-function relationships cannot be inferred from 
associations with whole-brain volume but it seems likely that atrophy in 
extrastriatal, as well as striatal regions, must underlie these associations, given 
the magnitude of the differences in brain volume seen here. Whole-brain volume 
has previously been found to be a good predictor of cognitive function (Harris et 
al. 1996) and as mentioned in chapter 1, there is increasing evidence that cortical 
and white matter atrophy is widespread quite early on in the disease (Rosas et al. 
2005; Paulsen et al. 2006b; Rosas et al. 2008).
4.4.4 Other comments
The Spot the Word test correlated well with the NART as an estimate of 
premorbid intelligence although underestimated IQ slightly across all groups 
(assuming that the NART, as the more established of the two, is giving accurate 
measures of IQ). However as this bias was the same for both HD subjects and 
controls. Spot the Word score could still be used as a covariate to adjust for
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differences due to premorbid IQ. The limits of agreement between the two 
measures were quite wide, however, meaning that the Spot the Word Test could 
give an estimate that was approximately one standard deviation over or under the 
NART estimate. Given that the NART is well-established as an estimate of 
premorbid IQ, it may be preferable to use the NART (at least in early HD) if IQ 
needs to be estimated accurately, rather than for use as a nuisance covariate.
It had been suggested that the Spot the Word might be less susceptible to 
problems related to HD such as dysarthria, which might unfairly penalise 
subjects on the NART test which requires words to be pronounced out loud. The 
AN ART has been found to decrease very slightly with proximity to onset in 
premanifest subjects (Solomon et al. 2007) and so this work is followed up in 
chapter 9 which looks at the stability of both tests over time.
Although this study used a range of cognitive tasks in a relatively large HD 
cohort it was still subject to a number of limitations. The battery, whilst 
extensive, could not cover all domains in detail and thus these findings may not 
fully describe the overall nature of the deficits seen in HD. Few tests of 
visuoperceptual function and naming were used, in part because these skills tend 
to be relatively less affected in the early disease stages and I wanted to focus on 
skills that were likely to show promise as markers of change using standard 
neuropsychometric tests. It is likely that deficits in these domains could have 
been detected in this cohort with more sensitive tests, as others have shown 
previously (Hodges et al. 1991 ; Lawrence et al. 2000).
Whilst the early HD cohort was relatively large, and in terms of CAG repeat
length and disease duration, relatively homogeneous, the premanifest subjects
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covered a wide range of estimated years to onset, and only one was thought to be 
within 10 years of clinical diagnosis (although as discussed it must not be 
forgotten that this measure is only an estimate). Subjects were recruited 
according to the criteria in section 2.1.1, i.e., they needed to have a copy of the 
abnormal gene without having been diagnosed as showing unequivocal motor 
signs. There was no attempt to recruit subjects at a particular proximity to onset, 
and CAG repeat sizes were not known until after recruitment was complete. The 
small size of this cohort, coupled with the distance from onset, meant it was 
unlikely that effects would be large enough to detect and in most domains this 
was the case. This reflects the nature of the cohort, and does not contradict the 
wide-ranging deficits which have been demonstrated in substantially larger, 
closer-to-onset cohorts (Paulsen et al. 2007).
4.5 CONCLUSION
This study demonstrated a wide range of impairments in early HD covering 
psychomotor, executive function, memory and emotion recognition, but sparing 
visuoperceptual and naming skills. Of note, deficits in recognition memory and 
emotion recognition were as great as those shown on some executive and 
psychomotor tasks, and increased naming latency was shown, in the absence of a 
naming deficit. In some, but not all tasks with a motor component, performance 
was explained by the subjects’ poor motor ability.
The premanifest group was on the whole very far from onset, at a stage where 
little impairment was expected to be evident. However impairment could be 
detected on some tasks, in particular the RT task for which results suggested that
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these subjects had relatively more difficulty acquiring a predictable motor skill 
than controls.
Whole-brain volume, despite being a measure that encompasses regions which 
are atrophying as well as regions which are not, was associated with CAG repeat 
length and performance on a number of cognitive tasks, suggesting that it may 
prove to be a sensitive marker of disease progression.
Work in the following chapters builds on these results, using both VBM (a 
whole-brain approach) and caudate volumetry to elucidate further the patterns of 
atrophy and structure-function relationships in this cohort. This cross-sectional 
study also served as a baseline assessment, and longitudinal follow-up of these 
subjects is reported in later chapters.
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5 CAUDATE VOLUME AND ITS RELATIONSHIP WITH 
COGNITION IN HUNTINGTON’S DISEASE
5.1 INTRODUCTION
Caudate atrophy is one of the earliest and most striking features of Huntington’s 
disease and has been demonstrated in premanifest subjects at around 15 years 
prior to estimated motor onset (Aylward et al. 2004; Paulsen et al. 2006b), but 
not in subjects who were on average more than 20 years from onset (Paulsen et 
al. 2006b). However, it is important to note that different estimates of onset have 
been used, including one that takes parental age at onset into account (Aylward et 
al. 2004) and the probabilistic survival model of Langbehn et al. (2004), and in 
some cases it is not clear what probability of onset was used to determine years 
to onset (Paulsen et al. 2006b). Caudate atrophy has also been shown to progress 
with advancing disease (Aylward et al. 1997; Aylward et al. 2004).
Recent work suggests that fronto-striatal circuits are important for integrating 
sensorimotor, associative and affective information in order to leam and 
modulate behaviours in response to the environment (Costa 2007; Samejima and 
Doya 2007). The striatum is thought to play a role in goal-directed behaviour 
and skill-leaming by associating actions with rewards and hence reinforcing 
particular stimulus -  action -  outcome associations (Poldrack 2002; Delgado 
2007). With increasing learning these associations become habitual or 
“automatic” and this is associated with a shift in activation from the cortex to the 
striatum (Saling and Phillips 2007) and from medial to more dorsal striatal 
regions (Balleine et al. 2007; Costa 2007).
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Parallel and largely functionally-segregated cortico-striatal circuits have been 
described (Alexander et al 1986), which are thought to underlie motor, 
oculomotor, associative (executive function) and emotional processes in humans 
(Penney, Jr. and Young 1983; Cummings 1993; Bonelli and Cummings 2007). 
More recently it has been suggested that the circuits are not completely separated 
and this explains why motor, cognitive and emotional symptoms are seen in HD, 
even though in the early stages damage is primarily to the putamen and 
dorsomedial caudate (motor and associative circuits) rather than the ventral 
striatum (thought to be part of the emotional circuit) (Joel 2001).
Many studies in HD assumed that caudate or putamen atrophy caused the early 
cognitive signs of the disease, although few included both neuropsychometiy and 
imaging in order to investigate this directly. There is some evidence that reduced 
caudate volume is associated with psychomotor, executive and visuospatial 
dysfunction in HD (Bamford et al 1989; Starkstein et a l 1992; Peinemann et al 
2005; Douaud et al 2006) although not all these studies tested function in other 
domains and those that did reduced cognitive skills to sets of factors making it 
hard to tease out specific structure-function correlates.
Manual segmentation is considered the “gold standard” method for quantifying 
volumes on MRI. However, although generally considered to be more accurate 
than automated methods, manual methods can be open to bias and measurement 
error. Techniques have been developed to minimise these effects, such as 
aligning scans in a standard orientation prior to segmentation, and blinding the 
segmentor to laterality. Reproducibility can also be aided by using interactive 
thresholding and arbitrary cut-offs. This study demonstrates a protocol which
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aimed to minimise potential operator bias and maximise inter- and intra-rater 
reproducibility.
The work in this chapter therefore aimed to measure caudate volume reliably, to 
examine whether caudate atrophy could be detected in the current cohort of 
premanifest HD subjects, and to investigate the clinical and cognitive correlates 
of this atrophy.
5.2 METHODS
5.2.1 Subjects
Subjects were the same 81 as those reported in chapter 4, see section 4.2.1 for 
details.
5.2.2 Assessments
Subjects underwent the same assessments described in chapter 4, sections 
4.2.2.1, 4.2.2.2, and 4.2.2.3. That is, they underwent clinical and cognitive 
assessments and had 1.5T MRI scans.
5.2.3 Caudate segmentation
Scans were segmented using MIDAS (see section 2.5.3.1 and Figure 5-1). 
Whole brains were segmented as in chapter 4. Whole brains were then registered 
into MNI (standard) space using a six degrees of freedom (dof) algorithm (using 
translations and rotations). This resulted in all whole brains being oriented in the 
same standard space to facilitate consistent segmentation.
Each image was then flipped across the mid-sagittal plane, in order to produce 
two mirror-image scans. The caudate was always segmented on the right-hand
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side of the image. The head and body of the caudate were included with the 
medial border defined by the lateral ventricle and the lateral border by the 
internal capsule. Anteriorly the caudate was included as soon as it was clearly 
visible next to the ventricle coronally, and posteriorly and superiorly the body 
was included for as long as was visible. Elsewhere arbitrary cut-offs were 
imposed to improve reproducibility: inferiorly segmentation stopped below the 
last slice in which the ventricle was visible, and the nucleus accumbens was 
excluded on coronal view, in line with the inferior edge of the ventricle if no 
border was clear.
Caudates were segmented axially from the most superior slice on which the 
structure was visible next to the lateral border of the ventricle, until the slice 
below the most inferior view of the ventricle. Intensity threshold constraints 
were used for initial delineation of the caudate boundary, using lower and upper 
thresholds of 69% and 110% of mean brain intensity to exclude CSF and WM 
respectively. Two orthogonal views were available to the operator who manually 
edited the boundary in those regions for which the thresholds were not sufficient 
(Figure 5-1). The initial region was then edited in coronal view to ensure that the 
nucleus accumbens was excluded. All caudates were segmented by two raters 
whose intra- and inter-rater reproducibility (intraclass correlation coefficients) 
was >0.99 (mean absolute difference ~4% of mean caudate volume).
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Caudates were segmented on the right o f the image in axial view, with sagittal 
(or coronal) view available for reference and later editing. Panel 1 shows initial 
seed placement and boundaries defined by thresholds; panel 2 shows the same 
slice after manual editing o f the region that spilled outside the caudate: panel 3 
shows the region after further segmenting; A shows axial view, B shows sagittal 
vieM>; (continued on following page).
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Figure 5-1 Screenshots of MIDAS software being used to segment the 
caudate nucleus
Panel 4 shows the region in coronal view (A) and sagittal view (B); panel 5 
shows where the nucleus accumbens has been excluded on coronal view.
5.2.4 Statistical analysis
To correct for differences in head size baseline caudate volumes were 
standardised for TIV as outlined in section 3.2.3.2. Where caudate volume is 
mentioned in the results it always refers to volume standardised to mean control 
TIV.
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5.2.4.1 Effect o f adjusting for head size on gender differences
As it has previously been shown that adjusting caudate volumes for the mid-skull 
area (an estimate of head size) reduced but did not eliminate differences due to 
gender (Raz et a l 1995), gender differences in caudate volume in controls were 
assessed both before and after standardising to mean control TIV, by regressing 
each measure of caudate volume on gender, with robust standard errors, and 
adjusting for age.
In the following analyses the effects of variables which can independently affect 
brain volume (age) and cognitive performance (age and estimated premorbid IQ) 
were controlled for by including them as covariates where necessary.
5.2.4.2 Group differences in caudate volume
In order to investigate whether differences between left and right caudate 
volumes differed between groups, a linear regression model was used to compare 
the ratio of left to right caudate volumes between groups, adjusting for age.
A linear regression model was then used to compare caudate volumes (both left 
and right caudates) between groups, with robust standard errors to allow 
variances to differ between groups, and adjusting for age. In order to investigate 
whether the association between volume and variables of interest differed 
between the left and the right caudate, variables of interest were regressed on a 
difference measure (left caudate - right caudate).
5.2.4.3 Associations with clinical and cognitive variables
Separate linear regression models were used to look at the associations between 
caudate volume and estimated probability of onset (Langbehn et al. 2004) in the
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premanifest group, and UHDRS TFC, independence score and disease duration 
in the early HD group, adjusting for age.
As in chapter 4, separate linear regression models (with robust standard errors) 
relating either CAG repeat length, cognitive scores or UHDRS motor score, to 
total caudate volume, group and their interaction, were used to investigate 
whether the association between these variables and caudate volume differed 
between the premanifest and HD groups. In situations where there were 
significant interactions the slope of the association in each group was examined 
to see if, in either group, the association was significantly different from zero. 
Secondly, for variables for which there was no evidence of an interaction, linear 
regression models were used to look for an association between volume and 
score in all gene carriers, having adjusted for differences due to group. Age and 
estimated premorbid IQ were included as covariates in all cognitive analyses.
The models described above were also used for data which were not Normally 
distributed, but where Normality assumptions were violated 95% bias-corrected 
bootstrap confidence intervals with 1000 replicates were used; these data were 
the RMW, trail-making and reaction times, and the Ekman emotion recognition 
score.
5.3 RESULTS
As subjects were the same as those reported in chapter 4, demographic data can 
be found in Table 4-1, page 135.
172
5.3.1 Effect o f adjusting for head size on gender differences 
Prior to adjustment for TIV males had, on average, larger total caudate volume 
than females (mean difference 1.1ml, 95% Cl 0.6, 1.7ml, p<0.0001, after 
adjusting for age, see Table 5-1). After adjustment for TIV this difference was 
reduced and no longer statistically significant (mean difference 0.2ml, 95% Cl 
-0.3, 0.8ml, p=0.34, after adjusting for age, see Table 5-1). This mean difference 
was therefore reduced from -14% to <3% of caudate volume (-8ml).
Table 5-1 Mean (SD) caudate volumes in male and female controls, before 
and after adjusting for TIV, with differences (95% confidence intervals)
Male Female Difference (95% Cl)
Caudate volume (ml)^ (N=7) (N=13)
Raw 8.6 (0.5) 7.5 (0.6) 1.1 (0.6, 1.7)
TIV-adjusted 8.1 (0.5) 7.8 (0.6) 0.2 (-0.3, 0.8)
a Volumes presented here are age-adjusted
Caudate volumes presented in the remainder of this chapter have all been 
standardised to mean control TIV.
5.3.2 Group differences in caudate volume
There was no evidence of a difference in the ratio of left to right caudate volumes 
between groups, after adjusting for age (all p>0.09). A post hoc paired t-test on 
all 81 subjects showed that the right caudate was on average significantly larger 
than the left (mean difference 0.08 ml, 95% Cl 0.04, 0.11 ml, p<0.0001).
The premanifest group had smaller caudates than controls (left: p=0.005; right:
p=0.001. -12% smaller for both left and right) and the early HD group had
smaller caudates than both controls and the premanifest group (vs. controls, left
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and right: both p<0.0001, -40% smaller for both left and right; vs. premanifest, 
left and right: both p<0.0001, -30% smaller for both left and right), adjusted for 
age (see Table 5-2, Figure 5-2).
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Table 5-2 Mean (SD) left and right caudate volumes in each group, standardised to mean control TIV, and differences with and without
adjustment for age
Control Premanifest Early HD Difference (Premanifest - Control) Difference (Early HD - Control)
(N=20) (N=21) (N=40) Crude Adjusted Crude Adjusted
Left (ml) 3.88 (0.30) 3.47 (0.60) 2.27 (0.50) -0.41 p=0.006 -0.43 p=0.005 -1.61 p<0.0001 -1.60 p<0.0001
95% Cl 3.74, 4.02 3.20, 3.74 2.11,2.43 -0.70, -0.12 -0.73,-0.14 -1.81,-1.40 -1.80,-1.39
Right (ml) 4.04 (0.26) 3.54 (0.61) 2.31 (0.47) -0.50p=0.001 -0.51 p=0.001 -1.73 p<0.0001 -1.72 p<0.0001
95% Cl 3.92, 4.16 3.26, 3.82 2.16, 2.46 -0.78, -0.21 -0.80, -0.22 -1.92,-1.54 -1.92,-1.53
Negative differences indicate smaller volume in HD subjects relative to controls; crude differences are the absolute difference between groups before adjustment for age; 
adjusted differences are the differences having adjusted for age by including it as a covariate in the linear regression models.
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Figure 5-2 Left and right caudate volumes in each group, standardised to 
mean age in the whole cohort
There was no evidence that the relationship between volume and other variables 
differed statistically significantly between the left and right caudate. This was 
true for CAG repeat length and cognitive scores (all gene carriers), probability of 
onset (premanifest group), disease duration, UHDRS motor score, total 
functional capacity and independence score (early HD group). Hence for all 
further analyses the left and right caudate volumes were combined.
5.3.3 Associations with clinical variables
In the 61 gene carriers CAO repeat length was associated with total caudate 
volume, after adjusting for age and group, such that an increase in CAG repeat 
length of 1 repeat was associated with a decrease in total caudate volume of 
0.3ml (95% Cl 0.1, 0.5ml, p<0.0001) (Figure 5-3). There was no evidence that 
the slope of this association differed between the premanifest and early HD
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groups. The addition of disease duration to this model (looking at early HD 
subjects only) had little effect on the relationship (an increase of 1 CAG was 
associated with a 0.3ml decrease in total caudate volume, 95% Cl 0.1, 0.4ml, 
p=0.013).
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Figure 5-3 Relationship between caudate volume (standardised to mean age 
in the whole cohort) and CAG repeat length in the premanifest and early 
HD groups
In the 21 premanifest subjects there was a tendency for greater probability of 
onset to be associated with smaller total caudate volume, such that an increase in 
probability of onset by 0.1 was associated with a 0.6ml decrease in total caudate 
volume (95% Cl -0.4, 13.2ml, p=0.065), after adjusting for age. Nine out of 21 
premanifest subjects had caudate volumes smaller than the smallest control, and 
six of them were more than 11 years from estimated motor onset (range 12-23 
years).
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There was no evidence of a relationship between total caudate volume and 
disease duration, independence score, or total functional capacity in the early HD 
group (all p>0.49).
The slope of the relationship between UHDRS motor score and caudate volume 
differed between groups (p=0.017). In the premanifest group a 1ml decrease in 
volume was associated with a 2.0 point increase in motor score (95% Cl 0.3, 3.6 
points, p=0.019) and in the early HD group a 1ml decrease in volume was 
associated with a 7.4 point increase in score (95% Cl 3.9, 10.9 points, p<0.0001), 
after adjusting for age.
5.3.4 Associations with cognitive variables
The relationship between cognitive score and caudate volume was significantly 
different between the premanifest and early HD groups for TMT A. There was 
no evidence of an association between score and volume in the premanifest 
group (p>0.05), but in the early HD group a 1ml decrease in caudate volume was 
associated with a 4.4 second increase in TMT A time (95% Cl 1.5, 7.8 sec, 
p<0.05).
For all other variables there was no evidence that the slope of the relationship 
between score and caudate volume differed between groups. Regression 
coefficients demonstrating the effect of a 1ml increase in caudate volume on 
scores in all gene carriers (N=61) are presented in Table 5-3. In general, smaller 
caudate volume was associated with lower scores or slower times at tests. 
Smaller caudate volume was significantly associated with worse UHDRS 
cognitive score (p=0.003), Stroop colour (p=0.003), Stroop word (p=0.006), 
SDMT (p=0.005), phonemic fluency (p=0.011), RMF (p=0.007), VOSP
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(p=0.002), Benton facial recognition (p=0.033), Ekman facial recognition of 
surprise, disgust and anger (all p<0.05) and time to press numbered buttons (all 
p<0.05). There was also a tendency for smaller volume to be significantly 
associated with worse scores on category fluency (p=0.09), HMGT (p=0.07) and 
cancellation (p=0.06). There was no evidence of an association between score 
and caudate volume for Stroop interference, TMT B, all the subtests of the 
HVLT, digit span forwards and backwards, RMW, the GNT, Ekman facial 
recognition of happiness, sadness and fear, and returning to press the central blue 
button (all p>0.05).
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Table 5-3 Slope (95% confidence intervals) of the relationship between
caudate volume and score in the 61 gene carriers, adjusted for age and
estimated premorbid IQ
Test
HD gene carriers (Premanifest & HD) 
Slope
UHDRS cognitive 17.0 (6.2, 27.9) p=0.003
Stroop colour 4.7 (1.7, 7.7) p=0.003
Stroop word 6.1 (1.8, 10.3) p=0.006
Stroop interference 0.3 (-2.2, 2.7) p=0.83
SDMT 3.2 (1.0, 5.5) p=0.005
Phonemic fluency 2.8 (0.7, 4.8) p=0.011
Category fluency 1.1 (-0.2, 2.4) p=0.09
HMGT 0.5 (-0.03, 1.0) p=0.07
TMT B (sec) -4.6 (-13.0, 4.7) p>0.05
TMT B-A (sec) -2.4 (-10.5, 7.1)p>0.05
TMT B/A (sec) 0.03 (-0.2, 0.3) p>0.05
Cancelling As (sec) -1.6 (-3.4, 0.1)p=0.06
HVLT immediate 0.8 (-0.5, 2.1)p=0.22
HVLT delayed 0.2 (-0.3, 0.7) p=0.48
HVLT % recalled 0.2 (-4.9, 5.4) p=0.92
HVLT discrimination 0.3 (-0.1, 0.7) p=0.13
Digit span forwards 0.1 (-0.6, 0.9) p=0.71
Digit span backwards 0.9 (-0.2, 2.1)p=0.10
RMF 2.2 (0.6, 3.8) p=0.007
RMW 0.2 (-0.6, 1.0) p>0.05
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Test
HD gene carriers (Premanifest & HD) 
Slope
GNT -0.1 (-1.1, 0.8) p=0.78
VOSP 0.8 (0.3, 1.3) p=0.002
Benton 1.1 (0.1,2.1)p=0.033
Ekman happiness -0.01 (-0.08, 0.04) p>0.05
Ekman sadness 0.02 (-0.1, 0.2) p>0.05
Ekman surprise 0.2 (0.004, 0.3), p<0.05
Ekman disgust 0.4 (0.2, 0.6) p<0.05
Ekman anger 0.4 (0.1, 0.6) p<0.05
Ekman fear 0.1 (-0.2, 0.4) p>0.05
Far button press (msec) -55.2 (-88.0, -30.5) p<0.05
Near button press (msec) -45.8 (-74.0,-18.2) p<0.05
Return from far button press (msec) -35.4 (-76.6, 9.3) p>0.05
Return from near button press (msec) -28.1 (-71.4, 13.3) p>0.05
Slope indicates the effect a 1ml increase in caudate volume has on the respective test; units are 
always points per ml, unless the test is timed in which case units are specified in brackets; where 
95% bootstrapped CIs were used precise p values were not obtained.
5.4 DISCUSSION
5.4.1 Caudate volume in HD
Caudate volume was significantly reduced in both early HD and premanifest 
subjects in this cohort. As with brain volumes it is difficult to compare absolute 
measures between studies, because of the different scanning parameters and 
segmentation protocols employed, and whether or not volumes are presented 
adjusted for head size. However in general where the head and body of the
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caudate have been measured they are reported to be about 60% of control volume 
in early HD (Rosas et al. 2003; Beglinger et al. 2005) which is very similar to the 
difference seen here, although one study in early HD found volumes to be less 
than 40% of control (Rosas et al. 2001). This seems more similar to volumes 
seen in advanced patients (Fennema-Notestine et al. 2004; Mascalchi et al.
2004), which is approaching the levels seen at post-mortem (de la Monte et al. 
1988; Maim g/ a/. 1993).
Caudate volume in this cohort of premanifest subjects, an average of 18 years 
from onset, was about 8 8 % of that in controls, compared with 78% in a nearer- 
to-onset cohort (on average 11 years from onset) (Paulsen et al. 2006b), 85% 
(subjects on average 14 years from onset) (Ay 1 ward et al. 2004) and 93% 
(subjects on average 23 years from onset) (Paulsen et al. 2006b), the latter 
difference not reaching significance. Together these results suggests a decrease 
in volume with proximity to onset and this was true of the current cohort 
although there was some variability in this, with some nearer-to-onset subjects 
with volumes in the control range, and some farther-from-onset subjects with 
volumes in the early HD range. Overall these results suggest that it may be 
possible to detect reduced caudate volume slightly earlier than previously 
thought, and certainly well before most cognitive or standard clinical measures 
can detect abnormalities (see chapter 4).
In this study a rightward asymmetry was found in both controls and HD subjects, 
with no evidence that this differed between groups. This contrasts with the 
findings of Rosas et al. (2001) who found a leftward bias in controls, and that 
this was reversed in subjects with HD. However, of the few studies in HD that
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have reported left and right caudate volumes, others have consistently found right 
caudates to be larger both in controls and premanifest and HD subjects 
(Mascalchi et al. 2004; Reading et al 2005) although in the former case the 
difference was not significant and in the latter it was not tested. One other study 
found no difference between right and left caudate volumes (in controls and early 
HD) although absolute volumes were not reported (Ruocco et al. 2006). 
Findings in healthy subjects have been varied (Raz et al. 1995) but the majority 
of studies have demonstrated a rightward bias in healthy caudate volumes 
(Peterson g/ a/. 1993; Raz et a/. 1995). Therefore, although this work replicates 
that of Rosas et al (2001) in finding a rightward asymmetry in caudate volumes 
in premanifest and early HD, this appears to parallel the relationship found in the 
healthy caudate and therefore does not support the suggestion that there is a 
reversal of asymmetry in HD. One study has reported an increase in rightward 
asymmetry (left-sided loss) in the caudate in HD relative to controls, (Miihlau et 
al. 2007a) but this has not been replicated. This issue merits further investigation 
as it may change as the disease progresses (something suggested by Miihlau et 
al). In this study all caudates were segmented on the left, with segmentors 
blinded to laterality so neither the protocol nor the segmentor could have biased 
the laterality findings.
Caudate volume was associated with CAG repeat length, which has been found 
previously (Rosas et al. 2001; Ruocco et al. 2006) but not consistently (Aylward 
et al. 1996; Harris et al. 1999) although the latter two studies had relatively small 
numbers and may have lacked power. As with whole-brains, this relationship 
could not be explained by longer disease duration or age at onset which suggests 
that caudate atrophy rate might vary with CAG repeat length, and there is some
183
evidence that this might be the case (Aylward et al 1997; Aylward et al 2000). 
It is also important to consider the inherent uncertainty surrounding age at onset 
(and therefore disease duration), and the fact that onset is defined as unequivocal 
motor signs (as opposed to signs in other domains) all of which may make 
disease duration a somewhat unreliable measure.
Caudate volume was also associated with UHDRS motor score in both patient 
groups, although a decrease in caudate volume of 1ml had a greater effect on 
motor score in the early HD than the premanifest group, perhaps reflecting the 
fact that a 1ml difference in the early HD represents on average a greater 
proportional loss of volume. However this may also be due to the non-linearity 
of the UHDRS motor score, with premanifest subjects likely to score at ceiling 
on this subtest. Although others have found a similar relationship between motor 
score and caudate volume, the association tends to be stronger with putamen 
volume (Harris et al 1992; Harris et al 1996; Harris et al 1999). Evidence 
suggests that the putamen, rather than the caudate, is involved in fronto-striatal 
motor circuits (Alexander et al 1986; Joel 2001) so the finding that motor score 
is associated with caudate volume may in part reflect the fact that the size of the 
two structures is highly correlated. Caudate volume was not associated with the 
TFC or Independence score. An association with TFC has been reported 
previously (Aylward et al 2003; Rosas et al 2003) in similar subjects, so this 
relationship needs further investigation. Inter-rater differences between studies 
may contribute to the disparate findings.
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5.4.2 Relationship between caudate volume and cognition 
In general smaller caudate volume was associated with worse performance on 
psychomotor, fluency or visuoperceptual tasks, rather than verbal memory tasks, 
naming, and tasks with a cognitive switching component (Stroop interference, 
TMT B, category fluency and HMGT). This was true across all gene carriers as 
there tended to be little difference in the slope of the association between the 
premanifest and early HD groups. The exception to this was TMT A for which 
there was a relationship with caudate volume in the early HD, but not the 
premanifest group, which may be because performance on this task remains 
relatively unaffected until atrophy of the caudate (and other structures) is more 
extensive.
Few volumetric studies in HD have included measures of cognitive performance. 
One study employing a large battery of tests identified a set of factors and found 
that caudate volume was most strongly associated with complex psychomotor 
tasks (including Stroop, Digit symbol, TMT A and B), followed by 
visuoperceptual tasks, and was less strongly associated with verbal learning, 
(Bamford et al. 1989). This fits well with the findings reported here, and 
although some studies have failed to replicate specific associations this may be 
due to lack of power as they had smaller sample sizes (Harris et al. 1996; 
Beglinger et al. 2005). Studies taking a whole-brain approach have also found 
that striatal volume was associated with psychomotor or executive function, 
although associations with other domains were not tested (Kassubek et al. 2005; 
Peinemann et al. 2005; Douaud et al. 2006).
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Many of the tasks for which an association was seen between caudate volume 
and performance are complex; most have an obvious motor and visual scanning 
component, both of which might depend to some extent on striatal integrity 
(Alexander et al. 1986), as well as requiring either a learnt skill (such as word- 
reading or number sequencing) or including a learning component (e.g., the 
SDMT, in which acquiring symbol-digit associations would improve task 
performance).
Degeneration of the dorsolateral striatum (putamen and dorsolateral caudate) is 
likely to result in deficits in well-learned (habitual or “automatic”) tasks 
(Balleine et al. 2007; Costa 2007). Deficits in implementing an automatic 
response program are thought to underlie at least some of the impairments seen 
in HD (Snowden et al. 2001) and the current results support this. Performance 
on Stroop colour, word and TMT A, all of which rely on relatively well-leamt 
skills, was worse in subjects with smaller caudate volumes, whilst performance 
on TMT B and Stroop interference, although impaired in this cohort, was not 
associated with caudate volume. The Stroop and trail-making tasks are largely 
equated for motor and scanning components, so if the deficits seen on the tasks 
were solely due to motor and scanning difficulties, one would expect the 
association between caudate volume and performance to be the same for all parts 
of the tasks. This was not the case, and the main difference was that subjects 
with smaller volumes performed worse on the aspects of the tasks which required 
learnt routines. The Stroop interference condition is thought to rely on prefrontal 
regions to inhibit attentional processes to the task-irrelevant dimension (Banich 
et al. 2000; Harrison et al. 2005) and TMT B similarly may rely on dorsolateral 
prefrontal cortex (Zakzanis et al. 2005). The results presented here suggest that
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whilst the caudate is related to performing habits or learning novel associations, 
aspects of executive tasks such as switching between two skills (number 
sequencing and letter sequencing) or over-riding a learnt skill (Stroop 
interference) are not related to the caudate as strongly. In fact, it may be that 
dorsal striatal damage and the associated deficit in performing habitual skills are 
advantageous in the Stroop interference task but that oculomotor and motor 
difficulties also contribute to slow performance. It would be interesting to 
investigate whether there are qualitative differences in the errors made depending 
on whether lesions affect the dorsal striatum or other regions; those with deficits 
at carrying out over-leamt skills might be less likely to make perseverative errors 
that those with, for example, lesions to the more medial fronto-striatal circuits 
who tend to be unable to inhibit habitual responses. Degeneration of the striatum 
is also likely to affect novel learning of stimulus-response associations (Poldrack 
2002; Balleine et al 2007), which could affect performance on tasks such as the 
SDMT.
Phonemic and category fluency are thought to depend on the ability to produce 
clusters of related words, and to switch between clusters (Troyer et al 1998); 
similarly the HMGT is likely to require the ability to switch between meanings 
for a given word (Warrington 2000). Switching and clustering have been shown 
to rely on prefrontal regions and temporal lobe regions respectively (Troyer et al 
1998; Hirshom and Thompson-Schill 2006). There is increasing evidence that 
switching ability is relevant for semantic as well as phonemic fluency (Hirshom 
and Thompson-Schill 2006) and a deficit in switching between phonemic 
subcategories has been associated with the deterioration seen over time on both 
tasks in HD (Ho et al 2002). In the current study there was a relatively strong
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association between caudate volume and phonemic fluency (a decline of 2 .8  
words per ml decrease in volume) whereas volume was less strongly (and not 
significantly) related to category fluency and HMGT. It is likely that frontal 
dysfunction contributes to the impairments seen across all three tasks in this 
cohort, but it may be that phonemic fluency relies more heavily on phonemic 
switching (which correlates with motor ability (Ho et al. 2002)) than the other 
two tasks, and hence shows a stronger association with striatal volume.
It is also important to consider that performance on all tasks with an overt motor 
component (such as psychomotor tasks, fluency, cancellation and reaction time 
used here) may also be associated with putamen volume, which is likely to be 
correlated with caudate volume. It is probable that, as for the UHDRS motor 
score discussed above, loss of putamen volume (and associated motor deficits) 
underlies at least some aspects of impaired performance on these tasks.
Performance on tasks which had a clear visuoperceptual component (the RMF, 
VOSP, Benton facial recognition test and several emotions from the Ekman 
emotion recognition battery) was also associated with caudate volume. Unlike 
those discussed above, these tasks do not depend on over-leamt (habitual) skills, 
are untimed, and do not require the acquisition of novel associations. Poor 
performance here may be related to dismption to the oculomotor circuit, which 
includes the central body of the caudate nucleus (Alexander et al. 1986; 
Cummings 1993). Three of the four tasks used facial stimuli, and visual 
scanning is known to impact on facial learning and recognition (Henderson et al.
2005) and facial emotion recognition (Wong et al. 2005). There is evidence that 
eye movements are impaired in premanifest and early HD (Golding et al. 2006;
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Blekher et al. 2006), and although visuoperceptual deficits are not considered 
one of the primary problems early in the disease, subtle impairments have been 
noted (Jacobs et al. 1995; Lawrence et al. 2000). The suggestion that abnormal 
eye movements contribute to poor visuoperceptual processing also means that it 
may be possible to improve performance, at least in the early stages of the 
disease, by directing subjects’ attention to specific regions of the stimulus 
(Adolphs et al. 2005). This is discussed further in chapter 8 , which investigates 
facial emotion recognition in more detail.
In contrast, performance on verbal measures of memory, both orally and visually 
presented, was not associated with caudate volume, although all these skills were 
impaired in the early HD group (see chapter 4). As discussed in the previous 
chapter, memory deficits in HD are thought to be due to poor encoding and 
retrieval, rather than problems with storage per se. This is difficult to explain in 
terms of striatal dysfunction, and may be due to damage, or reduced input, to 
associated prefrontal cortical structures (Henson et al. 2000; Wolf et al. 2007; 
Wolf et al. 2008). Whilst psychomotor task performance declines gradually in 
premanifest subjects (during which time striatal damage also seems to be 
progressive) there is evidence that memory performance deteriorates more 
suddenly around the time of clinical onset (Snowden et al. 2002). Recent work 
suggests that there is functional change in the dorsolateral prefrontal cortex 
(associated with working memory performance) in premanifest subjects, in the 
absence of volumetric differences (Wolf et al. 2007). It may be that frontal 
dysfunction (and atrophy) in HD is secondary to reduced input from striato- 
thalamic circuits and hence that it, and the associated behavioural deficits, 
become apparent some time after striatal atrophy can be detected.
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There was no evidence that the relationship between caudate volume and score 
differed between the left and the right caudate. As the volumes of the two are 
highly correlated this would be difficult to demonstrate, and it may be that there 
is some functional latéralisation which could be investigated further using 
techniques such as fMRI.
5.4.3 Technical considerations
As mentioned above, it is hard to compare absolute caudate volumes in the 
literature because of the range of scan parameters and segmentation protocols. 
However there are also more subtle differences which have a bearing on the 
variability and reproducibility of the measure.
Some studies do not align images into standard space, or blind operators to 
laterality, and most use manual outlining without the aid of intensity thresholds. 
In the current study attempts were made to minimise differences between images 
(for example due to alignment or laterality) by registering images into standard 
space, so that segmentation was done on similar views of each image. In order to 
reduce operator bias, images were flipped so that both the left and the right 
caudate were segmented on the right side of the scan, with segmentor blinded to 
laterality. In order to improve reproducibility segmentation used interactive 
thresholding and arbitrary cut-offs, with minimal manual editing. Intraclass 
correlation coefficients for the two segmentors in the current study compare 
favourably with those reported elsewhere (0.99 compared with around 0.97 
reported by Aylward et al. (2000; 2003)). The use of arbitrary cut-offs means 
that the method does not provide an estimate of total caudate volume, but 
nevertheless this measure does include the head and body of the caudate, whilst it
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does not encompass all of the tail. The result of using thresholding and arbitrary 
cut-offs is a standardised protocol that is reliable and reproducible, which is 
important for large-scale trials with a number of operators or measurements done 
over several time periods.
Volumes were also standardised for head size, which adjusts both for differences 
in head size between groups (Whitwell et al. 2001) and differences in gender. 
Studies which neither match exactly for gender nor adjust for head size are likely 
to over- or underestimate group differences in caudate volume depending on the 
relative proportions of gender in each group. It is also of note that although 
adjusting for head size (as was done here) eliminated difference due to gender, 
adjusting for intra-skull area did not (Raz et al 1995). Whilst ideally these 
methods need to be compared on the same dataset, intra-skull area is likely to be 
a more noisy estimate of head size than a volume measure, because it will be 
unduly influenced by head shape in the single plane in which it is measured, and 
hence it may be important to estimate head size more accurately in order to fully 
eliminate differences.
5.5 CONCLUSIONS
A protocol using standard-space-aligned, left-right flipped, and TIV-corrected 
volumes appears to give a measure of loss that compares favourably with 
methods in the literature, and suggests it is a relatively reliable and unbiased 
means of assessing caudate atrophy.
This work has shown that reduced caudate volume can be detected in premanifest 
gene carriers an average of 18 years prior to estimated motor onset. Individuals 
with higher CAG repeat lengths tended to have smaller volumes regardless of
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disease duration or age, suggesting that higher CAG repeat length may be 
associated with higher rates of caudate atrophy.
Associations between caudate volume and cognition support the role of the 
striatum in learnt (automatic) skill performance, goal-directed behaviour and in 
motor, oculomotor and psychomotor circuits, and suggest that striatal damage 
may not underlie deficits seen in memory tasks, or tasks under more cognitive 
control, such as those involving a switching component. These findings also 
suggest that although impairments seen in HD are often described as “executive 
function” (problems with planning, set-shifting, directing attention), there may be 
a qualitative difference between impairments on tasks such as the SDMT and 
phonemic fluency, which were related to caudate volume, and TMT B and 
Stroop interference, which were not. As with any structure-function 
correlations, future work should focus on establishing the causality of these 
relationships with functional imaging, and also on investigating the relative 
contributions of frontal and striatal sub-regions in more detail.
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6 VOXEL-BASED MORPHOMETRY: THE EFFECTS OF SOFTWARE 
VERSION, TEMPLATES, AND CONFOUNDING VARIABLES
6.1 INTRODUCTION
As discussed in chapter 1 (section 1.2.2), the technique of VBM is increasingly 
used in the study of neurodegeneration, and is an alternative, complementary 
approach to ROI methods because it is relatively automated and can be applied 
across the whole-brain and thus does not require a priori hypotheses about 
particular regions of interest. However VBM findings in HD are mixed. Whilst 
in some cases this might be due to the heterogeneity of the disease, it is possible 
that this is also caused by methodological or technical differences between 
studies, rather than reflecting real differences between populations. Despite 
being automated to some extent, a large number of parameters in the VBM 
process can be set by the operator and some processing steps are optional. In 
addition, statistical models vary widely.
The initial aims of this chapter were to maximise the accuracy of the SPM2 
normalisation and segmentation algorithms on the dataset used in this thesis, and 
to investigate the effects of some potential confounding variables. This led on to 
further work examining different estimates of intracranial volume (to adjust for 
head size differences). Finally, this chapter reviews previous VBM studies in 
HD in order to compare techniques and identify methodological differences 
which might partly explain discrepant findings in the literature.
6.1.1 Maximising the accuracy o f normalisation and segmentation in SPM 
The images on which the statistical analysis is performed in VBM are 
preprocessed to align them in the same space and to segment the different tissue
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types. The assumption of the analysis is that across a group of images all voxels 
at a given spatial location represent the same tissue type, and the same part of the 
brain (Ashbumer and Friston 2000). Inferences about the location of atrophy and 
the anatomical substructures affected depend to some extent on the accuracy of 
these preprocessing steps. There is also a circularity in the preprocessing steps in 
that segmentation would be better following accurate registration but registration 
would be improved by being performed after segmentation. Although other 
preprocessing steps can alter the interpretation of findings, as can the way in 
which differences are then modelled, misclassification of tissue or poor inter­
subject alignment could introduce basic errors into what is reported.
The standard VBM procedure normalises whole brains to a template whole-brain 
image prior to segmentation using prior probability maps, both of which are 
smoothed averages of a large number of images from healthy volunteers (e.g. the 
MNI-152 template, which is an average of 152 brains provided by the Montreal 
Neurological Institute). However it was noted that both alignment and 
segmentation could be improved by normalising each tissue type to a tissue- 
specific template image and by basing segmentation on study-specific prior 
probability maps (Good et al 2001b). The authors called this an “optimised” 
method and since then many others have used aspects of it, although not all stick 
to precisely what was outlined in the original paper, meaning that the term 
“optimised VBM” actually covers a range of non-standard normalisation and 
segmentation options (compare e.g., Karas et al 2003; Douaud et al 2006; Wolf 
et al 2007).
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SPM software is updated every few years and the work in this section was driven 
by the observation that identical datasets (images from the pilot study described 
in chapter 3) with the same preprocessing and statistical models yielded 
markedly different SPMs in SPM99 and SPM2. Since in both cases 
preprocessing included modulation, the same level of smoothing, and the same 
statistical models and contrasts it seemed likely that differences in the 
normalisation or segmentation algorithms were behind the differences in 
findings. At the time of starting this work a beta version of SPM5 had been 
released, with a new, iterative normalisation and segmentation algorithm which 
was said to yield better results than the sequential application of these steps used 
in SPM2, and SPM2 optimised (Ashbumer and Friston 2005). Therefore in order 
to compare the effects of the different normalisation and segmentation steps the 
current dataset was processed using SPM2, SPM2 optimised and SPM5, holding 
other options (modulation, smoothing and the statistical models) constant.
6.1.1.1 Methods
6.1.1.1.1 Subjects and assessments
Subjects were the same as those in chapter 4, and demographic data are shown in 
Table 4-1, page 135. Subjects had clinical, cognitive and MRI assessments as 
detailed in chapter 4 although only basic demographic data and the MR images 
were used in the work presented here.
6.1.1.1.2 VBM analysis
Good et al (2001b) advocated improving the default normalisation and 
segmentation in SPM in two ways: firstly by making study-specific templates for 
both processes, which may be particularly relevant for studies of
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neurodegeneration where patient neuroanatomy differs markedly from that of the 
healthy controls used to construct the default whole-brain templates and tissue 
probability maps; secondly by estimating parameters for normalisation from the 
tissue class of interest, rather than the whole brain (e.g. normalising grey matter 
to a grey matter template to “optimise” the alignment of that particular tissue 
class). This is easily implemented in SPM2 through a toolbox written by 
Christian Gaser and available at http://dbm.neuro.uni-iena.de/vbm/. With the 
advent of SPM5 and the new “unified” segmentation and normalisation 
algorithm (Ashbumer and Friston 2005) “optimised” VBM as described by Good 
et al. was deemed unnecessary; improvements in the new algorithm were judged 
to make study-specific templates and normalisation by tissue class unnecessary.
Consequently the initial investigation compared SPM2, SPM2 “optimised” 
(SPM2 opt) and SPM5. The different templates used for normalisation and 
segmentation are summarised in Table 6-1.
Table 6-1 Summary of normalisation and segmentation templates
Normalisation Segmentation
SPM2 MNI-152 whole-brain MNI-152 prior probability maps
SPM2 opt Study-specific GM template Study-specific prior probability
(average of 2 0  controls, 10 maps based on the same subset of
premanifest and 10 early HD 
subjects, matched for age and 
gender)
subjects
SPM5 MNI-152 whole-brain MNI-152 prior probability maps
Images from all 81 subjects in the study were segmented and normalised using 
the respective SPM routines and templates outlined in Table 6-1. All were then
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modulated, masked to exclude non-brain (using a binary region derived from the 
semi-automated segmentation method described in Appendix 2) and smoothed 
with a kernel of 8mm FWHM. For each method the same linear regression 
model was used to assess differences between the groups. Voxel intensity, V, 
was modelled as a function of group, controlling for age, gender and TIV (an 
index of head size) by including them as covariates. TIV was measured as 
described in Appendix 2. This model is shown in equation 6.1, where the 
contrasts of interest are the one-tailed t-tests between the estimates of the group 
parameters, pi > Ps, i.e., where the controls had more volume than the early HD 
group.
V = Pi Control + P2 PM + p^  HD + P4 age + P$ gender + Pô TIV + p + e (6.1) 
(where p is a constant, and 8 is error)
The reverse contrasts were also tested, i.e. P3 > Pi, looking for regions in which 
the early HD group had more volume than controls. Given that HD is 
neurodegenerative and that there are no reports of increased brain volume in 
symptomatic HD subjects any such findings would be most likely caused by 
misregistration or misclassification, rather than reflecting true anatomical 
differences. Statistical parametric maps were corrected for multiple comparisons 
using family-wise error (FWE) p<0.05; for the purposes of this section the exact 
level of correction was less important than the fact that all models were corrected 
to the same extent, in order to make the resulting SPMs comparable.
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6.1.1.2 Results
6.1.1.2.1 Optimised vs. standard SPM
Regions in which controls had significantly more grey matter volume than the 
early HD group, and regions in which the early HD group had significantly more 
grey matter volume than controls, are shown in Figure 6-1 for each of the three 
SPM implementations tested.
All SPMs are centred at the maximum t value, with the exception of the HD > 
Control contrast for SPM5 for which the maximum t value was in the cerebellum 
and centring there precluded display of regions of increased volume in the 
cerebrum.
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Control > HD HD > Control
m
( - 4 0 . 5 ,  - 6 ,  1 0 . 5 )
SPM2
SPM2 optimised
( 1 . 5 , - 6 ,  2 5 . 5 )
9 ,  1 0 ,  7 ( 1 , - 3 0 ,  2 0 )
( - 8 .  1 2 ,  4 ) ( - 8 ,  - 1 8 ,  0 )
SPM5
Figure 6-1 Regions of increased volume in controls relative to HD subjects 
(left panel) and HD subjects relative to controls (right panel) using SPM2, 
SPM2 optimised and SPM5.
SPMs are corrected for multiple comparisons, FWE p<0.05. The colour bar 
shows the t value. MNI coordinates are in brackets.
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The patterns of atrophy seen in early HD subjects relative to controls differed 
between SPM versions. In particular neither SPM2 or SPM5 detected large 
statistically significant effects in the caudate nucleus bilaterally, compared with 
SPM2 optimised, although results from the previous chapter confirmed that such 
differences exist in this cohort (see section 5.3). Although SPMs display t values 
(rather than effect sizes) one would expect large t values for the striatum 
compared with other brain regions; as the primary site of pathology in HD not 
only should group differences be large, but the true variance (i.e. not due to 
processing errors such as misregistration or misclassification) within the HD 
group should be relatively small compared to that in other brain regions, given 
that striatal atrophy has been ongoing for many years, and that striatal volumes 
are reduced long before atrophy is detected in other regions (Aylward et al 1996; 
Paulsen et al 2006b). As the data from chapter 5 showed, there was little 
overlap in left and right caudate volumes between the controls and the early HD 
group, and the t values for the group differences (adjusted for age and TIV) were 
15.28 (left caudate) and 17.52 (right caudate), both highly statistically 
significant. Although this is based on total volumes, not a voxel-wise analysis, 
VBM results in which there is little difference between the caudate volumes in 
the two groups do not seem to be compatible with these findings.
Both SPM2 and SPM5 showed widespread regions of increased volume in the 
early HD group relative to the controls, particularly above the ventricles (in what 
looks like white matter on the average template), and in regions just below the 
caudate bilaterally. In contrast, SPM optimised showed very little increased 
volume in the early HD group. Although there have been reports of increased 
grey matter volume in very far-from-onset premanifest HD (Paulsen et al
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2006b), and reports of relatively spared preffontal cortex in early HD (Mühlau et 
al. 2007b), there are no reports of an absolute increase in grey matter after motor 
symptom onset.
These findings suggest that there is an element of misregistration and/or 
misclassification in SPM2 and SPM5, in this particular cohort, which is leading 
to spurious findings. The optimisation process appeared to reduce this effect. In 
order to investigate this further, normalised grey matter segments for two 
controls and two early HD subjects from SPM2 were compared (Figure 6-2).
Although the four segments are centred on the same coordinates, the cross-hairs 
appear to fall just underneath grey matter in the two controls, and within the grey 
matter of the two early HD subjects. Although this is subtle, this could explain 
why the early HD subjects had more grey matter than controls in this region in 
the SPM2 analysis. The same issues are likely to underlie the similar findings in 
SPM5.
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Control HD
Female, age 34
Female, age 61
Female, age 36
Female, age 58
Figure 6-2 SPM2-normalised grey matter segments for two controls and two 
age- and gender-matched early HD subjects.
Note that whereas the cross-hairs in the controls appear just under grey matter, 
the equivalent voxel in the HD subjects appears within grey matter; although 
subtle, such differences might result in the finding o f increased grey matter in 
HD relative to controls at this point.
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6.1.1.2.2 Optimised normalisation vs. segmentation
Based on these three analyses it appeared that of the three software 
implementations tested, SPM2 optimised resulted in the best alignment of the 
subjects in this cohort. However it was also noted whilst looking at individual 
segmentations that there were regions in which SPM2 appeared to have produced 
segmentations more faithful to the original image than SPM2 optimised. 
Consequently a fourth analysis was run, using SPM2, in which normalisation 
was optimised (normalisation parameters were derived from warping grey matter 
segments to a grey matter template) but segmentation was not (SPM2 default 
templates and prior probability maps, as opposed to study-specific ones, were 
used for both normalisation and segmentation).
Segmentations from each of these versions of SPM2 (standard, optimised and 
“opt norm” in which only the normalisation was optimised as defined by Good et 
al.) are shown in Figure 6-3 and Figure 6-4. SPM2 optimised does not appear to 
segment grey matter as accurately as standard SPM2, or SPM2 opt norm. In 
addition, there are regions (notably the putamen in one subject) which SPM2 opt 
norm appears to segment better than either other version.
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SPM2 SPM2 optimised
SPM2 opt norm
m
Normalised image
SPM2 and SPM2 opt norm better than SPM2 optimised
Figure 6-3 Normalised grey matter segments from SPM2, SPM2 optimised 
and SPM2 opt norm, displayed with a normalised image.
The red circles highlight a region in which the folds o f the gyri appear to be 
better defined with SPM2 and SPM2 opt norm, compared with SPM2 optimised. 
The image is from a female HD subject, aged 64.
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SPM2 SPM2 optimised
SPM2 opt norm Normalised image
SPM2 and SPM2 opt norm better than SPM2 optimised
SPM2 opt norm better than both other versions
Figure 6-4 Normalised grey matter segments from SPM2, SPM2 optimised 
and SPM2 opt norm, displayed with a normalised image.
The blue circles highlight a region in which the folds o f the gyri appear to be 
better defined with SPM2 and SPM2 opt norm, compared with SPM2 optimised. 
The pink circles show a region in which SPM2 opt norm has picked out the 
putamen better than SPM2 optimised, and SPM2 (which appears to miss it 
entirely). The image is from a female HD subject, aged 36.
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Finally, the same model investigating group differences in volume was applied to 
the segments produced by the SPM2 opt norm procedure, and Figure 6-5 
displays the resulting SPM together with that produced by SPM2 optimised. The 
two SPMs differ very little, particularly compared with the differences seen in 
Figure 6-1, suggesting that varying the template used for segmentation had a 
relatively smaller effect on findings than varying that used for normalisation (i.e. 
normalisation was relatively more important here than segmentation).
Control > HD HD > Control
9 .  1 0 ,  7 ( 1 , - 3 0 ,  2 0 )
SPM2 optimised
w m
( 9 ,  8 ,  9 ) ( 1 , - 3 1 .  1 9 )
SPM2 opt norm
Figure 6-5 Regions of increased volume in controls relative to HD subjects 
(left panel) and HD subjects relative to controls (right panel) using SPM2 
optimised and SPM2 opt norm.
Images are corrected for multiple comparisons, p<0.05. The colour bar shows 
the t value. MNI coordinates are in brackets.
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6.1.1.3 Discussion
This section began by comparing three different implementations of SPM, and it 
was shown that each version produced results that differed with respect to both 
the extent of voxels reaching significance and the location of maxima. Notably 
two versions (SPM2 and SPM5) found much more extensive regions of increased 
volume in HD compared with SPM2 optimised, and showed fewer significant 
differences in the caudate bilaterally. These phenomena are likely to be related; 
it has been suggested that where ventricular size differs between groups, whole- 
brain normalisation can lead to erroneous normalisation of the surrounding 
tissues (Mechelli et al. 2005). Normalising grey matter to grey matter has been 
suggested as a solution for this, since this prevents differences in ventricle size 
from contributing to the normalisation parameters at all (Mechelli et al. 2005). It 
is interesting that optimised SPM2 improved the results compared to standard 
SPM2 (which is why it was developed initially) but that SPM5 appeared not to 
be as good. It may be that although the unified algorithm in SPM5 gets rid of 
some of the errors associated with the somewhat circular processing in SPM2 
optimised, it still introduces some bias between the healthy and diseased brains. 
The problems in SPM5 have been recognised by the authors and improvements 
to the registration algorithm in particular are currently being incorporated 
(Ashbumer 2007). In future it will be important to compare these simple models 
on newer versions of SPM in order to assess the impact of further improvements 
to processing on results. It should also be noted that even with SPM2 optimised 
and “opt norm” there was still a small region in which the HD group had 
increased volume relative to controls. As discussed above, there is no evidence 
from other modalities that manifest HD subjects show increased brain volume
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relative to controls and so this is also likely to be due to imperfect normalisation, 
but the error is much reduced compared with the other implementations tested 
here.
In the current study normalising the images to a study-specific grey matter 
template reduced misalignment (judged by looking at regions in which the HD 
group were shown to have more volume than controls). However this 
improvement remained when the images were normalised to a non-study-specific 
(i.e. healthy average) grey matter template, suggesting that in this cohort the 
main improvement was achieved by maximising the alignment of the tissue class, 
rather than by making the template more representative of the cohort. A similar 
finding was reported by Keller et al. (2004) who also concluded that the better 
alignment provided by grey matter to grey matter normalisation had far more 
influence on results than the choice of segmentation template. Whilst it is true 
that in studies of neurodegeneration, use of a healthy whole-brain template might 
lead to systematic processing bias between controls and patients, it has also been 
suggested that to be representative a study-specific template would need to 
consist of a minimum of ~ 100 images (J. Ashbumer, personal communication). 
Most studies cannot provide such subject numbers, and may therefore be 
introducing another source of error by using study-specific templates based on 
too few subjects. There were subtle differences between the segmentations of all 
three versions of SPM2, and in particular it was noted that the putamen for one 
subject was segmented better using SPM2 opt norm, rather than SPM2 opt. 
Assuming that images are well-normalised to standard space after GM to GM 
normalisation, it seems reasonable that segmentation with a prior based on > 1 0 0  
subjects might be better than with one based on 40.
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As a result of this work the SPM2 opt norm procedure was used for all the 
subsequent VBM work presented in this thesis, including in the following 
sections. The important recommendation from this work is to assess reverse 
contrasts in SPM comparisons and to recognise the degree of dependence of the 
findings upon the analysis method used, including the specific version of the 
algorithms used for pre- and post-processing, and to report these.
6.1.2 Effect o f head size and gender on brain volume
Apart from the effects of pathology, total brain volume in “healthy” subjects is 
known to vary with both head size (Acer et al. 2007) and gender (Good et al. 
2001a) and it has been shown that adjusting whole-brain volume for TIV 
eliminates differences due to gender (Whitwell et al. 2001). In Whitwell et al. 
the adjustment was simply to divide brain volume by TIV. It is common for 
volumetric studies to include an adjustment for some index of head size in order 
to ensure that differences in head size are not influencing findings (e.g., 
Kassubek et al. 2004a; Paulsen et al. 2006b). However a number of VBM 
studies in HD and other areas do not adjust for head size.
After normalisation in VBM, brains (or grey matter segments) have been warped 
to the same global space, and at this point differences due to head size (or the 
size of the brain initially) are lost. If a voxel from a large brain was compressed 
during normalisation, there would then be nothing to suggest a difference 
between that voxel and one from a smaller brain, if they both had the same 
probability of being grey matter. However after the voxel value has been 
multiplied by the Jacobians from normalisation, intensity at that voxel then 
represents volume at that point (this is known as modulation). After modulation
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the voxel intensity is increased, to represent the fact that it has had to be 
relatively compressed to match the template, and in this way differences between 
volume, which were previously encoded spatially, are preserved in the voxel 
intensities. Therefore, with modulated data, it would seem necessary to adjust 
for a measure of head size.
The work in this section investigated the effect of TIV and gender on volume in a 
VBM analysis, and also looked at whether adjusting for TIV eliminated effects 
of gender on volume.
6.1.2.1 VBM analysis
This section used the images of the 20 healthy control subjects. Images were 
preprocessed as described above (using the SPM2 opt norm procedure) and were 
entered into the following models to look at the effect of head size and gender on 
brain volume.
V = pi TIV + p + £ (6.2)
V = pi gender + p + £ (6.3)
V = pi TIV + p2 gender + p + g (6.4)
In the first two models, the contrast Pi > 0 investigates regions in which the slope 
of the relationship between volume and TIV (or gender) is significantly greater 
than zero (i.e. where larger TIV (or being male) is associated with larger brain 
volume). The third model (6.4) allows investigation of the effect of each 
variable on volume, having adjusted for the effects of the other, by examining Pi 
> 0 and p2 > 0. For all models the reverse contrast was also investigated, i.e.
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looking for regions in which a volume decrease was associated with increasing 
head size or male gender.
6.1.2.2 Results
Regions in which grey matter volume increased with TIV, male gender and TIV 
having adjusted for gender are shown in Figure 6 -6 . Larger TIV was associated 
with increased grey matter volume in the cortex and subcortical structures. 
Volume also tended to be increased in men compared to women, although the 
effects were less widespread. When gender was adjusted for, there was still an 
effect of TIV on volume although it was less extensive. When TIV was adjusted 
for there was no longer an effect of gender on volume.
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Effect of TIV on volume Effect of gender on volume
&
(-57 , -6 , -3 )
Effect of TIV on volume, adjusted for gender
i m .
( 14 , -57 , - 11)
44
( -16 , -21 , - 9 )
Figure 6 -6  Regions in which grey matter volume increased with TIV, gender 
(male), and with TIV after adjusting for gender.
There were no regions in which volume increased with maleness, after adjusting 
for TIV. SPMs are corrected for multiple comparisons, FDR q<0.05. The 
colour bar shows the t value. MNI coordinates are in brackets.
6.1.2.3 Discussion
In the 20 controls in this cohort there was a clear effect of both TIV and gender 
on grey matter volume. TIV is known to correlate with gender, and adjusting for 
TIV removed the effect of gender, which agrees with previous findings using 
whole-brain volumes (Whitwell et al. 2001). Adjusting for gender alone did not.
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however, remove the effect of TIV, which is to be expected as TIV is a 
continuous variable and captures more between-subject variability than gender.
Few imaging studies report whether subjects are matched for TIV (or any index 
of head size), and even if such matching has been attempted this does not mean 
that subtle differences in head size between groups cannot influence results. 
Often a lack of a statistically significant difference between groups (e.g., in 
gender or TIV) is wrongly assumed to imply that these variables are not having a 
material influence on the results. Most volumetric studies address this by 
adjusting for TIV (or a similar correlated measure), although findings from at 
least one study in HD have been doubted because of a failure to consider the 
potential confounding effects of head size (Rosas et al 2003; Kassubek et al 
2004b).
However, few VBM studies in HD have included an index or measure of TIV as 
a covariate although many adjust for total grey matter volume. In healthy 
subjects total grey matter volume is likely to correlate with TIV (although will 
decrease with age) and so assuming age is adjusted for, adjusting for total grey 
matter volume approximates an adjustment for TIV and allows investigation of 
differences in grey matter volume that are not caused by differences in overall 
head size. However in subjects with a neurodegenerative disease total grey 
matter volume will almost certainly decrease with duration or severity of the 
disease, and hence adjusting for it is likely to mask some disease-related effects. 
At an extreme level, if degeneration proceeded uniformly throughout the brain 
then a comparison between healthy controls and patients that was adjusted for 
total grey matter volume would find no evidence of group differences.
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Adjusting for total grey matter volume does allow investigation of the relative 
loss or preservation of regions, compared with the amount of global loss (Good 
et al. 2001b; Mechelli et al 2005). This is an interesting question in itself, but 
needs careful interpretation. Some studies seem to equate adjustment for total 
grey matter volume with adjustment for head size, but in studies of 
neurodegeneration in particular, adjusting for the former will get rid of some 
disease-related effects, whereas adjusting for the latter will not.
It is important to note that the adjustment for TIV in the controls presented here 
also corrects for differences in brain volume that are due to gender. However if 
there is evidence that a disease characteristic also varies with gender then it may 
still be worth including gender as a covariate, either to adjust for these effects or 
to investigate them.
6.1.3 Measuring TIV
The previous section highlighted the importance of adjusting brain volumes for 
head size. In this thesis TIV is used as an index of head size and is measured 
according to the protocol in Appendix 2. Manual outlining is generally assumed 
to be the “gold standard” measure of volume, but it is also labour-intensive and 
time-consuming, taking time to train segmentors and needing about 30 minutes 
per TIV. In the protocol used here every 10* slice was segmented, and linear 
interpolation was used to estimate the total TIV, which speeds up the 
segmentation without resulting in a significant decrease in accuracy (Whitwell et 
al 2 0 0 1 ).
However SPM also generates a measure of TIV : the sum of the GM, WM, and 
CSF segments that are produced during preprocessing. These segments have
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been used previously to estimate total intracranial volume in HD (Kassubek et al. 
2004a; Mühlau et al 2007b) although some doubt has been expressed as to the 
accuracy of the CSF segmentations in particular (J. Ashbumer, personal 
communication). Given that manually-derived TIVs and SPM-derived GM, WM 
and CSF segments were available for all the subjects in this study the purpose of 
this section was to compare the two estimates of head size. As for the purposes 
of the work in this thesis TIV was used as a nuisance covariate, rather than a 
variable of interest, it would not be vital for the two estimates to agree perfectly, 
but it would be important for them to be highly correlated, and for this 
relationship to be consistent in both healthy controls and HD subjects. If this 
were found it might mean that in the future TIV could be estimated using the 
SPM segments, thus saving a large amount of operator time.
6.1.3.1 Methods
TIV was measured manually according the protocol described in Appendix 2. 
TIV was also estimated as the sum of the GM, WM and CSF volumes generated 
by the VBM preprocessing. This was done for all 81 subjects for whom baseline 
data were collected (see chapter 4).
6.1.3.1.1 Statistical analysis
The extent of association between the two measures was assessed using a 
correlation coefficient. Pitman’s test was used to compare the variance of each 
measure, both for the cohort as a whole and within each subject group. 
Agreement between the two measures was assessed through calculation of the 
mean and standard deviation of the difference between measures, again for the 
cohort as a whole and for each subject group (Bland and Altman 1986). Linear
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regression models were used to investigate whether the slope of the relationship 
between the two measures differed between groups (an interaction between slope 
and group) and/or whether the intercept differed between groups (as would occur 
if bias between the measures was not equal across the three groups).
6.1.3.2 Results
Mean (SD) TIVs from each method are presented in Table 6-2. The two 
measures were highly correlated for the whole cohort (r=0.94, p<0.0001). There 
was no evidence that the variance differed between methods, either for the whole 
cohort or for any of the subject groups (all p>0.1). SPM estimates were, on 
average, larger than the manual estimate for the entire cohort (bias (mean 
difference) = 34.7ml, 95% Cl 22.2, 47.2ml, p<0.0001) and this was driven by the 
early HD group (bias = 58.4ml, 95% Cl 39.2, 77.6ml, p<0.0001); bias in the 
control and premanifest groups was smaller and not statistically significant (all 
p>0.05).
Table 6-2 Mean (SD) TIVs for the whole cohort and each group, with 
differences
TIV (ml)
All
(N=81)
Control
(N=20)
Premanifest
(N=2 1 )
Early HD 
(N=40)
Manual 1448 (162) 1434(164) 1469(182) 1445 (153)
SPM 1483(157) 1452 (155) 1474(167) 1503(155)
Difference (bias) 34.7 (56.4) 18.2 (40.5) 5.3 (42.8) 58.4 (60.0)
95% Cl 22.2, 47.2 -0.8, 37.2 -14.2, 24.8 39.2, 77.6
Positive difference indicates higher estimates using SPM relative to manual measures.
216
There was no evidence that the slope of the relationship between manual- and 
SPM-derived TIVs differed between groups. Constraining the slope to be the 
same in each group, the intercept was greater in the early HD group compared 
with controls (p=0.006) and the premanifest group (p<0 .0 0 0 1 ), reflecting the fact 
that the bias in this group was significantly greater than in the other two.
Therefore, compared with manual measures, SPM overestimated TIV, and 
overestimated it significantly more in the early HD group than in the other two 
groups.
6.1.3.3 Discussion
This work demonstrates that the TIV measure derived from the sum of the SPM 
GM, WM and CSF segments is significantly larger than the manual measure. 
More importantly the amount by which SPM overestimates TIV differs 
significantly between healthy controls and early HD subjects.
As discussed in the introduction the fact that the SPM measure overestimates per 
se would not preclude it from being used as a nuisance covariate in place of the 
manual measure, particularly as the two were highly correlated. The 
overestimation may be because the CSF segments from SPM often spill outside 
the dura, whereas the manual measure excludes CSF outside dura. However it is 
worrying that the SPM measure overestimates TIV more in the early HD group 
(the group with the most atrophy) relative to the controls and premanifest 
subjects, as this could lead to a systematic bias in group differences when volume 
was adjusted for TIV. This may be because in the early HD group there is a 
greater discrepancy between the normalised brain and the tissue prior probability 
maps (because of increased atrophy) and this leads to relatively greater
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misclassification of non-brain and dura as tissue. In this cohort, this would affect 
the volume of the segmentations, although would not affect the final analysis as 
segments are masked to exclude non-brain tissue prior to analysis. However this 
bias has only been demonstrated on the current dataset, and further work needs to 
be done to investigate whether results are similar in cohorts with different 
amounts and patterns of atrophy.
This interpretation assumes that the manual measure is the more accurate 
representation of TIV. In fact, a similar manual measure of TIV on CT images 
was shown to underestimate true TIV (measured directly from dry skulls) (Sahin 
et al. 2007). However in the absence of real skull measurements on the cohort 
presented here manual measures have to be taken as the “gold standard” estimate 
of TIV, and in addition there is no a priori reason why manual segmentation 
(which is done blinded to gene status) should have systematically underestimated 
TIV only in the early HD group, which would be the alternative explanation for 
the pattern of results seen here.
Overall this work demonstrated that for this cohort SPM-derived TIVs were not 
an adequate alternative to manually-derived ones. This may have implications 
for other users of SPM-derived TIV measures but these findings need to be 
replicated in other cohorts.
6.2 GENERAL DISCUSSION AND REVIEW
6.2.1 Technical considerations
The work in this chapter has demonstrated a number of important
methodological points about VBM analyses. Firstly the SPM version can affect
the final results, and even within a version, it is worth investigating the impact of
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different normalisation and segmentation templates in order to maximise the 
accuracy of these steps for the cohort under investigation. A version of SPM2 in 
which normalisation was specific to the tissue class under investigation, and 
standard (rather than study-specific) templates were used for segmentation, was 
preferred to both standard SPM2 and SPM5, and SPM2 optimised. As future 
versions of SPM are released it will not be possible to rule out software 
differences as causes for differences between studies, but it would be useful for 
investigators to study the effects of different preprocessing options and in 
particular to try and maximise normalisation and segmentation accuracy for their 
cohort.
Secondly, although variables such as head size and gender are often adjusted for 
in volumetric analyses, they are less often considered as possible confounds in 
VBM analyses. However when modulated data were used there was a clear 
effect of head size and gender on the controls in this cohort. In contrast, it is 
common for VBM studies to adjust for total grey matter volume. Although this 
allows investigation of regionally-specific patterns of atrophy, and relative 
decrease or preservation of tissue, this is not an alternative to correcting for 
differences due to head size where neurodegenerative diseases are under 
investigation, as total grey matter volume will vary with disease severity and 
duration.
Finally, more work needs to be done to assess the validity of using SPM 
segments as an estimate of TIV, as work on this cohort suggested that SPM may 
introduce systematic differences between groups in its estimate of TIV.
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6.2.2 Implication for differences between findings in HD 
Within the relatively few published VBM studies in HD there are differences at 
almost every step, from the software version used, through the processing steps 
and statistical models, to correction for the resulting SPM. Table 6-3 summarises 
some of the processing methods and levels of correction used in HD VBM 
studies, including studies that reported group differences, and those which 
investigated neural correlates of variables, since both types of analyses are used 
in this thesis. These differences make it hard to interpret the various findings, 
and may mean that results do not generalise to the population as a whole.
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Table 6-3 Summary of processing methods employed by other groups
Study SPM
version
Normalisation Segmentation Mod. Smoothing 
FWHM, mm
Correction
Thieben et 
aA(2002)
99 Study-specific GM 
template, patients and 
controls
Unspecified Yes 10 SPM uncorrected, 
p<0.005; reported results 
mostly small-volume 
corrected
Wo et al. 
(2004)
99 Study-specific GM 
template, all controls only
Study-specific GM template, 
all controls only
Yes 12 SPM & reported results 
uncorrected, p<0.0001, 
cluster 10 voxels
Kassubek et 
üA (2004c)
99 Study-specific template, 
whole-brain or GM 
unspecified; subjects 
unspecified
Unspecified No 6 SPM & reported results 
FWE p<0.001, clusters 54 
voxels
Kassubek et 
a/. (2005)
99 Study-specific template, 
50:50 patients [controls; 
whole-brain or GM 
unspecified
Unspecified Yes 6 SPM & reported results 
FWE p<0.001
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Study SPM
version
Normalisation Segmentation Mod. Smoothing 
FWHM. mm
Correction
Kipps L’t al. 
(2005)
2b6L99 Study-specific GM 
template, 50:50 
patients.controls
Standard implied Yes 12 SPM uncorrected. 
p<0.005: reported results 
small-volume corrected 
(level unspecified)
Peinemann
c/wA(2005)
99 Study-specific template, 
whole-brain or GM only 
unspecified; subjects 
unspecified
Unspecified No 6 SPM & reported results 
FWE p<0.05
Douaud ct 
oA(2006)
2 Study-specific GM 
template, 50:50 
patients:eontrols, from 
original & symmetric 
images
Study-specific GM template, 
50:50 patients:controls, from 
original & symmetric 
images
Yes 8 SPM & reported results 
FDR q<0.01
Barrios et al. 
(2007)
Not
specified
Standard whole-brain 
template
Not specified No 4 SPM & reported results 
uncorrected. p<0.01. 
clusters > 10mm^
I l l
Study SPM
version
Normalisation Segmentation Mod. Smoothing 
FWHM. mm
Correction
Gavazzi et 
oA(2007)
2 Study-specific GM 
template, subjects 
unspecified
Study-specific GM template, 
subjects unspecified
Yes 10 SPM and reported results 
corrected, p<0.01, (type 
unspecified)
Jech el ui 
(2007)
2 Study-specific GM 
template, all patients; no 
controls in study
Study-specific GM template, 
all patients; no controls in 
study
Yes 10 SPM uncorrected p<0.001; 
reported results 
uncorrected in striatum or 
rolandic area, p<0.001, 
elsewhere, FDR q<0.05
Kipps et al. 
(2007)
2 Study-specific template, 
patients and controls, exact 
makeup unspecified
Not specified Yes 8 Uncorrected, p<0.05
Mühlau et 
al. (2007b)
2 Study-specific prior probability maps, subjects and whether 
used for normalisation as well as segmentation unspecified
Yes 8 SPM & reported results 
FWE p<0.05, clusters 
p<0.05
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Study SPM
version
Normalisation Segmentation Mod. Smoothing 
PWHM, mm
Correction
Mühlau et 2 Study-specific prior probability maps, subjects and whether Yes 8 SPM & reported results
wA (2007a) used for normalisation as well as segmentation unspecified FWE p<0.05, extent
p<0.05, clusters p<0.001
Ruocco cl 2 Study-specific GM Study-specific GM template. Yes 10 SPM & reported results
wA(2007) template, healthy volunteers healthy volunteers otherwise FDR q<0.05
otherwise unused in study unused in study
Wolf ct al. 2 Study-specific whole-brain Study-specific GM Yes 8 SPM not shown; reported
(2007) template, 50:50 templates, 50:50 results FWE p<0.001
patients-.controls patients-.controls
Wolf et al. 2 Study-specific whole-brain Study-specific GM Yes 8 SPM & reported results
(2008) template, 50:50 templates, 50:50 FWE p<0.001
patients:controls patients:controls
Mod. = modulation
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Firstly, SPM itself changes as newer versions are released, as has been 
demonstrated in the first part of this chapter. Whilst this is unavoidable these 
upgrades can incorporate changes to the segmentation algorithms, and the 
statistics, which can mean that the same dataset analysed in different versions 
will not necessarily yield identical SPMs. This needs to be taken into account 
when comparing results from earlier studies.
Secondly, there are obvious differences in the preprocessing. Although SPM is 
automated in that there is very little manual processing of images, there are a 
number of options that can be set by the user. As discussed above, the original 
paper to advocate an “optimised” normalisation and segmentation for VBM 
(Good et a l  2001b) described normalising grey matter to grey matter to get 
better alignment, and also using a study-specific grey matter template for both 
this normalisation and the subsequent segmentation. However since then a 
range of “optimisation” methods have been reported; some studies just optimise 
the normalisation but do not refer to segmentation, some use a study-specific 
template but for the whole brain rather than different tissue classes, and some 
introduce other new steps (compare e.g., Thieben et a l 2002; Peinemann et a l 
2005; Douaud et a l  2006). Since misalignment or bad segmentation could 
introduce false group differences, the normalisation and segmentation processes 
are other factors which need to be considered when comparing results from 
different groups. At the very least interpretation would be aided by the 
knowledge that preparatory work had tried to overcome (population-specific) 
problems with either step (e.g., Douaud et al 2006).
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Another important issue is that of modulation. Normalisation is supposed to 
correct for global differences in head position and structure (e.g. line up the left 
superior temporal gyri on all subjects) but not local differences due to atrophy. 
However in practice it is likely that normalisation will result in some atrophy 
being lost. To correct for this, the modulation step multiplies the voxel intensity 
by the Jacobian from the normalisation process (i.e. by an index of by how much 
that voxel was stretched or contracted) so that intensity is a more accurate 
representation of volume. With modulated data one is testing for “. . . regional 
differences in the absolute amount (volume) of grey matter . . .” (Good et al. 
2001b, p24) whereas with unmodulated data one is looking at “. . . differences in 
concentration of grey matter (per unit volume in native space).” (Ashbumer and 
Friston 2000; Good et al. 2001b, p24). Three of the 16 HD studies that have 
used VBM do not mention modulation (Kassubek et al. 2004c; Peinemann et al. 
2005; Barrios et al. 2007) and hence the SPMs from these studies may not be 
showing the same sort of data as the others. There are clear differences between 
findings with modulated and unmodulated data, and incorporating a modulation 
step is the preferred way of ensuring inter-subject alignment without losing inter­
group differences in morphology (Keller et al. 2004).
A final preprocessing option is the smoothing kernel. Smoothing is required in
order to render the data more normally distributed and to correct for some error
in the registration process (Ashbumer and Friston 2000). Ashbumer and Friston
(2000) state that “Whenever possible, the size of the smoothing kemel should be
comparable to the size of the expected regional differences between the groups of
brains.” (Ashbumer and Friston 2000, p807). A kemel of 8 mm was used in the
current work because it was shown to give a better representation of simulated
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atrophy than smaller or larger kernels (R. Scahill, PhD Thesis, University of 
London). The larger the kemel, the wider the region over which the signal is 
averaged, which tends to yield more extensive areas of significant differences but 
make precise anatomical localisation harder. This again means that differences 
between studies in which different kernels have been used might not reflect true 
differences in the cohorts being studied.
After preprocessing a common analysis is to regress intensity at each voxel 
against a group variable, including other variables in the model as necessary in 
order to control for their effects (e.g. age, TIV). The test of interest is the t-test 
between the parameter estimates for the group variable. There is huge variation 
between research groups in the covariates they have included in this model: some 
(as in this study) include age, gender, and TIV since these are factors that can 
affect brain volume independently of disease, but some do not. The different 
effects of adjusting for either head size or total grey matter volume in a disease 
population have been discussed earlier in section 6.1.2. Another common 
analysis is to use simple regression models to look at the association between a 
variable of interest and brain volume. Whilst some groups model this as a 
regression, others choose to compare the outcome of two separate contrasts, e.g. 
high CAG repeat length vs. controls, and low CAG repeat length vs. controls. 
Whilst this can yield interesting SPMs, visual comparison of the two resulting 
statistical maps does not constitute a valid statistical comparison in itself.
Finally, very different pictures can be obtained by varying the level and type of 
correction used. One of the benefits of VBM is the fact that it looks at the whole 
brain in an unbiased way (as has been done in this chapter) but in doing so many
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thousands of statistical tests are performed at once. At a standard alpha level of 
0.05, approximately 5000 voxels in an image of 100000 voxels would be 
expected to be false positives. One solution to this is to control the family-wise 
error (FWE) rate, by thresholding the statistic at a level so as to control the 
probability of there being at least one false positive voxel in the entire SPM, but 
this can lack power and hence omit many true positives (Genovese et al. 2002). 
Recently a new method has been described in which the proportion of false 
positives in significant voxels is controlled (the False Discovery Rate (FDR), 
Benjamini and Hochberg 1995). This might be particularly useful for the 
multiple testing problem in neuroimaging, as it is more powerful than controlling 
the FWE and the thresholds are determined directly from the data (rather than 
from the test statistic) making comparison between studies simpler (Genovese et 
al. 2 0 0 2 ).
As can be seen from Table 6-3, alpha levels in HD VBM studies range from the
conservative 0 .0 0 1  (controlling the family-wise error rate) to the more
exploratory 0.005 (without correction for multiple comparisons). Uncorrected
results are often published where group numbers or effect sizes are small, and
hence would not survive FWE correction, although as discussed above, this is
likely to result in a large number of false positives. Conversely extremely
stringent control o f the FWE rate is likely to lead to under-reporting of true
effects. Overall, the wide variation in the type and level of correction makes it
difficult to compare results between studies. Recently sets of guidelines have
been published to encourage more uniformity in the reporting of functional and
structural imaging studies and these suggest that the multiple testing problem
should be addressed clearly, and that unthresholded statistical or effect maps
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should also be presented in order to aid inter-study comparison (Poldrack et al. 
2007; Ridgway et al. 2008). Showing unthresholded effect or statistical maps 
would also make neuroimaging data more similar to those presented in other 
fields, where typically both significant and non-significant effects are reported, 
together with p values or confidence intervals. In future, both use of the FDR 
(which is easily interpretable across studies) and presentation of effect maps 
across the whole search volume, are likely to help emphasise similarities, rather 
than differences, between studies.
A related issue is that some studies have also opted to threshold clusters of 
results (for example, excluding groups of voxels that are smaller than a certain 
size or fail to reach significance at a certain level), although this statistic is 
thought to be invalid in VBM (Good et al. 2001b; Mechelli et al. 2005) as it 
requires uniform smoothness throughout the image. Since smoothness is 
variable in VBM. larger clusters are likely to be found by chance where data are 
more smooth, and hence this approach risks missing valid differences that fail to 
meet the specified cluster threshold.
6.3 CONCLUSION
One of the aims o f the work in this chapter was to investigate the effect of 
different software versions of SPM on the HD dataset. Choice of normalisation 
template (whole-brain or specific to a tissue type) appeared to have the largest 
effect on findings, whilst choice of segmentation template had a much less 
obvious effect. SPM2, using a grey matter (but not study-specific) template for 
normalisation, resulted in the best alignment of images (judged by looking at 
regions in which the early HD subjects were shown to have greater volume than
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controls) and marginally better segmentations (judged by visual comparison of 
segmentations) than the other two implementations tested. Consequently this set 
of VBM processing steps was used for the VBM work presented in the remainder 
of this thesis.
Finally, it is clear that any two VBM papers rarely use exactly the same methods 
and parameters which can mean that results are not directly comparable. More 
importantly, seemingly conflicting results may be due to methods rather than a 
false finding or inherent differences in the population studied. This problem is 
not restricted to VBM, although the methodological variations in the 16 studies 
in Table 6-3 illustrate the difficulties well. Recently there has been a call for 
work to focus on validating methods and reproducing and confirming earlier 
findings in order to reduce inconsistencies in the imaging literature (Nopoulos et 
al 2007). A better consensus on some of the options highlighted in this chapter 
might aid interpretation and generalisation of results, and will be needed if robust 
conclusions are to be drawn about brain atrophy in HD.
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7 PATTERNS OF ATROPHY AND THE RELATIONSHIP BETWEEN 
CAG REPEAT LENGTH AND ATROPHY IN HUNTINGTON'S 
DISEASE: A VOXEL-BASED MORPHOMETRIC STUDY
7.1 INTRODUCTION
As discussed in section 1.2.2, although it is clear that extra-striatal atrophy is 
present even early in HD, findings differ as to the exact location and extent of 
this atrophy. There are similarly disparate findings on the relationship between 
CAG repeat length and volume loss, using both region of interest volumetry and 
VBM techniques.
The work and technical review in the previous chapter demonstrated how, in the 
field of VBM, methodological differences can influence results, and also showed 
that few studies in HD have used identical preprocessing and analysis 
parameters, suggesting that at least some of the discrepancies between studies 
can be attributed to these differences. This makes it hard to judge the veracity of 
effects which may or may not be specific to HD. The work in the previous 
chapter also sought to maximise the accuracy of the normalisation and 
segmentation algorithms for the HD dataset and to demonstrate the effects of 
some confounding variables. VBM processing in this and subsequent chapters 
follows the “opt norm” procedure outlined in chapter 6 .
The work in this chapter was undertaken to address two questions in particular: 
1) using a strict level of whole-brain correction in a large cohort of subjects at 
different stages of HD, could atrophy be detected and where; and 2) what effect 
does CAG repeat length have on brain volume?
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7.2 METHODS
7.2.1 Subjects
Subjects were the same 81 as those reported in chapter 4, see section 4.2.1 for 
details.
7.2.2 A ssessments
Subjects underwent the same assessments described in chapter 4, sections 
4.2.2.1, 4.2.2.2, and 4.2.2.3. That is, they underwent clinical and cognitive 
assessments and had 1.5T MRI scans.
7.2.3 VBM analysis
Images were preprocessed following the steps described in section 2.5.5.
7.2.3.1 Group differences
Linear regression models were used to examine differences in grey matter 
volume between groups. Voxel intensity, V, was modelled as a function of 
group, controlling for age, gender and TIV (an index of head size) by including 
them as covariates. TIV was measured as described in Appendix 2. Although 
TIV can be calculated as the sum of the GM, WM and CSF segments derived 
from the preprocessing stages of SPM, measurement error is likely to be 
increased relative to manually-delineated measures (see section 6.1.3). This 
model is shown in equation 7.1, with the contrasts of interest being the one-tailed 
t-tests between the estimates of the group parameters, i.e. pi> P2, or pi> P3 etc.
V=Pi Control + P2 PM + P3 HD + P4 age + p5 gender + p6 TIV + p + e (7.1)
(where p is  a constant, and 8 is error).
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The analysis was repeated with global GM as an additional covariate to look for 
areas in which there was relative sparing or loss of tissue having controlled for 
the global effect of the disease (equation 7.2).
V=pi Control + p2 PM + p3 HD + p4 age + p5 gender + Pô TIV + p? global + p + e
(7.2)
7.2.4 A trophy and CA G repeat length
All 61 subjects with the HD gene expansion (premanifest and early HD) were 
entered into a simple regression model to look for associations between volume 
and CAG repeat length, having controlled for the effects of age, gender and TIV 
(equation 7.3). The contrast of interest is p, < 0, i.e. regions in which there is a 
significant negative association between volume and CAG repeat length.
V=pi CAG + p2 age + p3 gender + P4 TIV + p + £ (7.3)
The resulting SPMs were masked as described in section 2.5.5 and thresholded at 
p<0.05 using family-wise error (FWE) correction.
7.3 RESULTS
As subjects were the same as those reported in chapter 4, demographic data can 
be found in Table 4-1, page 135.
7.3.1 Early HD vs. Controls
Early manifest HD subjects had significantly less grey matter than controls (after 
controlling for age, gender and TIV) in the caudate, putamen and insula 
bilaterally, as well as the anterior cingulate and thalamus (Table 7-1, Figure 
7-1 A). There was also evidence of more widespread cortical atrophy, including
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the medial frontal gyrus bilaterally, the left inferior frontal gyrus, the postcentral 
gyrus bilaterally, left parietal cortex as well as the right angular gyrus, and 
bilateral regions in the temporal and occipital lobes (Figure 7-IB). There was a 
small region of increased grey matter in the HD group relative to controls (shown 
in the bottom right panel of Figure 6-5) which is likely to reflect imperfect 
normalisation (see section 6.1.1.3 for further discussion of this).
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Figure 7-1 A) Regions of reduced grey matter in early HD relative to 
controls; the colour bar shows the t score (coordinates 9, 10, 9mm); B) the 
same contrast rendered on the MNI-152 average brain to show cortical 
atrophy; p<0.05 FWE
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Table 7-1 Location of maxima for regions in which early HD subjects had 
significantly reduced GM volume relative to controls, FWE corrected, 
p<0.05
Region L /R MNI coordinates p value
X y z
Caudate L -7 8 8 <0.0001
Caudate R 9 10 9 <0.0001
Putamen L -26 1 11 <0.0001
Insula L -42 -5 8 <0.0001
Insula R 42 -11 10 <0.0001
Thalamus L -10 -21 16 0.001
Thalamus R 12 -25 13 0.001
Inferior frontal gyrus L -43 7 38 <0.0001
Medial frontal gyrus L -44 6 52 0.001
Medial frontal gyrus R 49 44 3 0.01
Precentral gyrus L -53 4 35 0.001
Precentral gyrus R 50 -13 56 0.036
Antero-medial temporal lobe L -35 9 -19 0.001
Inferior temporal gyrus L -51 -65 -18 <0.0001
Superior temporal gyrus L -64 -33 16 0.027
Superior temporal gyrus R 60 -43 11 0.013
Angular gyrus R 53 -64 39 <0.0001
Inferior parietal lobule L -43 -44 43 0.002
Postcentral gyrus L -45 -17 36 <0.0001
Postcentral gyrus R 61 -18 27 0.004
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Region L /R MNI coordinates p value
X y z
Superior parietal lobule L -40 -56 54 0.025
Supramarginal gyrus L -60 -51 35 0.042
Medial occipital gyrus L -33 -92 6 < 0 .0 0 0 1
Superior occipital gyrus L -25 -87 2 2 <0.0001
Superior occipital gyrus R 36 -83 2 0 <0.0001
Cuneus R 10 - 8 6 36 <0.0001
Cingulate gyrus R 3 27 17 0.029
SPM  sm oothness 9.4, 10.2, 9.5m m , 1773.6  resels (see  section 2.5.5); FWE = fam ily-w ise error
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7.3.2 Early HD vs. Premanifest
The early HD group also had significantly less grey matter than the premanifest 
group. 1 he pattern of atrophy was similar to above but reduced in extent and 
mainly restricted to small regions of the striatum and insula; there was much less 
extreme atrophy in the cortical areas mentioned above (Table 7-2, Figure 7-2). 
1 here were no significant differences between the controls and premanifest 
group. There were no regions of significant increase in premanifest subjects 
compared to controls.
Figure 7-2 Regions of reduced grey matter in early HD relative to 
premanifest subjects (coordinates 10, 9 ,13mm); p<0.05 FWE
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Table 7-2 Location of maxima for regions in which early HD subjects had 
significantly reduced GM volume relative to premanifest, FWE corrected, 
p<0.05
Region L /R MNI coordinates p value
X y z
Caudate L -9 9 13 <0.0001
Caudate R 10 9 13 <0.0001
Putamen L -24 -1 11 <0.0001
Putamen R 27 6 8 <0.0001
Insula L -42 -5 7 <0.0001
Insula R 37 11 5 <0.0001
Medial frontal gyrus L -26 -8 57 0.023
Inferior frontal gyrus L -58 10 25 0.024
Precentral gyrus R 61 -11 39 0.005
Superior temporal gyrus L -45 14 -7 0.02
Medial temporal gyrus L -46 -77 23 0.002
Medial occipital gyrus L -36 -89 6 0.001
Medial occipital gyrus R 35 -83 19 0.004
Inferior occipital gyrus R 15 -97 -11 0.032
Cuneus L -13 -98 18 0.033
Cuneus R 21 -91 23 0.001
SPM smoothness 9.4, 10.2, 9.5mm, 1773.6 resels; FWE = family-wise error
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7 3 3  HD vs. Controls, adjusting for total grey matter volume 
After controlling for total grey matter loss, the early HD group still had 
significantly less grey matter than controls; the caudate, putamen and insula 
bilaterally show focal atrophy disproportionately greater than the overall volume 
loss (Table 7-3, Figure 7-3). There were no areas in which there was significant 
relative sparing of grey matter relative to controls.
Figure 7-3 Regions of reduced grey matter in HD relative to controls after 
controlling for global disease effects (coordinates 9,10, 9mm); p<0.05 FWE
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Table 7-3 Location of maxima for regions in which early HD subjects had 
significantly reduced GM volume relative to controls after controlling for 
global atrophy, FWE corrected, p<0.05
Region L /R MNI coordinates p value
X y z
Caudate R 9 10 9 <0.0001
Caudate L -7 8 8 <0.0001
Putamen R 26 8 8 <0.0001
Putamen L -26 1 11 <0.0001
Insula R 39 -19 15 0.007
Insula L -42 -5 8 <0.0001
Superior occipital gyrus L -24 -87 2 2 0.001
SPM smoothness 9.2, 9.9, 9.2mm, 1927.6 resels; FWE = family-wise error
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7. i. 4 Effect o f CA G repeat length
After controlling for age, gender and head size (TIV), higher CAG repeat length 
was significantly associated with reduced volume in the body of the caudate 
nucleus bilaterally, left putamen, right insula, right parahippocampal gyrus, right 
anterior cingulate, and right occipital lobe (Figure 7-4). CAG-related atrophy 
was more extensive on the right than on the left. There were no regions in which 
higher CAG repeat length was significantly associated with less atrophy.
Figure 7-4 Regions in which grey matter decreases with increased CAG 
repeat length (coordinates 10, 17, 8mm); p<0.05 FWE
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Table 7-4 Location of maxima for regions in which grey matter decreased 
with increased CAG repeat length, FWE corrected, p<0.05
Region L /R MNI coordinates p value
X y z
Caudate L -9 5 13 <0.0001
Caudate R 10 17 8 <0.0001
Putamen L -24 -4 11 0.009
Insula R 44 0 7 0.045
Parahippocampal gyrus R 14 2 -18 <0.0001
Anterior cingulate R 1 4 -13 0.001
Inferior occipital gyrus R 25 -71 -16 0.048
SPM smoothness 9.5, 10.4, 9.6mm, 1702.8 resels; FWE = family-wise error 
7.4 DISCUSSION
This work has confirmed that there is widespread cortical, striatal and insular 
atrophy in early HD. Cortical atrophy was less prominent after controlling for 
global grey matter loss, suggesting that the striatum and insula are relatively 
more affected in this early HD cohort. In contrast there were no significant 
differences between controls and the premanifest group. The results also show 
that CAG repeat length does affect atrophy in HD, with greater CAG repeat 
length associated with greater loss of caudate, insula and cortical volume.
7.4.1 Volume changes in HD
Striatal atrophy is well documented in HD, and the current study confirmed this. 
In addition atrophy was also found in the insula bilaterally and the thalamus, in 
contrast to some previous VBM studies (Kassubek et a l 2004c; Kassubek et al.
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2005). The presence and extent of cortical atrophy in HD also varies between 
studies with some reporting very little extra-striatal atrophy outside the insula, 
whilst others report motor, somatosensory or fronto-parietal cortical changes 
(Kassubek et a l 2004c; Peinemann et a l 2005; Douaud et a l 2006). Of 
particular relevance to this study is the finding by Mühlau et a l (2007b) of more 
extensive atrophy involving parietal, occipital, and frontal regions, a pattern of 
change which was also found here. Techniques such as cortical thickness 
measurement support this, showing regions of cortical thinning including 
occipital, temporal and (in more advanced stages) frontal lobes (Rosas et al 
2002). This fits well with post-mortem data, where there is a >20% reduction in 
cortical grey matter, compared with controls (de la Monte et a l 1988; Halliday et 
a l 1998).
This evidence that cortical atrophy is quite widespread -  even early in the disease 
-  has not been consistently reported in the HD imaging literature. It is plausible 
that cortical effects, if less severe than striatal atrophy, are failing to reach 
significance owing to insufficient power in studies with smaller sample sizes. 
When I examined the contrast maps' for the differences between HD and 
controls these differences were largest in the striatum, possibly because the 
striatum starts to atrophy prior to cortical regions, or because it atrophies at a 
faster rate.
' The contrast map is the numerator of the t-statistic (it shows the difference between the 
parameter estimates before being divided by the pooled standard deviation) and is hence a 
measure of the magnitude of the effect.
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There is some evidence of abnormal cortical volume in premanifest subjects, 
ranging from decreased cortical thickness and grey matter volume (Thieben et al 
2002; Rosas et a l 2005; Kipps et a l 2007), to increased total grey matter volume 
(Paulsen et a l 2006b). However, in keeping with the findings of Wolf et al 
(2007), in my sample of 21 premanifest subjects I found no significant regions of 
reduced grey matter compared with controls, although the group did include a 
number (57%) who were >15 years prior to predicted onset. Whole-brain 
volumes in this group were slightly smaller than controls (see section 4.3.3), so 
although there may be some volume loss it is likely to be small this many years 
prior to onset.
Finally there is the interesting issue of asymmetry of these cortical changes. A 
recent VBM study reported leftward bias in atrophy in HD (Mühlau et a l 2007a) 
but in this cohort such asymmetry was not obvious from visual inspection of the 
SPM (in contrast to Mühlau et a l)  although there were differences in some 
structures between the left and the right hemisphere.
7.4.2 CAG repeat length and volume changes in HD
Higher CAG repeat length was associated with reduced volume in the body of 
the caudate bilaterally, and the right insula, as well as small regions in the 
anterior cingulate, temporal, and inferior occipital lobes (after adjusting for age). 
Most other ROI studies have found a relationship between CAG repeat length 
and striatal volume in manifest subjects (Rosas et a l 2001; Ruocco et a l 2006). 
In my study the effect was smaller (and less widespread) in the putamen than the 
caudate, which may reflect a quantitative difference in that the effect of repeat 
length on caudate volume is simply larger than that on the putamen volume, as
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the medium spiny neurons in the caudate are known to degenerate preferentially 
in HD (Wanker and Droge 2002). It is also not clear whether atrophy in extra- 
striatal regions is secondary to striatal atrophy or represents an independent 
parallel degenerative process, but given that CAG repeat length varies across 
brain regions (Shelboume et al. 2007) it is possible that independent parallel 
processes of degeneration occur at different CNS sites, and that these may also 
account for some of the early non-motor features of the disease.
In HD brain volume will be affected by the rate and duration of the pathological 
process, as well as age (because of the normal loss from healthy ageing). 
Assuming that the pathological process in HD starts some time prior to symptom 
manifestation rather than progressing linearly from birth (Rosenblatt et a l 1998) 
then for people of the same age, those with a higher number of CAG repeats are 
likely to have had earlier symptom onset and hence a longer pathological 
process. There is also some evidence that higher CAG repeat length causes 
faster rates of progression (Aylward et al 1997; Rosenblatt et al 2006). 
However, it is not possible to determine the length of time for which the 
pathological process has been occurring; duration of motor symptoms is a very 
approximate guide, often determined retrospectively and in any case not 
applicable to premanifest subjects. Therefore it is not possible to conclude 
whether the effect of CAG repeat length seen here is due to differences in the 
duration or rate of the pathological process. However it is clear that both striatal 
and extra-striatal atrophy are predicted by CAG repeat length. Future work with 
prospective longitudinal whole-brain studies need to be undertaken to explore the 
regional change in atrophy rates and their relationship to CAG repeat length.
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7.4.3 Technical implications
There are several explanations for the differences between these findings and 
those of previous studies. One reason for the lack of consensus may be that HD 
is clinically a highly variable disease, and so conflicting findings reflect real 
differences in the populations being studied. However the mean ages, disease 
durations and CAG repeat lengths (where specified) of the early HD cohorts in 
other studies are not very different to those in the current study (Kassubek et al. 
2004c; Peinemann et al. 2005; Mühlau et al. 2007b). One explanation that must 
therefore be considered is variations in methodology; the techniques used in this 
study have been successfully employed in other studies in patients with 
neurodegenerative disorders, but, as discussed in the previous chapter, 
differences in processing parameters and statistical models may have relatively 
large effects on findings. Many of the previous studies using VBM in HD have 
used some form of “optimised” VBM which is likely to have improved 
normalisation relative to standard VBM. However, some did not modulate data, 
smoothing kernels were variable, few studies considered the effects of head size 
or gender, and the resulting SPMs were thresholded at widely varying levels 
using different types of correction, all of which are likely to have contributed to 
the disparity between findings.
The work in the previous chapter aimed to maximise the accuracy of the SPM2
normalisation and segmentation algorithms for this dataset, and models included
age, head size and gender as covariates. Results were only considered
statistically significant after controlling the FWE rate, so false positives are
unlikely, although there is a caveat that some true positives are undoubtedly
missed. Overall this work aimed to minimise sources of error from VBM
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preprocessing, through to model-fitting and statistical inference, meaning that the 
effects seen here are likely to be relatively robust.
7.5 CONCLUSION
Voxel-based morphometry is becoming increasingly used as a tool to investigate 
patterns of atrophy in HD, but it is hard to generalise results because of the many 
different options that can be set by the operator. Despite this there are a number 
of common findings between this study and other studies using both VBM and 
different techniques, which allows one to draw some conclusions regarding the 
pattern of atrophy in HD. In my large cohort I used a whole-brain analysis 
(rather than predefined regions of interest) with a strict correction level and 
found evidence for atrophy of the striatum and insula as well as a number of 
cortical areas. I have also shown that CAG repeat length is related to volume in 
the caudate nucleus, putamen and some regions of the cortex, in a sample of 61 
mutation-positive HD subjects (21 premanifest, 40 early). This has important 
implications for research and in particular studies assessing disease-modifying 
therapies, as CAG repeat length will affect the pattern and extent of atrophy. The 
finding of cortical atrophy even in the early stages reinforces the idea that striatal 
damage is not the only underlying cause of many of the deficits seen in HD and 
probably occurs in parallel and independently of the basal ganglia pathology.
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8 THE NEURAL BASIS OF THE EMOTION RECOGNITION 
DEFICIT IN HUNTINGTON’S DISEASE
8.1 INTRODUCTION
As discussed in chapter I , deficits in emotion recognition have been reported in 
premanifest and early HD, and been shown in the visual, vocal, olfactory and 
gustatory domains (Sprengelmeyer et al. 1996; Gray et a l 1997; Mitchell et al 
2005; Hayes et a l 2007). However although a number of studies found that 
disgust recognition was disproportionately impaired, others have failed to 
replicate this (Milders et a l  2003; Johnson et al 2007). As with other 
discrepancies in the literature, this may be attributable to the heterogeneity of the 
disease, but these authors also point out analytic differences that might have 
influenced results.
The presence of focal striatal atrophy in HD (Vonsattel et al 1985) has often led 
to suggestions that striatal damage might underlie the impairment in disgust 
recognition, and recently functional and structural imaging studies have found 
evidence for striatal involvement in recognition of disgust in both visual and 
auditory modalities (Sprengelmeyer et al 1998). However, the specificity of this 
association has not been established. In functional imaging studies the anterior 
insula is also implicated in recognition of disgust (Phillips et a l 1997; Phillips et 
al 1998; Sprengelmeyer et a l  1998; Murphy et a l 2003; Hennenlotter et al 
2004; Kipps et a l 2007), while striatal activation is also associated with fear 
recognition (Phillips et a l 1998). These findings suggest that the striatum and 
insula may jointly participate in processing disgust and other negative emotions. 
Functional imaging evidence is reinforced both by depth electrode studies of
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disgust processing (Krolak-Salmon et a l 2003), and by human lesion studies 
(Calder et a l 1996; Sprengelmeyer et a l 1997; Calder et al 2000; Calder et al
2004).
The work in this chapter was therefore carried out in order to clarify the emotion 
recognition deficit in early HD and its brain basis by studying facial emotion 
recognition in a large, well-defined disease cohort. Voxel-based morphometry 
(VBM) (Ashbumer and Friston 2000) was used to examine associations between 
emotion recognition performance and grey matter atrophy, both across the whole 
brain and in specific regions of interest suggested by previous research. It was 
predicted that a distributed network of structures would be involved including the 
striatum, insula, amygdala and orbitofrontal cortex, as these regions have been 
widely implicated in emotion recognition both in HD and other disease states and 
in healthy subjects (Sprengelmeyer et al 1998; Blair et a l 1999; Kipps et a l 
2007).
8.2 METHODS
8.2.1 Subjects
Subjects were the same 81 as those reported in chapter 4, see section 4.2.1 for 
details.
8.2.2 Assessments
Subjects underwent the same assessments described in chapter 4, sections 
4.2.2.1, 4.2.2.2, and 4.2.2.3. That is, they underwent clinical and cognitive 
assessments and had 1.5T MR! scans. Of the large cognitive battery reported in 
chapter 4, scores for Recognition Memory for Faces (RMF), the silhouette
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subtest of the VOSP, the Benton Facial Recognition Test and the Beck 
Depression Inventory (BDI) are reported again here as the skills they tap are 
relevant to the main skill under investigation, facial emotion recognition.
Subjects were given an emotion recognition test as described in section 4.2.2.2. 
Twenty-four faces from the Ekman and Friesen battery were used (Ekman and 
Friesen 1976; see Gray et al. 1997). This set was chosen so that the resulting 
dataset would be comparable to that of Gray et a l who were able to demonstrate 
a selective impairment in disgust recognition using the same set on a cohort of 
premanifest HD subjects. It was also shorter than the set of 60 faces or morphs 
sometimes used, which made it more suitable for the assessment of manifest 
subjects. Faces were displayed on individual cards and presented to subjects in a 
random order. The words “Happiness”, “Sadness”, “Surprise”, “Disgust”, 
“Anger”, “Fear” were printed beneath each face in a pseudo-random order, and 
subjects were instructed to look at the face, read the choices, and decide which of 
the words best described the emotion shown by the face. Six practice faces were 
administered beforehand. There was no time limit.
8.2.3 Statistical A nalysis
Linear regression models were used to compare mean levels on the VOSP, RMF, 
Beck and Benton between groups. The effects of variables which could 
independently affect cognitive performance were controlled for by including 
them as covariâtes where necessary. Age and estimated premorbid IQ were 
included as covariates for variables other than the Beck (as mood is not known to 
vary with age and IQ) and the Benton, which is already adjusted for age and 
education.
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Linear regression models were also used to compare mean levels on each 
emotion score from the Ekman data. In addition to age and estimated premorbid 
IQ. scores on the Benton test were included as a covariate in this model to adjust 
for any differences in the perceptual analysis of faces. As there were only five 
possible scores per emotion, and consequently Normality assumptions were 
seriously violated, a 95% bias-corrected bootstrap confidence interval with 1000 
replicates was used, here and in later analyses.
In order to allow for the fact that some emotions are harder to recognise than 
others, scores were standardised by subtracting the control mean from each score 
and dividing this difference by the control standard deviation (i.e. converted to z- 
scores). Because of the discrete nature of the data the resultant z-scores were not 
Normally distributed. For this reason Wilcoxon signed-rank tests were used to 
look for differences between the z-scores for disgust and the other two worst 
recognised emotions (anger and fear). Z-scores were not calculated for happy as 
the control group scored at ceiling and thus had a standard deviation of zero. A 
95% bias-corrected bootstrap confidence interval with 1000 replicates was also 
used to compare control data to Ekman’s published mean levels.
8.2.4 VBM analysis
Images were preprocessed following the steps described in section 2.5.5.
Scores on the Ekman facial emotion recognition test were entered into linear 
regression models to look at group by score interaction, with the exception of 
happiness on which most subjects were at ceiling. For each emotion, voxel 
intensity, V, was modelled as a function of group and score and their interaction.
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controlling for age, gender, TIV, IQ and Benton facial recognition score by 
including them in the model as covariates (equation 8 .1).
V = Pi Control + [h HD gene + P3 Control x score + P4 HD x score + ps age +
Pô gender + pv TIV + Ps IQ + P^  Benton + g + c (8.1 )
I his model allows investigation of the association between GM volume and 
score in HD subjects and/or controls (p4 > 0 or p3 > 0). and also to test whether 
the magnitude (slope) of the association differs between groups (p4 > p )^ thus 
suggesting a disease-related finding. TIV was measured according to the 
protocol described in Appendix 2.
For these analyses all HD gene carriers were included as a single group (N=61) 
since the onset of motor signs is not necessarily associated with the onset (and 
therefore severity) of cognitive signs, and this provided the maximum power to 
detect relationships between score and atrophy. A number of studies have now 
shown that both atrophy and reduced emotion recognition performance can be 
detected prior to motor onset (Aylward et al. 1994; Johnson et al. 2007).
Each emotion was examined at the whole-brain level, and then in pre-specified 
ROIs based on existing literature. Anatomical small volumes for the 
orbitofrontal cortex, right insula and striatum were created in MRIcro 
(http://www.sph.sc.edu/comd/rorden/mricro.html) by manually outlining ROIs 
on a control brain in MNI space, with reference to an anatomical map. The left 
insula ROI was a mirror image of the right insula ROI. The amygdala was 
segmented on a healthy control by an image analyst at the DRC using semi­
automated software (Freeborough et al. 1997) and this was put into standard
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space in SPM2 and converted into a binary mask. All ROIs were smoothed at 
2mm FWHM and thresholded at 0.25. ROI analysis was performed by selecting 
“Small Volume Correction” in SPM2 and then applying the particular region of 
interest. ROIs are shown in Figure 8-1.
The resulting SPMs were masked as described in section 2.5.5.2 and thresholded 
at q<0.05 using FDR correction (Genovese et al 2002) (see also section 6.2).
m
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Figure 8-1 Regions of interest (ROIs) used in the small volume analysis. A) 
striatum, B) orbitofrontal cortex, C) right insula (left also tested), D) 
amygdala
The association between volume and score for each emotion was investigated 
within these five ROIs.
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8.3 RESULTS
As subjects were the same as those reported in chapter 4, demographic data can 
be found in Table 4-1, page 135.
8.3.1 Cognition
There was no evidence of differences between the groups on the Beck and VOSP 
silhouette test but the HD group was worse at the Benton than both controls 
(p<0.0001) and premanifest (p<0.0001) and at the RMF (HD vs. controls, 
p<0.0001, HD vs. premanifest, p=0.001). Table 8-1.
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Table 8-1 Mean (SD) cognitive scores, and differences (95% confidence intervals) with and without adjustment for age and estimated
premorbid IQ
Control Premanifest Early HD Difference (Premanifest - Control) Difference (Early HD - Control)
(N=20) (N=21) (N=40) Crude Adjusted Crude Adjusted
BDI 5.6 (3.9) 6.8 (6.3) 9.3 (8.7) 1.3 (-3.2, 5.7) 3.7 (-0.2, 7.7)
p=0.57 p=0.06
VOSP (/15) 9.5 (2.3) 8.6 (3.2) 8.6 (2.3) -0.8 (-2.4, 0.8) -1.1 (-2.7, 0.6) -0.8 (-2.2, 0.6) -0.6 (-2.0, 0.8)
p=0.31 p=0.20 p=0.25 p=0.40
Benton (/54) 48.0 (3.8) 47.7 (3.7) 43.5 (4.7) -0.3 (-2.9, 2.4) -4.5 (-6.8, -2.2)
p=0.83 p<0.0001
RMF (/50) 42.7 (4.0) 41.3 (5.3) 34.8 (7.0) -1.4 (-5.1, 2,3) -1.5 (-5.2, 2.3) -7.9 (-11.2, -4.7) -7.5 (-10.7, -4.3)
p=0.47 p=0.44 p<0.0001 p<0.0001
Negative differences indicate a lower score in HD subjects relative to controls; crude differences are the absolute difference between groups before adjustment for age and 
IQ; adjusted differences are the differences having adjusted for age and IQ by including them as covariates in linear regression models; the BDI was not adjusted for age and 
IQ, and the Benton scores are already age- and education-adjusted.
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After adjusting for age, IQ and Benton facial recognition score the premanifest 
group was significantly worse than controls at recognising happiness (p<0.05), 
although there was no evidence of a difference between the two patient groups 
for this emotion. The early HD group was significantly worse than controls at 
recognising facial expressions of surprise, disgust, anger and fear (all p<0.05) 
and worse than premanifest subjects at recognising disgust and anger (all p<0.05. 
Table 8-2, Figure 8-2).
o
00
O S
8
o
Happiness Sadness Surprise Disgust Anger Fear
■ Control ^  Premanifest ♦  Early HD
Figure 8-2 Mean emotion score (% correct) for each group with 95% bias- 
corrected bootstrap confidence intervals calculated from 1000 replications
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Table 8-2 Mean (SD) % correct for Ekman Pictures of Facial Affect with differences (95% confidence intervals) with and without
adjustment for age, estimated premorbid IQ and Benton score
Control Premanifest Early HD Difference (Premanifest - Control) Difference (Early HD - Control)
(N=20) (N=21) (N=40) Crude Adjusted (95% Cl) Crude Adjusted (95% Cl)
Happiness 100 (0) 98.8 (5.5) 96.9 (8.4) -1.2 (-4.8, 0.0) -1.8 (-4.6, -0.1) -3.1 (-6.3, -0.7) -1.4 (-3.9, 0.7)
Sadness 86.3 (22.2) 92.9 (14.0) 81.9 (21.2) 6.6 (-3.6, 18.2) 8.4 (-4.4,21.5) -4.4 (-15.0, 8.3) -1.7 (-15.9, 11.7)
Surprise 95.0(10.3) 92.9 (14.0) 85.0(15.8) -2.1 (-9.7, 4.8) -2.3 (-11.1,5.1) -10.0 (-17.1,-3.6) -8.7 (-16.6, -1.6)
Disgust 90.0 (12.6) 82.1 (21.1) 66.3 (30.8) -7.9 (-19.0, 1.1) -2.7 (-12.6, 7.6) -23.8 (-35.0,-13.5) -20.3 (-31.0, -8.7)
Anger 91.3(14.7) 84.5 (24.3) 49.4 (32.3) -6.7 (-19.6,5.0) -7.7 (-21.8, 6.3) -41.9 (-53.0, -29.3) -36.8 (-52.1,-22.4)
Fear 71.3 (23.3) 64.3 (31.2) 41.3 (32.8) -7.0 (-26.3, 8.0) -8.3 (-24.2, 8.6) -30.0 (-43.7,-15.0) -21.4 (-37.4, -4.3)
Negative differences indicate a lower score in HD subjects relative to controls; crude differences are the absolute difference between groups before adjustment for age, IQ 
and Benton score; adjusted differences are the differences adjusting for age, IQ and Benton by including these as covariates in the linear regression models; confidence 
intervals are 95% bias-corrected bootstrap confidence intervals calculated from 1000 replications; differences shown in bold are significant at p<0.05.
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When emotion recognition scores were expressed as z-scores in order to control 
for emotion difficulty, subjects with HD were worse at recognising anger 
compared with disgust (p=0.023) and anger compared with fear (p=0.0006). The 
difference between disgust and fear was not statistically significant (Figure 8-3).
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Figure 8-3 Premanifest and early HD z-scores with 95% bias-corrected 
bootstrap confidence intervals calculated from 1000 replications
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The control group was statistically significantly worse than the Ekman published 
norms at recognising sadness, anger and fear (all p<0.05, Table 8-3).
Table 8-3 Control mean % correct with 95% bootstrap confidence intervals 
and Ekman norms
Control
(N=20)
Ekman
Happiness 100(100) 100.0
Sadness 86.3 (76.3, 95.0) 95.8
Surprise 95.0 (91.3, 100) 95^
Disgust 90.0 (85.0, 96.3) 96.0
Anger 91.3 (85.0, 97.5) 98.3
Fear 71.3 (62.5,81.3) 93.0
Means shown in bold are significantly different to the Ekman norms, p<0.05.
8. S. 2 Neuroanatomical correlates
8.3.2.1 Whole-brain analyses
When associations between emotion recognition score and grey matter volume 
were examined across the whole brain none were significant after correction for 
multiple comparisons. However the effect maps are shown in Figure 8-4 in order 
to demonstrate how the associations varied both across the brain and between 
emotions. Results for the ROI analyses are reported below, with the exception of 
sadness, for which there was no evidence of significant associations (see also 
Table 8-4).
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Figure 8-4 Effect maps for the associations between grey matter volume and 
surprise, disgust, anger and fear
Colour bar represents the size o f the effect from positive (red) through zero 
(green) to negative (blue) (coordinates 14, 14, 12mm). This maps the strength o f 
the association between volume and emotion score at each voxel (rather than the 
significance o f that effect). Red indicates a strong positive association (larger 
volume = larger score), green indicates no association and blue indicates a 
negative association.
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8.3.2.2 Surprise
In the HD gene carriers (N=61) impaired recognition of surprise was associated 
with atrophy in the caudate body bilaterally (Figure 8-5). There were no 
significant associations in the other ROIs or in the control group.
Figure 8-5 Regions in which surprise performance was associated with grey 
matter atrophy in the striatal ROI (coordinates 14, 14, 12mm); q<0.05 FDR, 
smoothness 9.5,10.3, 9.6mm, 54.7 resels; colour bar shows t score
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8.3.2.3 Disgust
In the HD gene carriers deficits in disgust recognition were associated with grey 
matter atrophy throughout the striatal ROI, with peaks in the left caudate head 
and caudate body bilaterally (Figure 8-6). There were no significant associations 
in the other ROIs or in the control group.
€
Figure 8-6 Regions in which disgust performance was associated with grey 
matter atrophy in the striatal ROI (coordinates 14, 14, 12mm); q<0.05 FDR, 
smoothness 9.5,10.3, 9.6mm, 54.4 resels
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8.3.2.4 Anger
Deficits in anger recognition in the HD gene carriers were also associated with 
grey matter atrophy throughout the striatal ROI, with peaks in the head and body 
of the caudate bilaterally, and the right putamen (Figure 8-7). There were no 
significant associations in the other ROIs or in the control group.
Figure 8-7 Regions in which anger performance was associated with grey 
matter atrophy in the striatal ROI (coordinates 14, 14, 12mm); q<0.05 FDR, 
smoothness 9.5,10.3, 9.6mm, 54.7 resels
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8.3.2.5 Fear
In the striatal ROI worse fear recognition in HD gene carriers was associated 
with atrophy of the putamen and caudate head bilaterally. Fear recognition was 
also associated with small regions of atrophy in the right insula (but not the left), 
and with the left middle frontal gyrus and right inferior frontal gyrus in the OFC 
ROI (Figure 8-8). Better fear recognition in controls, but not HD gene carriers, 
was associated with increased amygdala volume bilaterally (SPM not shown).
8.3.2.6 Other contrasts
For all the emotions tested there were no significant interactions between slope 
and group (i.e. regions in which the slope of the association in the HD gene 
carriers was significantly greater than that in the control group). We also 
investigated the reverse associations, i.e. looking for regions in which increased 
brain volume was associated with worse emotion recognition performance in the 
HD group. There was no evidence of any such regions for any of the emotions 
tested.
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Figure 8-8 Regions in which fear performance was associated with grey matter atrophy in A) striatal ROI (14, 14 12mm) smoothness 
9.5, 10.2, 9.6mm, 54.9 resels; B) right insula ROI (47, -15, 6mm), smoothness 9.5, 10.2, 96.mm 28.3 resels; C) orbitofrontal ROI (-25, 29, - 
19mm) smoothness 9.5, 10.2, 9.6mm, 67.0 resels; all q<0.05 FDR
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Table 8-4 Summary table of anatomical correlates for each emotion in each ROI for the HD gene carriers
Striatum Insula (L or R) Orbitofrontal cortex Amygdala (L and R)
Surprise Caudate body bilaterally - -
Disgust Left caudate head and caudate - -
body bilaterally
Anger Head and body of caudate - -
bilaterally, right putamen
Fear Putamen and caudate head Right anterior and posterior Left middle frontal gyrus, right -
bilaterally inferior frontal gyrus
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8.4 DISCUSSION
The work presented here demonstrates impaired recognition of negative facial 
emotions in a well-characterised cohort of 40 subjects with early HD. The early 
stage non-depressed HD subjects were significantly worse than healthy subjects 
at recognising facial expressions of anger, disgust, fear and surprise, and 
significantly worse at recognising anger than disgust or fear. Although there was 
no evidence of significant deficits in individuals with premanifest HD, for all 
emotions other than sadness there were small effects in the same direction.
Despite the focus on disgust recognition, the original study to report a 
disproportionate impairment for this emotion also found that recognition of angry 
faces was impaired (Sprengelmeyer et al. 1996) as have others (Milders et al. 
2003; Wang et al. 2003; Montagne et al. 2006; Johnson et al. 2007), and a 
similar deficit has recently been demonstrated for recognition of angry body 
language (de Gelder et al. 2008).
There was no evidence of impaired sadness recognition in these HD subjects: 
although some studies do report this (Sprengelmeyer et al. 1996; Milders et al. 
2003; Johnson et al. 2007), in most cases the impairment is slight relative to 
other negative emotions. This suggests that particular negative emotions may be 
intrinsically more difficult to recognise, perhaps because they impose greater 
demands on perceptual processing resources (for example, the need to 
disambiguate the facial expressions of disgust and anger, which share a number 
of configurational features (e.g., Simon et al. 2007)). In common with most 
other studies of HD this cohort was not significantly impaired at recognising 
happiness; this was the least difficult emotion for the controls to recognise and,
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as the only positive emotion in the test, is easily contrasted with the other five. 
This is likely to reflect in part the relative paucity of universally agreed 
subcategories within the general category of ‘positive’ emotion, in contrast to the 
well-established subcategories within the field of ‘negative’ emotion. The 
apparently inferior performance for recognition of happiness shown by 
individuals with premanifest HD relative to healthy controls is difficult to 
interpret as all groups performed at or near ceiling for this emotion. In fact, 
given that controls scored entirely at ceiling it is unlikely that this represents a 
clinically meaningful difference. The lack of a statistically significant difference 
in the early HD group is probably due to the increased variance in that group.
Impaired recognition of facial emotions in HD was not attributable simply to a
perceptual processing defect, since effects persisted after adjusting for perceptual
factors. However this does not rule out the possibility that an abnormality of
facial feature analysis contributed to the emotion recognition defect. I noted that
some subjects who scored poorly on the test seemed to attend only to features of
the faces in isolation; for example they would comment on the eyes, and then the
mouth, and then justify their final decision based on just one rather than the
features as a whole. While this strategy works for some emotions (e.g. all and
only the happy stimuli have a smiling mouth) it does not for others (e.g. the
angry and disgusted stimuli all have lowered eyebrows and a range of mouth
positions). Differences in patterns of visual scanning with ageing have been
associated with the (in)ability to recognise certain emotions (e.g., Wong et al.
2005). It would be interesting therefore to examine the pattern of subjects’ eye
movements as they scan the images, since eye movements are known to be
impaired in premanifest and early HD (e.g., Golding et al. 2006) or to see if
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performance could be improved by explicit instructions to attend to specific 
facial features, as has been shown with amygdala damage (Adolphs et al 2005). 
However, it is likely that there is a higher-level, supramodal failure of emotion 
recognition even taking into account specific strategies of facial feature analysis; 
this would follow from evidence for cross-modal emotion recognition deficits in 
both HD and other conditions (e.g., Scott et al 1997; Calder et al 2000).
Recognition deficits for anger, disgust, fear and surprise correlated with grey
matter loss in a number of brain regions known to be involved in HD. Impaired
recognition of anger, the most severe deficit in this cohort, was associated with
volume loss in the ventral putamen and other striatal regions. Damage to the
ventral putamen has been shown previously to disrupt anger recognition (Calder
et al 1996; Scott et al 1997; Calder c/ al 2004). In HD striatal atrophy
progresses in a dorsal to ventral direction (Vonsattel et al 1985), which may
mean there was sufficient inter-subject variability in involvement of the ventral
striatum in this cohort to detect the correlation with anger recognition
performance. Impaired recognition of disgust was also associated with atrophy
of the striatum, but not the insula or globus pallidus; these latter regions have
been implicated in disgust recognition in other studies, including premanifest HD
(Krolak-Salmon et al 2003; Murphy et al 2003; Kipps et al 2007). Comparison
with the healthy control group confirmed that bilateral insula atrophy was present
in this HD cohort (see chapter 7), suggesting that any association between
disgust recognition performance and insula volume was weak, or perhaps that
uniform involvement of the insula precluded correlation with performance in the
HD group. Impaired fear recognition was also associated with striatal volume
loss, although the effect here was weaker than for anger and disgust. At least one
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fMRI study has found a similar relationship between fear and the striatum 
(Phillips et al. 1998). The fear recognition deficit in this cohort was associated 
with additional atrophy of the right insula, and lateral orbitofrontal cortex. The 
insula has been implicated in the prediction of aversive stimuli and the 
behavioural relevance of stimuli, (Buchel et al. 1998; Hennenlotter et al. 2004; 
Simmons et al. 2004), while the orbitofrontal cortex is involved in modulating 
behaviour in response to emotive stimuli in general (Sprengelmeyer et al. 1998; 
Blair et al. 1999; Gomo-Tempini et al. 2001). There was no evidence that fear 
recognition was related to amygdala volume in the HD group. This association 
was present in controls, although this is hard to interpret without further 
investigation. This may reflect the distinction between categorisation of emotion 
in others as in the task used here, versus subjective feeling states, for which the 
amygdala may be critical (e.g., Lang et al. 2000b; Calder et al. 2001; Skuse et al. 
2003). The association between impaired surprise recognition and caudate 
atrophy in the present study was relatively weak and further work is needed to 
confirm this. There is little evidence for a specific neural substrate for surprise 
recognition (Murphy et al. 2003).
These associations between brain volume and emotion recognition performance
were found in the HD gene-carrying cohort, and not in controls, but the
difference between the associations in the two groups was not significant,
meaning that disease-specificity of these effects was not shown. However the
findings are suggestive of such an effect, and most likely reflect a lack of power
which could be addressed with a larger sample size. Indeed some studies infer
disease-specificity from associations seen in the HD group alone (Douaud et al.
2006). It may also be useful in future work to model volume as a function of all
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the emotions as one could then investigate which regions were associated with 
one emotion and not others. However to have adequate power such a model 
would probably require a larger dataset than that presented here and as such was 
beyond the scope of this thesis.
Whilst these findings are in general agreement with other studies showing
impaired recognition of negative emotions in HD (Sprengelmeyer et al. 1996;
Gray et al. 1997; Milders et al. 2003; Johnson et al. 2007; Kipps et al. 2007), the
pattern of this impairment differs between studies. Whereas Grey et al. (1997)
and Sprengelmeyer et al. (1996) described selective deficits in disgust
recognition, Milders et al. (2003) found fear to be most severely affected, while
anger was most severely affected in the present study. The data presented here
support the idea that damage to a distributed network of brain regions underpins
a broad emotion recognition deficit in early HD; the symptomatic cohort was at a
very early stage of disease and yet was already impaired at recognising a range of
negative emotions. The common association of these deficits with striatal
volume loss suggests that the striatum might play a generic role in the processing
of negative emotions. However, it is likely that emotion recognition deficits in
HD arise from damage involving a cortico -  basal ganglia -  thalamic network,
rather than focal damage to a specific area. The ventral part of this network,
which is thought to process emotional or reward information, receives input from
orbitomedial prefrontal regions and insula and outputs predominantly from the
thalamus via the basal ganglia (Parent and Hazrati 1995; Haber 2003). These
regions are involved even in very early or premanifest HD (e.g., Thieben et al.
2002; Rosas et al. 2005). The present findings imply that emotion recognition
deficits in HD may appear selective but represent ‘snapshots’ of a more generic
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structure-fimction relationship that is distributed in the brain and perhaps also 
evolving in time. Involvement of the network may not be uniform for all 
emotions: rather, the difference between emotions may emerge as a relatively 
greater or lesser involvement or correlated involvement of particular components 
of the shared network.
It should also be noted that use of ROIs in this study means that it cannot be 
concluded that brain regions outside those investigated here are not involved in 
emotion recognition in HD. Although no statistically significant effects were 
found in the whole-brain analysis the effect maps showed that there were positive 
relationships between volume and score in the temporal lobes (for surprise and 
fear recognition in particular) and the posterior cortex (fear), as well as in the 
striatum, insula and orbitofrontal cortex. This is something that merits further 
investigation with both structural and functional imaging.
8.4.1 Methodological considerations
As with findings throughout the HD literature, the variability amongst studies of 
emotion recognition in HD might reflect a number of different factors, including 
the characteristics of the HD population under investigation, the test used, and 
the choice of control group. Different study cohorts may represent different 
disease stages with varying burdens and patterns of brain atrophy. For example, 
it is likely that in the earliest stages of the disease striatal atrophy is more severe 
than insula. It may also be that linguistic and cultural differences contributed to 
the diverse findings, as early studies were undertaken in Germany in contrast to 
the later studies which have been predominantly in English-speaking countries.
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However, in addition the three main tools for assessing facial emotion 
recognition in the literature -  the “emotion hexagon” which uses morphs of a 
single subject; a set of 60 Ekman faces; and the set of 24 Ekman faces used here 
and by Gray et al. (1997) -  are not of equivalent difficulty (based on the mean 
percent correct achieved by Ekman’s normative sample). In addition, the 
emotion hexagon is not a simple facial emotion recognition task. Morphs of a 
single subject (“JJ”) were constructed by blending different proportions of two 
emotions, placing each next to one it was most likely to be confused with (Calder 
et al. 1996) although in fact, in order to fit all six canonical emotions into the 
hexagon this is not always true for each pair of emotions. Blocks tend to be 
repeated in testing which might inflate differences between controls and HD 
subjects if controls benefited from learning over the earlier blocks whilst HD 
subjects did not.
Investigators have also used widely varying criteria for selecting controls,
ranging from normal healthy adults, to at-risk subjects who are undergoing
genetic testing, to gene-negative and HD family members, and these groups are
unlikely to be equivalent. Impaired anger recognition has been shown in at-risk
controls who subsequently turn out to be gene negative (Gray et al. 1997;
Sprengelmeyer et al. 2005), and there is also evidence that fear and anger
recognition might deteriorate slightly with age, whilst disgust recognition is
relatively spared (Calder et al. 2003). The original finding of impaired disgust
recognition in HD used controls who were on average five years older than HD
subjects, and did not control for the effects of age (Sprengelmeyer et al. 1996).
The controls in the current study found fear most difficult to recognise, followed
by sadness and anger, and their performance on these emotions was significantly
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worse than that of Ekman’s (presumably younger) normative college student 
sample (Table 8-3); however the overall rank ordering of scores was similar.
8.5 CONCLUSION
These findings suggest a widespread impairment of facial emotion recognition in 
HD. Anger, disgust, fear and surprise recognition were all affected to a variable 
degree early in the disease process, and these deficits were associated with 
reduced grey matter volume in a network of cortical and subcortical regions. 
Striatal damage was associated with impaired recognition of different negative 
emotions. It is likely that these brain regions constitute a distributed functional 
network that mediates emotion recognition: this network may have a generic 
neurobiological role in processing threat to self, whether direct external (anger), 
indirect external (fear) or internal (disgust), and is therefore predicted to underpin 
a number of aspects of human social behaviour and behavioural derangements in 
disease. This hypothesis should motivate further work, including longitudinal 
structural and functional brain imaging, in order to clarify when deficits become 
manifest and how their brain substrate evolves over time. From the clinical 
perspective, emotion recognition deficits may be useful in determining the onset 
of cognitive involvement and in tracking disease progression in HD. 
Anecdotally, many of the carers in this study described episodes during which 
their HD-affected partner failed to recognise that they were in some way upset, 
and the distress that this caused. A better understanding of the pattern of deficits 
might also therefore have implications for anticipating and managing the often 
devastating social difficulties faced by people with HD and their carers.
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9 DETECTING COGNITIVE DECLINE IN PREMANIFEST AND 
EARLY HUNTINGTON’S DISEASE
9.1 INTRODUCTION
As mentioned in section 1.4.1, tracking change in cognition in HD is difficult, 
because of the many non-disease-related factors that can affect performance, and 
the slow progression of the disease. There have been conflicting findings as to 
which domains show decline in early HD and few studies have been able to 
detect cognitive decline in premanifest subjects using standard cognitive 
measures.
In this study a number of factors which might contribute to change in cognitive 
performance were considered and where possible, controlled for. Subjects were 
all assessed by the same investigator, using alternative test forms at the follow-up 
assessment where they were available. Testing was done in similar surroundings 
although it was not always possible to assess subjects in the same room or at the 
same time of day at both assessments.
Estimated premorbid IQ at baseline was adjusted for, since it could 
independently affect cognitive decline (Snowden et al. 2001; Ward et al. 2006). 
Age was also included as a covariate. Although in previous studies the effect of 
age on rate of decline was negligible, the current cohort spanned a wide range of 
ages and preliminary analysis showed that age had a small but sometimes 
statistically significant effect on the rate of decline in controls, particularly for 
timed tests.
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This chapter describes changes over one year in cognition, whilst the following 
chapters look at changes in brain volume and the associations between the two. 
The aims of this chapter were to investigate in which domains cognitive decline 
could be detected, over a relatively short time period, and how change was 
related to CAG repeat length and other baseline demographic variables.
9.2 METHODS
9.2.1 Subjects and assessments
Subjects and assessments were the same as in chapter 4 (sections 4.2.1 and 
4.2.2). All subjects from the baseline assessment were invited to return for 
repeat cognitive, clinical and MRI assessments approximately one year later. As 
described in chapter 4, where alternative test versions were available half the 
subjects did each form at each timepoint. All subjects who returned for follow- 
up are reported in this chapter (77 of the 81 assessed at baseline, see section 9.3 
for demographic details). The vast majority, 72 subjects, had all three follow-up 
assessments on the same day or over two consecutive days. Three (two early HD 
subjects and one control) had the clinical assessment after the other two 
assessments (five, seven and 18 weeks later); and one early HD subject had the 
scan and clinical assessment eight days before the cognitive assessment for 
logistical reasons. One early HD subject completed the cognitive assessment but 
suffered from anxiety during the scan and had to return nine weeks later to 
complete the MRI and clinical assessments.
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9.2.2 Statistical analysis
9.2.2.1 Group differences
t-tests assuming unequal variance were used to investigate group differences in 
age, estimated premorbid IQ and CAG repeat length at baseline. A chi  ^ test was 
used to compare gender in each group. Fisher’s exact test was used to see if the 
proportion of right-handed subjects, or the proportion of subjects classified as 
depressed at baseline or follow-up, differed between groups.
As controls were at ceiling on the UHDRS motor score, independence score and 
TFC, and premanifest were at ceiling on the independence score and TFC, paired 
t-tests were used to assess change between visits within each group (i.e., change 
in premanifest and early HD subjects was not compared with change in controls). 
Control motor scores did change very slightly over the year and are presented for 
comparison only.
In order to investigate whether performance differed significantly between 
cognitive test versions, follow-up score was regressed on test form, adjusting for 
age and estimated premorbid IQ, for all tests for which an alternative version was 
available.
As slightly fewer subjects returned for follow-up than were assessed at baseline, 
linear regression models with robust standard errors were used to investigate 
group differences in baseline score (as in chapter 4) for the 77 subjects who 
returned for follow-up.
For cognitive variables a change score was generated from the baseline and 
follow-up score. Linear regression models were used to compare change scores
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between groups, with robust standard errors to allow variances to differ between 
groups, and controlling for age and estimated premorbid IQ at baseline by 
including them as covariates. Change scores for the Ekman emotion recognition 
task were not Normally distributed and so linear regression models were used 
with a 95% bias-corrected bootstrap confidence interval with 1000 replicates.
Examination of the raw data showed that some subjects scored at ceiling on the 
HVLT delayed recall and discrimination tasks, and the RMW, at both timepoints, 
and hence change scores are unlikely to be very sensitive in this cohort. Floor or 
ceiling effects were not apparent in the other tasks.
Data from the reaction time task were unable to be analysed longitudinally as an 
unavoidable software change half-way through the follow-up meant that reaction 
times differed systematically between some subjects.
9.2.2.2 Relationship with CA G repeat length
A linear regression model (with robust standard errors) relating cognitive change 
to CAG repeat length, group and their interaction was used to investigate 
whether the relationship between change and CAG repeat length differed 
between groups. The effects of age and estimated premorbid IQ were controlled 
for by including them as covariates. If there was no evidence of an interaction 
then the analysis was repeated without interaction terms, but adjusting for 
differences due to group, and age and estimated premorbid IQ.
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9.2.2.3 Relationship with baseline motor score, disease duration and 
interaction between CAG repeat length and duration
Separate linear regression models were used to investigate the association 
between cognitive change and both baseline motor score, and disease duration (at 
baseline) in the early HD group, again controlling for the effects of age and 
estimated premorbid IQ at baseline. As duration and age at baseline linearly 
combine to give age at onset, this model implicitly investigates the effect of age 
at onset after adjustment for baseline age, as well as the effect of disease duration 
after adjustment for baseline age.
Finally, in view of the recent finding that both repeat length and disease duration 
had an interactive effect on rate of decline (Rosenblatt et al. 2006), change scores 
were also regressed on CAG repeat length, duration and their interaction, with 
age and IQ included as covariates.
9.2.2.4 Relationship between probability o f onset and other variables 
Probability of motor onset within five years was calculated using the equation 
given by Langbehn et al. (2004) (see section 4.2.3.5 for more details). To assess 
whether rate of cognitive change was influenced by closeness to motor onset in 
the premanifest group cognitive change scores were regressed on probability of 
onset, controlling for the effects of age and IQ by including them as covariates.
9.2.2.5 Comparison o f NART and Spot the Word test
In order to compare the stability of these two tests over time, firstly the Spot the
Word test was transformed to be on the same scale as the NART (converting a
distribution with a mean of 10 and standard deviation of 3 to one with a mean of
100 and a standard deviation of 15). Paired t-tests were used to investigate
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whether there was a significant amount of change in either test between baseline 
and follow-up, in the whole cohort. For each measure a change score was 
generated (follow-up score - baseline score) and t-tests assuming unequal 
variance were used to determine whether the amount of change in each test 
differed between groups.
Pitman’s test was used to compare the standard deviation of the change score for 
each test. A paired t-test was used to investigate whether the amount of change 
differed significantly between tests.
9.3 RESULTS
Two controls and two premanifest subjects did not return for the follow-up 
assessment. Demographic data for the remaining 77 subjects are shown in Table 
9-1. There were small non-significant differences in gender, handedness and IQ 
between the groups. There was no evidence of a difference in assessment 
interval between the groups. The mean age of the premanifest group was eight 
and a half years lower than that of controls (95% Cl 2.5, 14.6 years, p=0.006). 
The premanifest group had significantly shorter CAG repeat lengths, on average, 
than the early HD group (mean difference 1.5 repeats, 95% Cl 0.3, 2.8, p=0.015). 
One control (6%), five premanifest (26%) and 12 early HD subjects (33%) were 
classified as depressed at baseline; the BDI was not available to be administered 
to four early HD subjects at baseline (see section 4.2.2.1). Five controls (28%), 
five premanifest (26%) and 13 early HD subjects (33%) were classified as 
depressed at follow-up and these proportions did not differ significantly between 
groups at either timepoint (baseline p=0.07, follow-up p=0.90).
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Table 9-1 Demographic data for the longitudinal cohort
Control Premanifest Early HD
(N=18) (N=19) (N=40)
Gender (M:F) 6:12 9:10 20:20
Age (year)^ 46.3 (9.7) 37.7 (7.6) 48.5 (9.6)
Estimated premorbid IQ 106.8(11.5) 104.2 (9.1) 105.3(13.0)
Handedness (R:L) 17:1 18:1 36:4
CAG repeat length^ NA 42.2(1.8), 43.7 (2.4),
range 40 -  45 range 4 0 -5 0
Predicted years to onset‘s NA 17.8 (7.4), NA
range 9 -3 5
Disease duration (year) NA NA 4.1 (2.6)
UHDRS Motor" 1.1 (0.9) 3.6 (4.3) 28.9(12.6)
UHDRS Independence 100 (0) 100(0) 90.4 (9.6)
UHDRS TFC 13(0) 13(0) 10.9(1.8)
BDI 5.4 (3.3) 6.2 (5.9) 9.3 (8.7)
Assessment interval (year) 1.0 (0.1) 1.0 (0.1) 1.0 (0.1)
NA: not applicable
Data are mean (SD ) with the exception o f  gender and handedness; handedness was taken as the 
hand used to write with; UHDRS: motor is out o f  124, higher score = more severely impaired; 
independence is scored as a percentage, higher score = better function; Total Functional Capacity 
is out o f  13, higher score = better function, 
a PM<Control (p=0.006); PM <HD (p<0.0001) 
bPM <H D  (p -0 .0 1 5 )
c Calculated from age using the equation from Langbehn et al. (2004), with onset defined as a 
60% chance o f  showing motor signs 
d HD<Control, HD<PM (both p<0.0001)
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After correcting for age and IQ there were no statistically significant differences 
between scores on alternative test versions, except for the HMGT at baseline in 
which subjects performed worse on form B than form A. As half of each group 
did each form this is unlikely to bias between-group comparisons but form was 
included as a covariate in all analyses of the HMGT in order to control for this. 
One control had no motor assessment at follow-up. Three HD subjects failed to 
complete TMT B at baseline, and four failed to complete it at follow-up so 
change scores for TMT B are based on data from 72 subjects. In all cases 
subjects made errors on the alternating sequencing and struggled to work out the 
correct number (or letter) from which to continue, and if this carried on for more 
than four minutes the test was stopped.
9.3.1 Clinical measures
Change in UHDRS motor score, independence score, and TFC for the groups is 
shown in Table 9-2. On average the early HD group declined in all three 
measures over one year (see table for details). Change between baseline and 
follow-up motor score in the control and premanifest groups was not statistically 
significant although was approaching this in the latter group (p=0.07). On 
average all subjects scored slightly higher on the BDI at follow-up compared 
with baseline although this difference was not statistically significant (mean 
change 0.7 points, 95% Cl -0.5, 2.0 points, p=0.25), and there was no evidence 
that the amount of change differed between the groups.
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Table 9-2 Mean (SD) UHDRS scores in the patient groups at baseline and
12-month assessments, with change (95% confidence intervals)
Baseline
Control 
12 months
(N=17)
Change
Motor 1.1 (0.9) 2.1 (2.4) 1.0 (-0.2, 2.2) p=0.10
Baseline
Premanifest (N=19)
12 months Change
Motor 3.6 (4.3) 5.2 (4.4) 1.6 (-0.2, 3.4) p=0.07
Baseline
Early HD (N=40)
12 months Change
Motor
Independence score 
TFC
28.9(12.6) 
90.4 (9.6) 
10.9(1.8)
34.3(12.9) 
88.6 (9.3) 
10.4(1.9)
5.4 (3.0, 7.7) p<0.0001 
-1.8 (-3.1,-0.4) p=0.0114 
-0.4 (-0.7, -0.1)p=0.0112
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9.3.2 Cognitive performance
9.3.2.1 Group differences at baseline
In general group differences at baseline mirrored those seen in the whole cohort 
(N=81, see chapter 4) and will be summarised here for brevity. The early HD 
group was impaired, relative to controls, at exactly the same tests, namely all 
tests of psychomotor skills, reaction time, executive function, immediate, free 
recall and recognition memory, digit span, Benton facial recognition, and Ekman 
facial emotion recognition. The premanifest group was impaired at returning to 
press the central blue button in the RT task. In addition, in an effect not seen at 
baseline, this group was impaired at HVLT discrimination (p=0.035). The two 
subjects who withdrew were estimated to be 19 and 23 years from onset, i.e. 
even within the far-from-onset cohort presented here they had greater than 
average time to onset. Their withdrawal meant that the remaining 19 were 
slightly closer to onset, on average, and which may explain the finding of this 
deficit. As with the full cohort, neither group was impaired at naming or 
visuoperceptual skills.
9.3.2.2 Group differences in cognitive decline
In general the early HD group tended to decline slightly at the majority of tests, 
with the exception of the GNT, VOSP, emotion recognition, Stroop interference, 
cancellation, and the two parts of the HVLT on which many were performing at 
ceiling. In contrast the control group tended to show slight improvements, with 
the exception of Stroop word, category fluency and TMT A (all of which are 
timed) and most subtests of the HVLT (Table 9-3).
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After adjusting for estimated premorbid IQ and age at baseline the mean change 
over time in the early HD group was significantly different to that in controls for 
the UHDRS cognitive score (p^O.OOl), RMF (p=0.047) RMW (p=0.02) and 
TMT B (p=0.01), with the HD group declining whilst the controls improved 
slightly. Although some early HD subjects had scored at ceiling on the RMW at 
baseline none had at follow-up, suggesting that the test was sensitive at detecting 
decline. However six controls were at ceiling at follow-up, so relative to the 
control group this test may still have over- or under-estimated group differences 
(Table 9-3).
Change in the premanifest group was similar to that in controls, in that 
performance in most tests improved slightly on average, with the exception of 
Stroop word and interference, cancellation, and two subtests of the HVLT (Table 
9-4).
Both groups showed statistically significantly different change to controls at 
phonemic fluency (early HD vs. control p=0.003, premanifest vs. control p=0.05) 
although the difference in this case was driven by a large improvement in 
controls (Figure 9-1). There were no other statistically significant changes in 
either HD group relative to controls (Table 9-3, Table 9-4).
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Premanifest Early HDControl
■ Phonemic fluency •  Category fluency
Figure 9-1 Change in phonemic and category fluency scores in each group, 
adjusted for age and estimated premorbid IQ at baseline, with 95% 
confidence intervals
Negative change indicates decline over time.
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Table 9-3 Mean (SD) baseline and change in cognitive scores for controls and early HD subjects, with differences (95% confidence
intervals) with and without adjustment for age and estimated premorbid IQ at baseline
Control (N=18) Early HD (N=40) Difference in change (Early HD - Control)
Test Baseline Change Baseline Change Crude Adjusted
UHDRS cognitive (n) 335.6 (35.6) 10.2(16.7) 231.5 (53.6) -7.4(19.3) -17.6 (-27.5,-7.7) p=0.001 -17.6 (-27.3,-7.8) p=0.001
Stroop colour (n) 80.7 (9.6) 1.7 (6.2) 57.0(12.7) -1.5 (7.5) -3.1 (-6.9, 0.6) p=0.10 -2.8 (-6.4, 0.9) p=0.14
Stroop word (n) 107.3 (13.6) -2.7 (8.4) 75.4 (21.2) -5.0(10.0) -2.3 (-7.4, 2.7) p=0.37 -2.7 (-7.7, 2.2) p=0.27
Stroop interference (n) 46.4 (7.8) 1.7 (3.6) 32.8 (9.2) 0.4 (5.1) -1.3 (-3.7, 1.0) p=0.26 -1.4 (-3.9, 1.0) p=0.25
SDMT (n) 55.8 (8.3) 1.8 (5.5) 33.3(10.3) -0.9 (4.8) -2.8 (-5.7, 0.2) p=0.07 -2.8 (-5.9, 0.2) p=0.07
Phonemic fluency (n) 45.4 (9.1) 7.6 (9.8) 33.0(11.3) -0.5 (8.2) -8.1 (-13.3,-2.8) p=0.003 -7.8 (-13.0. -2.7) p—0.003
Category fluency (n) 24.1 (4.1) -1.1 (4.0) 17.9 (5.6) 0.0 (4.2) 1.1 (-1.2. 3.3) p=0.37 1.1 (-1.0. 3.3)p=0.31
HMGT (n) 12.1 (2.3) 0.4 (3.1) 10.25 (2.5) -0.4 (2.3) -1.0 (-2.2, 0.3)p=0.15 -1.0 (-2.3. 0.4) p=0.16
TMT A (sec) 21.1 (6.6) -0.8 (7.3) 37X5(1 E5) -1.5(13.3) -0.7 (-6.1. 4.7) p=0.79 -0.9 (-6.1. 4.2) p—0.72
TMT B (sec) 64.7 (42.7) 10.1 (30.0) 119.6 (55.6) -15.3 (38.4) -25.3 (-44.5.-6.2) p=0.01 -26.0 (-45.6. -6.5)p=0.01
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Control (N=18) Early HD (N=40) Difference in change (Early HD - Control)
Test Baseline Change Baseline Change Crude Adjusted
Cancelling As (sec) 16.8(4.0) 0.7 (1.3) 28.1 (8.5) 0.3 (5.3) -0.4 (-2.2, 1.4) p=0.65 -0.5 (-2.3, 1.2) p=0.56
HVLT imm. (/36) 26.1 (6.1) 2.1 (5.6) 19.7 (5.2) -0.5 (5.7) -2.6 (-5.7, 0.6) p=0.11 -2.6 (-6.0, 0.7) p=0.13
HVLT del. (/12) 9.9 (1.8) -0.1 (1.7) 6.4 (2.4) 0(L9) 0.1 (-0.9, 1.0) p=0.91 0.1 (-0.9. l.l)p=0.90
HVLT % recall 97.0(11.5) -7.8(15.9) 80.2 (24.0) -0.8 (25.4) 7.0 (-3.9, 18.0) p=0.21 6.8 (-4.8. 18.3)p=0.25
HVLT discrim. (/12) 11.2(1.0) -0.3 (1.3) 8.8 (2.3) 0.1 (2.2) 0.4 (-0.5, 1.3) p=0.41 0.3 (-0.6. 1.3) p=0.50
Digits forwards (/21) 13.1 (3T0 0.8 (2.2) 10.5 (3.2) -0.1 (1.9) -0.9 (-2.1,0.3)p=0.14 -0.9 (-2.1.0.3)p=0.14
Digits backwards (/21 ) 12.1 (4.1) 0.4 (2.7) 8.7 (3.8) -0.6 (3.1) -1.0 (-2.6. 0.6) p=0.22 -1.1 (-2.7, 0.5)p=0.19
RMF (/50) 42.4 (4.0) 1.8 (3.5) 34.8 (7.0) -0.7 (5.3) -2.5 (-4.8. -0.2) p=0.036 -2.5 (-4.9. -0.03) p-0.047
RMW (/50) 48.0 (2.5) 0.1 (1.7) 43.4 (4.7) -1.5 (3.8) -1.4 (-3.0, -0.1)p=0.031 -1.7 (-3.2.-0.3)p=0.02
GNT (/30) 21.6 (3.8) 0.4 (1.7) 20.7 (4.7) 0.3 (1.9) -0.1 (-1.2. 0.8) p=0.70 -0.1 (-1.1. 0.8) p=0.78
VOSP (/15) 9.4 (2.4) 0.8 (1.7) 8.6 (2.3) 0.6 (1.3) -0.2 (-1.1, 0.7) p=0.61 -0.2 (-1.1. 0.7) p—0.61
Benton (/54) 47.7 (4.0) 0.9 (4.1) 43.5 (4.7) -0.9 (4.2) -1.9 (-4.2. 0.4) p-0.11
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Control (N= 18) Early HD (N=40) Difference in change (Early HD - Control)
Test Baseline Change Baseline Change Crude Adjusted
Ekman happiness (/4) 4.0 (0.0) 0.0 (0.0) 3.9 (0.3) 0.03 (0.5) 0.03 (-0.1, 0.2) p>0.05 0.02 (-0.1, 0.2) p>0.05
Ekman sadness (/4) 3.4 (0.9) -0.1 (0.6) 3.3 (0.8) -0.1 (0.7) 0.01 (-0.4, 0.4) p>0.05 -0.02 (-0.4, 0.4) p>0.05
Ekman surprise (/4) 3.8 (0.4) -0.1 (0.5) 3.4 (0.6) -0.03 (1.1) 0.1 (-0.4, 0.5) p>0.05 0.1 (-0.4, 0.5) p>0.05
Ekman disgust (/4) 3.7 (0.5) -0.1 (0.7) 2.7 (1.2) 0.1 (1.0) 0.2 (-0.2, 0.6) p>0.05 0.2 (-0.2, 0.6) p>0.05
Ekman anger (/4) 3.6 (0.6) 0.0 (0.6) 2.0 (1.3) -0.1 (1.0) -0.1 (-0.5, 0.4) p>0.05 -0.1 (-0.5, 0.4) p>0.05
Ekman fear (/4) 2.9 (0.8) 0.4 (0.7) 1.7 (1.3) 0.1 (1.4) -0.3 (-0.9, 0.2) p>0.05 -0.4 (-1.0, 0.2) p>0.05
Ekman total (/24) 21.4(1.6) 0.2 (1.2) 16.8 (3.3) 0.1 (2.4) -0.1 (-1.0, 0.9) p>0.05 -0.2 (-1.1, 0.9) p>0.05
Negative change indicates a decrease in score or in speed (longer time taken in timed tasks); negative difference in change indicates that early HD declined more than 
controls; crude differences are the absolute difference between groups before adjustment for age and IQ; adjusted differences are the differences having adjusted for age and 
IQ by including them as covariates in linear regression models; Benton score is already age- and education adjusted and hence only crude difference is reported; where 95% 
bootstrapped CIs were used precise p values were not obtained.
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Table 9-4 Mean (SD) baseline and change in cognitive scores for controls and premanifest subjects, with differences (95% confidence
intervals) with and without adjustment for age and estimated premorbid IQ at baseline
Control (N= 18) Premanifest (N= 19) Difference in change (Premanifest -  Control)
Test Baseline Change Baseline Change Crude Adjusted
UHDRS cognitive 335.6 (35.6) 10.2(16.7) 326.4 (51.1) 2.5 (20.5) -7.6 (-20.1, 4.8) p=0.23 -6.9 (-20.4, 6.6) p=0.31
Stroop colour 80.7 (9.6) 1.7 (6.2) 78.5 (9.7) 2.3 (6.6) 0.6 (-4.0, 5.2) p=0.80 0.1 (-4.1, 4.4) p=0.94
Stroop word 107.3 (13.6) -2.7 (8.4) 106.6(18.2) -2.6 (6.7) 0.1 (-5.8, 5.9) p=0.98 1.4 (-4.1,7.0) p=0.62
Stroop interference 46.4 (7.8) 1.7 (3.6) 47.7 (9.9) -U2(7.5) -2.9 (-6.7, 0.9) p=0.14 -2.5 (-6.5, 1.4) p=0.20
SDMT 55.8(8.3) 1.8 (5.5) 53.9(10.5) 2.2 (4.8) 0.3 (-2.9, 3.6) p=0.84 0.7 (-2.9, 4.3) p=0.69
Phonemic fluency 45.4 (9.1) 7.6 (9.8) 39.6(14.0) 1.8 (7.7) -5.8 (-11.3,-0.2) p=0.042 -6.6 (-13.2, -0.002) p—0.05
Category fluency 24.1 (4.1) -1.1 (4.0) 24.2 (7.2) 0.3 (4.9) 1.4 (-1.5, 4.2) p=0.34 1.3 (-1.9, 4.5) p=0.43
HMGT 12.1 (2.3) 0.4 (3.1) 11.7 (2.8) 0.3 (2.9) -0.3 (-1.7, 1.2) p=0.72 -0.2 (-1.9, 1.5) p=0.84
TMT A (sec) 2U1(&6) -0.8 (7.3) 22.5 (5.2) 0.9 (5.5) 1.7 (-2.5, 5.9) p=0.43 1.4 (-3.4, 6.1) p=0.57
TMT B (sec) 64.7 (42.7) 10.1 (30.0) 61.8(25.9) 4.6 (24.4) -5.5 (-23.3, 12.4) p=0.54 4.2 (-12.2, 20.6) p=0.61
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Control (N=18) Premanifest (N= 19) Difference in change (Premanifest -  Control)
Test Baseline Change Baseline Change Crude Adjusted
Cancelling As (sec) 16.8(4.0) 0.7 (1.3) 18.5 (4.7) -0.4 (4.5) -1.1 (-3.2, 1.0) p=0.31 -0.6 (-3.3,2.1)p=0.66
HVLT imm. (/36) 26.1 (6.1) 2.1 (5.6) 26.7 (5.1) -0.3 (3.2) -2.3 (-5.3, 0.7) p=0.13 -1.8 (-5.0, 1.5) p=0.28
HVLT del. (/12) 9.9 (1.8) -0.1 (1.7) 9.3 (2.3) 0.3 (2.1) 0.4 (-0.9, 1.6) p=0.56 0.5 (-0.8, 1.9) p=0.42
HVLT % recall 97.0(11.5) -7.8(15.9) 90.6(15.6) 0.7(19.1) 8.5 (-2.9, 19.9) p=0.14 8.4 (-4.1,20.8) p=0.18
HVLT discrim. (/12) 11.2(1.0) -0.3 (1.3) 10.8(1.2) -0.1 (1.0) 0.3 (-0.5, 1.0) p=0.45 0.4 (-0.4, 1.2) p=0.30
Digits forwards (/21 ) 13.1 (3T0 0.8 (2.2) 13.3 (3.3) 0.3 (2.5) -0.5 (-1.9, 0.9) p=0.46 -0.5 (-2.2, 1.3) p=0.58
Digits backwards (/21 ) 12.1 (4.1) 0.4 (2.7) 11.3 (4.1) 0.1 (2.3) -0.4 (-2.3, 1.5) p=0.68 -0.1 (-1.8, 1.6) p—0.91
RMF (/50) 42.4 (4.0) 1.8 (3.5) 41.1 (5.3) 0.6 (3.7) -1.2 (-4.2, 1.8) p=0.43 -1.1 (-3.7, 1.5) p—0.40
RMW (/50) 48.0 (2.5) 0.1 (1.7) 48.1 (2.0) 0.6 (1.9) 0.5 (-0.7, 1.6) p=0.43 0.8 (-0.6, 2.2) p=0.26
GNT (/30) 21.6 (3.8) 0.4 (1.7) 22.4 (3.9) 0.4 (1.8) -0.1 (-1.3, 1.1) p=0.90 -0.4 (-1.6, 0.7) p=0.46
VOSP (/15) 9.4 (2.4) 0.8 (1.7) 8.6 (3.3) 0.9 (2.4) 0.1 (-1.2. 1.4) p=0.86 0.1 (-1.3, 1.6) p=0.85
Benton (/54) 47.7 (4.0) 0.9 (4.1) 47.7 (3.8) 0.9 (3.2) -0.05 (-2.6. 2.5) p=0.97
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Control (N=18) Premanifest (N=19) Difference in change (Premanifest -  Control)
Test Baseline Change Baseline Change Crude Adjusted
Ekman happiness (/4) 4.0 (0.0) 0.0 (0.0) 3.9 (0.2) 0.1 (0.2) 0.1 (-0.0, 0.2) p>0.05 0.1 (-0.02, 0.3) p>0.05
Ekman sadness (/4) 3.4 (0.9) -0.1 (0.6) 3.7 (0.6) 0.2 (0.8) 0.2 (-0.2, 0.7) p>0.05 0.3 (-0.1, 0.9) p>0.05
Ekman surprise (/4) 3.8 (0.4) -0.1 (0.5) 3.7 (0.6) 0.1 (0.6) 0.2 (-0.2, 0.5) p>0.05 0.2 (-0.1, 0.7) p>0.05
Ekman disgust (/4) 3.7 (0.5) -0.1 (0.7) 3.3 (0.9) 0.1 (1.0) 0.2 (-0.4, 0.7) p>0.05 0.2 (-0.4, 0.6) p>0.05
Ekman anger (/4) 3.6 (0.6) 0.0 (0.6) 3.5 (1.0) 0.2 (0.7) 0.2 (-0.2, 0.6) p>0.05 0.2 (-0.2. 0.7) p>0.05
Ekman fear (/4) 2.9 (0.8) 0.4 (0.7) 2.5 (1.3) 0.3 (1.1) -0.2 (-0.8, 0.4) p>0.05 -0.2 (-0.8, 0.4) p>0.05
Ekman total (/24) 21.4(1.6) 0.2 (1.2) 20.6 (2.4) 0.8 (1.9) 0.6 (-0.3, 1.7) p>0.05 0.9 (-0.2, 2.0) p>0.05
Negative change indicates a decrease in score or in speed (longer time taken in timed tasks); negative difference in change indicates that premanifest declined more than 
controls; crude differences are the absolute difference between groups before adjustment for age and IQ; adjusted differences are the differences having adjusted for age and 
IQ by including them as covariates in linear regression models; Benton score is already age- and education adjusted and hence only crude difference is reported; where 95% 
bootstrapped CIs were used precise p values were not obtained.
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9.3.2.3 Relationship with CA G repeat length
In general there was very little evidence of any association between CAG repeat 
length and the amount of change on the UHDRS, BDI or cognitive scores. In the 
premanifest group higher CAG repeat length was associated with greater decline 
in digit span forwards such that an increase of one triplet was associated with a 
0.9 point decline in digit span forwards (95% Cl -1.5, -0.4 points, p=0.001), but 
this relationship was not statistically significant in the early HD group (p=0.12) 
(after adjusting for age and estimated premorbid IQ). In the gene carriers as a 
whole higher CAG repeat length was associated with greater decline in 
cancellation time (-0.9 seconds per CAG repeat, 95% Cl -1.8, -0.1 seconds, 
p=0.037) and Ekman fear recognition (-0.2 points per CAG repeat length, 95% 
Cl -0.4, -0.01 points, p<0.05), after adjusting for group. A post hoc analysis 
looking at the early HD group alone found that the relationship between CAG 
repeat length and decline in cancellation time was still statistically significant 
(-1.1 seconds per CAG repeat, 95% Cl -2.3, -0.04, p=0.043) and there was no 
evidence that the slope of the relationship differed from that found in the gene 
carriers as a whole. The association with fear recognition was not statistically 
significant in the HD group alone (p>0.05).
There was also a tendency for higher CAG repeat length to be associated with 
greater decline at category fluency (-0.7 words per CAG repeat length, 95% Cl 
-1.5, 0.05, p=0.066). Higher CAG repeat length was associated with less decline 
at Ekman disgust recognition (0.2 points per CAG repeat length, 95% Cl 0.05, 
0.4, p<0.05). There were no other statistically significant associations between 
change in cognitive score and CAG repeat length.
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9.3.2.4 Relationship with baseline motor score, disease duration and 
interaction between CAG repeat length and duration
In general there was little evidence of any relationship between baseline motor 
score and cognitive change, with most of the associations small and very close to 
zero, and no statistically significant associations.
There was also little evidence of any relationship between disease duration or age 
at onset and cognitive change, with the exception of cancellation for which a 
one-year increase in disease duration (having adjusted for age at baseline) was 
associated with a one second larger decline in cancellation time (95% Cl 0.1, 1.7 
seconds, p=0.004). No other associations approached statistical significance.
Finally, there was also little evidence that the effects of CAG repeat length or 
disease duration on cognition interacted. In general the interaction terms were 
close to zero and not statistically significant.
9.3.2.5 Relationship with probability o f onset
In general there was little evidence of associations between change and 
probability of onset in the 19 premanifest subjects, with the exception of digit 
span forwards, for which there was a trend for proximity to onset to be associated 
with greater decline (1.3 point decrease in change for a 0.1 increase in 
probability of onset, 95% Cl -2.7, 1.1 points, p=0.068). There were no other 
statistically significant associations between change in cognitive score and 
probability of onset.
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9.3.2.6 Comparison o f NART and Spot the Word test
Mean (SD) NART and Spot the Word scores (transformed to be on the same 
scale as the NART) at both timepoints, with change over time, are shown in 
Table 9-5. In the cohort as a whole mean NART score increased over time 
(p=0.0026), whilst mean Spot the Word score did not (p=0.57). There was no 
evidence that the amount of change in either measure differed between groups.
Table 9-5 Mean (SD) NART and Spot the Word scores at baseline and 12 
months for the whole cohort (N=77) with change over time and 95% 
confidence intervals for the change
NART Spot the Word
Baseline 105.4(11.7) 102.5(14.0)
12 months 106.4(11.9) 101.9(15.9)
Change I.l (3.0) -0.6(10.0)
95% Cl 0.4, 1.8 -2.9, 1.6
Positive change indicates an improvement in score from baseline to 12-month assessment.
The standard deviation of change in Spot the Word score was larger than that for 
the change in NART score (p<0.0001). However the difference between the 
amount of change for each measure was not statistically significant (mean 
difference 1.7, 95% Cl -0.5, 4.0, p=0.13).
9.4 DISCUSSION
9.4.1 Cognitive decline in early HD
In this large group of early and premanifest HD subjects followed over one year, 
cognitive change was variable, and decline in most tasks was very slight. Whilst 
there was a tendency for the early HD group to decline in all domains except
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auditory verbal memory and facial emotion recognition, decline was only 
statistically significant for the RMF, RMW, TMT B, phonemic fluency and the 
UHDRS cognitive score (which was possibly driven by the contribution of 
phonemic fluency). At baseline the early HD group showed impairment across 
domains (see chapter 4), whilst the premanifest group did not, which suggests 
that performance in many tasks in the early HD group represents a decline 
relative to previous levels of ability. Subjects were not scoring at floor level on 
any tasks, and where possible alternative test versions were used at each 
assessment in order to minimise practice effects. Hence, although many of the 
tasks used here were insensitive to the effects of the disease over one year, 
change in these domains might be detectable over a longer time period.
On the whole the findings in the early HD group confirm those of other studies, a
number of which have found decline over time in TMT B and phonemic fluency
(Bachoud-Lévi et al. 2001; Snowden et al. 2001; Ho et al. 2002; Ho et al. 2003;
Lemiere et al. 2004; Ward et al. 2006). Most of these studies also found
significant decline in other executive function and psychomotor tasks including
Stroop colour and word reading, category fluency, SDMT and TMT A, although
with the exception of Snowden et al. (2001) the other studies had longer follow-
up periods than the current one, which was likely to have increased their ability
to detect relatively small effects. In the current study, slight (but not statistically
significant) decline was seen on all these tasks, with the exception of category
fluency. As mentioned in chapter 4, category fluency was thought to decline at a
point at which many subjects were performing at floor on phonemic fluency (i.e.
at a later point in the disease process), so this may explain the relative
insensitivity of category fluency in this particular cohort. Interestingly, decline
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in Stroop colour and word reading was greater in magnitude than decline in 
Stroop interference, again supporting the theory that a deficit in relatively 
automatic, well-learned skills (such as word reading) is one aspect of the 
impairment seen in HD. However, it was in phonemic fluency and TMT B, both 
of which have a switching component, that statistically significant decline was 
detected. UHDRS motor score also declined significantly in this cohort, and 
both TMT B and phonemic fluency have motor components, as well as relying 
on cognitive switching and (in the case of TMT B) oculomotor skills. It is likely 
that the combination of skills required for these tasks (visual scanning, motor, 
switching, working memory) and their knovm reliance on striatal and frontal 
regions makes them particularly sensitive to decline in this cohort, even over the 
relatively short time period used here.
There have been mixed findings in relation to digit span decline in early HD, 
with some studies reporting a decline (Snowden et al. 2001; Ho et al. 2003) and 
others no change (Bachoud-Lévi et al. 2001; Lemiere et al. 2004). In this study 
change in early HD subjects was not significantly different to that seen in 
controls. Subjects did decline, on average, very slightly at forwards and 
backwards digit span. Notably they did not display the slight practice effects 
seen in controls, suggesting that digit span might have the potential to detect 
change with larger numbers or over a longer time period.
Studies that have used the HVLT (or the similar Rey Auditory Verbal Learning 
Test) have tended to find no change over periods of up to four years in early HD 
(Bachoud-Lévi et al. 2001; Ho et al. 2003; Lemiere et al. 2004), an exception 
being Ward et al. (2006) who found that HVLT immediate recall declined over
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four years. Similarly in this study there was no evidence of decline in the early 
HD group relative to controls on any subtest. However some subjects in all 
groups scored at ceiling on delayed recall and discrimination at both timepoints, 
meaning that these two subtests probably lacked sensitivity. In contrast, the early 
HD group showed, on average, significant decline at both subtests of the RMT. 
Although on the RMW some of the controls were at ceiling at both timepoints, 
meaning that the variance of change in controls was likely to have been reduced 
and perhaps lead to over- or under-estimation of the effect of group differences, 
none of the early HD subjects scored at ceiling at follow-up; also no subjects 
were scoring at ceiling in the relatively harder RMF. As discussed in chapter 4, 
the RMT differs from the HVLT in that recognition for 50 items is tested with a 
two-altemative forced choice paradigm, rather than a yes / no decision to 
separate target and distractor stimuli. Baseline data from the HVLT suggested 
that whilst recognition of true positives might be reduced, but reasonable given 
the number of words encoded, early HD subjects still tended to make more false 
positives than controls. The recognition task in the RMT is relatively harder, as 
more stimuli must be recognised correctly, and the subject must choose between 
two stimuli (one true positive, one false positive) both of which he may think he 
has seen before. This task may therefore be more susceptible to increasing 
fronto-striatal dysfunction.
In contrast to the RMW, group differences in change on the RMF were due
mainly to improvement in controls and very little real decline in the early HD
group (although as some of the controls were at ceiling at follow-up on the RMW
there may also have been a practice effect on the latter task which was not
detected). Whilst early HD subjects were not at floor level on the RMF at either
299
timepoint, they were already performing relatively worse at the RMF than the 
RMW at baseline (apparent from both age-scaled scores and the effect sizes of 
the group differences at baseline) suggesting that decline at this task might occur 
earlier (and perhaps faster) relative to decline at the RMW. The fact that 
baseline differences are concordant with the change scores suggests that the tests 
are reflecting real disease-related deficits.
As discussed in chapter 5, facial recognition ability is affected by eye 
movements, which are known to be abnormal even early in the disease, so this 
might partly explain a different time-course of decline in the two skills. Also, 
since there was no evidence of impairment in the far-from-onset premanifest 
group, but impairment is clear in the early HD group, there may be a time 
(perhaps in closer-to-onset premanifest subjects, or around the time of 
phenoconversion) when this test is sensitive to change in this population.
In general the memory deficit in HD would benefit from further probing; whilst 
performance on auditory verbal learning tests tends not to show decline, story 
and object recall (Snowden et al. 2001), visual span (Bachoud-Lévi et al. 2001), 
spatial span (Ho et al. 2003) and digit span forwards and backwards (Snowden et 
al. 2001; Ho et al. 2003) have all shown decline in some early HD populations. 
Given that some of the early HD subjects in this study were at ceiling on some 
subtests of the HVLT, it may be that test difficulty needs to be manipulated by 
increasing the number of items to be remembered, or the number of distractor 
items in recognition paradigms, in order to detect small changes in ability.
Performance on the ONT and VOS? was not impaired at baseline and did not
show significant decline over one year, although as discussed in chapter 4, these
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tasks tap single aspects of naming and visual perception and hence these findings 
do not preclude subtle decline in language or visuoperceptual abilities. In 
general others have also failed to find evidence of significant decline in these 
skills in early HD (Bachoud-Lévi et al. 2001; Ho et al. 2003) although one study, 
with follow-up of just under three years, found that both naming and VOSP 
performance declined (Lemiere et al. 2004), perhaps indicative of the fact that 
decline is relatively slow in these domains.
Performance on the Benton and the Ekman facial emotion recognition battery 
was impaired at baseline, but there was no statistically significant change in these 
skills over one year, again perhaps reflecting a slow rate of change in these skills, 
or a lack of test sensitivity to change. The version of the Ekman used here had 
only four exemplars of each emotion, which could have contributed to practice 
effects and made it harder to detect decline. Only one study to date has 
investigated decline in emotion recognition, and this was in premanifest, rather 
than early HD subjects, in which there was no evidence of decline over one year 
(Sprengelmeyer et al. 2005). Given the potential impact of changes in emotion 
recognition skills on patients’ and carers’ lives more work needs to be done to 
clarify whether, and how, these deficits change over time.
P. 4.2 Cognitive decline in premanifest HD
There was very little difference between change in the premanifest group and 
that seen in controls over the time period investigated here. As discussed in 
previous chapters, the premanifest subjects presented here were on average 18 
years from predicted motor onset (with most over 10 years from onset) and the 
rate of decline in many domains is thought to be negligible until within the last
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decade prior to onset (Paulsen et al. 2007). On many tasks this group showed 
slight improvements over time. Practice effects tend to be largest between the 
initial test and the next follow-up (Bachoud-Lévi et al. 2001) which might have 
played a role in this although alternative test versions were used where they were 
available. Practice effects seemed similar in the premanifest groups and controls, 
reinforcing the fact that in this cohort there was little to distinguish the two 
groups, at least using current clinical or cognitive scales. With the exception of 
studies in which premanifest subjects have phenoconverted during the 
assessment period (Paulsen et al. 2001; Snowden et al. 2002), change in 
premanifest subjects has rarely been detected (Lemiere et al. 2002; Lemiere et al. 
2004; Witjes-Ane et al. 2007).
In the current study phonemic fluency was the only task on which the 
premanifest group showed significant decline relative to controls. In fact both 
groups showed slight improvement (perhaps due to practice effects), but the 
improvement was far greater in the control group. One other study has reported 
a decline in phonemic fluency performance in 70 premanifest subjects who had 
converted over the two years of the study, relative to those who had not (Paulsen 
et al. 2001). In that study the converters also showed significant decline at the 
SDMT and the three Stroop subtests. Others have failed to detect decline, 
although some have summed the words generated for three different letters for a 
minute each (as was done here), whilst others have used just one letter for one 
minute, and so test differences may have contributed to the differences between 
studies, (compare e.g., Snowden et al. 2002; Witjes-Ane et al. 2007). One 
slightly smaller study found a similar pattern of results to those seen here, over
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an average of 2.5 years, but group differences were not statistically significant 
(Lemiere et al. 2004).
As discussed in chapter 5, phonemic fluency has a switching component, which 
is thought to rely more on frontal parts of fronto-striatal circuits, but also has a 
motor component, and phonemic switching ability has been shown to decrease 
with increasing motor impairment in HD (Ho et al. 2002). On average, UHDRS 
motor score increased slightly in the premanifest subjects over the course of the 
study; this change approached statistical significance and may have had clinically 
relevant effects on function. Phonemic fluency was the only executive function 
task for which premanifest performance at baseline approached early HD levels, 
so together these results suggest that the combination of demands of this task 
might be such that decline in performance can be detected very early in the 
disease course. Given that not all studies have found decline in phonemic 
fluency in premanifest subjects, further longitudinal work is needed, to clarify 
whether decline is detectable a certain number of years prior to motor onset, or in 
subjects with particular levels of motor ability.
It is notable that on some tasks the early HD group declined more relative to 
controls, whilst the change in the premanifest group was not statistically 
significantly different to that in either of the other two groups, suggesting that 
their performance was lying somewhere between the two. Other work in this 
cohort has shown that both caudate (see chapter 5) and whole-brain volumes (see 
chapter 4) are reduced in this relatively far-from-onset group, and hence it is not 
unreasonable to assume that some cognitive sequelae may be detectable given 
sensitive enough tests.
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9.4.3 Associations between change and clinical variables 
In the premanifest group there was little evidence that proximity to onset was 
related to a faster rate of decline in cognitive tasks. Even for digit span forwards, 
for which there was a trend towards a significant association, performance was 
generally stable or improved over time, with only five premanifest subjects 
declining. It seems unlikely that these findings would be replicable, particularly 
since other evidence suggests that memory performance declines around the time 
of onset (Snowden et al. 2002) and that in general decline in premanifest subjects 
does not become obvious until within 10 years of predicted onset (Paulsen et al. 
2007), whereas the current cohort was on average 18 years from estimated onset.
CAG repeat length was not associated with change in most variables, and there
was also little evidence that either baseline motor score or disease duration was
predictive of rate of cognitive decline in any domains. Although higher CAG
repeat length was associated with faster decline at cancellation, facial fear
recognition, and digit span forwards (the latter in the premanifest group only),
the lack of association in other similar tasks makes this pattern hard to interpret.
Higher CAG repeat length was not associated with longer disease duration in the
early HD group so the associations cannot be explained simply as an effect of the
latter. In general the amount of cognitive decline was so slight and variable, that
it is unsurprising that change was not associated with these demographic
variables. As mentioned in section 1.4.1, there are likely to be many other
factors contributing to cognitive performance and change over time, which may
mask the (probably small) effects of the variables investigated here. Others have
also found little effect of repeat length on rate of cognitive decline (Bachoud-
Lévi et al. 2001; Snowden et al. 2001; Ward et al. 2006). However the two
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larger studies, one of which followed subjects for four years, have found that 
disease duration or indices of motor function explained some of the variance in 
change scores (Snowden et al. 2001; Ward et al 2006), with the suggestion that 
motor score might better reflect disease severity than duration. Others have 
demonstrated small but statistically significant effects of both CAG repeat 
length, disease duration, and their interaction on decline across domains 
(Rosenblatt et al 2006) although cognition was measured using the Mini Mental 
State Examination (MMSE) (Folstein et al 1975) which does not provide a very 
specific measure of many of the skills known to be impaired in HD. Ideally the 
effects of these variables on change in individual tasks still needs to be 
investigated in large cohorts over longer time periods than that used in this study.
9.4.4 Comparison o f NART and Spot the Word Test
Finally, following the suggestion that the Spot the Word Test might be a more 
suitable estimate of premorbid IQ than the NART in HD, because of the 
dysarthria associated with increasing progression of the disease, the ability of the 
two tests to produce stable estimates of premorbid IQ over time was investigated. 
Although the NART showed significant change (increase) over time whilst the 
Spot the Word test did not, there was no evidence that the amount of change 
differed between the tests. In fact the 95% confidence intervals for change in 
Spot the Word demonstrate that it could well be of a similar magnitude to that 
seen in the NART, but the greater variance associated with change in Spot the 
Word meant that the change was not statistically significant. Overall, the lack of 
difference in the amount of change between the two measures, and the reduced 
variance associated with change in the NART, suggests that the NART gave a 
more stable estimate of premorbid IQ in the cohort presented here.
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9.5 CONCLUSION
This work confirmed that of a number of others, demonstrating that cognitive 
change in premanifest and early HD was slight and variable, particularly over the 
one-year time period used here. However, even over this short time period the 
early HD group showed decline in two executive function tasks and a memory 
task, and there may be potential for more sensitive tasks to be developed, 
particularly in the domain of memory. In the premanifest group change in 
phonemic fluency was also reduced relative to controls, and as cognitive change 
is so hard to detect in this widely variable population this finding merits further 
investigation, in order to see whether it is replicable and if so, how this depends 
on the characteristics of the premanifest population under investigation.
Although there is some evidence that rate of decline is determined at least in part 
by CAG repeat length and disease duration, there was little evidence to support 
that in the current study. However, it seems likely that such effects exist, but that 
they are relatively small, making associations hard to detect over short time 
periods and particularly in the domain of cognition.
One of the aims of this work was to investigate potential markers of disease 
progression. Problems with cognition as a marker were discussed in the 
introduction, predominantly its susceptibility to practice effects and other non­
disease-related factors, all of which contribute to its variability. However, unlike 
markers than can be measured more objectively, such as brain volume or “wet” 
biofluid markers, cognitive tests provide a direct measure of the day-to-day 
function of patients. It is these outward signs of the disease that patients and 
carers notice and find difficult; further understanding of these changes will help
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with disease management, and potential therapies for the symptomatic population 
will need to have a positive effect on function (i.e., at the very least prevent 
further decline) in order to improve the quality of life of people with HD. Hence, 
despite the fact that the change seen here was, as in other studies, small and 
variable, it is important that further work continues to focus on aspects of 
cognitive change in HD, and how it can best be measured.
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10 MEASURING WHOLE-BRAIN ATROPHY IN HUNTINGTON’S 
DISEASE: AGREEMENT BETWEEN THE BBSI AND “TRUE” 
VOLUME LOSS
10.1 INTRODUCTION
The BBSI measures the shift in intensity within a specific window, chosen to 
encompass the boundary under investigation (the CSF/brain boundary, which is 
mainly CSF/grey matter) (see section 2.5.4.3). The intensity window is 
described in terms of its centre and width, and these parameters can be adjusted 
depending on the typical intensities of the set of images being investigated.
The changes in intensity across the CSF/brain boundary, and the intensity 
window within which the BBSI is calculated, are demonstrated in Figure 2-5, 
page 85. Chapter 11 reports whole-brain atrophy rates in HD, measured using 
the BBSI, as well as the associations between atrophy rate and the cognitive and 
clinical changes described in the previous chapter. This chapter describes how 
the BBSI parameters were adjusted to get the best agreement between volume 
loss estimated by this technique, and estimates of the “true” volume loss. The 
final parameters were then used to generate the BBSIs from which the atrophy 
rates in the following chapter were calculated.
In T1-weighted images CSF appears dark (low intensity), grey matter lighter
(medium intensity) and white matter bright (high intensity). Scans are
normalised to mean white matter intensity prior to BBSI calculation meaning that
intensities vary from 0 to 1, with CSF typically around 0.2 and GM around 0.8.
The default window for BBSI calculations has a centre of 0.5 with a width of 0.5,
i.e. it is designed to fall in the middle of the CSF and grey matter intensities and
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cover a range of intensities around this. This reflects the original validation 
which was based on a particular acquisition and scanner.
The optimal parameters are those for which the BBSI most closely agrees with 
the “real” volume difference and these will vary with different scan intensities. 
If the BBSI measured the volume change for two scans exactly, then the mean 
and standard deviation of the difference between the BBSI and the real change 
would be zero. In practice this is rarely the case; the BBSI has been shown to 
underestimate change slightly (Freeborough and Fox 1997) so the mean 
difference is unlikely to be zero. This is because even the optimal window centre 
and width will not encompass the boundary perfectly on all scans, due to 
variability between scans, and also because in some areas there is no “boundary” 
in terms of signal intensity, e.g., brain stem or areas where cortex overlaps or is 
contiguous with dura or other non-brain tissue of a similar signal intensity. Also, 
the “gold standard” measure of volume change is the difference between two 
manual segmentations and both manual segmentation and the BBSI are subject to 
error, so the difference between the two is unlikely to have a standard deviation 
of zero. The agreement between the BBSI and manual measures is assessed by 
looking at the standard deviation (SD) of the difference between the two 
measures (Bland and Altman 1986). The mean of this difference is a measure of 
the bias of the BBSI compared to manual measures (Bland and Altman 1986). 
Therefore in order to maximise agreement between the BBSI and manual 
measures, the BBSI is calculated for a set of registered scan pairs using different 
window centres and widths, to find the window centre and width which 
minimises the standard deviation of the difference between the two measures.
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This chapter describes three methods of working out the “best” parameters for 
the BBSI: the first method derives parameters directly from the scan intensities; 
the second and third look for the best agreement between the BBSI and two sets 
of manual measurements. BBSIs from each method are then compared with 
manual measurements to see which agrees best. Finally, when the final BBSI 
parameters are chosen, the agreement between these measurements of loss and 
manual measurements is discussed.
10.2 METHOD 1: DETERMINING PARAMETERS FROM FIRST
PRINCIPLES
The optimum window centre should lie approximately half-way between the
mean CSF intensity and mean grey matter intensity, since it is change across this
window that will represent a boundary shift. Tissue intensities are normalised to
the mean white matter intensity prior to calculation of the BBSI, so samples of
white matter, grey matter and CSF were taken from three pairs of images
(baseline and follow-up) in order to calculate representative normalised
intensities. The subjects were chosen to cover a range of age, gender and status:
a young female control, a middle-aged male premanifest subject and an elderly
female HD subject. For white matter and CSF, 64-voxel cubes (4 voxels deep in
each plane) were drawn manually, in similar regions for each image: the right
frontal white matter and the left lateral ventricle respectively. Cubes were
inspected visually to ensure that no other tissue type intruded. Because of the
convoluted nature of the cortical grey matter perfect cubes were not sufficient to
sample grey matter without intrusion from other tissue types. Two-dimensional
regions were drawn manually on four consecutive coronal slices of the left insula
to give a three-dimensional grey matter region of 76 voxels. The mean
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intensities for each tissue type and each scan were measured from these regions 
and were normalised by dividing by the mean white matter intensity.
10.3 RESULTS 1
The mean (SD) normalised intensities were CSF 0.20 (0.02) and grey matter 0.65 
(0.04) giving a hypothetical window centre of 0.425 (half way between the mean 
intensities of the two tissue types) (Table 10-1). Based on this a set of window 
centres around 0.425 (from 0.3 to 0.5 in steps of 0.05) was used to generate the 
BBSIs reported in the following sections.
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Table 10-1 Raw and normalised CSF and GM intensities, with overall mean and range, for the images used for parameter estimation
Subject CSF (mean, range) GM (mean, range) WM (mean) CSF/WM (mean, range) GM/WM (mean, range)
1 baseline 26(20-36) 84(73-96) 120 0.22 (0.17-0.30) 0.70 (0.61-0.80)
2 baseline 26(18-33) 80(67-93) 124 0.21 (0.14-0.27) 0.64 (0.54-0.75)
3 baseline 24(14-35) 77(66-88) 125 0.19(0.11-0.28) 0.61 (0.53-0.70)
1 12 months 24(16-32) 84 (72 - 100) 119 0.20 (0.13-0.27) 0.71 (0.60-0.84)
2 12 months 28(20-33) 81 (63-93) 125 0.22 (0.16-0.26) 0.64 (0.50 -  0.74)
3 12 months 22(14-34) 78 (65-90) 127 0.18(0.11-0.27) 0.61 (0.51-0.71)
Mean 0.20 (0.11 -0.30) 0.65 (0.50-0.84)
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10.4 METHOD 2: DETERMINING PARAMETERS FOR A SUBSET OF 
IMAGES
A subset of images was chosen to be representative of the set as a whole (see 
chapter 11 for details of the 62 scan pairs). Five subjects from each of the three 
groups (controls, premanifest and early HD) were chosen, and paired t-tests or 
Fisher’s exact test were used to ensure that the mean age, gender, CAG repeat 
length and amount of atrophy (measured by the default BBSI) for the five 
subjects chosen were not significantly different to those for the subjects not 
included in each group. In addition these variables were not significantly 
different for the entire subset of 15 compared with the remaining 47 subjects. 
Demographic data for this subset and remaining cohort are shovm in Table 10-2.
Table 10-2 Demographic data for the optimisation subset and remaining 
cohort
Optimisation subset 
(N=15)
Remaining cohort 
(N=47)
Gender (M:F) 7:8 2324
Age (year) 44.0(12.4) 45.4 (9.1)
CAG repeat length^ 43.2 (3.0) 43.7 (2.5)
Atrophy (ml)^ 3.9 (6.1) 5.0 (6.6)
Data are shown as mean (SD ) with the exception o f  gender, 
a For 10 gene carriers in the optimisation subset and 34 in the remaining cohort 
b BBSI with an interval o f  12 months, estimated using the default BSI parameters, centre 0.5, 
width 0.5
The baseline and registered-repeat images for each of these 15 subjects were
segmented manually (according to the protocol in Appendix 2), and the volume
difference was calculated; this volume difference should not be influenced by
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scanner drift affecting voxel size, since registration (which incorporates scaling 
factors) should correct for such changes (Whitwell et al. 2004). The BBSI was 
calculated using a range of window centres and widths and for each window 
centre and width combination the standard deviation of the difference between 
the BBSI and manually-estimated volume difference was calculated in order to 
see when it reached a minimum.
10.5 RESULTS 2
There was no evidence of statistically significant differences in demographic 
variables between the optimisation subset and the remainder of the cohort, or 
between the five subjects selected from each group and the remainder of each 
group.
Figure 10-1 shows the standard deviations of the difference between the BBSI 
and volume difference, for a range of window widths and centres.
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Figure 10-1 SDs of differences between volume change estimated by the 
BBSI and manual measures for a range of window widths and centres 
(subset)
The centre that minimised the SD (and therefore was showing best agreement 
between measures) was between 0.4 and 0.45, and so further analyses were run 
with centres varying from 0.4 to 0.44 in steps of 0.01. The width was kept 
constant at 0.2, which was preferred to 0.1 since a width of 0.1 might cause the 
boundary to fall outside the window due to variations in scan quality, resulting in 
a more variable BBSI measurement.
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Figure 10-2 shows the SDs of the difference between measures for these 
parameters, the best of which was 0.41. At this stage a change of window centre 
by 0.01 was changing the SD very little and so no other parameters were tested.
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Figure 10-2 SDs of differences between volume change estimated by the 
BBSI and manual measures for a small range of centres (width 0.2) (subset)
10.6 METHOD 3: DETERMINING PARAMETERS FOR ALL IMAGES 
All 124 images (62 baseline and 62 follow-up) were segmented in native space 
prior to registration. The volumes of these segmentations were used to calculate 
change in volume between baseline and follow-up. The registered scan pairs had 
the BBSI recalculated a series of times using the same range of window centres 
and widths as in section 10.4. Agreement between measures was again assessed 
by looking at the standard deviation of the differences between them. Whilst this 
method has the advantage that it includes the whole dataset, the volume
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difference against which the BBSI is compared is calculated from non-registered 
images. As the images are taken on average one year apart it is possible that 
scanner changes during the intervening months could contribute to the measured 
difference (Whitwell et al 2004), as well as real change (and segmentor error). 
Thus whilst this might still yield the same optimal parameters as method 2, the 
mean differences between the measures will not be a good estimate of the 
amount by which the BSI and “true” volume change differ.
10.7 RESULTS 3
Figure 10-3 shows the SDs of the difference between measures for a range of 
window widths and centres.
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Figure 10-3 SDs of differences between volume change estimated by the 
BBSI and manual measures for a range of window widths and centres 
(entire cohort)
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The centre that minimised the SD was between 0.5 and 0.55, with a width of 0.2 
and therefore further analyses were run with centres varying from 0.5 in steps of 
0.01, until the SD started to increase (keeping the width constant at 0.2). Figure 
10-4 shows the SDs of the differences between measures for these different 
centres, the best of which was 0.51. At this stage a change of window centre by 
0.01 was again changing the slope very little and so no other parameters were 
tested.
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Figure 10-4 SDs of differences between volume change estimated by the 
BBSI and manual measures for a small range of centres (width 0.2) (entire 
cohort)
10.8 COMPARISON OF THE THREE SETS OF OPTIMISATION 
PARAMETERS
Thus far the parameters have been chosen either because they maximised
agreement between the BBSI and manual measures (methods 2 and 3) or because
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they were derived from looking directly at scan intensities (method 1). Two sets 
of manual measures have been used, using segmentations of registered scan pairs 
(on the subset) and segmentations from non-registered scan pairs (on the whole 
cohort) with the caveat that in the latter case the manual measures are likely to be 
subject to more error because of scanner change over time.
In order to compare the three sets of parameters directly each set was used to 
generate BBSIs for the subset, so that it could be compared against the manual 
measures which are the best estimate of volume change available. The mean 
difference between each set of BBSIs and manual measures, and the SD of this 
difference, are show in Table 10-3.
Table 10-3 Parameters from the three methods, with the mean and SD of the 
difference between each set of BBSIs and manual measures (subset)
Optimised on: Intensities Subset Entire cohort
Window centre 0.425 0.41 0.51
Window width (0.2) 0.2 0.2
Mean of difference (ml) -3.23 -330 -3.40
95% Cl -5.62, -0.84 -5.68, -0.91 -6.08, -0.71
SD of difference 432 4.31 4.85
As discussed in section 10.1, the ideal mean difference between the BBSI and 
segmented volume difference is zero, but in practice the BBSI is known to 
underestimate volume loss slightly (Freeborough and Fox 1997). All three sets 
of parameters were significantly underestimating the true volume difference, and 
the parameters which led to the least bias were those derived from image 
intensities (-3.23 ml). The parameters which led to the best agreement were
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those derived from the subset of images (SD of 4.31). Pitman’s test was used to 
see whether the standard deviations of the difference differed between these two 
sets of parameters, but there was no evidence to support this (ratio of standard 
deviations=0.997, 95% Cl 0.97, 1.02, p=0.79). A paired t-test was used to see 
whether the bias (mean difference) was significantly different between the two 
sets of parameters but again there was no evidence to support this (mean 
difference=0.07, 95% Cl -0.04, 0.17, p=0.18).
In the light of these findings it was decided to proceed with the window centre 
derived from the image intensities (0.425); BBSIs showed the least bias, 
although marginally, and the agreement between BBSIs and manual measures 
was not significantly different to the centre of 0.41 (which showed the best 
agreement). A window width of 0.2 was chosen rather than 0.1 because although 
the narrower window tends to increase agreement there is also more chance that 
a poor scan will fall completely outside the window and thus fail to have the 
boundary shift estimated accurately. The BBSIs reported in the rest of this 
chapter (and in chapter 11) are thus derived from the final parameters of centre 
0.425, width 0.2.
10.9 COMPARISON OF THE BBSI AND MANUAL MEASURES 
Volume loss as estimated by segmentation and the BBSI, for the entire cohort, is 
shown in Figure 10-5. As volume loss from segmentation is estimated from the 
images in native space, and so is subject to scanner drift in addition to segmentor 
error, the mean differences between each measure look greater than the 3.23ml it 
was shown to be (see section 10.6 for discussion of using non-registered images
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to estimate volume loss and section 10.8 for derivation of the mean difference 
between volume loss and the BBSI).
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Figure 10-5 Volume loss for each group measured manually and with the 
BBSI
Pitman’s test was used to compare the variance of each measure within each 
group, and in all cases use of the BBSI reduced group variance compared to the 
manual measure (controls: ratio=2.09, 95% Cl 1.52, 2.86, p<0.0001; 
premanifest: ratio=2.05, 95% Cl 1.43, 2.94, p<0.0001; early HD: ratio=1.86, 
95% Cl 1.34, 2.59, p<0.0001).
Linear regression models were used to investigate differences between groups, 
for each measure. Differences between groups were slightly larger for volume 
change estimated by the BBSI (see Table 10-4).
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Table 10-4 Mean (SD) volume loss from manual and BBSI measures, with group differences
Control
(N=18)
Premanifest
(N=17)
Early HD 
(N=27)
Difference
(Premanifest - Control) (Early HD - Control)
Manual (ml) 11.0(11.9) 6.2(11.9) 16.2 (12.7) -4.8 (p=0.25) 5.2 (p=0.17)
95% Cl 5.1, 17.0 0.05, 12.3 11.2,21.2 -13.1,3.4 -2.3, 12.6
BBSI (ml) 4.5 (5.7) -0.5 (5.8) 9.8 (6.8) -5.0 (p=0.022) 5.3 (p=0.007)
95% Cl 1.6, 7.3 -3.5, 2.5 7.1, 12.4 -9.2, 0.7 1.5, 9.1
Positive differences indicate greater volume loss in HD subjects relative to controls.
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10.10 DISCUSSION
In this section I have discussed three methods of finding the BBSI parameters 
which give best agreement between this measure and manual measures, which 
are the current “gold standard”.
Two methods gave similar parameters: deriving parameters from intensities, and 
deriving parameters from a subset of scans where the manual measure was 
calculated from registered pairs. The first method, based on image intensities, 
was only based on six images suggesting that even this small sample size was 
sufficient to obtain a reasonable estimate of the window centre and width. This 
requires subject selection, and careful manual outlining of the regions of interest. 
It is likely to be influenced by the placing of the regions of interest, particularly 
in images with some inhomogeneity. The second method compared the BBSI 
with the best “gold standard” measurement, manual measures from registered 
scan pairs. This method is time-consuming, again requiring careful subject 
selection in addition to resegmentation of the registered images, but having done 
this it allows the best estimate of agreement and bias.
The third method used the whole cohort which is the most practical method, 
since all the images have been segmented in native space prior to registration, but 
parameters derived from this were quite different to those from the other two 
methods and were associated with greater bias and less agreement than the 
previous two methods, almost certainly because of the added error associated 
with manual measures derived from non-registered scan pairs.
The fact that the first two methods give very similar results is encouraging, and it
suggests that for future work it may be sufficient to use either method to get a set
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of parameters which will maximise agreement. The third method was not very 
satisfactory. In a large-scale study which method is chosen will depend on 
practicalities such as time constraints and segmentor availability.
All agreement improved as the window widths narrowed, which suggests that the 
set of scans here were uniform enough that the intensity changes associated with 
a shift of border were all contained within quite a narrow window. This is 
possibly due to the fact that all the images here were from the same scanner and a 
single site, with a relatively short and invariant time interval. A window width of 
0.1 seemed to work for most centres; however it did not produce the best 
agreement for some centres, suggesting that at this width some noisy images 
might be falling outside the range. Hence a window width of 0.2 was chosen for 
the fmal parameters.
10.11 CONCLUSION
This chapter discussed three ways of calculating BBSI parameters which 
maximised agreement between this measure and the best estimate of true volume 
change (manual segmentation). Parameters estimated from scan intensities, or 
from volumes derived from segmented registered scan pairs were similar, whilst 
those from non-registered scan pairs were different and led to the BBSI agreeing 
less well with manual measurements. The bias for the parameters finally chosen 
was -3.23ml (95% Cl -5.62, -0.84) suggesting that the BBSI was underestimating 
volume loss slightly. However, as has been found previously, the BBSI 
significantly reduced within-group variance and also slightly increased group 
separation, compared with manual measures (Freeborough and Fox 1997).
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BBSIs from these parameters were used to calculate the atrophy rates that are 
presented in the following chapter.
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11 LONGITUDINAL CHANGE IN HUNTINGTON’S DISEASE: 
APPLICATION OF THE BBSI TO MEASURE CEREBRAL 
ATROPHY RATE AND ASSESS ITS ASSOCIATIONS
11.1 INTRODUCTION
There have been relatively few longitudinal structural MRI studies in HD, and 
the majority of them have focused on the striatum. However, cross-sectional 
work, including that reported in earlier chapters, suggests that extra-striatal 
atrophy occurs early on in the disease, and that change in volume can be detected 
in these regions (e.g., Kipps et al. 2005). The work in chapter 3 demonstrated 
that increased rates of whole-brain atrophy could be detected in HD, and that the 
BBSI was a useful technique for this measure. However the study described 
there had a small sample size and took place over a short period of time (six 
months) and thus part of the aim of the following work was to replicate and 
expand on those findings in a larger cohort, over a longer time scale. In addition 
to investigating whether the finding of increased rates of whole-brain atrophy 
could be replicated, this work also focused on whether this measure could be a 
potential biomarker of progression in HD, by looking at associations with genetic 
and demographic variables, as well as whether atrophy rate was predictive of 
decline in other domains.
11.2 METHODS
11.2.1 Subjects and assessments
The 77 subjects who returned for the follow-up assessment were also asked to 
have a repeat MRI scan (18 controls, 19 premanifest, 40 early HD, see section 
9.2). At the follow-up assessment two back-to-back volumetric images, with the
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same parameters, were acquired. This increased the chances of obtaining at least 
one image free of motion or other artefact at the time of the assessment and 
reduced the risk that subjects would need to be called back for rescans.
One early HD subject was unable to be scanned at follow-up due to anxiety and 
three early HD subjects had chorea that affected image quality. Thus 
longitudinal MRI data were initially acquired for 18 controls, 19 premanifest 
subjects and 36 early HD subjects.
11.2.2 Image segmentation and the BBSI
Whole brains were segmented following the protocol in Appendix 2. Follow-up 
scans were then positionally matched to their baseline images using an affine 
registration with 12 degrees of freedom (in which the cost function minimized 
was the standard deviation of the ratio image, see section 2.5.4.2) (Woods et al 
1998). The BBSI was calculated from the registered scan pairs as described in 
section 2.5.4.3, using the parameters determined in chapter 10.
Registered scan pairs were checked by an experienced imager with no 
knowledge of the subjects’ disease status or atrophy rates. Eleven subjects were 
deemed to have inadequate scan pairs for analysis because of movement or 
scanner artefact (two premanifest and nine early HD). Thus 18 controls, 17 
premanifest subjects and 27 early HD subjects were included in the longitudinal 
MRI analysis. Demographic data for the included and excluded subjects were 
subsequently compared to investigate whether exclusion was related to factors 
such as disease status or chorea score.
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At baseline 53 subjects had all assessments on the same day or within three days, 
four subjects had rescans after the clinical and cognitive assessments (mean (SD) 
interval 5.7 (2.6) weeks, range 2 - 7  weeks), and five subjects had the clinical 
assessment after the other two for logistical reasons (mean (SD) interval 11.5 
(6.1) weeks, range 7 - 2 2  weeks). At follow-up 58 subjects had all assessments 
on the same day or within two days, three subjects had clinical assessment after 
the other two for logistic reasons (mean (SD) interval 10.2 (7.2) weeks, range 5 -  
18 weeks) and one subject completed the cognitive assessment but was 
claustrophobic and had to return to complete the scan and clinical assessment 
nine weeks later.
11.2.3 Statistical analysis
t-tests assuming unequal variance were used to investigate group differences in 
age, estimated premorbid IQ and CAG repeat length at baseline. A cluf test was 
used to compare gender in each group. Fisher’s exact test was used to see if the 
proportion of right-handed subjects differed between groups.
Atrophy rates were analyzed on a logarithmic scale according to equation 11.1 in 
order to ensure that doublings and halvings be treated as effects of equal 
magnitude; follow-up volume was calculated from the BBSI.
( ln ( ^ /o / /o w - u /?  /^ba se lin e  ) )
time
11.1
Regression models relating the log-transformed variables to subject group and 
age were used to obtain individual age-standardized atrophy rates. Geometric 
mean atrophy rates (as annualized percentage change from baseline, % per year)
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were calculated by back transformation with standard deviations (SDs) 
calculated from variance transformation formulae.
For cognitive and clinical change a simple difference score was calculated for 
scores at the two timepoints such that a negative difference score signified 
decline (see chapter 9). The majority of the tests were timed or open-ended 
(subjects could provide as many answers as possible) and on these there was no 
evidence of floor or ceiling effects. As discussed in chapter 9, some subjects in 
all groups were scoring at the maximum at both timepoints for HVLT delayed 
recall and discrimination, and the RMW, and hence these scores may not be 
sensitive to change over the time period employed here.
11.2.3.1 Group differences
A linear regression model with robust standard errors was used to compare rates 
of whole-brain atrophy (% per year) between groups. Although the effect of age 
on atrophy rates is thought to be relatively small in this age range (Scahill et al 
2003), age at baseline was included as a covariate in this model in order to ensure 
that any group differences seen could not be attributed to this.
11.2.3.2 Associations with baseline clinical measures
Separate linear regression models were used to assess the association between 
atrophy rate and probability of onset (in the premanifest group) and disease 
duration, UHDRS independence score and TFC (in the early HD group), 
adjusting for age at baseline.
As in previous chapters a linear regression model (with robust standard errors) 
relating atrophy rate to CAG repeat length, group and their interaction was used
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to investigate whether the relationship between atrophy rate and CAG repeat 
length differed between groups, having adjusted for age at baseline. A similar 
model was used to assess the relationship between atrophy rate and UHDRS 
motor score. If there was no evidence of an interaction then the analysis was 
repeated without interaction terms, with and without adjusting for differences 
due to group, and adjusting for age.
11.2.3.3 Associations with change in clinical and cognitive measures 
Separate linear regression models (adjusting for age) were used to assess the 
relationship between atrophy rate and change in UHDRS independence score and 
total functional capacity (in the HD group alone).
For each of the cognitive change variables a linear regression model (with robust 
standard errors) relating atrophy rate to change score, group and their interaction 
was used to investigate whether the relationship between atrophy rate and change 
score differed between groups, having adjusted for age at baseline and estimated 
premorbid IQ at baseline. Where it did, slopes in each group were examined to 
see whether they were significantly different to zero. If there was no evidence of 
an interaction then the analysis was repeated without interaction terms, but 
adjusting for differences due to group, age and IQ.
Where a statistically significant association between atrophy rate and cognitive 
decline was found, the above analysis was repeated adjusting for the effects of 
CAG repeat length by including it as a covariate.
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11.2.3.4 Excluded scan pairs
In order to check whether scan-pair exclusion had biased the remaining sample 
Fisher’s exact test was used to see whether the proportion of accepted scans 
differed between groups. Following this, Fisher’s exact test was used to 
investigate differences in gender and stage between the accepted and rejected 
subjects in each group, and unpaired t-tests (two-tailed, allowing for unequal 
variances where necessary) were used to check for differences in other 
demographic and clinical variables.
11.3 RESULTS
Demographic data are shown in Table 11-1. There were no statistically 
significant differences in gender, handedness or estimated premorbid IQ between 
the groups. The mean age of the premanifest group was 8.7 years lower than 
controls (95% Cl 2.8, 14.7 years, p=0.005). The premanifest group had a shorter 
mean CAG repeat length than the early HD group (mean difference 1.3 repeats, 
95% Cl 0.2, 2.3 repeats, p=0.023).
Mean (SD) interval between baseline and follow-up MRI scans was 1.0 (0.1) 
year for each group and did not differ significantly between groups.
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Table 11-1 Demographic data for the longitudinal imaging cohort
Control
(N=18)
Premanifest
(N=17)
Early HD 
(N=27)
Gender (M:F) 6:12 8:9 16:11
Age (year)^ 46.3 (9.7) 37.5 (7.4) 48.9 (9.0)
Estimated premorbid IQ 106.8(11.5) 103.2 (8.7) 105.0(13.2)
Handedness (R:L) 17:1 16:1 25:2
CAG repeat length^ NA 42.4(1.7), 43.7(1.7),
range 40 -  45 range 40 -  47
Predicted years to onset^ NA 16.8 (6.6), NA
range 9 - 3 1
Disease duration (year) NA NA 4.5 (2.9)
UHDRS Motor‘d 1.1 (0.9) 3.9 (4.4) 28.1 (11.9)
UHDRS Independence 100 (0) 100 (0) 92.0 (9.1)
UHDRS TFC 13(0) 13(0) 11.1 (1.7)
Scan interval (year) 1.0 (0.1) 1.0 (0.1) 1.0 (0.1)
NA: not applicable
Data are mean (SD) with the exception o f  gender and handedness; handedness was taken as the 
hand used to write with; UHDRS: motor is out o f  124, higher score = more severely impaired; 
independence is scored as a percentage, higher score = better function; Total Functional Capacity 
is out o f  13, higher score = better function, 
a PM<Control p=0.005, PM<HD p<0.0001 
b PM<HD, p=0.023
c Calculated from age using the equation from Langbehn et al. (2004), with onset defined as a 
60% chance o f  showing motor signs 
d HD<PM, HD<Control, both p<0.0001
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11.3.1 Application o f the BBSI
Representative sagittal slices from scans from each timepoint for a control and 
early HD subject (matched for age and gender) are shown in Figure 11-1. The 
difference in caudate size is notable between the two subjects. The colour 
overlay shows regions of loss (red) or gain (green) between the two timepoints, 
detected in the boundary region by the BBSI algorithm. Although the main shift 
in boundary in the HD subject is around the caudate, there is also clear 
ventricular enlargement and some increase in the sulcal spaces. There is very 
little change in the control over the same period.
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CONTROL EARLY HD
BASELINE
12 MONTHS
BBSI COLOUR OVERLAY
Figure 11-1 Sagittal sections through the left caudate of a control (left panel) 
and early HD subject (right panel) taken at baseline, 12 months, and 
showing the BBSI as a colour overlay
Subjects were male and aged 34 at baseline. The control atrophy rate was 0.2% 
(of baseline brain) per year, and the early HD subject 1.2%> per year. Red shows 
regions o f loss, green o f gain (defined as a change o f >20% o f mean brain 
intensity).
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11. s. 2 Group differences
The HD group had a higher mean rate of atrophy compared with controls (0.92% 
per year vs. 0.38% per year, p=0.005) and the premanifest group (0.92% per year 
vs. -0.06% per year, p<0.0001) after adjusting for age (see Table 11-2 for means 
and Figure 11-2 for individual rates standardized to mean age in the whole 
cohort). Although mean atrophy rates were higher in controls than in the 
premanifest group this difference was not statistically significant after adjusting 
for age (p=0.10).
CM -
I
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Control Premanifest Early HD
Figure 11-2 Whole-brain atrophy rates (% per year) in each group, 
standardized to mean age in the whole cohort
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Table 11-2 Mean (SD) atrophy rates with differences with and without adjustment for age at baseline
Control
N=18
Premanifest
N=17
Early HD 
N=27
Difference (Premanifest - Control) 
Crude Adjusted
Difference (Early HD - Control) 
Crude Adjusted
Atrophy rate (%/yr) 
95% Cl
0.38(0.51) 
0.12, 0.63
-0.06 (0.47) 
-0.30, 0.18
0.92 (0.67) 
0.66, 1.19
-0.44 (p=0.011) -0.31 (p-0.10) 
-0.77, -0.10 -0.68,0.06
0.55 (p=0.003) 
0.19, 0.90
0.51 (p=0.005) 
0.16, 0.85
Positive differences indicate a higher atrophy rate in HD subjects relative to controls; crude differences are the absolute difference between groups before adjustment 
for age at baseline; adjusted differences are the differences having adjusted for age by including it as a covariates in the linear regression model.
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11. s. 3 Associations with baseline clinical measures
In the early HD group there was no evidence of an association between atrophy 
rate and baseline disease duration, UHDRS independence score or TFC (all 
p>0.43). There was also no evidence of an association between atrophy rate and 
probability of onset in the premanifest group (p=0.29).
Combining subjects from both patient groups an increase of CAG repeat length 
by one was associated with an increase in whole-brain atrophy rate by 0.12% per 
year after adjusting for age (95% Cl 0.005, 0.24% per year, p=0.042) (Figure 
11-3).
CM
■ ■
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CAG repeat length 
Û Premanifest ■ Early HD
Figure 11-3 Atrophy rate (% per year, standardised to mean age in the 
whole cohort) plotted against CAG repeat length
This association reflects, in part, the fact that CAG repeat length is associated
with earlier progression to manifest HD and that early HD subjects have higher
atrophy rates than premanifest subjects. After adjusting for this, the slope was
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close to zero, and not statistically significant (p=0.79). There was no evidence 
that the slope of this association differed between the patient groups (p=0.37).
After adjusting for age, there was no evidence that the association between 
baseline motor score and atrophy rate differed between premanifest and early HD 
subjects (p=0.51). In the gene carriers as a whole a one point increase in motor 
score was associated with a 0.02% per year increase in atrophy rate (95% Cl 
0.01, 0.04, p=0.005) but as above, this could be explained by group differences 
and the association was no longer statistically significant when the effect of 
group was adjusted for (p=0.42).
11.3.4 Associations with change in clinical and cognitive measures 
In the early HD group there was no evidence of an association between whole- 
brain atrophy rate and decline in UHDRS independence score or TFC (both 
p>0.76).
In the gene carriers as a whole higher whole-brain atrophy rate was associated 
with greater decline at Stroop word reading (-4.3 points per 1% increase in rate, 
95% Cl -8.3, -0.4 points, p=0.034) and TMT B (-17.5 seconds per 1% increase in 
rate, 95% Cl -32.6, -2.4 seconds, p=0.024), after adjusting for age and IQ. 
Higher whole-brain atrophy rate was also associated with less decline in digit 
span backwards in the early HD group, but not the premanifest group (1.7 points 
per 1% increase in rate, 95% Cl 0.1, 3.3 points, p=0.039 in the early HD group). 
Atrophy rates were not significantly associated with change in any of the other 
cognitive variables.
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When CAG repeat length was included in this analysis higher atrophy rates were 
still associated with greater decline in Stroop word reading (-4.2 points per 1% 
increase in rate, 95% Cl -8.1, -0.3 points, p=0.035) and TMT B score (-17.3 
seconds per 1% increase in rate, 95% Cl -33.1, -1.5 seconds, p=0.033) in the 
gene carriers as a whole. The relationship between digit span backwards and 
atrophy rate in the early HD group was also unchanged.
11.3.5 Excluded scan pairs
Demographic data for included and excluded subjects are shown in Table 11-3. 
There was a significant difference in the proportions of subjects from each group 
who were rejected, with no controls (0%), 2 premanifest (11%) and 9 early HD 
subjects (25%) rejected (p=0.034). Within the premanifest group there were no 
statistically significant differences between the accepted and rejected subjects for 
any demographic or clinical variables at baseline or follow-up except for CAG 
repeat length (lower in rejected subjects, p=0.0008) and baseline motor score 
(lower in rejected subjects, p=0.016). Within the early HD group there were 
again no differences between the accepted and rejected subjects for most 
demographic and clinical measures, except that a higher proportion of women 
than men were rejected (p=0.002), and rejected subjects were more depressed at 
follow-up than accepted ones (p=0.0254).
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Table 11-3 Demographic data for the included and excluded subjects in each patient group
Included
(N=17)
Premanifest
Excluded
(N=2)
Early HD
Included
(N=27)
Excluded
(N=9)
Gender (M:F) 8:9 1:1 16:11 0:9*
Age (year) 37.5 (7.4) 39.5(12.0) 48.9 (9.0) 47.8(12.6)
Stage (1:2) NA NA 20:7 4:5
CAG repeat length 42.4(1.7) 40.0 (0)* 43.7(1.7) 43.6 (3.8)
Predicted years to onset 17.0(10.3) 26.5(11.4) NA NA
Disease duration (year) NA NA 4.5 (2.9) 3.6 (2.1)
UHDRS Motor (baseline) 3.9 (4.4) 1.0 (0)* 28.1 (11.9) 31.0(14.5)
UHDRS Motor (12 months) 5.4 (4.5) 4.0 (2.8) 34.3 (12.2) 34.1 (13.7)
UHDRS Independence (baseline) NA NA 92.0 (9.1) 88.3(11.7)
UHDRS Independence (12 months) NA NA 89.4 (9.0) 88.3(11.7)
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UHDRS TFC (baseline) NA NA 11.1 (1.7) 10.4 (2.0)
UHDRS TFC (12 months) NA NA 10.4(1.9) 10.6(1.9)
BDI (baseline) 5.8 (6.1) 9.0 (2.8) 7.8 (6.9) 13.8(13.1)
BDI (12 months) 6.5 (7.6) 11.5 (4.9) 7.3 (6.8) 14.1 (9.9)*
* excluded statistically significantly different to included, p<0.05
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11.4 DISCUSSION
This work demonstrates that rates of whole-brain atrophy are increased in early 
HD, and that this can be detected with serial MRI and the BBSI over one year. 
The mean rate of whole-brain atrophy, of just under 1% per year in the HD 
group, was similar to that found previously, in a smaller sample examined over a 
six-month period, reported in chapter 3.
There is increasing evidence that neurodegeneration in HD occurs throughout the 
brain, even in the early stages (Beglinger et al. 2005; Rosas et al. 2005; Paulsen 
et al. 2006b) and this is reinforced by these findings. A whole-brain rate of 1% 
per year equates to about 10ml of loss per year, and the total volume of the 
healthy striatum is only approximately 20ml (Aylward et al. 2004); therefore 
striatal atrophy alone, occurring at rates of <5% per year in manifest HD subjects 
(Aylward et al. 2003), cannot account for the whole-brain rates seen here. The 
control atrophy rate, of 0.38% per year, was also similar to previously reported 
figures (Scahill et al. 2003). This cohort of manifest HD subjects consisted of 
those in the early stages of the disease, with an average range of CAG repeat 
lengths (40-47), and was thus representative of the relatively mildly affected and 
young HD population most likely to go into clinical trials of disease-modifying 
treatments.
These findings differ from an earlier study which found evidence that white 
matter (but not grey matter) volumes decreased over time in premanifest 
subjects, but that neither grey nor white matter volume decreased in early HD 
subjects (Ciarmiello et al. 2006). However the segmentation algorithm used 
there was fully automated with reproducibility of around 1.1% (calculated as the
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standard deviation of repeated measures as a proportion of their mean); the 
equivalent figure for our semi-automated manual method is ~0.3% for both intra- 
and inter-rater reproducibility. In addition, the BBSI uses intensity shifts to 
quantify volume change in a region defined by the segmentations, rather than 
segmentations per se, and so is less susceptible to segmentor error than methods 
which rely on segmentation alone as an estimate of volume. It is likely that 
relative to Ciarmiello et al.'s method, the BBSI is more sensitive for detecting 
change on the scale seen here, which is small relative to some other 
neurodegenerative diseases (Fox and Freeborough 1997).
There was no evidence of increased atrophy rates in the premanifest group but
the majority of this group was more than 15 years from predicted motor onset,
and there was also no evidence that this group differed fi*om controls on most
cross-sectional measures, (see chapter 4). However, this group did have
significantly smaller whole-brain volume than controls, which could be due to
either a developmental abnormality, or very slightly increased atrophy rates
acting over several years, or both. Others have suggested abnormal gyrification
in premanifest subjects, as well as increased grey (but not white) matter (Paulsen
et a l 2006b; Nopoulos et al 2007), in the absence of differences in total brain
size. Further investigation is therefore needed to determine the relative
contribution of these two possibilities to the volumetric findings presented here.
Given the findings of Paulsen et al (2006b), one would need to posit slightly
increased atrophy rates in order to explain the decreased brain and caudate
volumes in this premanifest cohort. However, the BBSI technique may not be
sensitive enough to pick up changes in whole-brain atrophy rates during these
very early stages. This result may also suggest that cerebral volume losses are
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likely to be subtle, slow and possibly regionally confined many years before 
onset (Aylward et al. 2004; Paulsen et al. 2006b).
An increase of CAG repeat length by one CAG was associated with an increase 
in whole-brain atrophy rate of 0.12% per year in the entire HD gene carrier 
sample, with CAG repeat length accounting for about 10% of the variance in 
atrophy rate. This was largely explained by the fact that people with a higher 
number of CAG repeats tended to be those with manifest disease, and also those 
with higher rates of atrophy. Although in other domains such as neurological 
function and cognition, rate of decline has been reported to increase with disease 
duration or severity (Ward et al. 2006; Rosenblatt et al. 2006), that was not the 
case for whole-brain atrophy rates, which did not vary significantly with 
proximity to motor onset (in the premanifest group), duration of motor signs (in 
the HD group) or putative measures of disease severity such as motor score, 
TFC, or clinical stage. Whole-brain atrophy rate may be relatively constant, at 
least over the period of early disease examined here. It is also likely that motor 
signs are more strongly associated with regional, rather than global atrophy, 
particularly that of the putamen and associated motor areas in the frontal cortex.
However, although whole-brain atrophy rates were not predictive of motor 
decline, higher atrophy rates were associated with greater decline in some 
cognitive tests (both before and after taking into account the effect of CAG 
repeat length), notably timed psychomotor tasks tapping both automatic skills 
and cognitive switching. There is evidence that such skills are associated with 
cortical as well as sub-cortical regions (Rosas et al. 2005; Kassubek et al. 2005; 
Hirshom and Thompson-Schill 2006) all of which the BBSI, as a whole-brain
344
measure, encompasses. In the early HD group, higher atrophy rate was also 
associated with less decline on digit span backwards although it would be 
unlikely for this to represent a causal association. The robustness of these 
associations will be followed up in a subset of subjects who are having a third 
assessment approximately 27 months after baseline, in order to assess whether 
the changes detected at one year are representative of those measured over a 
longer period.
The BBSI is relatively fast, unbiased and operator efficient (two whole-brain 
images can be processed in ~30 minutes); registration corrects for voxel size 
changes introduced by scanner drift; and the impact of segmentor variability is 
limited because the technique measures the intensity shift in the images, and does 
not rely on the segmentations per jg as a measure of volume. Furthermore the 
scanning time is relatively short and well-tolerated, with ninety-five percent of 
our initial cohort returning for the follow-up assessment.
Some registered scan pairs were not analysed because of scanning artefacts (e.g. 
flow artefact affecting temporal lobe signal). Subjects whose images were 
rejected did not have higher motor scores than those who were accepted, nor 
were they more advanced on any other measure, suggesting that non-disease- 
related factors influenced scan quality. However, in the case of those subjects 
who were unable to produce useable images in the first place, this was due to 
disease-related factors such as chorea or claustrophobia. Any imaging technique 
is likely to be subject to such drawbacks, particularly in this patient population, 
and MRI measures may not be suitable as biomarkers in the later stages of the 
disease when motor signs become more severe.
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Further work should add to this finding by investigating which brain regions 
(other than the striatum) are contributing to the increased whole-brain atrophy 
rates seen here. Techniques such as cortical thickness measurements, and voxel- 
based morphometry have the potential to localise regions of greater or smaller 
brain volume loss over time, although as yet they have rarely been applied 
longitudinally in HD, and where they have, techniques differ widely (e.g., Kipps 
et al 2005; Ruocco et al 2007). However, increased knowledge of the focal 
regions of atrophy in HD, which may vary with disease stage, might suggest a 
number of potential structural biomarkers appropriate for use in different HD 
populations.
11.5 CONCLUSION
Overall whole-brain atrophy rate meets some of the criteria required for a
biomarker (Biomarkers Definitions Working Group 2001 ; Aylward 2007). It can
be measured objectively, is associated with the length of the abnormal CAG
repeat that causes HD and predicts some cognitive decline. Importantly, in
encompassing the whole brain, the BBSI is capturing the full extent of the diffuse
cerebral volume loss in HD and hence might be relatively more sensitive to
disease modification by treatments that target multiple brain regions, than would
a more focal measure. There was no evidence that whole-brain atrophy rate was
increased in the far-ffom-onset premanifest group, whereas it has been shown in
a premanifest population closer to predicted onset that caudate atrophy rates are
increased and predictive of motor onset (Aylward 2007). Ultimately it is likely
that different markers, or combinations of markers, will be appropriate for
different disease stages, and that practical considerations including necessary
sample size will also influence the choice of marker for a particular trial. Based
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on the findings in this study 278 early stage HD subjects per treatment arm 
would need to complete a one-year trial in order to detect a 20% reduction in 
whole-brain atrophy rate (note that this is a reduction in total atrophy rate, not 
relative to controls) (Fox et al. 2000). The BBSI technique is already used as a 
marker in other neurodegenerative diseases (Fox et al. 2005), and would seem to 
be an attractive measure for clinical trials in the early symptomatic stages of HD. 
Further work is now needed, particularly in the premanifest population, to see at 
what point an increase in whole-brain atrophy becomes detectable and whether 
rates do remain constant through early disease.
347
12 CONCLUSIONS
12.1 CLINICAL FINDINGS
This thesis used serial MRI and cognitive testing to investigate the cognitive 
deficits and brain volume loss seen in premanifest and early Huntington’s disease 
and to assess the potential of these measures to detect change over time.
Chapter 3 demonstrated that serial MRI is well-tolerated in HD, that the BBSI 
can be applied to measure atrophy in this cohort and that whole-brain atrophy 
rates are increased in early HD.
Chapter 4 showed that whole-brain volume was already decreased at baseline 
assessment, in both early and relatively far-from-onset premanifest subjects. 
Cognitive deficits were fairly widespread in the early HD group, although of 
particular note was the finding that deficits in recognition memory and facial 
emotion recognition were of similar magnitude to those in psychomotor and 
executive function tasks. Recognition of true target stimuli was relatively good, 
given the level of encoding achieved by early HD subjects, confirming previous 
work. However there was a tendency for these subjects to make more false 
positives, both confirming theories that storage per se is not the main domain of 
impairment, and suggesting that strategies for monitoring retrieval, or making 
confidence judgements, might be impaired. Although naming ability was 
unimpaired, naming latency was slowed, and this was not explained by 
dysarthria, suggesting that cognitive as well as motor slowing was contributing to 
the impairments in this group.
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As has been found in a number of other studies, there was little evidence of 
cognitive impairment in the premanifest group, which was relatively far from 
predicted motor onset. Interestingly the one task on which these subjects were 
slower than controls was pressing a button in a predictable motor task, which 
seems indicative of early striatal damage given the proposed role of the striatum 
in goal-directed behaviour and habit learning.
Caudate volume was also decreased in both patient groups (chapter 5) further 
suggesting that striatal atrophy could be present even in those very far from 
estimated disease onset, and had probably been ongoing for some time prior to 
entry to the study. Together with the whole-brain findings these results imply an 
insidious and early increase in cerebral atrophy, initially focused on striatal 
regions. Although research on caudate laterality has been equivocal, the work 
presented here added to previous suggestions of a slight normal rightward 
asymmetry, and this was found in both patients and controls. There was an 
interesting dichotomy in the associations between cognitive performance and 
caudate volume, that supported the role of the striatum in learnt (automatic) skill 
performance, goal-directed behaviour and in motor, oculomotor and 
psychomotor circuits, but suggesting that striatal damage might not underlie 
deficits seen in memory tasks, or tasks under more cognitive control, such as 
those involving a switching component.
In terms of the locus of atrophy across the whole brain, chapter 7 demonstrated 
that it was more widespread than previously thought, including the insula, and 
regions of the frontal, parietal and occipital lobes, as well as subcortical regions. 
Higher CAG repeat length was associated with increased atrophy of the striatum
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as well as some extra-striatal regions. Chapter 8 went on to look at emotion 
recognition in more detail, showing a broad impairment of negative emotions 
with anger and fear at least as badly affected as disgust. These impairments were 
all associated with reduced grey matter in the striatum predominantly, as well as 
in some other regions, suggesting that they might be caused by damage to a 
common underlying network, most likely including ffonto-subcortical circuits. 
This did not support theories that atrophy in HD causes selective deficits to 
recognition of specific emotions (namely disgust), although further work, 
probably including fMRI, is needed to confirm the underlying neural substrates 
of the impairments.
12.2 TRACKING CHANGE
Whole-brain atrophy rates were significantly increased in early HD and this 
increased loss was detectable over only one year, using serial MRI and the BBSI 
(chapter 11 ). Atrophy rates were variable, with some overlap between groups, 
and this was in part explained by CAG repeat length, but not by disease duration 
or the interaction between CAG repeat length and disease duration. Given that 
HD is clearly a whole-brain disease, even in the early stages, this semi­
automated, robust technique shows promise. Further work will assess the effect 
of longer intervals between scans, whether other variables contribute to the 
variance, and whether the BBSI is also sensitive to change in the close-to-onset 
premanifest population. It will also be important to assess other measures of 
atrophy, such as cortical thickness, and other imaging modalities, for example 
using diffusion imaging to assess white matter deficits.
350
Cognitive change over one year was generally small and variable (chapter 9), 
although in the early HD group decline was detected in both executive function 
and memory tasks. Lack of significant decline in other tasks might be due to 
slowness of progression or because this group had already undergone decline and 
was performing relatively poorly at both timepoints; in both cases the relative 
insensitivity of tests could also be a factor, and this could be addressed, 
particularly in the memory domain. The premanifest group showed a relative 
decline in phonemic fluency, and although this was only in relation to the large 
practice effect seen in controls, it nevertheless suggests some early prefrontal 
dysfunction which could be a focus of further testing in this group.
CAG repeat length was associated with smaller whole-brain and caudate volume, 
as well as higher whole-brain atrophy rates. VBM analysis suggested that it was 
also related to extra-striatal volume although this was quite focal (chapter 7). 
There was little evidence that it was associated with greater rate of cognitive or 
clinical decline, however, although this may be due to the variability of cognitive 
and clinical change. It may also reflect the fact that the subjects studied here had 
CAG repeat lengths of between 40 and 50, i.e. in the low pathological range, and 
it may be that the effect of CAG repeat length on rate of decline becomes more 
apparent in subjects with higher repeat lengths. In addition, very few of the 
cognitive, clinical or MRI measures employed here showed rate of change to be 
associated with disease duration.
12.3 TECHNICAL CONSIDERATIONS
With increasingly diverse imaging techniques in use, many differences in 
findings between studies may be attributed to these, rather than true differences
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in the populations studied. Confounding factors need to be considered for both 
manual and voxel-based morphometric techniques, as was demonstrated in 
chapter 6, in particular the effects of head size and gender. Adjusting for total 
intracranial volume corrects for differences due to gender, but it is important to 
note that this is not the case for all estimates of head size (for example using 
intracranial area instead of volume) and that some estimates may be biased (for 
example intracranial volume estimated by automated segmentation methods). 
Manual techniques can limit sources of bias by blinding investigators to 
laterality, and using the same segmentation protocol for each hemisphere. With 
automated techniques, such as SPM, is it vital to investigate the accuracy of any 
preprocessing steps for the particular cohort under investigation, and to consider 
these and other potential methodological problems in interpreting, and 
generalising results (chapter 6). With the advent of improved normalisation and 
segmentation techniques, such as DARTEL (implemented in SPM5, (Ashbumer 
2007)) it should be possible to reduce some of the errors and hence findings will 
be more robust. This work also suggested and compared methods for ensuring 
maximum agreement between the BBSI and “true” volume loss (chapter 10).
Cognitive testing can be unreliable because of the many non-disease-speciflc 
factors that can affect performance, including demographic variables such as age 
and IQ, which can have small (but potentially significant) effects on findings. As 
with imaging methods, the effects of these confounding variables can be adjusted 
for statistically, in order to minimise their impact on findings.
In this thesis cognitive findings were not adjusted for multiple comparisons, 
because each test was considered of independent interest, and therefore the risk
352
of missing true positives was kept low. Whether or not researchers opt to control 
the false positive rate more stringently it would be helpful if all studies reported 
mean effects, since in this way it is possible to compare results, even if some 
smaller studies have not found statistically significant differences (perhaps due to 
lack of power). Choice of control group is also important, and it may be possible 
to minimise the effects of some non-disease-related factors by recruiting controls 
from HD families, who have similar environmental, social and emotional 
influences.
In general, particularly with the publication of guidelines as to the reporting of 
some widely-used imaging techniques, it is to be hoped that future work 
increasingly confirms what is known about HD, and generates new hypotheses, 
rather than queries about methodology.
12.4 LIMITATIONS
The early HD cohort studied here was relatively large, and all subjects were stage 
1 or 2 and their HD was of fairly short duration, meaning that the group was not 
too heterogeneous. However the premanifest group was smaller, and on average 
very far from predicted onset. Thus, whilst results might generalise to a similar 
population, this cohort needs continued follow-up in order further to clarify the 
nature of the deficit in premanifest subjects, to investigate when other early signs 
can be detected, and to confirm actual years to onset.
A time period of one year, whilst preferable for clinical trials, means that the 
signal was small and it would undoubtedly be improved with measurements 
taken over a longer period. It remains to be seen whether the benefits of this
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outweigh the costs in the context of a trial for a potentially disease-modifying 
therapy.
There is currently some debate about the extent to which both CAG repeat length 
and disease duration affect rate of progression in HD, as well as prediction of 
motor onset in the premanifest population (see section 1.4). Although very little 
of the decline shown in this study (cognitive, clinical and atrophy rates) was 
associated with disease duration, it is likely that disease duration is a very 
imprecise measure; firstly the diagnosis of onset depends on the diagnosing 
clinician, and then how soon after “true” onset the patient is seen by that 
clinician; secondly, onset is still defined purely in terms of motor signs, although 
there is increasing evidence that behavioural and cognitive impairments may be 
present prior to this, and that the burden of different symptom types might also 
differ between patients.
There are similar problems with estimated years to onset. In the published 
literature a number of different methods have been used to estimate time to onset, 
meaning that seemingly similar groups of patients may in fact not be. Recently 
more researchers are using the equation developed by Langbehn et al. (2004), but 
this estimate seems somewhat conservative, based as it is usually on estimated 
time to reach a 60% probability of showing motor signs. Whilst classifying 
subjects in this way facilitates comparison between studies, it does not allow one 
to consider premanifest and early HD subjects on the same scale. Using this 
equation the predicted mean age at onset of the premanifest group presented here 
is 55.4 years, whereas the mean age at onset of the early HD group was 44.4 
years, and although the premanifest subjects have, on average, slightly fewer
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CAG repeats this seems unlikely to translate into such a large discrepancy in 
onset ages. Future work to refine the equation to take into account other 
potential predictors (such as the CAG repeat length on the normal gene, paternal 
or maternal inheritance, parental age at onset and other potential genetic 
modifiers) may give better estimates, as will follow-up of the current premanifest 
population to see whether there is a discrepancy between the real and predicted 
points at which they phenoconvert. Future work is also needed to assess the 
predictive (possibly additive) value of non-genetic measures (e.g. caudate 
volume or cognitive deficits). Finally, there is a move towards more consistent 
documentation of the earliest signs of the disease, whether they be motor, 
cognitive or behavioural, in an attempt to define “onset” (and thus disease 
duration) more accurately. Advances in these measures will be needed in order 
to draw more robust conclusions about the progression of the disease. It seems 
clear that different measures may be appropriate to track change at different 
stages of the disease process, and stratification accuracy (based on disease 
duration or years to onset) will need to improve in order to reduce within-group 
inhomogeneity and maximise the chances of detecting the optimum markers.
12.5 FUTURE WORK
The data and results presented in this thesis are encouraging, particularly in the 
use of whole-brain measures (such as the BBSI) to monitor change in HD, and 
the findings of specific types of cognitive impairment and decline over time. 
Further work will focus on expanding these findings: applying the BBSI to new 
cohorts, over longer time periods, and using the cognitive data to inform the 
development of more sensitive tests.
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Memory tests may have great potential in HD because their difficulty can be 
manipulated. Controls and premanifest subjects tended to score at ceiling on 
some parts of both auditory and visual recall and recognition memory tasks, 
whilst early HD subjects were impaired to the extent that there was little scope to 
detect change on at least one task (some subjects were scoring towards floor 
levels on recognition memory for faces). These deficits seemed to be caused by 
poor initial encoding, and problems with recognition judgements in forced choice 
procedures, and there should be an interim stage (in the group of close-to-motor- 
onset subjects which was not well-represented in the current work) during which 
these deficits start to become detectable. Memory tasks can be manipulated in a 
number of ways: briefer stimulus presentation, longer time between encoding 
and recall, more items to be remembered, more distractor stimuli in recognition 
paradigms, and therefore it seems likely that tests could be developed which 
were more sensitive to early (frontal) dysfunction in HD, with the aim of adding 
to the very few tests that can detect deficits, if not decline, in the premanifest 
population.
The finding that premanifest subjects were slowed at a predictable button press 
also merits follow-up. This suggests that even in far-from-onset subjects, tasks 
that tap skill-leaming, habit acquisition or automation of skills (all of which are 
thought to rely strongly on striatal integrity) are likely to be sensitive to some of 
the earliest signs of the disease. Future work will build on this, following-up the 
current cohort and investigating other potentially sensitive tasks, similar to the 
one used here.
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The contribution of the eye movement impairments in HD to the deficits seen 
here is as yet unknown. Given that fear recognition impairment has, in one case, 
been attributed to erroneous gaze direction, and temporarily corrected by explicit 
instructions as to which part of the face to attend (Adolphs et al. 2005), it would 
be interesting to investigate the role of eye movements to the facial emotion 
recognition impairment in HD in particular, with a view to determining whether 
instructions could similarly improve recognition performance. Whilst it would 
be unlikely to improve performance to control levels, minimising the effect of 
poor scanning might be of some benefit to patients and their carers in their daily 
social interactions. Many of the cohort presented here are also undergoing 
assessment using a multimodal battery, including facial, vocal and musical 
emotion stimuli, in order to investigate whether the impairments seen here are 
modality-specific, and whether performance is associated with similar neural 
substrates.
All the subjects presented here have been invited back for further follow-up. 
Many are now enrolled in Track-HD (a three-year prospective study 
investigating a number of potential markers in premanifest and early HD). Those 
who are not (mainly premanifest subjects very far from predicted motor onset) 
continue to be offered annual assessments as part of the present study, and it will 
be vital to follow-up the premanifest subjects in particular, as when they 
phenoconvert it will be possible to reanalyse these data with accurate years-to- 
onset figures, and thus to assess the predictive power of a number of the tests 
used here.
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12.6 SUMMARY
This thesis examined cognitive and MRI measures in a large cohort of 
premanifest and early Huntington’s disease subjects over one year. Cross- 
sectionally it is clear that differences are apparent on MRI and cognitive testing, 
even in relatively far-from-onset premanifest subjects. Subjects tolerated serial 
MRI well, and whole-brain atrophy rate measured with the BBSI could 
potentially be a marker of progression. Despite the problems associated with 
repeated cognitive testing and the slow progression of the disease, some 
cognitive tests also showed promise as potential markers of change.
There are a number of conflicting findings in the HD literature and there have 
been calls for better-validated and consistent research in order to measure and 
track progression at a time when markers are vital if potentially disease- 
modifying therapies are to be assessed in clinical trials (Nopoulos et al. 2007; 
Witjes-Ane et al. 2007). In a large part these differences can be explained by 
methodological inconsistencies, and demographic (as opposed to disease- 
specific) differences in the populations being studied. The work in this thesis 
addressed many of these factors by identifying and adjusting for confounding 
variables, eliminating sources of bias, and validating imaging techniques. Only 
when techniques (both cognitive and imaging) are well-validated, as free from 
bias as possible, and after adjusting for any possible confounds, will it be 
possible in future to draw firm conclusions and move on to new research 
questions.
This work adds to the body of knowledge showing that atrophy in HD is not 
confined to the striatum, and that cognitive deficits are wide-ranging and in some
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cases detectable many years before motor signs are apparent. Although motor 
slowness and chorea are tangible signs of the disease, deficits in skill learning, 
phonemic fluency, memory, and emotion recognition are also apparent early in 
the disease, and in some cases prior to motor onset. Future work should aim for 
better understanding, and hence management, of these very early symptoms, in 
order to help those patients, families and carers who live with the devastating 
effects of this disease.
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PUBLICATIONS AND COLLABORATIONS
Peer-reviewed papers based on results described in this thesis are detailed below 
together with the contributions of all other individuals who were involved in this 
work. I am indebted to all of my colleagues for these contributions.
Pilot study (Chapter 3)
Henley, S.M.D., Frost, C., MacManus, D.G., Warner, T.T., Fox, N.C., Tabrizi, 
S.J. (2006). Increased rate of whole-brain atrophy over 6 months in early 
Huntington’s disease. Neurology^ 67, 694-696.
Subjects were recruited by me. Sarah Tabrizi and Tom Warner assessed patients 
using the UHDRS. Neuropsychological assessment was carried out by me under 
the supervision of Elizabeth Warrington, and volumetric analysis was done by 
me. Registrations were checked by Rachael Scahill. Statistical advice was 
provided by Chris Frost. I carried out the analysis and drafted the paper which 
was revised by Chris Frost, Sarah Tabrizi and Nick Fox.
London longitudinal study (Chapters 4 - 11 )
Subjects were recruited by me, Edward Wild and Roger Barker. 
Neuropsychological assessment was administered by me, with advice from 
Elizabeth Warrington and Seb Crutch. The BDI and clinical parts of the UHDRS 
were administered by Edward Wild. Volumetric measurements and registrations 
were done by me and Nicola Hobbs (whole brains, caudates and TIVs). Images 
were quality-checked by Shona Clegg. Statistical advice was provided by Chris 
Frost and technical VBM advice by Ged Ridgway and Rachael Scahill. All
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analysis and voxel-based morphometry was performed by me. Further details 
specific to each chapter are listed below.
Chapter 7
Henley, S.M.D., Wild, E.J., Hobbs, N.Z., Scahill, R.I., Ridgway, G.R., 
MacManus, D.G., Barker, R.A., Fox, N.C., Tabrizi, S.J. Relationship between 
CAG repeat length and brain volume in premanifest and early Huntington’s 
disease. Journal o f Neurology (in press)
Recruitment, assessment and analysis were carried out as outlined above. I 
drafted the paper which was revised by Ged Ridgway, Roger Barker, Sarah 
Tabrizi and Nick Fox.
Chapter 8
Henley, S.M.D., Wild, E.J., Hobbs, N.Z., Warren, J.D., Frost, C., Scahill, R.I., 
Ridgway, G.R., MacManus, D.G., Barker, R.A., Fox, N.C., Tabrizi, S.J. 2008. 
Defective emotion recognition in early HD is neuropsychologically and 
anatomically generic. Neuropsychologia, 46, 2152-2160.
Recruitment, assessment and analysis were carried out as outlined above. Jason 
Warren and Rohani Omar provided useful advice about creating ROIs in MRJcro 
and Jo Foster provided an amygdala segmentation on which to base one of the 
ROIs. I drafted the paper which was revised by Jason Warren, Ged Ridgway, 
Roger Barker, Sarah Tabrizi and Nick Fox.
361
Chapter 11
Henley, S.M.D., Wild, E.J., Hobbs, N.Z., Frost, C., MacManus, D.G., Barker, 
R.A., Fox, N.C., Tabrizi, S.J. Whole-brain atrophy as a biomarker of progression 
in early Huntington’s disease, (submitted to Movement Disorders)
Recruitment, assessment and analysis were carried out as outlined above. 1 
drafted the paper which was revised Roger Barker, Edward Wild, Sarah Tabrizi 
and Nick Fox.
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APPENDIX 1: IMAGE ACQUISITION PROTOCOLS
Pilot study (Chapter 3)
Images were obtained using an IR prepared FAST spoiled GRASS sequence with 
24cm X 75% field of view and 256 x 256 matrix, reconstructed to provide 124 
contiguous 1.5mm-thick coronal slices. In-plane pixel dimensions were 0.9375 x 
0.9375mm. Acquisition parameters were: repetition time = 15ms; echo time = 
5.4 ms; flip angle = 15°; inversion time = 650ms; receiver bandwidth = 16kHz, 
NEX=1.
All other studies (Chapters 4-8)
Images were obtained using an IR prepared FAST spoiled GRASS sequence with 
a 24cm x 75% field of view and 256 x 256 matrix reconstructed to provide 124 
contiguous 1.5-mm thick coronal slices. In-plane pixel dimensions: 0.9375 by 
0.9375 mm. Acquisition parameters: repetition time = 13ms; echo time = 5.2ms; 
flip angle = 13°; inversion time = 650ms; receiver bandwidth = 16kHz, NEX=1.
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APPENDIX 2: VOLUMETRIC ANALYSIS
Volumetric analysis was performed using MIDAS software (section 2.5.3.1) 
following the protocols detailed below. All segmentations were done on Tl- 
weighted images. Reproducibility error was estimated as the mean absolute 
percentage difference between repeat segmentations on the same scan, and with 
the intra-class correlation coefficient.
Whole brain
Whole-brain segmentation was done using the protocol described by 
Freeborough et al. (1997). This algorithm is semi-automated and identifies brain 
voxels using interactive thresholding. The region thus outlined is eroded and 
then dilated a number of times to isolate non-brain tissue such as scalp and dura 
(see Figure A2-1). All segmentations for the pilot study (chapter 3) were 
performed by me, and those for the other studies by me and Nicola Hobbs. Intra­
rater reproducibility (intraclass correlation coefficient) was >0.99 for both 
segmentors (SH, average difference 0.19% of mean; NH, average difference 
0.27% of mean); inter-rater reproducibility was >0.99 (average difference 0.52% 
of mean).
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$Figure A2-1 A) MRI showing intensity thresholding excluding high and low 
(non-brain) intensities; B) the region has been eroded by one voxel (cutting 
off skull); C) the region has been dilated by two voxels, expanding to the 
edges of the brain
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Total Intracranial Volume
Total Intracranial Volume (TIV) was delineated using a protocol described by 
Whitwell et al. (2001). A lower threshold of 30% of mean brain intensity was 
set to outline the edge of the dura, which was then edited manually where 
necessar>'. The inferior boundary was the lowest slice in which cerebellar tissue 
could be seen. Every tenth axial slice was segmented with the superior boundary 
being the highest slice in which brain tissue could still be seen (see Figure A2-2). 
A volume estimate was obtained using linear interpolation. All measurements 
for the pilot study (chapter 3) were performed by me, and those for the other 
studies by me and Nicola Hobbs. Intra-rater reproducibility was >0.99 for both 
segmentors (SH, average difference 0.07% of mean; NH, average difference 
0.56% of mean); inter-rater reproducibility was >0.99 (average difference 0.24% 
of mean).
f
Figure A2-2 TIV segmentation in sagittal view
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APPENDIX 3: NEUROPSYCHOLOGICAL ASSESSMENT
The following standard neuropsychological tests (presented in alphabetical order) 
were used in the study.
Benton Facial Recognition Test (Benton et al. 1983): this thesis used the short 
version. Subjects are shown a series of faces and asked to pick the identical face 
from a set of six presented below it, and subsequently are shown a series of faces 
and asked to pick three faces from a set of six which are the same subject as the 
target face but with slightly different orientations or lighting. Faces are black 
and white and distinguishing features such as hair are minimal. The final score 
on this test is age- and education-adjusted and scores can be classified as normal 
or abnormal.
Category fluency (Benton and Hamsher 1978): subjects are asked to generate the 
names of as many animals as possible in one minute.
Digit span (Wechsler 1981): subjects are read out a series of numbers with each 
series increasing in length, and required to repeat each one back to the 
experimenter. For the first set of trials the subjects must repeat the numbers 
verbatim; for the second set subjects are required to reverse the order of the 
numbers. There are usually two or three trials for each series length, with testing 
discontinued if the subject fails to repeat all of the numbers at a given length 
correctly. Alternative versions can be generated by using different numbers. 
There is no time limit.
Ekman Pictures o f Facial Affect (Ekman and Fries en 1976; after Gray et al.
1997): this thesis used the set of 24 pictures of facial affect used by Gray et al. in
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a similar study, in order to aid comparison between results. This subset was 
preferred to larger subsets of 60 faces because it required less time to administer. 
The set consists of black and white pictures of people portraying happiness, 
sadness, surprise, disgust, anger and fear, with four exemplars of each emotion. 
Pictures are presented in a random order, with the constraint that three pictures of 
the same emotion could not appear in sequence, and the names of all six 
emotions were printed in a pseudo-random order underneath each face. Subjects 
were asked to pick the emotion which best matched the face. There was no time 
limit.
Graded Naming Test (ONT) (McKenna and Warrington 1983): a series of 30 line 
drawings, of increasingly unfamiliar objects, is presented to the subject who is 
asked to name them. In the event of the subject’s making a perceptual error the 
subject is given the opportunity to answer again. The task is not timed.
Homophone Meaning Generation Test (Warrington 2000): subjects are asked to 
generate as many homophones as possible for a set of four words, e.g. “bear”, 
“tip”. There are two alternative versions and the task is not timed.
Hopkins Verbal Learning Test (Brandt and Benedict 2001): subjects are read a 
list of 12 words, which fit into three semantic categories, and then asked to recall 
as many words as possible. This is repeated three times to give an immediate 
recall score. Twenty-twenty-five minutes later subjects are again asked to recall 
the words (generating a delayed score and percentage recall) and then asked to 
give yes/no recognition responses to a list of 24 words read out by the examiner, 
giving a discrimination score (true positives - false positives). There are six
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alternative versions, two of which were used in the current study, and this is not 
timed.
Letter cancellation’, this is an in-house timed pencil and paper task consisting of 
a page of regularly spaced capital letters (“A” to “E”). Subjects are asked to 
cross out all of the “A”s as fast as they can.
National Adult Reading Test (NART) (Nelson and Willison 1991)’. this task 
requires subjects to read a list of irregular English words ranging from e.g. 
“CHORD” to “DEMESNE”, and in diseases in which reading aloud is relatively 
spared, score tends to correlate with pre-morbid IQ. There is no time limit.
Phonemic (letter) fluency (Benton and Hamsher 1978): subjects have three one- 
minute periods in which to generate as many words beginning with “F”, “A” and 
“S” as they can.
Recognition Memory Test (RMT) (Warrington 1984): subjects are shown 50 
faces (or words) sequentially and asked to make a yes/no judgement as to 
whether the face (or word) is pleasant or unpleasant. Subsequently subjects are 
presented with a two alternative forced choice test in which they have to pick out 
the target face (or word) from a pair, one of which was not in the original 
stimulus set. There are two alternative versions. There is no time limit.
Spot the Word Test (Baddeley et al. 1993): subjects are shown 60 word -  non­
word pairs and asked to circle the real word. Real words tend to be uncommon 
and score correlates highly with IQ. There are two alternative versions. There is 
no time limit.
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Stroop Test (Stroop 1935; Delis et al. 2001): this is a timed test in which subjects 
first read out colour names printed in incongruous coloured inks, and then have 
to name the ink colour of incongruous colour-words (this version was used in 
chapter 3). In later versions subjects are asked to name colour patches, then to 
read out colour names printed in black ink, and then to name the ink colour of 
incongruous colour-words (this version was used in the rest of the thesis).
Symbol Digit Modalities Test (SDMT ) (Smith 1968): this is a timed pencil and 
paper task in which subjects follow a key to fill in digits underneath a set of 
symbols, as fast as they can.
Trail Making (D-KEFS) (Delis et al 2001): this is a timed pencil and paper task 
comprising five separate sections for number cancellation, number sequencing, 
letter sequencing, alternating sequencing, and motor speed.
Trail Making Test for Adults (Reitan and Wolfson 2004): this is a timed pencil 
and paper task with two parts; in part A subjects draw a line to connect 25 
numbers in sequence, and in part B they must draw a line to connect 25 numbers 
and letters in alternating sequence.
Visual Object and Space Perception Battery (VOSF) (Warrington and James 
1991): the silhouette (objects) subtest was used in which subjects are asked to 
identify a series of 15 black silhouettes of everyday objects, which increase in 
unfamiliarity.
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APPENDIX 4: COGNITIVE SCORES FROM CHAPTER 4
Table A4-1: Mean (SD) neuropsychological performance at baseline for the control and early HD groups, with differences (95%
confidence intervals) with and without adjustment for age and estimated premorhid IQ
Control Early HD Difference (Early HD - Control)
Test rr=20 N=40 Crude Adjusted
UHDRS cognitive (n) 334.8 (33.8) 231.5 (53.6) -103.3 (-125.9, -80.7) p<0.0001 -98.2 (-119.2,-77,2) p<0.0001
Stroop colour (n) 80.25 (9.3) 57.0(12.7) -23.2 (-29.0,-17.5) p<0.0001 -22.8 (-28.5,-17.2) p<0.0001
Stroop word (n) 107.3 (14.0) 75A(2E2) -31.9 (-41.0, -22.7) p<0.0001 -29.9 (-38.7, -21.1)p<0.0001
Stroop interference (n) 45.9 (7.5) 32.8 (9.2) -13.1 (-17.5,-8.7) p<0.0001 -12.0 (-16.1,-7.8) p<0.0001
SDMI (n) 55.6 (7.8) 33.3(10.3) -22.3 (-27.0,-17.5) p<0.0001 -21.0 (-25.6,-16.4) p<0.0001
Phonemic fluency (n) 45.9 (9.0) 33.0(11.3) -12.9 (-18.2,-7.5) p<0.0001 -12.5 (-17.4, -7.6) p<0.0001
Category fluency (n) 24.1 (3.9) 17.9 (5.6) -6.2 (-8.7, -3.7) p<0.0001 -5.8 (-8.2, -3.3) p<0.0001
HMGT (n) 11.9 (2.2) 10.3 (2.5) -1.6 (-2.8, -0.4) p—0.01 -1.4 (-2.5,-0.4) p=0.007
TMT A (sec) 2T3(6.5) 37.6(11.5) -16.2 (-20.6,-11.7) p<0.05 -14.8 (-19.5,-10.4) p<0.05
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Control Early HD Difference (Early HD - Control)
Test N=20 N=40 Crude Adjusted
TMT B (sec) 62.4 (41.0) 119.6 (55.6) -57.2 (-82.2, -30.7) p<0.05 -53.7 (-79.5,-29.3) p<0.05
TMT B-A (sec) 41.1 (40.1) 83.6 (51.5) -42.5 (-64.1,-19.1) p<0.05 -39.8 (-65.1,-15.8) p<0.05
TMT B/A 3.0 (1.9) 3.4 (1.3) -0.4 (-1.2, 0.7) p>0.05 -0.3 (-1.2, 0.8) p>0.05
Cancelling As (sec) 17.3 (4.2) :28.1 (8.5) -10.8 (-14.1,-7.5) p<0.0001 -10.2 (-13.5,-7.0) p<0.0001
RT near (msec) 654(83) 932(175) -277.4 (-342.9, -211.1) p<0.05 -260.0 (-322.4.-195.4) p<0.05
RT far (msec) 711(81) 980(178) -269.0 (-333.0, -203.7) p<0.05 -253.8 (-321.2,-191.1) p<0.05
RT return from near (msec) 290(95) 594(248) -303.9 (-390.3,-215.1) p<0.05 -274.6 (-355.5,-190.7) p<0.05
RT return from far (msec) 299(112) 593 (233) -294.4 (-388.9. -212.1) p<0.05 -271.1 (-361.5.-180.8) p<0.05
HVLT immediate (/36) 25.6 (6.1) 19.7 (5.2) -5.9 (-9.0, -2.7) p<0.0001 -5.1 (-8.1. -2.1) p=0.001
HVLT delayed (/12) 9.7 (2.2) 6.4 (2.4) -3.2 (-4.4, -2.0) p<0.0001 -2.9 (-4.0.-1.7) p<0.0001
HVLT % recalled 95.7(14.5) 80.2 (24.0) -15.5 (-25.4, -5.6) p=0.003 -13.1 (-23.0. -3.2) p=0.01
HVLT discrimination (/12) 11.1 (1.2) 8.8 (2.3) -2.3 (-3.2,-1.4) p<0.0001 -2.1 (-2.9,-1.2) p<0.0001
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Control Early HD Difference (Early HD - Control)
Test N=20 N=40 Crude Adjusted
Digit span forwards (/21 ) 13.4 (3.8) 10.5 (3.2) -3.0 (-4.9,-1.0) p=0.004 -2.7 (-4.3.-1.0) p=0.002
Digit span backwards (/21 ) 12.5 (4.1) 8.7 (3.8) -3.8 (-6.0,-1.6) p=0.001 -3.5 (-5.5.-1.6) p<0.0001
RMF (/50) 42.7 (4.0) 34.8 (7.0) -7.9 (-10.8,-5.1) p<0.0001 -7.5 (-10.5, -4.6) p<0.0001
RMW (/50) 48.2 (2.5) 43.4 (4.7) -4.8 (-6.5, -2.9) p<0.05 -4.3 (-5.5, -2.7) p<0.05
RMT difference -5.5 (4.6) -8.6 (6.1) -3.1 (-5.9, -0.3)p=0.03 -3.3 (-6.2,-0.3) p=0.029
GNT (/30) 21.4 (3.7) 20.7 (4.7) -0.7 (-2.9, 1.5) p—0.54 -0.7 (-2.2, 0.7) p=0.32
Naming latency (In(sec)) 0.6 (0.4) 0.8 (0.4) -0.3 (-0.4. -0.2) p<0.0001 -0.2 (-0.3.-0.1)p<0.0001
VOSP (/15) 8.4 (2.6) 7.5 (2.7) -0.8 (-2.1, 0.4) p=0.20 -0.6 (-1.8, 0.6) p—0.20
Benton (/54) 48.0 (3.8) 43.5 (4.7) -4.5 (-6.8. -2.2) p<0.0001
Emotion recognition (/24) 21.4(1.5) 16.8 (3.3) -4.5 (-5.7. -3.2) p<0.05 -4.3 (-23.6,-12.9) p<0.05
Negative differences indicate a lower score or slower speed (longer time taken in timed tasks) in HD subjects relative to controls; crude differences are the absolute difference 
between groups before adjustment for age and IQ; adjusted differences are the differences having adjusted for age and IQ by including them as covariates in linear regression 
models; the Benton scores are already age- and education-adjusted; where 95% bootstrapped CIs were used precise p values were not obtained.
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Table A4-2: Mean (SD) neuropsychological performance at baseline for the control and premanifest groups, with differences (95%
confidence intervals) with and without adjustment for age and estimated premorhid IQ
Test
Control
N=20
PM
N=21
Difference (PM
Crude
- Control)
Adjusted
UHDRS cognitive (n) 334.8 (33.8) 321.9(51.1) -12.9 (-39.6, 13.8) p=0.34 -14.4 (-37.4,8.6) p=0.22
Stroop colour (n) 80.25 (9.3) 77.5(10.5) -2.8 (-8.9, 3.4) p=0.37 -2.9 (-9.1,3.3)p=0.36
Stroop word (n) 107.3 (14.0) 104.1 (19.8) -3.2 (-13.7,7.4) p=0.55 -3.8 (-13.1, 5.5) p—0.42
Stroop interference (n) 45.9 (7.5) 47.8 (9.5) 1.9 (-3.4, 7.2) p=0.47 1.1 (-4.2, 6.3) p=0.69
SDMT (n) 55.6 (7.8) 53.4(10.3) -2.1 (-7.8, 3.5) p=0.46 -3.3 (-8.8, 2.2) p=0.24
Letter fluency (n) 45.9 (9.0) 39.1 (13.5) -6.8 (-13.8, 0.3)p=0.06 -5.5 (-12.5, 1.6) p=0.13
Category fluency (n) 24.1 (3.9) 23.0 (7.7) -1.0 (-4.7, 2.7) p=0.59 -0.8 (-4.1, 2.5) p=0.64
HMGT (n) 11.9 (2.2) 11.6 (2.7) -0.3 (-1.7, l.l)p=0.67 0.0 (-1.1, l.l)p=1.0
TMT A (sec) 2L3(&5) 22.4 (5.0) -1.1 (-4.9, 2.5) p>0.05 -3.3 (-1.1, 7.9) p>0.05
TMT B (sec) 62.4 (41.0) 60.2 (25.1) 2.3 (-14.8, 26.5) p>0.05 -2.5 (-19.7, 17.3)p>0.05
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Test
Control
N=20
PM
N=21
Difference (PM
Crude
- Control)
Adjusted
TMT B-A (sec) 41.1 (40.1) 37.7 (22.3) 3.4 (-13.8, 26.7)p>0.05 0.1 (-14.5, 18.4) p>0.05
TMT B/A 3.0 (1.9) 2.7 (0.8) 0.4 (-0.4, 1.4) p>0.05 0.3 (-0.3, 1.4) p>0.05
Cancelling As (sec) 17.3 (4.2) 18.5(4.5) 1.2 (-1.5, 3.9) p=0.37 -2.0 (-5.0, 1.0) p=0.18
RT near (msec) 654 (83) 641 (91) 12.7 (-38.2, 66.3) p>0.05 -7.7 (62.1,39.7) p>0.05
RT far (msec) 711(81) 690(96) 21.7 (-35.9, 75.4) p>0.05 -0.8 (-58.3, 51.9) p>0.05
RT return from near (msec) 290(95) 357 (138) -67.9 (-136.5,5.0) p>0.05 -118.4 (-206.3, -45.2) p<0.05
RT return from far (msec) 299(112) 356 (143) -57.2 (-129.3,23.6) p>0.05 -99.3 (-183.6. -26.5) p<0.05
HVLT immediate (/36) 25.6 (6.1) 27.0 (4.9) 1.5 (-2.0, 4.9) p=0.40 0.7 (-2.3, 3.6) p=0.66
HVLT delayed (/12) 9.7 (2.2) 9.2 (2.2) -0.4 (-1.8, 1.0) p=0.55 -0.8 (-2.2, 0.6) p=0.24
HVLT % recalled 95.7(14.5) 89.5 (15.6) -6.2 (-15.5, 3.1) p=0.19 -9.1 (-20.0, 1.7) p=0.10
HVLT discrimination (/12) 11.1 (1.2) 10.7(1.2) -0.4 (-1.1, 0.3) p=0.28 -0.7 (-1.4, 0.1) p—0.10
Digit span forwards (/21 ) 13.4 (3.8) 13.3 (3.2) -0.1 (-2.2, 2.1)p=0.95 0.02 (-2.0.2.1)p=0.98
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Control PM Difference (PM - Control)
Test N=20 N=21 Crude Adjusted
Digit span backwards (/21 ) 12.5 (4.1) 11.5 (4.0) -1.0 (-3.5, 1.5) p=0.44 -0.9 (-3.2, 1.4) p=0.43
RMF (/50) 42.7 (4.0) 41.3 (5.3) -1.4 (-4.3, 1.5) p=0.35 -1.5 (-4.6, 1.7) p=0.36
RMW (/50) 48.2 (2.5) 48.2(1.9) 0.04 (-1.3, 1.4) p>0.05 -0.3 (-1.4, 0.9) p<0.05
RMT difference -5.5 (4.6) -6.9 (5.5) -1.4 (-4.5, 1.7) p=0.38 -1.2 (-4.5,2.1)p=0.48
GNT (/30) 21.4 (3.7) 21.8(4.5) 0.4 (-2.2, 2.9) p=0.78 1.7 (0.01. 3.3) p=0.049
Naming latency (In(msec) 0.6 (0.4) 0.7 (0.4) -0.1 (-0.2, 0.05) p>0.05 -0.1 (-0.2, 0.03) p>0.05
VOSP (/15) 8.4 (2.6) 7.5 (3.5) -0.8 (-2.6, 0.9) p=0.34 -1.1 (-2.7. 0.6) p=0.20
Benton (/54) 48.0 (3.8) 47.7 (3.7) -0.3 (-2.6, 2.1)p=0.81
Emotion recognition (/24) 21.4 (1.5) 20.6 (2.3) -0.7 (-2.0, 0.5) p>0.05 -2.7 (-7.9, 3.0) p>0.05
Negative differences indicate a lower score or slower speed (longer time taken in timed tasks) in HD subjects relative to controls; crude differences are the absolute difference 
between groups before adjustment for age and IQ; adjusted differences are the differences having adjusted for age and IQ by including them as covariates in linear regression 
models; the Benton scores are already age- and education-adjusted; where 95% bootstrapped CIs were used precise p values were not obtained.
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